

Challenger Capital Notes 4

Prospectus for the issue of capital notes to raise \$350 million,
with the ability to raise more or less

Issuer

Challenger Limited
(ABN 85 106 842 371)

Date of this Prospectus

15 March 2023

Arrangers

UBS AG, Australia Branch
National Australia Bank Limited
Westpac Institutional Bank
(a division of Westpac Banking Corporation)

Joint Lead Managers

UBS AG, Australia Branch
ANZ Securities Limited
Morgans Financial Limited
National Australia Bank Limited
Westpac Institutional Bank
(a division of Westpac Banking Corporation)

Co-Managers

LGT Crestone Wealth Management Limited
JBWere Limited

Challenger Capital Notes 4 are complex and involve different risks to a simple debt or ordinary equity instrument. They are not suitable for all investors and contain features which may make Challenger Capital Notes 4 difficult to understand. Challenger strongly recommends that you seek professional advice from a qualified financial adviser before you make an investment decision.

If you are a Retail Investor and wish to participate in the Offer, you must seek professional advice as to whether you are within the Challenger Capital Notes 4 Target Market and if an investment in Challenger Capital Notes 4 is suitable for you in light of your particular investment objectives, financial situation and needs. You can only apply for Challenger Capital Notes 4 if you are within the Challenger Capital Notes 4 Target Market and you have received personal advice from a qualified financial adviser. If you wish to apply for Challenger Capital Notes 4, you must contact a Syndicate Broker.

Important notices

About this Prospectus

This Prospectus relates to the offer by Challenger Limited (ABN 85 106 842 371) (“**Challenger**”) of subordinated, unsecured, perpetual notes, Challenger Capital Notes 4 (“**Challenger Capital Notes 4**”), to raise \$350 million, with the ability to raise more or less (the “**Offer**”).

This Prospectus is dated and was lodged with the Australian Securities and Investments Commission (“**ASIC**”) on 15 March 2023 pursuant to section 718 of the Corporations Act. It is a transaction-specific prospectus issued by Challenger under section 713(1) of the Corporations Act (as modified by ASIC Corporations (Offers of Convertibles) Instrument 2016/83). This is a replacement prospectus which replaces the prospectus dated 7 March 2023 and lodged with ASIC on that date (“**Original Prospectus**”). This Prospectus expires on the date (“**Expiry Date**”) which is 13 months after 7 March 2023 (being the date of the Original Prospectus) and no Challenger Capital Notes 4 will be issued on the basis of this Prospectus after the Expiry Date.

Neither ASIC nor ASX Limited takes any responsibility for the contents of this Prospectus or the merits of the investment to which this Prospectus relates.

How to obtain a Prospectus

This Prospectus is available to Australian investors in electronic form at www.challengercapitalnotes.com.au or may be available through a Syndicate Broker. The Offer contained in this Prospectus in electronic form is available only to persons accessing and downloading or printing the electronic copy of the Prospectus within Australia and is not available to persons in any other jurisdictions (including the United States) without the prior approval of Challenger. If you access an electronic copy of the Prospectus, you should ensure that you download and read the entire Prospectus before submitting an Application for Challenger Capital Notes 4.

During the Offer Period, an electronic version of a replacement prospectus will be available to eligible investors through www.challengercapitalnotes.com.au and may be available through a Syndicate Broker.

Applications for Challenger Capital Notes 4 under this Prospectus may only be made through a Syndicate Broker, following the opening of the Offer.

Application Form

The Corporations Act prohibits any person from passing an Application Form to another person, unless it is attached to or accompanied by a printed copy of this Prospectus or the complete and unaltered electronic version of this Prospectus.

Defined words and expressions

Certain capitalised words and expressions used in this Prospectus have defined meanings which are explained in the Terms of Challenger Capital Notes 4 as set out in Appendix A and in the Glossary in Appendix B of this Prospectus. If there is any inconsistency in definitions between Appendix A and Appendix B, the definitions in Appendix A prevail.

Unless otherwise stated or implied, references to times in this Prospectus are to the time in Sydney, New South Wales, Australia.

Offer and issuer

The Offer contained in this Prospectus is an offering by Challenger of Challenger Capital Notes 4 at \$100 per Challenger Capital Note 4 to raise \$350 million, with the ability to raise more or less. The Offer comprises the New Money Offer and the Reinvestment Offer. Applications (under both the New Money Offer and the Reinvestment Offer) will only be accepted from investors who satisfy the eligibility requirements in accordance with the Target Market Determination (“**TMD**”) (see Section 1.7 for further detail). As there is no general public offer or securityholder offer, no applications can be made directly to Challenger. The Reinvestment Offer provides eligible holders of Challenger Capital Notes 2 issued by Challenger on 7 April 2017 (“**Challenger Capital Notes 2**”) with the opportunity to reinvest the proceeds of the sale of their Challenger Capital Notes 2 (“**CCN2 Resale Proceeds**”) into Challenger Capital Notes 4. For further information on who is eligible and how to apply, refer to Section 7.4.

Challenger Capital Notes 4 are issued by Challenger, an ASX-listed non-operating holding company incorporated in Australia. Challenger is the ultimate parent company of an investment management group comprising a life business, a funds management business and an authorised deposit-taking institution (“**ADI**”). Challenger Life Company Limited (ABN 44 072 486 938) (AFSL 234670) (“**CLC**”), which is the principal operating entity of the life business, is a subsidiary of Challenger and is a life company registered under the Life Insurance Act.

References in this Prospectus to Challenger are to the parent company on a standalone basis and references to the Challenger Group are to Challenger and its subsidiaries on a consolidated basis.

This Prospectus describes the activities and the financial performance and position of the Challenger Group.

Challenger Capital Notes 4 are not policy liabilities of Challenger, CLC or any other member of the Challenger Group, and are subordinated, unsecured and not guaranteed.

Challenger Capital Notes 4 are not:

- policy liabilities of Challenger, CLC or any other member of the Challenger Group;
- investments in any superannuation or other fund managed by a member of the Challenger Group;
- guaranteed or insured by any government, government agency or compensation scheme of Australia or any other jurisdiction; or
- protected accounts with an ADI for the purposes of the depositor protection provisions of, or the financial claims scheme established under, the *Banking Act 1959* (Cth).

Challenger Capital Notes 4 (including any amounts payable in respect of each Challenger Capital Note 4) do not have the benefit of security granted by, and are not guaranteed by, Challenger or any other member of the Challenger Group or any other person. Challenger Capital Notes 4 are complex and may not be suitable for all investors. The investment performance of Challenger Capital Notes 4 is not guaranteed by Challenger or any other member of the Challenger Group or any other person.

Challenger Capital Notes 4 are unsecured and subordinated and may be either Converted into Ordinary Shares or Written-Off in the circumstances detailed in the Terms. There is a risk that you may lose some or all of the money you invested in Challenger Capital Notes 4 because a Non-Viability Trigger Event occurs, or if on a winding-up of Challenger there are insufficient assets to satisfy securities and obligations ranking ahead of Challenger Capital Notes 4. In either case you will not be repaid any or all of the Face Value and will not receive any or all of the interest payments due and unpaid at that time.

Challenger Capital Notes 4 are unsecured notes for the purposes of section 283BH of the Corporations Act. Challenger Capital Notes 4 are issued by Challenger under the Trust Deed and Holders have no direct right to claim against Challenger except as provided in the Trust Deed (which includes the Terms).

The risks associated with investing in Challenger Capital Notes 4 are further detailed in Section 6 and you should read these carefully and consider these factors in light of your personal circumstances (including financial and taxation issues).

ASX quotation

Challenger has applied for Challenger Capital Notes 4 to be quoted on ASX. Challenger Capital Notes 4 are expected to trade under the ASX code "CGFPD".

About the Trustee

Equity Trustees Limited (ABN 46 004 031 298) ("**Trustee**"), and its directors, employees, officers, affiliates, agents, advisers, intermediaries, and related bodies corporate:

- have not authorised or caused the issue or distribution of this Prospectus, were not involved in preparing this Prospectus and do not make any statement or purport to make any statement in this Prospectus or any statement on which a statement in this Prospectus is based;
- do not assume any responsibility for or make representations as to the truth, accuracy or completeness of any information contained in this Prospectus;
- to the maximum extent permitted by law, expressly disclaim all liability in respect of, make no representation or any statement regarding, and take no responsibility for, any part of this Prospectus, or any statements in, or omissions from, this Prospectus, other than (in the case of the Trustee only) references to its name which are included in this Prospectus with its written consent;
- in the case of the Trustee only, has given, and has not, before the lodgement of this Prospectus with ASIC, withdrawn, its written consent to be named in this Prospectus in the form and context in which it is named;
- have relied on Challenger for the accuracy of the contents of this Prospectus;
- do not make any representation or warranty as to the performance of Challenger or its maintenance of capital, the performance of Challenger Capital Notes 4, the payment of Distributions or Exchange of Challenger Capital Notes 4, or the value of any Ordinary Shares issued (or their proceeds of sale) on Conversion; and
- are not, subject to the Trustee's obligations under the Corporations Act, responsible for monitoring Challenger's business.

Role of the Arrangers and Joint Lead Managers

Neither the Arrangers nor any Joint Lead Managers nor their related bodies corporate, and/or their directors, officers, employees or clients act as the adviser of or owe any fiduciary or other duties

to any recipient of this Prospectus in connection with Challenger Capital Notes 4 and/or any related transaction (including, without limitation, in respect of the preparation and due execution of the transaction documents and the power, capacity or authorisation of any other party to enter into and execute the transaction documents). No reliance may be placed on the Arrangers or any Joint Lead Manager for financial, legal, taxation, accounting or investment advice or recommendations of any sort.

Exposure Period

The Corporations Act prohibited Challenger from accepting Applications to subscribe for Challenger Capital Notes 4 under the Original Prospectus in the seven-day period after the date of lodgement of the Original Prospectus with ASIC ("**Exposure Period**"). This period was to enable the Original Prospectus to be examined by market participants prior to the raising of funds. The examination may have resulted in the identification of certain deficiencies in the Original Prospectus in which case any Application may have needed to be dealt with in accordance with section 724 of the Corporations Act. Application Forms were not available until after the Exposure Period had ended.

Providing personal information

You may be asked to provide personal information to Challenger via Computershare Investor Services Pty Limited (ABN 48 078 279 277) ("**Registry**") if you apply for Challenger Capital Notes 4. See Section 9.15 for details of how your personal information is handled.

Withdrawals

Investors should note that no cooling-off rights (whether by law or otherwise) apply to an Application for Challenger Capital Notes 4. This means that, in most circumstances, Applicants may not withdraw their Applications once submitted, except as permitted by the Corporations Act.

Refunds

Applicants who are not issued any Challenger Capital Notes 4, or are issued fewer Challenger Capital Notes 4 than the number applied and paid for as a result of a scale back, will have all or some (as applicable) of their Application Payments refunded (without interest) as soon as practicable after the Issue Date.

In the event that the Offer does not proceed for any reason, all Applicants will have their Application Payments refunded (without interest) as soon as practicable. Challenger takes no responsibility for handling of Application Payments by any Syndicate Broker.

Restrictions on distribution of this Prospectus and Challenger Capital Notes 4

This Prospectus does not constitute an offer in any place in which, or to any person to whom, it would not be lawful to make such an offer. As at the date of this Prospectus, no action has been taken to register or qualify Challenger Capital Notes 4 or the Offer or to otherwise permit a public offering of Challenger Capital Notes 4 outside Australia.

This Prospectus (including electronic copies) may not be distributed or released, in whole or in part, in the United States. Neither Challenger Capital Notes 4 nor Ordinary Shares have been or will be registered under the U.S. Securities Act or the securities laws of any state of the United States, and they may not be offered or sold in the United States. Challenger Capital Notes 4 are being offered and sold solely outside the United States pursuant to Regulation S under the U.S. Securities Act.

See Section 7.6.1 for further information.

Financial information and forward-looking statements

Section 5 sets out in detail the financial information referred to in this Prospectus. The basis of preparation of that information is also set out in Section 5.

All financial amounts contained in this Prospectus are expressed in Australian dollars and rounded to the nearest million unless otherwise stated. Any discrepancies between totals and sums of components in tables contained in this Prospectus are due to rounding.

This Prospectus contains forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'expects', 'intends' and other similar words that involve risks and uncertainties.

Any forward-looking statements are subject to various risk factors that could cause actual circumstances or outcomes to differ materially from the circumstances or outcomes expressed, implied or anticipated in these statements. Forward-looking statements should be read in conjunction with the risk factors as set out in Section 6, and other information in this Prospectus.

No representations other than in this Prospectus

No person is authorised to give any information or to make any representation in connection with the Offer which is not contained in this Prospectus. You should rely only on information in this Prospectus.

Unless otherwise indicated, all information in this Prospectus, while subject to change from time to time, is current as at the date of this Prospectus.

This Prospectus does not provide financial product or investment advice – Challenger strongly recommends that you seek your own personal advice from a qualified financial adviser before making an investment decision.

The information in this Prospectus does not take into account your investment objectives, financial situation, or particular needs as an investor. You should carefully consider these factors in light of your personal circumstances (including financial and taxation issues). See in particular the risks set out in Section 6.

If you do not understand any part of this Prospectus, or are in any doubt as to whether to invest in Challenger Capital Notes 4 or not, it is recommended that you seek personal advice from a qualified financial adviser before deciding whether to invest.

If you are a Retail Investor and wish to participate in the Offer, you must seek professional advice as to whether you are within the Challenger Capital Notes 4 Target Market and if an investment in Challenger Capital Notes 4 is suitable for you in light of your particular investment objectives, financial situation and needs. You can only apply for Challenger Capital Notes 4 if you are within the Challenger Capital Notes 4 Target Market and you have received personal advice from a qualified financial adviser. If you wish to apply for Challenger Capital Notes 4, you must contact a Syndicate Broker.

This Prospectus also contains information in relation to (among other things) the Reinvestment Offer which involves the CCN2 Nominated Purchaser. Neither Challenger, the CCN2 Nominated Purchaser nor any other person is providing any investment advice or making any recommendation to Eligible CCN2 Holders in respect of the Reinvestment Offer.

Website

Challenger maintains a website at www.challenger.com.au. Information contained in or otherwise accessible through this or a related website is not a part of this Prospectus.

Diagrams

The diagrams used in this Prospectus are illustrative only. They may not necessarily be shown to scale. The diagrams are based on information which is current as at the date shown.

Enquiries

If you are considering applying for Challenger Capital Notes 4 under the Offer, this Prospectus is important and should be read in its entirety.

If you have any questions in relation to the Offer, please visit www.challengercapitalnotes.com.au or call the Offer Information Line on 1800 780 782 (within Australia) or +61 3 9415 4065 (outside Australia) Monday to Friday 8:30am to 5:00pm (Sydney time).

Table of contents

Guidance for Retail Investors	6
Impact of the DDO Regime	7
Key dates	8
Section 1 Investment overview	9
Section 2 About Challenger Capital Notes 4	25
Section 3 About the Reinvestment Offer	46
Section 4 About the Challenger Group	52
Section 5 Financial information	60
Section 6 Investment risks	68
Section 7 About the Offer	90
Section 8 Australian taxation summary	94
Section 9 Additional information	99
Appendix A Challenger Capital Notes 4 Terms	108
Appendix B Glossary	129
Corporate directory	138

Guidance for Retail Investors

- 1. Read this Prospectus in full**
 - This Prospectus is important and should be read in its entirety.
 - You should have particular regard to the:
 - “Important notices” at the front of this Prospectus;
 - “Investment overview” in Section 1 and “About Challenger Capital Notes 4” in Section 2;
 - “About the Reinvestment Offer” in Section 3 (if you are an Eligible CCN2 Holder);
 - “Investment risks” in Section 6; and
 - “Challenger Capital Notes 4 Terms” in Appendix A.
 - In considering whether to apply for Challenger Capital Notes 4, it is important that you consider all risks and other information regarding an investment in Challenger Capital Notes 4 in light of your particular investment objectives and circumstances.
- 2. Speak to a Syndicate Broker and obtain personal advice**
 - The overall complexity of Challenger Capital Notes 4 may make the Terms difficult to understand.
 - If you are a Retail Investor and wish to participate in the Offer, you must seek professional advice as to whether you are within the Challenger Capital Notes 4 Target Market and if an investment in Challenger Capital Notes 4 is suitable in light of your particular investment objectives, financial situation and needs.
 - You can only apply for Challenger Capital Notes 4 if you are within the Challenger Capital Notes 4 Target Market and you have received personal advice from a qualified financial adviser. The Challenger Capital Notes 4 Target Market is set out in Section 7.4.2. Unlike the previous offers of Challenger Capital Notes 2 in April 2017 and Challenger Capital Notes 3 in November 2020, Retail Investors wishing to apply for Challenger Capital Notes 4 must be in the Challenger Capital Notes 4 Target Market and all applications for Challenger Capital Notes 4, including applications by Eligible CCN2 Holders, must be submitted through a Syndicate Broker. No applications can be made directly to Challenger.
 - If you have any questions about the Offer, Challenger Capital Notes 4 or the Challenger Capital Notes 4 Target Market, you should contact a Syndicate Broker or other professional adviser or seek personal advice from a qualified financial adviser who is licensed by ASIC to give that advice.
 - ASIC has published guidance on how to choose a professional adviser on its MoneySmart website. You can also search “choosing a financial adviser” at www.moneysmart.gov.au.
- 3. CCN2 Holders**
 - This Prospectus contains information relevant to CCN2 Holders. If you are a CCN2 Holder, you may be eligible to reinvest your Challenger Capital Notes 2 into Challenger Capital Notes 4 under the Reinvestment Offer to maintain an ongoing investment in Challenger.
 - Participation in the Reinvestment Offer is optional. If you choose not to participate, you will continue to hold your Challenger Capital Notes 2 in accordance with the CCN2 Terms.
 - Challenger intends to redeem all outstanding Challenger Capital Notes 2 for \$100 per Challenger Capital Note 2 on their optional exchange date of 22 May 2023, in accordance with the CCN2 Terms. While Challenger has obtained APRA’s approval to redeem Challenger Capital Notes 2, it does not imply that Challenger’s other outstanding capital instruments with call dates (including, when issued, Challenger Capital Notes 4) will be redeemed and any such redemption will be in accordance with the relevant capital instrument’s terms and conditions and subject to APRA’s approval, which may or may not be given.
- 4. Consider ASIC guidance for retail investors**
 - ASIC has published guidance on its MoneySmart website which may be relevant to your consideration of Challenger Capital Notes 4. You can find this guidance by searching “hybrid securities and notes” at www.moneysmart.gov.au.
 - The guidance includes a series of questions you should ask before you invest in hybrid securities, to check your understanding of how hybrids work, their features and risks.
- 5. Obtain further information about Challenger and the Challenger Capital Notes 4**
 - Challenger is a disclosing entity for the purposes of the Corporations Act and, as a result, is subject to regular reporting and disclosure obligations under the Corporations Act and the ASX Listing Rules. In addition, Challenger must notify ASX immediately (subject to certain exceptions) if it becomes aware of information about Challenger that a reasonable person would expect to have a material effect on the price or value of its securities, including Challenger Capital Notes 4.
 - Copies of documents lodged with ASIC can be obtained from, or inspected at, an ASIC office or ASIC’s website www.asic.gov.au (a fee may apply) and Challenger’s ASX announcements may be viewed at www.asx.com.au or www.challenger.com.au/shareholder/market-announcements.
 - In addition, further information about Challenger, including Challenger’s half-yearly and annual financial reports, presentations and other investor information, can be obtained from www.challenger.com.au/shareholder.
- 6. Use of franking credits**
 - The value and availability of franking credits to you will depend on your particular circumstances and the tax rules that apply at the time of each Distribution.
- 7. Enquiries**
 - If you have any questions in relation to the Offer, please visit www.challengercapitalnotes.com.au, call the Offer Information Line on 1800 780 782 (within Australia) or +61 9415 4065 (outside Australia) Monday to Friday 8:30am to 5:00pm (Sydney time) or call a Syndicate Broker.

Impact of the DDO Regime

Challenger Capital Notes 4 will be the first retail hybrid security issued by Challenger under the design and distribution obligations regime contained in Part 7.8A of the Corporations Act (“**DDO Regime**”). Under the DDO Regime, Challenger is required to make and publish a target market determination (“**TMD**”) that sets out the class of Retail Investors to whom Challenger Capital Notes 4 are targeted (“**Challenger Capital Notes 4 Target Market**”), and the conditions for how Challenger Capital Notes 4 are to be distributed to ensure that the persons who invest are, or are likely to be, within the Challenger Capital Notes 4 Target Market. The TMD is available at www.challengercapitalnotes.com.au.

To ensure Challenger Capital Notes 4 are distributed in accordance with the TMD, Challenger has made the decision not to include a specific offer to Challenger securityholders and to not allow Eligible CCN2 Holders to apply directly to Challenger to participate in the Reinvestment Offer. All Applications under the Offer (including the Reinvestment Offer) must be submitted through a Syndicate Broker.

A summary of the key elements of the DDO Regime and eligibility to apply under the Offer is set out below.

LEGAL REQUIREMENTS

From October 2021, the DDO Regime requires issuers of financial products to prepare a TMD, make the TMD publicly available, set the conditions under which those financial products can be sold to Retail Investors, take reasonable steps in relation to distribution of those financial products, and review the TMD to ensure it remains appropriate, among other things.



TARGET MARKET DETERMINATION

The TMD for Challenger Capital Notes 4 describes the class of Retail Investors for whom an investment in Challenger Capital Notes 4 is likely to be consistent with their investment objectives, financial situation and needs.

The Challenger Capital Notes 4 Target Market is set out in Section 7.4.2 and a copy of the TMD is available at www.challengercapitalnotes.com.au.



DISTRIBUTION CONDITIONS

The TMD also sets out the conditions on how Challenger Capital Notes 4 can be sold to Retail Investors to ensure that they are, or are likely to be, in the target market.

WHAT DOES THIS MEAN FOR CHALLENGER CAPITAL NOTES 4?

Challenger Capital Notes 4 will be issued by Challenger under the DDO Regime, and several changes have been made to the way in which the Offer is conducted compared to the previous offers of Challenger Capital Notes 2 in April 2017 and Challenger Capital Notes 3 in November 2020.



ALL APPLICATIONS MUST BE SUBMITTED THROUGH A SYNDICATE BROKER

Retail Investors must seek professional advice as to whether they are within the Challenger Capital Notes 4 Target Market and if an investment in Challenger Capital Notes 4 is suitable for them in light of their particular investment objectives, financial situation and needs.

Retail Investors can only apply for Challenger Capital Notes 4 if they are within the Challenger Capital Notes 4 Target Market and they have received personal advice from a qualified financial adviser.

ELIGIBLE

- You are a company or an individual over 18 years of age with a registered address in Australia;

AND EITHER

- You are an Institutional Investor;

OR

- You are a client of a Syndicate Broker who is either a Wholesale Client or a Retail Investor who has received personal advice from a qualified financial adviser concerning an investment in Challenger Capital Notes 4.

INELIGIBLE

- There will be no direct offer available for existing Challenger shareholders or other securityholders (including any Challenger Capital Notes 2 holders wishing to reinvest in Challenger Capital Notes 4) other than those who satisfy the eligibility criteria and apply through a Syndicate Broker.



The DDO Regime does not apply to Wholesale Clients.



If you have any questions about the Offer, Challenger Capital Notes 4 or the Challenger Capital Notes 4 Target Market, you should contact a Syndicate Broker or seek personal advice from a qualified financial adviser.

You can also visit www.challengercapitalnotes.com.au or call the Offer Information Line on 1800 780 782 (within Australia) or +61 3 9415 4065 (outside Australia), Monday to Friday 8:30am to 5:00pm (Sydney time).

Satisfactory evidence must be held by, or provided to, a Syndicate Broker that you are either a Wholesale Client or, if you are a retail investor, you have received personal advice from a qualified financial adviser in relation to the acquisition of Challenger Capital Notes 4. For further information on how to apply, see Section 7.4 “Applying for Challenger Capital Notes 4”.

Key dates

Key dates for the Offer	Date
Lodgement of the Original Prospectus with ASIC	7 March 2023
Bookbuild period commenced for the Syndicate Brokers to determine the Margin	7 March 2023
Announcement of the Margin and confirmation of Bookbuild allocations to the Syndicate Brokers	10 March 2023
Lodgement of this Prospectus with ASIC	15 March 2023
Opening Date for investors to apply for Challenger Capital Notes 4 allocated by the Syndicate Brokers under the Bookbuild	15 March 2023
Closing Date for investors to apply for Challenger Capital Notes 4 allocated by the Syndicate Brokers under the Bookbuild (5:00pm Sydney time)	30 March 2023
Issue Date of Challenger Capital Notes 4	5 April 2023
Challenger Capital Notes 4 commence trading on ASX (normal settlement basis)	6 April 2023
Holding Statements dispatched	11 April 2023

Key dates for Challenger Capital Notes 4	Date
First Distribution Payment Date ¹	25 August 2023
Optional Exchange Dates ²	25 May 2029 25 August 2029 25 November 2029 25 February 2030
Scheduled Mandatory Conversion Date ³	25 February 2032

Key dates for CCN2 Holders	Date
Record date for determining Eligible CCN2 Holders for the Reinvestment Offer (7:00pm Sydney time)	3 March 2023
Opening Date for the Reinvestment Offer	15 March 2023
Record date for the First CCN2 Pro Rata Distribution (7:00pm Sydney time)	28 March 2023
Closing Date for the Reinvestment Offer (5:00pm Sydney time)	30 March 2023
Payment date for the First CCN2 Pro Rata Distribution	5 April 2023
Transfer of Reinvestment CCN2 to CCN2 Nominated Purchaser	5 April 2023
Issue Date of Challenger Capital Notes 4 for the Reinvestment Offer	5 April 2023
Last day of trading in Challenger Capital Notes 2	10 May 2023
Record date for the Second CCN2 Pro Rata Distribution (7:00pm Sydney time)	12 May 2023
Payment date for the Second CCN2 Pro Rata Distribution	22 May 2023
Optional exchange date for remaining Challenger Capital Notes 2	22 May 2023

Dates may change

These dates are indicative only and may change without notice. Except as otherwise specified in the Terms, if any of these dates are not Business Days and an event under the Terms is stipulated to occur on that day, then the event will occur on the next Business Day.

Challenger and the Joint Lead Managers may at their discretion agree to vary the timetable, including extending any Closing Date, closing the Offer early without notice or accepting late Applications, whether generally or in particular cases, or withdrawing the Offer at any time before Challenger Capital Notes 4 are issued.

You are encouraged to apply as soon as possible after the Opening Date.

- ¹ Subject to the absolute discretion of Challenger to pay the Distribution and no Payment Condition existing on 25 August 2023.
- ² With APRA's prior written approval, Challenger may elect to Exchange the Challenger Capital Notes 4 on a Distribution Payment Date falling on or about 25 May 2029, 25 August 2029, 25 November 2029 and 25 February 2030. Holders should not expect that APRA's approval will be given for any optional Exchange.
- ³ Challenger Capital Notes 4 will Convert into Ordinary Shares on 25 February 2032 (subject to the Mandatory Conversion Conditions being satisfied and only if, prior to that date, Challenger Capital Notes 4 have not been Exchanged with APRA's prior written approval or Written-Off).



Section 1

Investment overview

1. Investment overview

This Section provides a summary of information that is key to making a decision as to whether to invest in Challenger Capital Notes 4. Challenger Capital Notes 4 are not policy liabilities of CLC, Challenger or any member of the Challenger Group and are not guaranteed by any government or other person. Further details are provided in other Sections of this Prospectus, which you should read in its entirety. If you do not fully understand how Challenger Capital Notes 4 work or the risks associated with them, you should not apply.

If you wish to apply for Challenger Capital Notes 4, you must contact a Syndicate Broker. All Applications must be submitted through a Syndicate Broker.

1.1 Key features of the Offer

Topic	Summary	Further information
Who is the issuer?	<ul style="list-style-type: none">The issuer is Challenger Limited (“Challenger”).Challenger is an ASX-listed non-operating holding company of an investment management group which manages \$99 billion in assets (as at 31 December 2022) and is Australia’s largest annuity provider as well as one of its largest active fund managers.	Section 4
What is the Offer?	<ul style="list-style-type: none">The Offer is for the issue of Challenger Capital Notes 4 to raise \$350 million, with the ability to raise more or less.	Section 7.1 and 7.5.2
What are Challenger Capital Notes 4?	<ul style="list-style-type: none">Challenger Capital Notes 4 have the following features:<ul style="list-style-type: none">fully paid – at \$100 per Challenger Capital Note 4;subordinated – to claims of Senior Creditors, and rank equally with other Relevant Perpetual Subordinated Instruments (see Section 2.6.4 for further information) and ahead of Ordinary Shares;convertible – in certain circumstances (including where a Non-Viability Trigger Event occurs), Challenger will be required to Convert Challenger Capital Notes 4 into Ordinary Shares and in certain circumstances Challenger may elect to Convert Challenger Capital Notes 4 into Ordinary Shares;redeemable and transferable – in certain circumstances, Challenger may be permitted to repay the Face Value of Challenger Capital Notes 4 or transfer Challenger Capital Notes 4 to a third party (but there are restrictions on repayment or transfer of the Challenger Capital Notes 4);perpetual – no fixed maturity date and could remain on issue indefinitely, in which case Holders may not get their investment capital back or be issued any Ordinary Shares;distributions – are discretionary, non-cumulative and are expected to be fully franked; andnot guaranteed or secured – are not guaranteed or secured, are not policy liabilities of any member of the Challenger Group and do not constitute protected accounts or deposit liabilities for the purposes of the Banking Act or protected policies under the Insurance Act.The Terms are complex and include features to comply with the detailed regulatory capital requirements which APRA applies to these securities. Challenger’s ability to pay Distributions or to optionally Exchange (Convert, Redeem or Resell) Challenger Capital Notes 4 is dependent on APRA either not objecting (in the case of payment of Distributions) or giving prior written approval (in the case of Exchange at Challenger’s option).	Section 2
Will Challenger Capital Notes 4 be quoted?	<ul style="list-style-type: none">Challenger has applied for Challenger Capital Notes 4 to be quoted on ASX so that they can be bought and sold on ASX.If ASX does not grant permission for Challenger Capital Notes 4 to be quoted, Challenger Capital Notes 4 will not be issued and all Application Payments will be refunded (without interest) as soon as practicable.Quotation of Challenger Capital Notes 4 on ASX does not mean that there will be a liquid market for Challenger Capital Notes 4.	Section 7.6.2

Topic	Summary	Further information
Why is Challenger issuing Challenger Capital Notes 4?	<ul style="list-style-type: none"> Challenger intends to use the proceeds of Challenger Capital Notes 4 to fund a subscription for Additional Tier 1 Capital of CLC, the registered life company of the Challenger Group. Challenger Capital Notes 4 will help refinance Challenger Capital Notes 2 through the Reinvestment Offer. The Challenger Capital Notes 4 and Challenger's equity capital help to protect creditors of the Challenger Group by providing a loss-absorbing capital buffer that may support losses incurred by the Challenger Group. The contribution of Additional Tier 1 Capital to CLC will assist with funding the regulatory capital requirements of CLC resulting from annuity sales growth and will similarly help protect CLC's creditors and policyholders. 	Sections 2.6.1, 2.6.3 and 2.6.4

1.2 Key features of Challenger Capital Notes 4

Topic	Summary	Further information
Do Challenger Capital Notes 4 have a maturity date?	<ul style="list-style-type: none"> Challenger Capital Notes 4 are perpetual, which means they do not have any fixed maturity date and could remain on issue indefinitely. However, Challenger has rights to Convert Challenger Capital Notes 4 to Ordinary Shares or to Redeem or Resell Challenger Capital Notes 4 for cash at least five years after the Issue Date (or on an earlier date in certain circumstances) subject to APRA's prior written approval. Otherwise, Challenger Capital Notes 4 will mandatorily Convert to Ordinary Shares on 25 February 2032 subject to certain conditions being satisfied. What will happen to Challenger Capital Notes 4 is uncertain and depends on a number of factors including whether Mandatory Conversion will occur, whether Challenger elects to Convert, Redeem or Resell Challenger Capital Notes 4, and whether APRA's approval to a Conversion, Redemption or Resale is given when required under the Terms. Holders should not expect that APRA will give its approval for any Conversion, Redemption or Resale. Holders will have no right to request Challenger to Convert Challenger Capital Notes 4 or Redeem or Resell them. 	Sections 2.2 to 2.5
What Distributions are payable?	<ul style="list-style-type: none"> Challenger Capital Notes 4 are expected to pay quarterly, floating rate, discretionary Distributions in arrears until Converted, Redeemed or Written-Off. The Distribution Rate is calculated in accordance with the following formula: Distribution Rate = (BBSW Rate + Margin) x (1 – Tax Rate) Where: <ul style="list-style-type: none"> BBSW Rate is the relevant rate (described in Section 2.1.3) on the first Business Day of the relevant Distribution Period, or such other rate set in accordance with the Terms where the BBSW Rate is not published by the relevant time on the day for publication or is affected by an obvious error, or where Challenger determines that a Rate Disruption Event has occurred; Margin is 3.60% per annum as determined under the Bookbuild; and Tax Rate means the Australian corporate tax rate applicable to Challenger's franking account at the relevant Distribution Payment Date. As at the date of this Prospectus, the Tax Rate is 30%. Payment of Distributions is subject to the absolute discretion of Challenger and subject to no Payment Condition existing in respect of the relevant Distribution Payment Date. This includes that APRA does not object to a Distribution being paid. Distributions are non-cumulative, which means that if a Distribution has not been paid on a Distribution Payment Date, then Challenger has no obligation to pay the Distribution at any later date. Holders will not have any right to compensation if Challenger does not pay Distributions. Failure to pay a Distribution when scheduled will not constitute an event of default. 	Section 2.1

Topic	Summary	Further information
	<ul style="list-style-type: none"> If a Distribution is not paid in full on a Distribution Payment Date, Challenger must not, without the approval of Holders by a Special Resolution, declare, determine to pay or pay a dividend on its Ordinary Shares, or buy back or reduce capital on any of its Ordinary Shares, until and including the next Distribution Payment Date. This restriction will not apply if the relevant Distribution is paid in full within three Business Days of the relevant Distribution Payment Date. 	
Will Distributions be franked?	<ul style="list-style-type: none"> Distributions are expected to be fully franked. However, Holders should be aware that franking is not guaranteed and the laws relating to the availability of franking may change. If a Distribution is not fully franked, it will be adjusted to reflect the applicable Franking Rate. The effect of Distributions being franked is to reduce the cash amount received by Holders on each Distribution Payment Date by an amount equal to the franking credit attached to the Distribution. The ability of Holders to use franking credits will depend on their individual tax position. Holders should also be aware that the potential value of any franking credits does not accrue at the same time as the receipt of any cash Distribution. Holders should refer to the Australian taxation summary in Section 8 and each Holder should obtain professional advice in relation to its tax position. 	Sections 2.1.4 and 2.1.5
Will Challenger Capital Notes 4 be Redeemed?	<ul style="list-style-type: none"> If certain conditions are met, Challenger will have a right, but not an obligation, to Redeem Challenger Capital Notes 4: <ul style="list-style-type: none"> on any Optional Exchange Date, which will be a date at least five years after the Issue Date; on the occurrence of a Tax Event (for example, this may include where a change in Australian tax law after the Issue Date results in a more than insignificant increase in the costs to Challenger in relation to Challenger Capital Notes 4); or on the occurrence of a Regulatory Event (for example, this may include where a change in Australian law or regulation after the Issue Date would impose additional requirements on Challenger in relation to Challenger Capital Notes 4 which the Directors determine would have a not insignificant impact on Challenger or if the proceeds of Challenger Capital Notes 4 may no longer be used to fund Additional Tier 1 Capital of CLC). Challenger can only Redeem Challenger Capital Notes 4 if it has received APRA's prior written approval, and APRA is satisfied with the projected capital position of Challenger and the Challenger Group. This may mean that Challenger must replace the Challenger Capital Notes 4 with an instrument considered by APRA to be of the same or better quality. This is intended to protect Challenger's Senior Creditors. Holders should not expect that APRA will give its approval for any Redemption. 	Section 2.3
Will Challenger Capital Notes 4 Convert to Ordinary Shares?	<ul style="list-style-type: none"> Challenger Capital Notes 4 will be Converted to Ordinary Shares automatically on the occurrence of certain events, or at Challenger's option in a number of circumstances. In each case, a Challenger Capital Note 4 will Convert to a number of Ordinary Shares calculated based on the VWAP at the time of Conversion, but subject always to a Maximum Conversion Number. Except in the case of a Non-Viability Trigger Event, Conversion is subject to certain conditions designed to prevent Conversion from occurring in circumstances where, due to the Maximum Conversion Number, Holders would receive a number of Ordinary Shares per Challenger Capital Note 4 worth substantially less than Face Value. Mandatory Conversion or Acquisition Event: All Challenger Capital Notes 4 must be Converted to Ordinary Shares on the Scheduled Mandatory Conversion Date (25 February 2032) or upon the occurrence of an Acquisition Event; however, Conversion cannot occur unless the Mandatory Conversion Conditions (or the equivalent tests for an Acquisition Event) are satisfied. Where these conditions are not satisfied, Conversion will be deferred until the next Distribution Payment Date where they are satisfied. Each Challenger Capital Note 4 which is the subject of a Conversion under these circumstances will be Converted to Ordinary Shares with a value of approximately \$101 based on the VWAP at the time of Conversion. 	Sections 2.2 to 2.5

- **Non-Viability Trigger Event:** Some or all Challenger Capital Notes 4 must be Converted to Ordinary Shares if APRA determines that a Non-Viability Trigger Event has occurred. Conversion under these circumstances is not subject to any conditions, and Holders are likely to receive a number of Ordinary Shares per Challenger Capital Note 4 which are worth substantially less than the Face Value.
- **Optional Exchange:** Challenger has the option, but not the obligation, to Convert, with APRA's prior written approval:
 - some or all (as Challenger may select) Challenger Capital Notes 4 to Ordinary Shares on any Optional Exchange Date (being a Distribution Payment Date falling on or about 25 May 2029, 25 August 2029, 25 November 2029 and 25 February 2030), or on the occurrence of a Tax Event or a Regulatory Event; and
 - all Challenger Capital Notes 4 to Ordinary Shares on the occurrence of a Potential Acquisition Event.

In each case Challenger is restricted from exercising its option to Convert if the Optional Conversion Restrictions apply. Each Challenger Capital Note 4 which is the subject of a Conversion under these circumstances will be Converted to Ordinary Shares with a value of approximately \$101 based on the VWAP at the time of Conversion.

Will Challenger Capital Notes 4 be Written-Off?

- Where Challenger is required to Convert some or all Challenger Capital Notes 4 to Ordinary Shares on account of a Non-Viability Trigger Event, but Conversion does not occur for any reason within five Business Days of APRA's determination, then those Challenger Capital Notes 4 will be Written-Off.
- If Challenger Capital Notes 4 are Written-Off, the relevant Holders' rights under the Challenger Capital Notes 4 (including to receive Distributions, payment of Face Value, or potential Conversion to Ordinary Shares) will be immediately terminated with effect on and from the date of the Non-Viability Trigger Event, and Holders will lose the entire amount of their investment in Challenger Capital Notes 4.


Section 2.4.6

1.3 Ranking of Challenger Capital Notes 4 in a winding-up of Challenger

In a winding-up of Challenger, if the Challenger Capital Notes 4 have not been Converted or Written-Off on account of a Non-Viability Trigger Event, the Challenger Capital Notes 4 will rank ahead of Ordinary Shares, equally with all other Relevant Perpetual Subordinated Instruments (including Challenger Capital Notes 2⁴ and Challenger Capital Notes 3), but behind any securities or instruments that rank in priority to Challenger Capital Notes 4 and all other creditors (present and future) of Challenger, as shown below.

The Relevant Perpetual Subordinated Instruments include the \$460 million Challenger Capital Notes 2 issued in April 2017 and the \$385 million Challenger Capital Notes 3 issued in November 2020. There are no other Relevant Perpetual Subordinated Instruments on issue as at the date of this Prospectus. The Challenger Capital Notes 4 will be Relevant Perpetual Subordinated Instruments if and when issued.

Challenger has a senior unsecured facility with an Australian bank having a limit of \$400 million. At the date of this Prospectus, this facility is undrawn. In a winding-up of Challenger, any money owing by Challenger under this facility would rank in priority to the Challenger Capital Notes 4.

	Type	Illustrative examples ⁵
	Preferred and secured debt	Liabilities in Australia in relation to protected accounts (generally, savings accounts and term deposits) and other liabilities mandatorily preferred by law, including policy or deposit liabilities, protected policies, employee entitlements and liabilities to secured creditors
	Unsubordinated and unsecured debt	Bonds and notes, trade and general creditors
	Subordinated and unsecured debt	Subordinated notes and other subordinated and unsecured debt obligations
	Relevant Perpetual Subordinated Instruments	Challenger Capital Notes 4, and any other securities expressed to rank equally with Challenger Capital Notes 4 (including Challenger Capital Notes 2 ⁶ and Challenger Capital Notes 3)
	Ordinary Shares	Ordinary Shares

Holders should be aware that if Challenger is in a winding-up, it is likely that a Non-Viability Trigger Event will have occurred. If a Non-Viability Trigger Event occurs, Challenger is required to Convert some or all Challenger Capital Notes 4 to Ordinary Shares. If Challenger Capital Notes 4 are Converted, Holders will hold Ordinary Shares and rank equally with other holders of Ordinary Shares in a winding-up of Challenger. If for any reason (including an Inability Event), a Conversion on account of a Non-Viability Trigger Event does not occur within five Business Days of the Non-Viability Conversion Date, those Challenger Capital Notes 4 will not Convert and instead will be Written-Off. If Challenger Capital Notes 4 are Written-Off, all rights in relation to those Challenger Capital Notes 4 will be terminated (and Holders will not get their investment capital back).

Challenger Capital Notes 4 are claims on Challenger, a non-operating holding company of the companies in the Challenger Group. Challenger Capital Notes 4 are not claims on any other member of the Challenger Group (including CLC). Challenger has claims on members of the Challenger Group, but its claims on each of those companies rank behind the relevant company's creditors and, in the case of CLC, also rank behind policyholders, in a winding-up of those companies. Challenger's right to receive dividends or other distributions from its subsidiaries may be restricted by regulation or by the terms of securities issued by those subsidiaries, including any regulatory capital securities.


4 On the date of the Original Prospectus, Challenger issued the CCN2 Exchange Notice in accordance with the CCN2 Terms confirming that on 5 April 2023 the CCN2 Nominated Purchaser will purchase all Reinvestment CCN2 for \$100 per Challenger Capital Note 2.

5 These examples note the order of ranking in the context of Challenger. Challenger is a non-operating holding company of companies in the Challenger Group and most of the claims Challenger has on these companies rank behind the relevant company's creditors, and in the case of CLC, also rank behind policyholders, and in the case of Challenger Bank, also rank behind deposit liabilities or protected accounts, in a winding-up of those companies.

6 Refer to footnote 4.

1.4 Summary of certain events that may affect what Holders receive and when they receive it

The diagram below summarises certain events that may affect what Holders are likely to receive on Challenger Capital Notes 4, and if and when they may receive it. The events are subject to contingencies such as legislative, prudential or taxation framework changes, a potential or actual takeover of Challenger, non-viability of Challenger (as determined by APRA) and in some cases election by Challenger upon occurrence of some of these events, or on specified dates. These events may never occur and the Challenger Capital Notes 4 could remain on issue indefinitely, in which case the Face Value will never be repaid.



The table below provides further summary details about events that may affect what Holders may receive in relation to Challenger Capital Notes 4 under the Terms.

Event	When? ⁷	Challenger Capital Notes 4 impacted	Is APRA approval required? ⁸	Do conditions apply?	What value will a Holder receive? ⁹	In what form will that value be provided to Holders?	Further information
Optional Redemption or Resale	On a Distribution Payment Date falling on or about 25 May 2029, 25 August 2029, 25 November 2029 and 25 February 2030 or following a Tax Event or Regulatory Event	All or some	Yes	Yes	\$100 per Challenger Capital Note 4	Cash	Section 2.3
Optional Conversion	On a Distribution Payment Date falling on or about 25 May 2029, 25 August 2029, 25 November 2029 and 25 February 2030 or following a Tax Event, Regulatory Event or Potential Acquisition Event	All or some	Yes	Yes	Approximately \$101 per Challenger Capital Note 4	Variable number of Ordinary Shares	Section 2.3
Mandatory Conversion on a specified date	On 25 February 2032 if the Mandatory Conversion Conditions are satisfied	All	No	Yes	Approximately \$101 per Challenger Capital Note 4	Variable number of Ordinary Shares	Section 2.2
Conversion upon Acquisition Event	On the Acquisition Conversion Date	All	No	Yes	Approximately \$101 per Challenger Capital Note 4	Variable number of Ordinary Shares	Section 2.5
Conversion or Write-Off upon Non-Viability Trigger Event	Immediately on Non-Viability Trigger Event occurring	Potentially all	No (although APRA will determine that a Non-Viability Trigger Event has occurred)	No	Between \$101 (and likely to be significantly less) and \$0 per Challenger Capital Note 4	Variable number (capped at a Maximum Conversion Number) of Ordinary Shares or, if Conversion does not occur for any reason, Challenger Capital Notes 4 are Written-Off ¹⁰	Section 2.4

7 In the case of Conversion, other than Conversion on account of a Non-Viability Trigger Event, if the relevant conversion conditions are not met, Conversion is deferred until the first Distribution Payment Date on which all the relevant Conversion conditions are satisfied.

8 Holders should not expect that APRA will give its approval if requested.

9 In the case of Conversion, the value stated is the value a Holder will receive on Conversion based on the price of Ordinary Shares during a specified period prior to Conversion called the VWAP Period (20 Business Days except in the case of a Non-Viability Trigger Event, where the VWAP Period is five Business Days). The price of Ordinary Shares on and after the date of Conversion may be higher or lower than this price. Conversion on account of a Non-Viability Trigger Event is not subject to any conditions and since the Conversion Number must not exceed the Maximum Conversion Number the value received is likely to be substantially less than \$101 per Challenger Capital Note 4.

10 If a Challenger Capital Note 4 is Written-Off, all rights (including rights to Distributions) in respect of that Challenger Capital Note 4 are terminated with effect on and from the date of the Non-Viability Trigger Event and the Holder will not be repaid the Face Value of the Challenger Capital Note 4.

1.5 Key risks associated with an investment in Challenger Capital Notes 4

Before applying for Challenger Capital Notes 4, you should consider whether Challenger Capital Notes 4 are a suitable investment for you. There are risks associated with an investment in Challenger Capital Notes 4 and in Challenger and in the life insurance, funds management and banking industries generally. Many of these risks are outside the control of Challenger and its Directors. These risks include those outlined below and in Section 6 and other matters referred to in this Prospectus.

Challenger Capital Notes 4 are not suitable for all investors and contain features which may make the Terms difficult to understand. The risks associated with Challenger Capital Notes 4 could result in the loss of your investment capital and associated income. The investment performance of Challenger Capital Notes 4 is not guaranteed by Challenger or any other person. If you are a Retail Investor and wish to participate in the Offer, you must seek professional advice as to whether you are within the Challenger Capital Notes 4 Target Market and if an investment in Challenger Capital Notes 4 is suitable for you in light of your particular investment objectives, financial situation and needs. You can only apply for Challenger Capital Notes 4 if you are within the Challenger Capital Notes 4 Target Market and you have received personal advice from a qualified financial adviser.

Topic	Summary	Further information
Not a policy or deposit liabilities	<ul style="list-style-type: none"> Challenger Capital Notes 4 are not policy liabilities of any member of the Challenger Group, do not constitute protected accounts or deposit liabilities for the purposes of the Banking Act or protected policies under the Insurance Act and are not guaranteed by any government or other person. The investment performance of Challenger Capital Notes 4 is not guaranteed by Challenger, any other member of the Challenger Group or any other person. 	Section 6.1.1
Challenger Capital Notes 4 are perpetual, unsecured and subordinated	<ul style="list-style-type: none"> Challenger Capital Notes 4 are perpetual with no maturity date but will Convert into Ordinary Shares on 25 February 2032 if they are still on issue on that date and if the Mandatory Conversion Conditions are satisfied. If the Mandatory Conversion Conditions are not satisfied, Challenger Capital Notes 4 may never be repaid, and may never be Converted into Ordinary Shares. Challenger is a non-operating holding company and substantially all its assets are made up of shares in, or other claims on, Challenger's subsidiaries. Accordingly, the claims of Holders against Challenger will be limited to the value of Challenger's residual claims to the net assets (if any) of the subsidiaries, after all liabilities, including to policyholders and depositors, have been discharged or provided for. In a winding-up of Challenger, if Challenger Capital Notes 4 have not been Redeemed, Converted or Written-Off, Challenger Capital Notes 4 will rank equally with all other Relevant Perpetual Subordinated Instruments, but behind all Senior Creditors of Challenger. If there is a shortfall of funds on a winding-up of Challenger to pay all amounts ranking higher than or equally with Challenger Capital Notes 4, Holders will lose all or some of their investment. If Challenger Capital Notes 4 have been Converted into Ordinary Shares on account of a Non-Viability Trigger Event prior to a winding-up of Challenger, the Ordinary Shares received on Conversion will rank equally with other Ordinary Shares. As such, a Holder's claim in a winding-up of Challenger will rank lower than it would have if the Challenger Capital Notes 4 had not been Converted. If Challenger Capital Notes 4 are Written-Off, those Challenger Capital Notes 4 will never be Exchanged and therefore the Holders will not get their investment capital back or receive compensation in respect of those Challenger Capital Notes 4. 	Sections 6.1.2 and 6.2.3
Market price of Challenger Capital Notes 4	<ul style="list-style-type: none"> The price at which Holders are able to sell Challenger Capital Notes 4 on ASX is uncertain. The market price may be below the Face Value of \$100 per Challenger Capital Note 4. Circumstances in which the price of Challenger Capital Notes 4 may decline include general financial market conditions, the availability of better rates of return on other securities, interest rates, investor perceptions and Challenger's financial performance or position. Unlike Ordinary Shares, Challenger Capital Notes 4 do not carry rights to variable amounts of distributions and capital which in each case may increase returns in the event of the improved financial performance or position of Challenger, and accordingly Challenger Capital Notes 4 do not provide a material exposure to growth in Challenger's business. 	Section 6.1.3
Liquidity of Challenger Capital Notes 4	<ul style="list-style-type: none"> There may be no liquid market for Challenger Capital Notes 4. Holders who wish to sell their Challenger Capital Notes 4 may be unable to do so at a price acceptable to them, or at all. 	Section 6.1.5

Topic	Summary	Further information
Market price and liquidity of Ordinary Shares	<ul style="list-style-type: none"> The market price of Ordinary Shares may go up or down due to various factors. These include investor perceptions, Australian and worldwide economic conditions and Challenger's financial performance and position. The market price may be affected by the actual or prospective Conversion of Challenger Capital Notes 4. Holders receiving Ordinary Shares on Conversion may not be able to sell those Ordinary Shares at the price on which the Conversion calculation was based, or at all. 	Section 6.1.6
Distributions may not be paid	<ul style="list-style-type: none"> Distributions are discretionary and are only payable subject to no Payment Condition existing in respect of the relevant Distribution Payment Date. Distributions are non-cumulative. Accordingly, in the event that Challenger does not pay a scheduled Distribution, a Holder has no entitlement to that Distribution. Non-payment of a Distribution is not an event of default. 	Section 6.1.7
Changes in Distribution Rate, Distributions and Franking Rate	<ul style="list-style-type: none"> The Distribution Rate will vary over time as a result of movements in the BBSW Rate. Changes in the Australian corporate tax rate will also affect the Distribution Rate. The Distribution Rate may be less than the Margin, or zero, depending on the levels of the BBSW Rate and the Tax Rate. The cash amount paid as a Distribution will change if there is a change in the Franking Rate. The effect of Distributions being franked is to reduce the cash amount received by Holders on each Distribution Payment Date by an amount equal to the franking credit attached to the Distribution. As at the date of this Prospectus, the Challenger Capital Notes 4 are expected to be fully franked. The Franking Rate for a Distribution Period will vary depending upon Challenger's level of available franking credits. The level of franking of Distributions is affected by the level of Challenger's available franking credits and distributable profits. Holders should be aware that the potential value of any franking credits does not accrue at the same time as the receipt of any cash Distribution. The value and availability of franking credits to a Holder will depend on that Holder's particular circumstances. 	Sections 6.1.8 and 6.1.9
It is not certain whether and when Challenger Capital Notes 4 may be Converted, Redeemed or Resold	<ul style="list-style-type: none"> There are a number of scenarios in which Challenger Capital Notes 4 may be Converted, Redeemed or Resold. It is uncertain whether and when a Conversion, Redemption or Resale may occur. The timing of any Conversion, Redemption or Resale may not suit Holders. Challenger Capital Notes 4 may not be Converted, Redeemed or Resold at all, in which case Challenger Capital Notes 4 are perpetual and have no maturity date. 	Sections 6.1.10 to 6.1.14
No right for Holders to request Exchange	<ul style="list-style-type: none"> Holders have no right to request that their Challenger Capital Notes 4 be Exchanged. Unless their Challenger Capital Notes 4 are Exchanged, in order to realise their investment, Holders would need to sell their Challenger Capital Notes 4 on ASX at the prevailing market price. That price may be less than the Face Value, and there may be no liquid market in the Challenger Capital Notes 4. The Terms contain no events of default. 	Section 6.1.10
Conversion or Write-Off following a Non-Viability Trigger Event	<ul style="list-style-type: none"> If Conversion occurs following a Non-Viability Trigger Event, Holders are likely to receive Ordinary Shares that are worth significantly less than the Face Value of Challenger Capital Notes 4. Where Conversion on account of a Non-Viability Trigger Event does not occur for any reason within five Business Days after the Non-Viability Conversion Date, Challenger Capital Notes 4 will be Written-Off. If Challenger Capital Notes 4 are Written-Off, all rights in relation to those Challenger Capital Notes 4 (including to Distributions) will be terminated and Holders will not get their investment capital back. 	Section 6.1.14
Challenger may issue further securities and engage in other dealings	<ul style="list-style-type: none"> Challenger may raise further debt or issue securities that rank equally with or ahead of Challenger Capital Notes 4 and may redeem, convert, buy back, return or distribute capital in respect of any share capital or other securities whether ranking behind, equally with or ahead of, Challenger Capital Notes 4. This may affect a Holder's ability to be repaid on a winding-up of Challenger. 	Section 6.1.17

Topic	Summary	Further information
Risks associated with Challenger generally	<ul style="list-style-type: none"> Challenger operates in a highly regulated and competitive industry and is subject to financial and non-financial risks that can adversely impact its businesses, results of operations, financial condition and future performance. Challenger's financial performance and position may affect the market price of Challenger Capital Notes 4 (and the Ordinary Shares into which they Convert). Key risks associated with an investment in Challenger and the business of the Challenger Group generally are set out at Section 6.2. 	Section 6.2

1.6 Comparison between Challenger Capital Notes 4 and other investments and securities

Challenger Capital Notes 4 are complex and are different from annuities, term deposits and ordinary shares. You should consider these differences in light of your investment objectives, financial situation and particular needs (including financial and taxation issues) before deciding to apply for Challenger Capital Notes 4 and if you are unsure if Challenger Capital Notes 4 are a suitable investment for you, you should seek personal advice from a qualified financial adviser.

Feature	Challenger Annuity	Term deposit	Challenger Capital Notes 2 ¹¹ and Challenger Capital Notes 3	Challenger Capital Notes 4	Ordinary Shares
Issuer	CLC	Bank (including Challenger Bank), credit union or building society	Challenger	Challenger	Challenger
Legal form	Policy (unsecured, unsubordinated debt obligation referable to a statutory fund under the Life Insurance Act)	Unsecured, unsubordinated debt	Unsecured, subordinated note	Unsecured, subordinated note	Ordinary share
Term	One year to lifetime (depending on the annuity)	One month to five years (usually)	Perpetual (subject to mandatory conversion into Ordinary Shares)	Perpetual (subject to Mandatory Conversion into Ordinary Shares)	Perpetual
Ranking in winding-up	Rank higher than Challenger Capital Notes 4 and Ordinary Shares	Rank higher than Challenger Capital Notes 4 and Ordinary Shares	Rank lower than senior creditors, equally with Challenger Capital Notes 4, but higher than Ordinary Shares ¹²	Rank lower than Senior Creditors, equally with Challenger Capital Notes 2 and Challenger Capital Notes 3 but higher than Ordinary Shares ¹²	Rank lowest of all securities
Transferability	No (but policies may be assigned subject to certain conditions)	No	Yes – Challenger Capital Notes 2 are quoted on ASX as "CGFPB" and Challenger Capital Notes 3 are quoted on ASX as "CGFPC"	Yes – Challenger Capital Notes 4 are expected to be quoted on ASX as "CGFPD"	Yes – Ordinary Shares are quoted on ASX as "CGF"
Protected under the Financial Claims Scheme	No	Yes ¹³	No	No	No

¹¹ Refer to footnote 4.

¹² Any return in a winding-up may be adversely affected if APRA determines that a Non-Viability Trigger Event has occurred. Following Conversion, Holders will hold Ordinary Shares and rank equally with other holders of Ordinary Shares in a winding-up of Challenger. If Conversion on account of a Non-Viability Trigger Event does not occur for any reason within five Business Days of the Non-Viability Conversion Date, Challenger Capital Notes 4 will be Written-Off.

¹³ The protection for all protected accounts that an account holder has with an Australian ADI is limited to \$250,000.

Feature	Challenger Annuity	Term deposit	Challenger Capital Notes 2 ¹¹ and Challenger Capital Notes 3	Challenger Capital Notes 4	Ordinary Shares
Distribution rate	Fixed or increasing by reference to the CPI or a fixed rate	Fixed (usually)	Challenger Capital Notes 2 – Floating (bank bill rate + margin of 4.40% per annum, adjusted for franking) Challenger Capital Notes 3 – Floating (bank bill rate + margin of 4.60% per annum, adjusted for franking)	Floating (BBSW Rate + Margin of 3.60% per annum, adjusted for franking)	Variable dividends
Distribution payment dates	Monthly, quarterly, semi-annually or annually	Monthly, quarterly, semi-annually or annually	Quarterly (distributions are discretionary)	Quarterly (Distributions are discretionary)	Semi-annually (dividends are discretionary)
Distributions cumulative / non-cumulative	Cumulative	Cumulative	Non-cumulative	Non-cumulative	Non-cumulative
Restriction on Ordinary Share dividends if distribution not paid	No	No	Yes, until the next distribution payment date	Yes, until the next Distribution Payment Date	No
Franking	Unfranked	Unfranked	Expected to be fully franked	Expected to be fully franked	Expected to be fully franked
Optional redemption (Challenger's option)	No	No	Yes. For Challenger Capital Notes 2, on 22 May 2023 and following a regulatory event or tax event For Challenger Capital Notes 3, on 25 May 2026 and following a regulatory event or tax event	Yes, on a Distribution Payment Date falling on or about 25 May 2029, 25 August 2029, 25 November 2029 and 25 February 2030 and following a Regulatory Event or Tax Event	No
Optional resale (obligation on Holder to sell instrument at Challenger's option)	No	No	Yes. For Challenger Capital Notes 2, on 22 May 2023 and following a regulatory event or tax event For Challenger Capital Notes 3, on 25 May 2026 and following a regulatory event or tax event	Yes, on a Distribution Payment Date falling on or about 25 May 2029, 25 August 2029, 25 November 2029 and 25 February 2030 and following a Regulatory Event or Tax Event	No

Feature	Challenger Annuity	Term deposit	Challenger Capital Notes 2 ¹¹ and Challenger Capital Notes 3	Challenger Capital Notes 4	Ordinary Shares
Optional conversion to Ordinary Shares (Challenger's option)	No	No	Yes. For Challenger Capital Notes 2, on 22 May 2023 and following a regulatory event, tax event or potential acquisition event For Challenger Capital Notes 3, on 25 May 2026 and following a regulatory event, tax event or potential acquisition event	Yes, on a Distribution Payment Date falling on or about 25 May 2029, 25 August 2029, 25 November 2029 and 25 February 2030 and following a Regulatory Event, Tax Event or Potential Acquisition Event	No
Mandatory conversion	No	No	Yes. For Challenger Capital Notes 2, on 22 May 2025 and each distribution payment date after this date, or at any time upon the occurrence of an acquisition event or a non-viability trigger event For Challenger Capital Notes 3, on 25 May 2028 and each distribution payment date after this date, or at any time upon the occurrence of an acquisition event or a non-viability trigger event	Yes, on 25 February 2032 and each Distribution Payment Date after this date, or at any time upon the occurrence of an Acquisition Event or a Non-Viability Trigger Event	No
Voting rights	No	No	No right to vote at general meetings of holders of Ordinary Shares	No right to vote at general meetings of holders of Ordinary Shares	Yes
Treated by APRA as regulatory capital?	No	No	No, but used to fund a subscription for Additional Tier 1 Capital of CLC	No, but may be used to fund a subscription for Additional Tier 1 Capital of CLC ¹⁴	Not currently ¹⁵

14 APRA has advised that it does not object to Challenger using the proceeds of Challenger Capital Notes 4 to fund a subscription for Additional Tier 1 Capital of CLC.


15 APRA has announced a roadmap for the review of the prudential framework that applies to Level 3 groups, such as Challenger. If APRA proceeds with the implementation of the capital related prudential standards for conglomerate groups, then Challenger's ordinary shares will be treated as regulatory capital.

1.7 Information about the Offer

Topic	Summary	Further information
How is the Offer structured and who can apply?	<ul style="list-style-type: none"> • The Offer comprises: <ul style="list-style-type: none"> – a New Money Offer made to eligible clients of the Syndicate Brokers and Institutional Investors wishing to make a new investment in Challenger Capital Notes 4; and – a Reinvestment Offer made to eligible clients of the Syndicate Brokers and Institutional Investors, who are Eligible CCN2 Holders wishing to reinvest some or all of their Challenger Capital Notes 2 in Challenger Capital Notes 4. • Applications (under both the New Money Offer and Reinvestment Offer) will only be accepted from investors who satisfy the eligibility requirements in accordance with the TMD. • Both components of the Offer require Applications to be made through a Syndicate Broker. As there is no general public offer or securityholder offer, no Applications can be made directly to Challenger. 	Section 7.1
Target Market Determination	<ul style="list-style-type: none"> • Challenger has made a target market determination for Challenger Capital Notes 4 in accordance with its obligations under the DDO Regime. • The TMD describes, among other things, the Challenger Capital Notes 4 Target Market. • The Challenger Capital Notes 4 Target Market is set out in Section 7.4.2 and a copy of the TMD is available at www.challengercapitalnotes.com.au. • The TMD describes, among other things, the class of Retail Investors that comprise the target market for Challenger Capital Notes 4 ("Challenger Capital Notes 4 Target Market") being Retail Investors who: <ul style="list-style-type: none"> – are seeking to acquire an investment product to generate income; – are able to bear the risks associated with an investment in Challenger Capital Notes 4 (which are summarised in Section 1.5 and detailed in Section 6, in particular, the lack of certainty as to payment of Distributions and potential loss of some or all of the investment capital in Challenger Capital Notes 4); – do not require certainty as to repayment of invested capital within a specific timeframe; and – seek the ability to dispose of Challenger Capital Notes 4 by sale on a licensed securities exchange, at the variable price available on the exchange. • If you are a Retail Investor and wish to participate in the Offer, you must seek professional advice as to whether you are within the Challenger Capital Notes 4 Target Market and if an investment in Challenger Capital Notes 4 is suitable for you in light of your particular investment objectives, financial situation and needs. • You can only apply for Challenger Capital Notes 4 if you are within the Challenger Capital Notes 4 Target Market and you have received personal advice from a qualified financial adviser. • If you have any questions about the Offer, Challenger Capital Notes 4, or the Challenger Capital Notes 4 Target Market, you should contact a Syndicate Broker or seek personal advice from a qualified financial adviser who is licensed by ASIC to give that advice. 	Section 7.4.2

Topic	Summary	Further information
Reinvestment Offer	<ul style="list-style-type: none"> The Reinvestment Offer provides Eligible CCN2 Holders with the opportunity to reinvest their CCN2 Resale Proceeds into Challenger Capital Notes 4 and maintain an ongoing investment in Challenger. On the date of the Original Prospectus, Challenger issued the CCN2 Exchange Notice in accordance with the CCN2 Terms. That notice confirms that on 5 April 2023 the CCN2 Nominated Purchaser will purchase all Reinvestment CCN2 for \$100 per Reinvestment CCN2 ("CCN2 Resale Proceeds"). To be eligible to participate in the Reinvestment Offer you must be registered as a holder of Challenger Capital Notes 2 at 7:00pm (Sydney time) on 3 March 2023 and you must still be the registered holder on 30 March 2023 at 5:00pm (Sydney time), which is the Closing Date for the Reinvestment Offer. In addition to this, to be eligible, unless Challenger determines otherwise, you must: <ul style="list-style-type: none"> be shown on the Challenger Capital Notes 2 register as having an address in Australia; not be an individual residing in a member state of the European Union; not be in the United States or acting as a nominee for, or for the account or benefit of, a U.S. Person, and not otherwise prevented from receiving the Reinvestment Offer or Challenger Capital Notes 4 under the laws of any jurisdiction; and be an Institutional Investor or a client of a Syndicate Broker who is either a Wholesale Client or a Retail Investor who has received personal advice from a qualified financial adviser concerning an investment in Challenger Capital Notes 4 (and who is otherwise within the Challenger Capital Notes 4 Target Market). The options available to Eligible CCN2 Holders are detailed in Section 3 "About the Reinvestment Offer". Before submitting an Application under the Reinvestment Offer, Eligible CCN2 Holders should read Section 3.2 which describes the differences between Challenger Capital Notes 2 and Challenger Capital Notes 4. In particular, Eligible CCN2 Holders should note that the margin applicable to Challenger Capital Notes 2 is 4.40% per annum, and the Margin for Challenger Capital Notes 4 is 3.60% per annum. There are differences between Challenger Capital Notes 2 and Challenger Capital Notes 4, and Challenger Capital Notes 4 may not suit your particular investment objectives, financial situation and needs. If you have any questions about the differences between Challenger Capital Notes 2 and Challenger Capital Notes 4, Challenger strongly recommends that you seek personal advice from a qualified financial adviser which takes into account your particular investment objectives, financial situation and needs before deciding whether to invest in Challenger Capital Notes 4. 	Section 3
When is the Offer Period?	<ul style="list-style-type: none"> The Offer is open from 15 March 2023 until the Closing Date on 30 March 2023. 	Key dates and Section 7
Is there a minimum amount to be raised?	<ul style="list-style-type: none"> No. The Offer is for the issue of Challenger Capital Notes 4 to raise \$350 million, with the ability to raise more or less. 	Section 7.1
How can I apply?	<ul style="list-style-type: none"> All Applications, including Applications from Eligible CCN2 Holders, must be submitted through a Syndicate Broker. A list of the appointed Joint Lead Managers and Co-Managers who are Syndicate Brokers to the Offer can be found on the front cover and in the Corporate Directory of this Prospectus. You should contact a Syndicate Broker to obtain more information on whether you meet the eligibility requirements. Your Syndicate Broker can also assist you with how to apply during the Offer Period. 	Section 7.4
How will Challenger Capital Notes 4 be allocated and how will I receive confirmation of my allocation?	<ul style="list-style-type: none"> Allocations will be determined by agreement of Challenger and the Joint Lead Managers. Challenger and the Joint Lead Managers reserve the right to scale back Applications. Allocations will be confirmed in accordance with Section 7.5.3. 	Sections 7.5.2 and 7.5.3

Topic	Summary	Further information
Is there a minimum Application size?	<p>New Money Offer</p> <ul style="list-style-type: none"> • Yes. • Your Application must be for a minimum of 50 Challenger Capital Notes 4 (\$5,000). <p>Reinvestment Offer</p> <ul style="list-style-type: none"> • There is no minimum number of Challenger Capital Notes 2 that you must hold to be able to participate in the Reinvestment Offer. • If you are an Eligible CCN2 Holder and own less than 50 Challenger Capital Notes 2, you can still apply to participate in the Reinvestment Offer but you must apply to reinvest the CCN2 Resale Proceeds relating to all of your Challenger Capital Notes 2. • If you are an Eligible CCN2 Holder and you own 50 or more Challenger Capital Notes 2, you must apply to reinvest the CCN2 Resale Proceeds relating to at least 50 of your Challenger Capital Notes 2. 	Section 7.4.1
Is brokerage, commission or stamp duty payable?	<ul style="list-style-type: none"> • No brokerage, commission or stamp duty is payable by you on your Application, provided that no person obtains, either alone or with associates, an interest of 90% or more in Challenger. In some circumstances, interests of persons who are not associates can be aggregated together in determining whether that threshold is met or exceeded. • You may be required to pay brokerage if you sell your Challenger Capital Notes 4 on ASX after Challenger Capital Notes 4 have been quoted on ASX. 	Section 7.4.3
What are the tax implications of investing in Challenger Capital Notes 4?	<ul style="list-style-type: none"> • A general description of the Australian taxation consequences of investing in Challenger Capital Notes 4 is set out in Section 8. • An outline of the Australian taxation consequences of participating in the Reinvestment Offer is also included in Section 8. 	Section 8
Where can I find more information about the Offer?	<ul style="list-style-type: none"> • If you have any questions in relation to the Offer, you should contact a Syndicate Broker or seek personal advice from a qualified financial adviser. Alternatively, you can visit www.challengercapitalnotes.com.au or call the Offer Information Line on 1800 780 782 (within Australia) or +61 3 9415 4065 (outside Australia) Monday to Friday 8:30am to 5:00pm (Sydney time). 	Section 7.7



Section 2

About Challenger Capital Notes 4

2. About Challenger Capital Notes 4

This Section is intended to provide information about the key features of Challenger Capital Notes 4. Where indicated, more detailed information is provided in other Sections of this Prospectus.

It is important that you read this Prospectus and the Terms in full before deciding whether to invest in Challenger Capital Notes 4. If you do not fully understand how Challenger Capital Notes 4 work or the risks associated with them or if you have any questions about the Offer, Challenger Capital Notes 4 or the Challenger Capital Notes 4 Target Market, you should contact a Syndicate Broker or a qualified financial adviser.

The full Terms are contained in Appendix A. Rights and liabilities attaching to Challenger Capital Notes 4 may also arise under the Corporations Act, the ASX Listing Rules and other applicable laws.

2.1 Distributions

Distributions on Challenger Capital Notes 4 are discretionary, non-cumulative, floating rate payments and are subject to no Payment Condition existing in respect of the relevant Distribution Payment Date.

Topic	Summary	Further information										
2.1.1 What are Distributions?	<ul style="list-style-type: none"> Distributions are discretionary, non-cumulative, floating rate payments and are scheduled to be paid quarterly in arrears on the Distribution Payment Dates. Distributions are subject to no Payment Condition existing in respect of the relevant Distribution Payment Date. Distributions are expected to be fully franked, and accordingly Holders are expected to receive Distributions comprised of a combination of cash and franking credits. Where any Distribution payment is not fully franked, then the cash amount of the Distribution will increase to compensate for the reduction in franking credits. Holders should be aware that the level of franking may vary over time and Distributions may be partially franked, fully franked or not franked at all. Holders should also be aware that the potential value of any franking credit does not accrue at the same time as the receipt of any Distribution and the ability of a Holder to use franking credits will depend on the individual tax position of each Holder. Distributions are non-cumulative. If a Distribution or part of a Distribution is not paid on a Distribution Payment Date, Holders will have no claim or entitlement in respect of non-payment and no right to receive that Distribution at a later time. Failure to pay a Distribution when scheduled will not constitute an event of default. 	Clause 3 of the Terms										
2.1.2 How will the Distribution Rate be calculated?	<ul style="list-style-type: none"> The Distribution Rate (expressed as a percentage per annum) for each quarterly Distribution will be calculated using the following formula: Distribution Rate = (BBSW Rate + Margin) x (1 – Tax Rate) Where: <ul style="list-style-type: none"> BBSW Rate is the relevant rate (as defined below in Section 2.1.3) on the first Business Day of the relevant Distribution Period; Margin is 3.60% per annum as determined under the Bookbuild; and Tax Rate means the Australian corporate tax rate applicable to Challenger's franking account at the relevant Distribution Payment Date. As at the date of this Prospectus, the Tax Rate is 30%. Below is a worked example of the Distribution Rate calculated using a BBSW Rate of 3.6400% per annum. Using a BBSW Rate of 3.6400% per annum As an example, assuming the BBSW Rate for a Distribution Period is 3.6400% per annum, the Margin is 3.6000% per annum, and the Tax Rate applicable to the franking account of Challenger is 30%, the Distribution Rate for that Distribution Period would be calculated as follows: <table border="1" style="width: 100%; margin-top: 10px;"> <tbody> <tr> <td>BBSW Rate</td> <td style="text-align: right;">3.6400% per annum</td> </tr> <tr> <td>plus Margin</td> <td style="text-align: right;">3.6000% per annum</td> </tr> <tr> <td>Equivalent unfranked distribution rate</td> <td style="text-align: right;">7.2400% per annum</td> </tr> <tr> <td>Multiplied by (1 – Tax Rate)</td> <td style="text-align: right;">x 70%</td> </tr> <tr> <td>Fully franked Distribution Rate =</td> <td style="text-align: right;">5.0680% per annum</td> </tr> </tbody> </table> 	BBSW Rate	3.6400% per annum	plus Margin	3.6000% per annum	Equivalent unfranked distribution rate	7.2400% per annum	Multiplied by (1 – Tax Rate)	x 70%	Fully franked Distribution Rate =	5.0680% per annum	Clause 3.1 of the Terms
BBSW Rate	3.6400% per annum											
plus Margin	3.6000% per annum											
Equivalent unfranked distribution rate	7.2400% per annum											
Multiplied by (1 – Tax Rate)	x 70%											
Fully franked Distribution Rate =	5.0680% per annum											

2.1.3 What is the BBSW Rate?

- The BBSW Rate in respect of a Distribution Period is the three month rate published through information vendors on the first Business Day of the relevant Distribution Period.
- The BBSW Rate is a benchmark floating interest rate for the Australian money market and is administered by ASX and expressed as a percentage per annum for a term of three months. It is the primary short-term interest rate benchmark used in the financial markets for the pricing and valuation of Australian dollar securities and as a lending reference rate. The BBSW Rate changes to reflect supply and demand in the cash and currency markets.
- Fallback procedures apply under the Terms if the BBSW Rate does not appear, if there is an obvious error in that rate or if that rate is otherwise subject to disruption (see further on this below).
- The graph below illustrates the movement in the BBSW Rate over the last 10 years. The rate on 10 March 2023 was 3.6400% per annum.

Clause 3.1 of the Terms

BBSW Rate (3 months) since March 2013



- The above graph is for illustrative purposes only and does not indicate, guarantee or forecast the actual BBSW Rate. The actual BBSW Rate for the first and any subsequent Distribution Periods may be higher or lower than the rates in the above graph.
- If the BBSW Rate is negative, the Distribution Rate will be reduced by taking account of the negative value of that rate in the calculation of the Distribution Rate as set out in Section 2.1.2 (but there is no obligation on Holders to pay Challenger if the Distribution Rate were to become negative).
- If Challenger determines that a Rate Disruption Event has occurred, then, subject to APRA's prior written approval (which may or not be given), Challenger will use as the BBSW Rate such Replacement Rate as it may determine and will make such adjustments to the Terms as it determines are reasonably necessary to calculate Distributions in accordance with such Replacement Rate. In making these determinations, Challenger is required to act in good faith and in a commercially reasonable manner, and may consult with such sources of market practice as it considers appropriate, but may otherwise make such determinations in its discretion.
- A "**Rate Disruption Event**" will occur if, in Challenger's opinion, the BBSW Rate has been discontinued or otherwise ceased to be calculated or administered, or is no longer generally accepted in the Australian market as a reference rate appropriate to floating rate debt securities of a tenor and interest period comparable to the Challenger Capital Notes 4.
- Any "**Replacement Rate**" would be the rate that is generally accepted in the Australian market as the successor to the BBSW Rate (or if Challenger is not able to ascertain such a rate, or there is no such rate, the rate would be a reference rate which is appropriate as a replacement for the BBSW Rate for securities such as the Challenger Capital Notes 4 or such other rate as Challenger considers appropriate as a replacement for the BBSW Rate having regard to comparable indices).

Topic	Summary	Further information												
2.1.4 How will the Distribution be calculated for each Distribution Period?	<ul style="list-style-type: none"> Distributions scheduled to be paid on each Distribution Payment Date will be calculated using the following formula: $\frac{\text{Distribution Rate} \times \\$100 \times N}{365}$ <p>Where:</p> <p>Distribution Rate means the rate (expressed as a percentage per annum) calculated as set out in Section 2.1.2; and</p> <p>N means the number of days in the Distribution Period calculated as set out in the Terms.</p> Following the formula above, if the Distribution Rate was 5.0680% per annum, then the Distribution on each Challenger Capital Note 4 for a Distribution Period (if the Distribution Period was 91 days) would be calculated as follows: <table border="0" data-bbox="453 636 1225 824"> <tr> <td>Fully franked Distribution Rate</td> <td>5.0680% per annum</td> </tr> <tr> <td>Multiplied by the Face Value</td> <td>x \$100.00</td> </tr> <tr> <td>Multiplied by the number of days in the Distribution Period</td> <td>x 91</td> </tr> <tr> <td>Divided by 365</td> <td>÷ 365</td> </tr> <tr> <td colspan="2"><hr/></td> </tr> <tr> <td>Fully franked cash Distribution payment per Challenger Capital Note 4 (rounded to nearest whole cent)</td> <td>\$1.26</td> </tr> </table> Distributions paid on Challenger Capital Notes 4 are expected to be fully franked, and accordingly Holders are expected to receive Distributions comprised of a combination of cash and franking credits. The effect of Distributions being franked is to reduce the cash amount received by Holders on each Distribution Payment Date by an amount equal to the franking credit attached to the Distribution. Where a Distribution is partially franked, the cash component of that Distribution will be calculated as set out in Section 2.1.5 below. The amount of franking credits will be notified to Holders shortly after a Distribution is paid. Following the above example, the amount of franking credits per Challenger Capital Note 4 would be \$0.54000000 (franking credit calculations will be rounded down to eight decimal places per \$100 Challenger Capital Note 4). The above example is for illustrative purposes only and does not indicate, guarantee or forecast the actual Distribution payment (or franking credits) for the first or any subsequent Distribution Period. Actual Distribution payments (and franking credits) may be higher or lower than this example (or may not be paid at all). 	Fully franked Distribution Rate	5.0680% per annum	Multiplied by the Face Value	x \$100.00	Multiplied by the number of days in the Distribution Period	x 91	Divided by 365	÷ 365	<hr/>		Fully franked cash Distribution payment per Challenger Capital Note 4 (rounded to nearest whole cent)	\$1.26	Clauses 3.1 and 3.2 of the Terms
Fully franked Distribution Rate	5.0680% per annum													
Multiplied by the Face Value	x \$100.00													
Multiplied by the number of days in the Distribution Period	x 91													
Divided by 365	÷ 365													
<hr/>														
Fully franked cash Distribution payment per Challenger Capital Note 4 (rounded to nearest whole cent)	\$1.26													
2.1.5 Will Distributions be franked? What is the effect of franking?	<ul style="list-style-type: none"> Distributions paid on Challenger Capital Notes 4 are expected to be fully franked. However, Holders should be aware that franking is not guaranteed. Holders are expected to receive Distributions comprised of a combination of cash and franking credits until Challenger Capital Notes 4 are Converted, Redeemed or Written-Off. The level of franking may vary over time and Distributions may be partially franked, fully franked or not franked at all. The level of franking of Distributions is affected by the level of Challenger's available franking credits and distributable profits. If any Distribution is not fully franked, then the Distribution will be adjusted to reflect the applicable Franking Rate (see clause 3.2 of the Terms). If any Distribution is not franked or only partially franked, the amount of the cash component of the Distribution which is being paid will be increased to compensate for the unfranked component according to the following formula: $\frac{D}{1 - [\text{Tax Rate} \times (1 - F)]}$ <p>Where:</p> <ul style="list-style-type: none"> D is the Distribution (as defined above in Section 2.1.4); and F is the applicable Franking Rate. 	Clauses 3.1 and 3.2 of the Terms												

- For example, if the Franking Rate applicable to the Distribution was only 50% (rather than 100%), then the cash Distribution on each Challenger Capital Note 4 for a Distribution Period (if the Distribution Period was 91 days) would be calculated as follows:

Fully franked Distribution Rate	5.0680% per annum
Multiplied by the Face Value	x \$100.00
Multiplied by the number of days in the Distribution Period	x 91
Divided by 365	÷ 365
Sub-total	\$1.2635
Divided by {1 – [Tax Rate x (1 – Franking Rate)]}	÷ 0.85
Partially franked cash Distribution payment per Challenger Capital Note 4 (rounded to nearest whole cent)	\$1.49

The above example is for illustrative purposes only and does not indicate, guarantee or forecast the actual Distribution payment (or franking credits) for the first or any subsequent Distribution Period. Actual Distribution payments (and franking credits) may be higher or lower than this example (or may not be paid at all).

- Holders should be aware that the potential value of any franking credits does not accrue at the same time as the receipt of any cash Distribution. Holders should also be aware that the ability to use the franking credits, either by offsetting a tax liability or by claiming a refund after the end of the income year, will depend on the individual tax position of each Holder.
- If the corporate tax rate were to change, the cash amount of Distributions and the amount of any franking credits will change.
- Holders should also be aware that the laws relating to the availability of franking may change.
- Holders should refer to the Australian taxation summary in Section 8 and each Holder should obtain professional advice in relation to its tax position.

2.1.6 When are the Distribution Payment Dates?

- The first Distribution Payment Date will be 25 August 2023.
- The number of days in the first Distribution Period will be 142 days.
- Distribution Payment Dates will be 25 February, 25 May, 25 August and 25 November in each year.
- If any of these dates is not a Business Day, then the Distribution Payment Date will be the next Business Day.

Clause 3.5 of the Terms

2.1.7 What are the Payment Conditions?

- Distributions may not always be paid. The payment of each Distribution is subject to the absolute discretion of Challenger and to no Payment Condition existing in respect of the relevant Distribution Payment Date.
- **“Payment Condition”** means:
 - the consolidated retained earnings of the Challenger Group as at the relevant Distribution Payment Date are, or would on payment of the Distribution become, negative;
 - the payment would result in Challenger becoming, or being likely to become, insolvent for the purposes of the Corporations Act; or
 - APRA objecting to the payment.

Clauses 3.3 and 18.2 of the Terms

2.1.8 What restrictions apply to Challenger if a Distribution is not paid?

- If for any reason a Distribution has not been paid on a Distribution Payment Date (**“Relevant Distribution Payment Date”**), Challenger must not, subject to certain exceptions, without the approval of a Special Resolution, until and including the next Distribution Payment Date:
 - declare, determine to pay or pay a dividend on any Ordinary Shares; or
 - buy back or reduce capital on any Ordinary Shares,
 unless the Distribution is paid in full within three Business Days of the Relevant Distribution Payment Date.
- The Terms contain no events of default and accordingly, failure to pay a Distribution when scheduled will not constitute an event of default.

Clause 3.8 of the Terms


Topic	Summary	Further information
2.1.9 How will Distributions be paid?	<ul style="list-style-type: none"> Distributions will be made to Holders whose details are recorded in the Register at the close of business on the relevant Record Date. Distributions and any other amount payable in respect of a Challenger Capital Note 4 may be paid in any manner in which cash may be paid as Challenger decides, including by any method of direct credit determined by Challenger. Where no account is specified by a Holder, or where Challenger attempts to pay the relevant amount and the transfer is unsuccessful, the amount Challenger attempted to pay will be held by Challenger for the Holder in a non-interest bearing deposit account with a bank selected by Challenger. The Terms include detailed provisions for the payment of Distributions - see clause 14 of the Terms. 	Clause 14 of the Terms
2.1.10 Are any deductions made on the Distributions?	<ul style="list-style-type: none"> Challenger may deduct from any Distribution or other amount payable in accordance with the Terms the amount of any withholding or other tax, duty or levy required by any applicable law to be deducted in respect of such amount, or on account of FATCA. Challenger is not required to pay an additional amount (or take any further action) where it has made a deduction as described above. 	Clauses 15.1, 15.2 and 15.3 of the Terms

2.2 Mandatory Conversion

Challenger must Convert any Challenger Capital Notes 4 that are outstanding on 25 February 2032 into Ordinary Shares, provided that the Mandatory Conversion Conditions (summarised below) are satisfied.

The Mandatory Conversion Conditions and the associated Conversion calculations (as set out below) are designed to ensure that Holders receive Ordinary Shares with a value of approximately \$101 per Challenger Capital Note 4, and that the Ordinary Shares they receive following Conversion may be sold on ASX.

Topic	Summary	Further information
2.2.1 What is Mandatory Conversion?	<ul style="list-style-type: none"> Holders will receive Ordinary Shares on Conversion of Challenger Capital Notes 4 on the Mandatory Conversion Date unless the Mandatory Conversion Conditions are not satisfied, or Challenger Capital Notes 4 are not outstanding on that date. Upon Conversion on the Mandatory Conversion Date, Holders will receive Ordinary Shares with a value of approximately \$101 per Challenger Capital Note 4 based on the VWAP (the volume weighted average price of Ordinary Shares) during a period of 20 Business Days on which trading in Ordinary Shares took place immediately preceding (but not including) the Mandatory Conversion Date. The VWAP that is used to calculate the number of Ordinary Shares that Holders receive will most likely differ from the Ordinary Share price on or after the Mandatory Conversion Date. This means that the value of Ordinary Shares received may be more or less than approximately \$101 when they are issued or at any time after that. 	Clauses 4.1 and 4.3 of the Terms
2.2.2 What are the consequences of Mandatory Conversion?	<ul style="list-style-type: none"> As a result of any Conversion of Challenger Capital Notes 4 to Ordinary Shares, Holders will hold Ordinary Shares in the capital of Challenger, which will rank equally with existing Ordinary Shares from the date of issue. The value of any holding of Ordinary Shares will fluctuate from time to time. For Challenger more broadly, the composition of its capital base will alter as a consequence of any Conversion and result in Challenger's equity capital increasing. 	Clauses 4 and 8.1 of the Terms
2.2.3 When is the Mandatory Conversion Date?	<ul style="list-style-type: none"> The Mandatory Conversion Date will be 25 February 2032, provided the Mandatory Conversion Conditions are satisfied on that date. If any of the Mandatory Conversion Conditions are not satisfied on that date, the Mandatory Conversion Date will be the next Distribution Payment Date on which they are satisfied. The Mandatory Conversion Conditions may never be satisfied and consequently, Mandatory Conversion may never occur. Distributions will continue to be paid (subject to Challenger in its discretion determining not to pay a Distribution and to no Payment Condition existing in respect of the relevant Distribution Payment Date) until Mandatory Conversion occurs. 	Clauses 4.2 and 4.3 of the Terms

Topic	Summary	Further information
<p>2.2.4 What are the Mandatory Conversion Conditions?</p>	<ul style="list-style-type: none"> The Mandatory Conversion Conditions are as follows: <ul style="list-style-type: none"> First Mandatory Conversion Condition: the VWAP of Ordinary Shares on the 25th Business Day immediately preceding (but not including) a possible Mandatory Conversion Date¹⁶ is greater than 110% x Relevant Fraction of the Issue Date VWAP; Second Mandatory Conversion Condition: the VWAP of Ordinary Shares during the period of 20 Business Days on which trading in Ordinary Shares took place immediately preceding (but not including) a possible Mandatory Conversion Date¹⁶ is greater than 101.01% x Relevant Fraction of the Issue Date VWAP; and Third Mandatory Conversion Condition: no Delisting Event applies in respect of a possible Mandatory Conversion Date. Broadly, a Delisting Event occurs when Challenger is delisted, or its Ordinary Shares have ceased to be quoted on ASX or have been suspended from trading for five consecutive Business Days prior to that date and suspension is continuing on the possible Mandatory Conversion Date, or it is prevented by any applicable law or order of any court or action of any government authority or any other reason from Converting Challenger Capital Notes 4. In the case of a Mandatory Conversion, the Relevant Fraction is 0.5¹⁷. This means that the Issue Date VWAP will be multiplied by 55% in the case of the First Mandatory Conversion Condition and 50.5050% in the case of the Second Mandatory Conversion Condition. The following diagram sets out the timeframes that are relevant for testing whether Conversion will occur, using the Scheduled Mandatory Conversion Date (25 February 2032) and a Relevant Fraction of 0.5. These dates are indicative only and may change.  <p>Note: In the diagram above, dates rest on the assumption that during the VWAP Period, trading takes place on each of the Business Days, which may not be the case if trading in Ordinary Shares is suspended during the period leading up to the possible Mandatory Conversion Date.</p>	<p>Clauses 4.3, 8.1 and 18.2 of the Terms</p>
<p>2.2.5 What is the purpose of the Mandatory Conversion Conditions?</p>	<ul style="list-style-type: none"> There is a limit on the number of Ordinary Shares that the Holder of a Challenger Capital Note 4 can be issued upon Conversion. This limit is the Maximum Conversion Number, described in Section 2.2.7 below. This limit arises from the prudential standards issued by APRA which govern the characteristics of instruments which may qualify as regulatory capital, and also from the equivalent criteria of rating agencies for such instruments. 	

16 If no trading in Ordinary Shares took place on that date, the VWAP is the VWAP on the first Business Day preceding that date on which trading in Ordinary Shares took place.

17 Please see Sections 2.3, 2.4 and 2.5 for descriptions of other circumstances in which Challenger Capital Notes 4 may be Converted into Ordinary Shares of Challenger and where the Relevant Fraction is 0.2.

- The purpose of the Mandatory Conversion Conditions is to prevent Mandatory Conversion from occurring in circumstances where a Holder would receive a number of Ordinary Shares having a value below the total Face Value of their Challenger Capital Notes 4 due to the limitation imposed by the Maximum Conversion Number, or in circumstances where the Ordinary Shares a Holder receives cannot be sold on ASX.
- The First Mandatory Conversion Condition and the Second Mandatory Conversion Condition are intended to help protect Holders against the risk of receiving a number of Ordinary Shares per Challenger Capital Note 4 limited to the Maximum Conversion Number, and hence having a value below approximately \$101 per Challenger Capital Note 4 (based on the VWAP during the 20 Business Days before the Mandatory Conversion Date).
- The Third Mandatory Conversion Condition is intended to protect Holders from the risk of receiving Ordinary Shares that cannot be sold on ASX, by making Conversion conditional on Ordinary Shares being quoted on ASX.
- If the Mandatory Conversion Conditions are not satisfied in relation to any potential Mandatory Conversion, it will be deferred until such time that those conditions are satisfied. If the Mandatory Conversion Conditions are never satisfied, Challenger Capital Notes 4 will never be Converted to Ordinary Shares (however, note that no such conditions apply to Non-Viability Conversion – please see Section 2.4).

2.2.6 How many Ordinary Shares will a Holder receive on the Mandatory Conversion Date?

- On the Mandatory Conversion Date, a Holder will receive a number of Ordinary Shares per Challenger Capital Note 4 ("**Conversion Number**") calculated in accordance with the following formula:

Clauses 4 and 8.1 of the Terms

$$\text{Conversion Number} = \frac{\text{Face Value}}{99\% \times \text{VWAP}}$$

subject always to the Conversion Number being no greater than the Maximum Conversion Number (see below in Section 2.2.7), where:

- **VWAP** broadly is the volume weighted average price of Ordinary Shares during the VWAP Period; and
- **VWAP Period** is the period of 20 Business Days on which trading in Ordinary Shares took place immediately preceding (but not including) the Mandatory Conversion Date.

Illustrative example of Mandatory Conversion

As an example, in the case of the Scheduled Mandatory Conversion Date on 25 February 2032, assuming the Issue Date VWAP was \$7.1500¹⁸, and using a Relevant Fraction of 0.5, determination of whether the Mandatory Conversion Conditions are satisfied and what number of shares will be received on Conversion would be calculated as follows:

Step 1: satisfying the Mandatory Conversion Conditions – worked example

The First Mandatory Conversion Condition

This condition requires that the VWAP on the 25th Business Day immediately preceding (but not including) 25 February 2032 (assuming there is trading in Ordinary Shares on that day) is greater than the First Test Date Percentage (being 110% x 0.5) of the Issue Date VWAP:

- The First Test Date Percentage is 55% (being 110% x 0.5).
- The First Test Date Percentage of the Issue Date VWAP would therefore be \$3.9325 (being 55% of \$7.1500).
- Assume that the VWAP on 20 January 2032 (being the 25th Business Day immediately preceding, but not including, 25 February 2032) is \$5.0000.
- Since the VWAP on 20 January 2032 (\$5.0000) is greater than the First Test Date Percentage of the Issue Date VWAP (\$3.9325), the First Mandatory Conversion Condition would be satisfied.

¹⁸ The Issue Date VWAP may be adjusted as described in Section 2.2.8.

The Second Mandatory Conversion Condition

This condition requires that the VWAP during the period of 20 Business Days on which trading in Ordinary Shares took place immediately preceding (but not including) 25 February 2032 is greater than the Conversion Test Date Percentage (being 101.01% x 0.5) of the Issue Date VWAP:

- The Conversion Test Date Percentage is 50.5050% (being 101.01% x 0.5).
- The Conversion Test Date Percentage of the Issue Date VWAP would be \$3.6111 (being 50.5050% of \$7.1500).
- Assume that the VWAP during the period from (and including) 28 January 2032 to (and including) 24 February 2032 (being the 20 Business Days in which trading in Ordinary Shares took place immediately preceding 25 February 2032) is \$5.5000.
- Since the VWAP from 28 January 2032 to 24 February 2032 (\$5.5000) is greater than the Conversion Test Date Percentage of the Issue Date VWAP (\$3.6111), the Second Mandatory Conversion Condition would be satisfied.

The Third Mandatory Conversion Condition

This condition requires that no Delisting Event applies on 25 February 2032, which means that on the Mandatory Conversion Date Challenger is listed on ASX, its Ordinary Shares are quoted on ASX and have not been suspended from trading for five consecutive Business Days prior to the Mandatory Conversion Date or on that date, and that Challenger is not prevented by any applicable law or order of any court or any action of any government authority or any other reason from Converting Challenger Capital Notes 4.

In these circumstances, the Third Mandatory Conversion Condition would be satisfied.

Step 2: calculating the number of shares to be received by Holders on Mandatory Conversion

On the Mandatory Conversion Date, Holders will be entitled to receive in respect of each Challenger Capital Note 4 the Conversion Number of Ordinary Shares determined as follows:

$$\text{Conversion Number} = \frac{\text{Face Value}}{99\% \times \text{VWAP}}$$

- The assumed VWAP from 28 January 2032 to 24 February 2032 (being the 20 Business Days on which trading in Ordinary Shares took place immediately preceding (but not including) 25 February 2032) is \$5.5000.
- The Face Value is \$100.
- The Conversion Number would be 18.3655 (being \$100 divided by (99% x \$5.5000)).
- Assuming a Holder has 100 Challenger Capital Notes 4, the Holder would be entitled to 1,836 Ordinary Shares (i.e. 100 x 18.3655)¹⁹.
- This example is for illustrative purposes only. The figures in it are not forward-looking statements and do not indicate, guarantee or forecast the Issue Date VWAP or future VWAP or other price of Ordinary Shares.

2.2.7 What is the Maximum Conversion Number?

- The Conversion Number (i.e. the number of Ordinary Shares a Holder will receive on Conversion per Challenger Capital Note 4) is subject always to a Maximum Conversion Number, which is calculated in accordance with the following formula:

Clause 8.1 of the Terms

$$\text{Maximum Conversion Number} = \frac{\text{Face Value}}{\text{Issue Date VWAP} \times \text{Relevant Fraction}}$$

where **Relevant Fraction** means 0.5 (in relation to a Mandatory Conversion).

- For example, if the Issue Date VWAP is \$7.1500, the Maximum Conversion Number would be 27.9720 (being the Face Value of \$100 divided by (\$7.1500 x 0.5)).
- In this example the Second Mandatory Conversion Condition has been satisfied and the Conversion Number is less than the Maximum Conversion Number. Where the Second Mandatory Conversion Condition (or any other Mandatory Conversion Condition) is not satisfied, Mandatory Conversion would not occur and would be deferred until the next Distribution Payment Date when all Mandatory Conversion Conditions were satisfied.

¹⁹ If the total number of Ordinary Shares to be issued in respect of a Holder's aggregate holding of Challenger Capital Notes 4 would include a fraction of an Ordinary Share, that fraction will be disregarded.

Topic	Summary	Further information
2.2.8 What adjustments to the Issue Date VWAP are made to account for changes to Challenger's capital?	<ul style="list-style-type: none"> The Issue Date VWAP, and consequently the Maximum Conversion Number, will be adjusted to reflect a consolidation, division or reclassification of Ordinary Shares and pro rata bonus issues as set out in the Terms (but not other transactions, including rights issues, which may affect the capital of Challenger). However, no adjustment will be made to the Issue Date VWAP where such adjustment (rounded if applicable) would be less than 1% of the Issue Date VWAP then in effect. 	Clauses 8.4 to 8.7 of the Terms
2.2.9 What will happen if the Mandatory Conversion Conditions are not satisfied on the Scheduled Mandatory Conversion Date?	<ul style="list-style-type: none"> If any of the Mandatory Conversion Conditions are not satisfied on 25 February 2032, Challenger Capital Notes 4 continue to be on issue and Conversion is deferred until the first Distribution Payment Date on which all of the Mandatory Conversion Conditions are satisfied. Challenger will give notice to the Holders and the Trustee that Conversion will not occur (or has not occurred) as a result of any of the Mandatory Conversion Conditions not being satisfied. The Mandatory Conversion Conditions may never be satisfied and consequently Mandatory Conversion may never occur. Distributions will continue to be paid (subject to Challenger in its discretion determining to pay a Distribution and to no Payment Condition existing in respect of the relevant Distribution Payment Date) until Mandatory Conversion occurs. 	Clauses 4.2 and 4.4 of the Terms

2.3 Optional Exchange by Challenger

Challenger may with APRA's prior written approval elect to Exchange all or some Challenger Capital Notes 4 on a Distribution Payment Date falling on or about 25 May 2029, 25 August 2029, 25 November 2029 and 25 February 2030 (each, an "Optional Exchange Date") or on the occurrence of certain events. Exchange means a Challenger Capital Note 4 is Converted into Ordinary Shares with a value of approximately \$101 (based on the VWAP over a specified period), or Redeemed or Resold for its Face Value (\$100).

For any such Redemption, Resale or Conversion to occur, certain conditions (summarised below) need to be satisfied and APRA's prior written approval is required. Holders should not expect that Challenger will exercise its option to Exchange Challenger Capital Notes 4, that any requirements for Exchange of Challenger Capital Notes 4 will be satisfied, or that APRA will give its approval to any Exchange of Challenger Capital Notes 4.

Topic	Summary	Further information
2.3.1 When may Challenger choose to Exchange?	<ul style="list-style-type: none"> Challenger may choose to Exchange: <ul style="list-style-type: none"> all or some Challenger Capital Notes 4 on any Optional Exchange Date; all or some Challenger Capital Notes 4 following the occurrence of a Tax Event or a Regulatory Event; or all Challenger Capital Notes 4 on an Exchange Date following the occurrence of a Potential Acquisition Event. In the case of an Exchange on any Optional Exchange Date, a Tax Event or a Regulatory Event, Exchange means: <ul style="list-style-type: none"> Challenger Converts Challenger Capital Notes 4 into a variable number of Ordinary Shares with a value (based on the VWAP during a period of 20 Business Days immediately preceding (but not including) the Exchange Date) of approximately \$101 per Challenger Capital Note 4; Challenger Redeems Challenger Capital Notes 4 for \$100 per Challenger Capital Note 4; or Challenger Resells Challenger Capital Notes 4 for \$100 per Challenger Capital Note 4. In the case of a Potential Acquisition Event, Exchange means only Conversion of Challenger Capital Notes 4 into a variable number of Ordinary Shares²⁰. Challenger's right to elect to Exchange is subject to APRA's prior written approval and is restricted in the circumstances described in Sections 2.3.4, 2.3.5, 2.3.6 and 2.3.7 below. Holders should not expect that APRA will give its approval for any Exchange. 	Clauses 6.1, 6.3, 6.4 and 18.2 of the Terms

²⁰ If Conversion occurs as a result of a Potential Acquisition Event, the period for calculating the VWAP will be the lesser of (i) 20 Business Days and (ii) the number of Business Days on which Ordinary Shares were traded between the occurrence of the Potential Acquisition Event and the Exchange Date.

Topic	Summary	Further information
2.3.2 When are the Optional Exchange Dates?	<ul style="list-style-type: none"> The Optional Exchange Dates are the Distribution Payment Dates falling on or about 25 May 2029, 25 August 2029, 25 November 2029 and 25 February 2030. 	Clause 18.2 of the Terms
2.3.3 What is a Tax Event, Regulatory Event or Potential Acquisition Event?	<ul style="list-style-type: none"> A summary of these events is as follows: <ul style="list-style-type: none"> Tax Event means broadly that the Directors receive advice that, as a result of a change in tax law or regulation in Australia on or after the Issue Date (which Challenger did not expect on the Issue Date), there is more than an insubstantial risk which Challenger determines in its discretion to be unacceptable that any Distribution would not be frankable or that Challenger would be exposed to a more than insignificant increase in its costs, charges and expenses in relation to Challenger Capital Notes 4; Regulatory Event means broadly that: <ul style="list-style-type: none"> the Directors receive legal advice that, as a result of a change in law or regulation on or after the Issue Date (which Challenger did not expect on the Issue Date), additional requirements would be imposed on Challenger in relation to Challenger Capital Notes 4, which the Directors determine would have a not insignificant adverse impact on it; or as a result of a change in law or regulation on or after the Issue Date (which Challenger did not expect on the Issue Date) or a statement received from APRA, the Directors determine that Challenger is not, or will not be, entitled to treat some or all Challenger Capital Notes 4 as a Relevant Perpetual Subordinated Instrument (as described in Section 2.6.4), except where this is because of a limit or other restriction on that treatment which is in effect on the Issue Date, or which Challenger expected on the Issue Date may come into effect; and Potential Acquisition Event means broadly that: <ul style="list-style-type: none"> a takeover bid is made to acquire Challenger's Ordinary Shares and the offer is, or becomes, unconditional and the bidder has a relevant interest in more than 50% of the Ordinary Shares on issue, or a majority of Directors recommend acceptance of the offer (without the need that all regulatory approvals necessary for the acquisition have been obtained); or a court orders the holding of meetings to approve a scheme of arrangement with respect to Challenger, which would result in a person having a relevant interest in more than 50% of the Ordinary Shares on issue after the scheme is implemented. 	Clause 18.2 of the Terms
2.3.4 What are the restrictions on Conversion being elected as the Exchange Method?	<ul style="list-style-type: none"> Challenger may not elect Conversion as the Exchange Method if, on the Non-Conversion Test Date (defined in Section 2.3.5 below), either of the Optional Conversion Restrictions apply. Further, if Challenger has elected Conversion as the Exchange Method and issued an Exchange Notice, Challenger may not proceed to Convert Challenger Capital Notes 4 if, on the Exchange Date, certain further Conversion restrictions apply (see Section 2.3.6 below). 	Clauses 6.5 and 6.6 of the Terms
2.3.5 What are the Optional Conversion Restrictions?	<ul style="list-style-type: none"> The Optional Conversion Restrictions are: <ul style="list-style-type: none"> First Optional Conversion Restriction: the VWAP on the Non-Conversion Test Date is less than or equal to 22% of the Issue Date VWAP; and Second Optional Conversion Restriction: a Delisting Event applies on the Non-Conversion Test Date. The Non-Conversion Test Date is the second Business Day before the date on which Challenger intends to send an Exchange Notice advising Holders that it wishes to Convert Challenger Capital Notes 4 (or, if trading in Ordinary Shares did not occur on that date, the last Business Day prior to that date on which trading in Ordinary Shares occurred). 	Clause 6.5 of the Terms

Topic	Summary	Further information
2.3.6 What are the further restrictions on Conversion on the Exchange Date?	<ul style="list-style-type: none"> • The further Conversion restrictions on the Exchange Date are that either the Second Mandatory Conversion Condition or the Third Mandatory Conversion Condition would not be satisfied in respect of the Exchange Date. • In determining whether the Second Mandatory Conversion Condition is satisfied in this case, the Relevant Fraction used is 0.2, i.e. the condition will be satisfied if the VWAP is greater than 20.2020% of the Issue Date VWAP. • Challenger will notify Holders if the further Conversion restrictions on the Exchange Date apply, and the Conversion will be deferred until the first Distribution Payment Date on which all of the Mandatory Conversion Conditions would be satisfied as if that Distribution Payment Date were a “Relevant Date” for the purpose of the Mandatory Conversion Conditions (unless Challenger Capital Notes 4 are otherwise Exchanged in accordance with the Terms). 	Clause 6.6 of the Terms
2.3.7 When can Redemption or Resale be selected as the Exchange Method?	<ul style="list-style-type: none"> • Challenger may only elect Redemption or Resale as the Exchange Method: <ul style="list-style-type: none"> – on any Optional Exchange Date (being a Distribution Payment Date falling on or about 25 May 2029, 25 August 2029, 25 November 2029 and 25 February 2030); or – in the case of a Tax Event or Regulatory Event; and provided in all cases where Challenger elects Redemption that APRA is satisfied that either: <ul style="list-style-type: none"> – Challenger Capital Notes 4 which are the subject of the Redemption are replaced concurrently or beforehand with a Relevant Perpetual Subordinated Instrument of the same or better quality or Ordinary Shares and the replacement of Challenger Capital Notes 4 is done under conditions that are sustainable for Challenger’s income capacity; or – having regard to the projected capital position of Challenger and the Challenger Group, Challenger does not have to replace Challenger Capital Notes 4 the subject of the Redemption. 	Clause 6.4 of the Terms
2.3.8 What is a Resale?	<ul style="list-style-type: none"> • Resale is a process by which Challenger may select one or more third parties in its absolute discretion (“Nominated Purchaser(s)”) to purchase some or all Challenger Capital Notes 4 from Holders (on such terms as may be agreed between Challenger and the Nominated Purchaser(s)). The terms of appointment may include terms: <ul style="list-style-type: none"> – as to the conditions of any Resale, the procedures for settlement of such Resale and the circumstances in which the Exchange Notice in respect of such Resale may be amended, modified, added to or restated; – as to the substitution of another entity as Nominated Purchaser (in accordance with the Terms); or – on which any Challenger Capital Notes 4 acquired by a Nominated Purchaser may be Redeemed, Converted or otherwise dealt with. • To the extent any of the terms on which the Nominated Purchaser(s) is appointed causes APRA to object to Challenger using, or having used, the proceeds of the Challenger Capital Notes 4 to fund Additional Tier 1 Capital of CLC then the prior written approval of APRA is required before the Nominated Purchaser is appointed on those terms. • If Challenger appoints more than one Nominated Purchaser, some or all Challenger Capital Notes 4 may be purchased by any one or any combination of Nominated Purchasers, as determined by Challenger, for the Resale Price. 	Clauses 10.1 and 10.2 of the Terms
2.3.9 What will I receive if my Challenger Capital Notes 4 are Resold?	<ul style="list-style-type: none"> • If a Challenger Capital Note 4 is Resold, the Holder of that Challenger Capital Note 4 will receive the Resale Price (being \$100 per Challenger Capital Note 4). The Resale Price is equivalent to the Face Value. 	Clause 18.2 of the Terms
2.3.10 When can a Resale occur?	<ul style="list-style-type: none"> • A Resale can occur on any Optional Exchange Date or following a Tax Event or a Regulatory Event. 	Clause 6.1 of the Terms

Topic	Summary	Further information
2.3.11 Are there any requirements in relation to the identity of Nominated Purchaser(s) that Challenger can appoint?	<ul style="list-style-type: none"> Challenger may not appoint a person as a Nominated Purchaser unless that person: <ul style="list-style-type: none"> has undertaken to acquire Challenger Capital Notes 4 from each Holder for the Resale Price on the terms and conditions that Challenger reasonably determines for the benefit of each Holder; has a long-term counterparty credit rating from one of S&P Global Ratings, Moody's Investors Service, Inc. or Fitch Ratings Ltd. of not less than investment grade; and is not a Related Entity of Challenger. 	Clause 10.3 of the Terms
2.3.12 What if a Nominated Purchaser does not pay the Resale Price?	<ul style="list-style-type: none"> If a Nominated Purchaser does not pay the Resale Price on the Exchange Date when due, the Resale to that Nominated Purchaser will not occur and Holders will continue to hold Challenger Capital Notes 4 in accordance with the Terms until Challenger Capital Notes 4 are otherwise Converted, Redeemed or Resold. 	Clause 10.6 of the Terms
2.3.13 Can Holders request Exchange?	<ul style="list-style-type: none"> Holdings do not have a right to request Exchange. 	Clauses 6 and 11.2(e)(i) of the Terms

2.4 Non-Viability Conversion

Challenger Capital Notes 4 have certain loss absorption features, which will be triggered if APRA determines that Challenger is or may become "non-viable". APRA has not provided specific guidance as to how it would determine non-viability (however, in the context of regulatory capital instruments issued by ADIs, APRA has indicated that non-viability is likely to arise prior to the insolvency of an ADI). It would be expected to include, but may not be limited to, serious impairment of Challenger's financial position. A determination by APRA of non-viability of Challenger may result in Conversion or Write-Off of Challenger Capital Notes 4. These features are required to be included in the Terms for prudential regulatory purposes.

Topic	Summary	Further information
2.4.1 Why do the Terms include a Non-Viability Trigger Event?	<ul style="list-style-type: none"> A Non-Viability Trigger Event is a regulatory requirement for Challenger Capital Notes 4 to be treated by APRA as described in Section 2.6. 	
2.4.2 What is a Non-Viability Trigger Event?	<ul style="list-style-type: none"> A Non-Viability Trigger Event occurs when: <ul style="list-style-type: none"> APRA issues a notice to Challenger that the conversion to Ordinary Shares or write-off of Relevant Perpetual Subordinated Instruments is necessary because, without it, APRA considers that Challenger would become non-viable; or APRA notifies Challenger that it has determined that, without a public sector injection of capital (or equivalent support) Challenger would become non-viable. If a Non-Viability Trigger Event occurs, Challenger must convert to Ordinary Shares or write-off: <ul style="list-style-type: none"> all Relevant Perpetual Subordinated Instruments; or where the first paragraph above applies, such amount of the Relevant Perpetual Subordinated Instruments which is required to enable APRA to conclude that Challenger is viable without further conversion or write-off. <p>Where APRA considers Challenger would become non-viable without a public sector injection of capital or equivalent support, all Relevant Perpetual Subordinated Instruments must be converted or written-off.</p> As Challenger Capital Notes 4 are Relevant Perpetual Subordinated Instruments, if a Non-Viability Trigger Event occurs, Challenger must immediately Convert some or all Challenger Capital Notes 4 to Ordinary Shares. If Conversion on account of a Non-Viability Trigger Event does not occur for any reason within five Business Days of the Non-Viability Conversion Date, those Challenger Capital Notes 4 which are required to be Converted will be Written-Off. 	Clauses 5.1, 5.2, 8.13 and 18.2 of the Terms

Topic	Summary	Further information
2.4.3 What does non-viable mean?	<ul style="list-style-type: none"> Where Challenger is required to convert or write-off some (but not all) Relevant Perpetual Subordinated Instruments, Challenger must endeavour to treat Holders of Challenger Capital Notes 4 and holders of other Relevant Perpetual Subordinated Instruments on an approximately proportionate basis (with some exceptions). As at the date of this Prospectus there are only two other Relevant Perpetual Subordinated Instruments on issue, being Challenger Capital Notes 2 (\$460 million issued in April 2017)²¹ and Challenger Capital Notes 3 (\$385 million issued in November 2020). For the meaning of Relevant Perpetual Subordinated Instrument, please see Section 2.6.4. <hr/> <ul style="list-style-type: none"> APRA has not provided specific guidance as to how it would determine non-viability (however, in the context of regulatory capital instruments issued by ADIs, APRA has indicated non-viability is likely to arise prior to the insolvency of an ADI). Non-viability would be expected to include serious impairment of Challenger's financial position and insolvency. However, it is possible that APRA's definition of non-viable may not necessarily be confined to solvency measures or capital ratios. Challenger intends to use the proceeds from the issue of Challenger Capital Notes 4 to fund a subscription for Additional Tier 1 Capital of CLC. CLC represents a substantial part of the business of the Challenger Group. If APRA determines that CLC would become non-viable then there is a significant risk it will also determine Challenger to be non-viable. APRA may publish further guidance on the parameters used to determine non-viability. However, it is possible that APRA will not provide further guidance, and Challenger has no control over whether or not it will do so. 	
2.4.4 When would Conversion on account of a Non-Viability Trigger Event occur?	<ul style="list-style-type: none"> If a Non-Viability Trigger Event occurs, Challenger must on that date (whether or not that day is a Business Day), immediately and irrevocably, Convert some or all Challenger Capital Notes 4 into Ordinary Shares. Conversion on the occurrence of a Non-Viability Trigger Event is not subject to any Mandatory Conversion Condition being satisfied. Conversion is immediate and from the Non-Viability Conversion Date, Challenger will treat Holders as having been issued the Conversion Number of Ordinary Shares for each Challenger Capital Note 4 they hold (noting that the Conversion Number is subject to a Maximum Conversion Number – see Section 2.4.5 below). Challenger expects any ASX trades in Challenger Capital Notes 4 that have not settled on the date a Non-Viability Trigger Event occurs will continue to settle in accordance with the normal ASX T+2 settlement, although Challenger expects the seller will be treated as having delivered, and the buyer will be treated as having acquired, the Conversion Number of Ordinary Shares for each Challenger Capital Note 4 which has been Converted as a result of the occurrence of the Non-Viability Trigger Event. Further, Challenger must make such decisions with respect to the identity of Holders whose Challenger Capital Notes 4 will Convert at the Non-Viability Conversion Date as may be necessary or desirable to ensure Conversion occurs in an orderly manner, including disregarding any transfers of Challenger Capital Notes 4 that have not been settled or registered at that time. Challenger must give Holders and the Trustee notice as soon as practicable that Conversion on account of a Non-Viability Trigger Event has occurred. The notice must state the Non-Viability Conversion Date and details of the amount of Challenger Capital Notes 4 Converted. 	Clause 5 of the Terms

²¹ Refer to footnote 4.

Topic	Summary	Further information
2.4.5 How many Ordinary Shares will Holders receive on the Non-Viability Conversion Date?	<ul style="list-style-type: none"> The number of Ordinary Shares a Holder will receive per Challenger Capital Note 4 on account of a Non-Viability Conversion is the Conversion Number (calculated as described below). The Conversion Number must not be greater than the Maximum Conversion Number. Since there are no conditions to a Non-Viability Conversion, the number of Ordinary Shares a Holder is likely to receive per Challenger Capital Note 4 on account of a Non-Viability Conversion may be worth significantly less than the Face Value of a Challenger Capital Note 4, and a Holder may suffer loss as a consequence. The Conversion Number which will apply on the occurrence of a Non-Viability Trigger Event is calculated in accordance with the following formula, subject always to the Conversion Number being no greater than the Maximum Conversion Number: $\text{Conversion Number} = \frac{\text{Face Value}}{99\% \times \text{VWAP}}$ <p>where VWAP broadly is the volume weighted average price of Ordinary Shares during the period of five Business Days on which trading in Ordinary Shares took place immediately preceding (but not including) the Non-Viability Conversion Date. The Maximum Conversion Number is calculated as:</p> $\text{Maximum Conversion Number} = \frac{\text{Face Value}}{\text{Issue Date VWAP} \times \text{Relevant Fraction}}$ <p>In the case of a Non-Viability Trigger Event, the Relevant Fraction is 0.2.</p> <p>Illustrative example of Non-Viability Conversion</p> <p>Step 1: calculating the potential number of shares to be received on Non-Viability Conversion</p> <p>Assume that on 24 September 2027 (as an example), a Non-Viability Trigger Event occurs. Holders would be potentially entitled to receive, in respect of each Challenger Capital Note 4 being Converted, the Conversion Number of Ordinary Shares determined as follows:</p> $\text{Conversion Number} = \frac{\text{Face Value}}{99\% \times \text{VWAP}}$ <ul style="list-style-type: none"> Assume the VWAP from (and including) 17 September 2027 to (and including) 23 September 2027 (being the five Business Days on which trading in Ordinary Shares took place immediately preceding 24 September 2027) is \$0.5000. The Face Value is \$100. The Conversion Number would be 202.0202 (being \$100 divided by (99% x \$0.5000)), subject to this number not being greater than the Maximum Conversion Number. <p>Step 2: calculating the maximum number of shares to be received on Non-Viability Conversion</p> <p>The Maximum Conversion Number is determined as:</p> $\text{Maximum Conversion Number} = \frac{\text{Face Value}}{\text{Issue Date VWAP} \times \text{Relevant Fraction}}$ <p>Assuming the Issue Date VWAP is \$7.1500, the Maximum Conversion Number would be 69.9301 (being \$100 divided by (\$7.1500 x 0.2)).</p>	Clauses 5, 8.1 and 18.2 of the Terms

Step 3: calculating the number of shares to be received on Non-Viability Conversion

Since the Conversion Number of 202.0202 is greater than the Maximum Conversion Number of 69.9301, the Conversion Number is equal to 69.9301, and the number of Ordinary Shares which the Holder of 100 Challenger Capital Notes 4 would receive would be limited to 6,993.

The market value of the Ordinary Shares received by the Holder of 100 Challenger Capital Notes 4 (based on the VWAP assumed in this example) is \$3,496.50 which is considerably less than \$10,000.00 (the nominal value of 100 Challenger Capital Notes 4 of \$100 each)²².

- The Maximum Conversion Number is described in Section 2.2.7 (as that number may be adjusted as described in Section 2.2.8).
- Additionally, if on the occurrence of a Non-Viability Trigger Event only some, but not all, Challenger Capital Notes 4 and other Relevant Perpetual Subordinated Instruments are required to be Converted, Challenger:
 - must endeavour to treat Holders and holders of other Relevant Perpetual Subordinated Instruments on an approximately proportionate basis, but may discriminate to take account of the effect on marketable parcels, other logistical considerations and the need to effect conversion immediately; and
 - where Relevant Perpetual Subordinated Instruments are not all in the same currency, Challenger may treat them as if converted into a single currency of Challenger's choice at such rate of exchange as Challenger considers reasonable (but may make adjustments among Holders and holders of other Relevant Perpetual Subordinated Instruments having regard to the need to effect Conversion immediately).

2.4.6 What happens if Challenger Capital Notes 4 cannot be Converted on the Non-Viability Conversion Date?

- If for any reason (including, without limitation, an Inability Event) Conversion of any Challenger Capital Notes 4 on account of a Non-Viability Trigger Event does not occur within five Business Days of the Non-Viability Conversion Date, then Conversion of those Challenger Capital Notes 4 will not occur and Holders' rights (including to Distributions and payment of Face Value in relation to those Challenger Capital Notes 4, and potential Conversion to Ordinary Shares), are immediately and irrevocably Written-Off and terminated (with effect on and from the Non-Viability Conversion Date). This means that Holders will lose all of the value of their investment in the Challenger Capital Notes 4 without compensation.
- An **Inability Event** means that Challenger is prevented by applicable law or order of any court or action of any government authority (including regarding insolvency, winding-up or external administration) or any other reason from Converting the Challenger Capital Notes 4. The laws under which an Inability Event may arise, and the grounds on which a court or government authority may make orders preventing the Conversion of Challenger Capital Notes 4 (or other reasons which prevent Conversion), may change.
- The law gives statutory recognition to the conversion and write-off provisions in regulatory capital instruments (such as Challenger Capital Notes 4), subject to limited exceptions.
- Challenger may (but is not required to) seek legal advice as to whether an Inability Event has occurred and is subsisting, and an Inability Event is taken to subsist if Challenger receives legal advice to that effect.

Clauses 5.3, 8.13 and 18.2 of the Terms

²² The price at which Ordinary Shares may be sold may differ from the VWAP. The Ordinary Shares may not be listed or may not be able to be sold at prices representing their value based on the VWAP calculation or at all.

2.5 Conversion on an Acquisition Event

Challenger is also required to Convert Challenger Capital Notes 4 into Ordinary Shares where Challenger is acquired by way of a takeover bid or scheme of arrangement which meets certain requirements (described below).

There are conditions to Conversion in these circumstances, which are designed to ensure that Holders receive Ordinary Shares with a value of approximately \$101 for each Challenger Capital Note 4 they hold, and that the Ordinary Shares received may be sold on ASX.

These conditions may never be satisfied and accordingly Challenger Capital Notes 4 may never Convert into Ordinary Shares.

Topic	Summary	Further information
2.5.1 What is an Acquisition Event?	<ul style="list-style-type: none"> • An Acquisition Event means: <ul style="list-style-type: none"> (a) either: <ul style="list-style-type: none"> (i) a takeover bid is made to acquire all or some Ordinary Shares and the offer is, or becomes, unconditional and: <ul style="list-style-type: none"> (A) the bidder has a relevant interest in more than 50% of the Ordinary Shares on issue; or (B) a majority of the Directors recommend acceptance of the offer; or (ii) a court approves a scheme of arrangement which, when implemented, would result in a person other than Challenger having a relevant interest in more than 50% of Ordinary Shares; and (b) all regulatory approvals necessary for the acquisition to occur have been obtained. • There may be ways in which control of Challenger or its business operations change, including as a result of regulatory intervention, which do not amount to an Acquisition Event. See Section 6.1.13 for further information. 	Clause 18.2 of the Terms
2.5.2 What must Challenger do on the occurrence of an Acquisition Event?	<ul style="list-style-type: none"> • If an Acquisition Event occurs, subject to the conditions described in Sections 2.5.3 and 2.5.4 below being satisfied, Challenger must give Holders an "Acquisition Conversion Notice" and, on the Acquisition Conversion Date, Convert all Challenger Capital Notes 4 into a number of Ordinary Shares with a value of approximately \$101 per Challenger Capital Note 4 (based on the VWAP during a period of 20 Business Days (or, if less, the number of Business Days on which trading in Ordinary Shares took place and on which Ordinary Shares were quoted for trading on ASX) immediately before (but not including) the Business Day before the Acquisition Conversion Date). 	Clauses 7.2, 8.1 and 18.2 of the Terms
2.5.3 Are there circumstances where Challenger is not required to give an Acquisition Conversion Notice?	<ul style="list-style-type: none"> • Challenger is not required to give an Acquisition Conversion Notice and Convert the Challenger Capital Notes 4 if either of the Optional Conversion Restrictions would apply (as if the Acquisition Conversion Notice were an "Exchange Notice" for the purpose of the Optional Conversion Conditions). 	Clauses 6.5 and 7.4 of the Terms
2.5.4 Are there cases where Challenger is not required to Convert the Challenger Capital Notes 4 following an Acquisition Event?	<ul style="list-style-type: none"> • If Challenger has given an Acquisition Conversion Notice, but either the Second Mandatory Conversion Condition or the Third Mandatory Conversion Condition would not be satisfied on the Acquisition Conversion Date, Conversion will not occur. • In determining whether the Second Mandatory Conversion Condition is satisfied in this case, the Relevant Fraction used is 0.2, i.e. the condition will be satisfied if the VWAP is greater than 20.2020% of the Issue Date VWAP. 	Clauses 4.3 and 7.5 of the Terms
2.5.5 What happens if Conversion does not occur?	<ul style="list-style-type: none"> • If Challenger is not required to give an Acquisition Conversion Notice because either of the Optional Conversion Restrictions apply, or Conversion has not occurred because the Second Mandatory Conversion Condition or the Third Mandatory Conversion Condition would not be satisfied, then Challenger will notify Holders that Conversion will not (or did not) occur (a "Deferred Acquisition Conversion Notice"). • Challenger must then (provided the Optional Conversion Restrictions would not apply) give a new Acquisition Conversion Notice providing for Conversion to occur on the next Distribution Payment Date (provided such date is at least 25 Business Days after the date of the Deferred Acquisition Conversion Notice). Conversion will not occur if the Second Mandatory Conversion Condition or the Third Mandatory Conversion Condition would not be satisfied on that date. This process will be repeated until Conversion occurs or an alternative arrangement is made (see Section 2.5.6 below). 	Clauses 7.4 and 7.5 of the Terms

Topic	Summary	Further information
2.5.6 What other obligations does Challenger have in connection with a takeover or scheme of arrangement?	<ul style="list-style-type: none"> On the occurrence of a recommended takeover or scheme of arrangement which would result in an Acquisition Event, if the Directors consider that Challenger will not be permitted to Exchange Challenger Capital Notes 4, or the Second Mandatory Conversion Condition or Third Mandatory Conversion Condition will not be satisfied, the Directors will use all reasonable endeavours to procure that equivalent takeover offers are made to Holders, or that Holders are entitled to participate in the scheme of arrangement or a similar transaction. 	Clause 12 of the Terms

2.6 Ranking and regulatory treatment of Challenger Capital Notes 4

In relation to payments in a winding-up of Challenger and payments of Distributions, Challenger Capital Notes 4 will rank ahead of Ordinary Shares, equally with all other Relevant Perpetual Subordinated Instruments (which include Challenger Capital Notes 2 and Challenger Capital Notes 3), and behind the claims of all Senior Creditors.

Challenger Capital Notes 4 will not constitute Additional Tier 1 Capital or any other form of regulatory capital of Challenger. APRA has advised that it does not object to Challenger using the proceeds of Challenger Capital Notes 4 to fund a subscription for Additional Tier 1 Capital of CLC.

Topic	Summary	Further information
2.6.1 How do Challenger Capital Notes 4 rank in relation to other Challenger instruments?	<ul style="list-style-type: none"> In a winding-up of Challenger, Challenger Capital Notes 4 will rank, for payment of Face Value (being \$100 per Challenger Capital Note 4) and for payment of Distributions, ahead of Ordinary Shares, equally with all other Relevant Perpetual Subordinated Instruments (including Challenger Capital Notes 2 and Challenger Capital Notes 3), but behind all Senior Creditors of Challenger. However, any return in a winding-up may be adversely affected if a Non-Viability Trigger Event occurs because all or some Challenger Capital Notes 4 will be required to be Converted or, if Conversion does not occur for any reason within five Business Days of the Non-Viability Trigger Event, Written-Off (see Sections 1.3 and 2.4 for further information). 	Clauses 2.1, 5, 16.2 and 18.2 of the Terms
2.6.2 Who is APRA?	<ul style="list-style-type: none"> APRA is an independent statutory authority that supervises institutions across banking, insurance and superannuation industries and is accountable to the Australian Parliament. Prudential regulation is concerned with maintaining the safety and soundness of financial institutions, so that the community can have confidence that those institutions will meet their financial commitments under all reasonable circumstances. APRA's purpose is to ensure Australians' financial interests are protected and that the financial system is stable, competitive and efficient. APRA's website at www.apra.gov.au includes further details of its functions and prudential standards. 	
2.6.3 What is regulatory capital?	<ul style="list-style-type: none"> Any business requires capital to support its income generating activities in its chosen industry. APRA's regulatory capital prudential standards aim to ensure that regulated institutions including life insurers, ADIs, general insurers and regulated registrable superannuation entities maintain adequate capital to support the risks associated with their activities and can withstand unexpected losses. APRA has detailed guidelines and restrictions on the types of capital instruments that are permitted to form the capital base of the institutions it regulates. The types of capital deemed eligible for inclusion in the capital base of a regulated institution are referred to as regulatory capital. APRA classifies regulatory capital of life insurers into two tiers for its supervisory purposes – referred to as Tier 1 Capital and Tier 2 Capital. Tier 1 Capital is higher quality capital than Tier 2 Capital and is comprised of: <ul style="list-style-type: none"> Common Equity Tier 1 Capital; and Additional Tier 1 Capital. Tier 2 Capital is comprised of capital instruments with loss-absorption characteristics required for prudential capital instruments that do not satisfy the criteria for Tier 1 Capital. 	

Topic	Summary	Further information
	<ul style="list-style-type: none"> The Challenger Group is subject to APRA's non-capital related prudential standards for the supervision of conglomerate groups (known as a "Level 3 group"). APRA has published draft capital-related prudential standards applicable to Level 3 groups (such as the Challenger Group) but in 2017 APRA announced that it had deferred their implementation until a number of domestic and international policy initiatives were further progressed. On 24 October 2022, APRA further announced a new roadmap for the review of the prudential framework that applies to Level 3 groups. The aim of the review is to ensure that the Level 3 group prudential framework is fit for purpose to cater to an increasing array of new groups, and consistently applied to existing structures to ensure a level playing field. The multi-year review of the Level 3 group prudential framework will be conducted in 2023 and 2024, with revised prudential standards expected to be effective from 2025. 	

2.6.4 What is the regulatory treatment of Challenger Capital Notes 4?	<ul style="list-style-type: none"> APRA has advised that: <ul style="list-style-type: none"> it does not object to Challenger using the proceeds of Challenger Capital Notes 4 to fund a subscription for Additional Tier 1 Capital of CLC; and Challenger Capital Notes 4 will not constitute Additional Tier 1 Capital or any other form of regulatory capital of Challenger. An instrument (such as Challenger Capital Notes 4) which: <ul style="list-style-type: none"> is capable of being converted into Ordinary Shares of Challenger or written-off where APRA makes a determination of non-viability; and has been confirmed in writing by APRA to Challenger as constituting, as at the date of its issue, an instrument the proceeds of which APRA does not object to the Challenger Group using to fund a subscription for Additional Tier 1 Capital of CLC, <p>is referred to in this Prospectus and the Terms as a "Relevant Perpetual Subordinated Instrument".</p> Challenger Capital Notes 2, Challenger Capital Notes 3 and Challenger Capital Notes 4 are each Relevant Perpetual Subordinated Instruments and this concept is relevant to determining what happens on the occurrence of a Non-Viability Trigger Event (see Section 2.4.2 for further information). Changes to the law in 2018 have given statutory recognition to the conversion and write-off provisions in regulatory capital instruments (such as the Challenger Capital Notes 2, Challenger Capital Notes 3 and Challenger Capital Notes 4), subject to limited exceptions. If APRA's treatment of Challenger Capital Notes 4 as a Relevant Perpetual Subordinated Instrument changes, a Regulatory Event (as described in Section 2.3.3) may occur and Challenger may have an option to Exchange Challenger Capital Notes 4. 	
--	--	--

2.7 Other

Topic	Summary	Further information
2.7.1 Can Challenger issue further Challenger Capital Notes 4, or other instruments?	<ul style="list-style-type: none"> Challenger may, without the consent of any Holder, issue any securities ranking equally with Challenger Capital Notes 4 (on the same terms or otherwise) or ranking in priority or junior to Challenger Capital Notes 4, or incur or guarantee any indebtedness upon such terms as it may think fit in its sole discretion. Challenger Capital Notes 4 confer no rights on a Holder to subscribe for new securities in Challenger or to participate in any bonus issues of shares in Challenger's capital. Challenger may also redeem, convert, buy back, return or distribute capital in respect of any share capital or other securities whether ranking behind, equally with or ahead of Challenger Capital Notes 4. 	Clauses 1.8 and 17.9 of the Terms
2.7.2 What voting rights do Challenger Capital Notes 4 carry?	<ul style="list-style-type: none"> Holders have no voting rights at meetings of holders of shares in Challenger. Holders may vote at meetings for Holders in accordance with the Trust Deed. Ordinary Shares issued on Conversion would have all the usual rights conferred by Ordinary Shares. 	Clause 1.8 of the Terms

Topic	Summary	Further information
2.7.3 Can Challenger amend the Terms and Trust Deed?	<ul style="list-style-type: none"> • Challenger may amend the Terms and Trust Deed without the approval of Holders in certain circumstances, with the approval of the Trustee. This may include amendments: <ul style="list-style-type: none"> – of a formal, minor or technical nature; – made to cure any ambiguity or correct any manifest error; – necessary or expedient for the purpose of enabling Challenger Capital Notes 4 to be listed for quotation, or to retain quotation, on ASX (or any other securities exchange) or their offering for sale; – necessary to comply with the provisions of any statute, the requirements of any statutory authority or the ASX Listing Rules (or the listing or quotation requirements of any securities exchange); – to dates or time periods stated, required or permitted in connection with a Mandatory Conversion, Non-Viability Conversion or Exchange; – to the Terms to align with the terms of any Relevant Perpetual Subordinated Instruments after the Issue Date; or – that are not materially prejudicial to the interests of Holders as a whole. • Challenger may also, with the Trustee’s approval (and APRA’s prior written approval where required), amend the Terms and Trust Deed if the amendment has been approved by a Holder Resolution. Certain types of amendments require the approval of Holders by a Special Resolution. • APRA’s prior written approval to amend the Terms and Trust Deed is required where the amendment may cause APRA to object to Challenger using, or having used, the proceeds of the issue of Challenger Capital Notes 4 to fund Additional Tier 1 Capital of CLC. 	Clauses 17.4 to 17.6 of the Terms
2.7.4 Issues of Ordinary Shares to a Nominee	<ul style="list-style-type: none"> • In certain circumstances Challenger will issue the Ordinary Shares which a Holder is obliged to accept on Conversion to a nominee appointed by the Issuer (“Nominee”). • Ordinary Shares will be issued to a Nominee: <ul style="list-style-type: none"> – where the Holder does not wish to receive Ordinary Shares as a result of Conversion and notifies Challenger of this at any time on or after the Issue Date and no less than 15 Business Days prior to the Conversion Date; – where the Holder is a Foreign Holder, unless Challenger is satisfied that the laws of the Foreign Holder’s country of residence permit the issue of Ordinary Shares to the Foreign Holder (subject to certain conditions); or – to the extent that a FATCA Withholding is required to be made in respect of Ordinary Shares. • Challenger will treat a Holder as a Foreign Holder if the Holder’s address in the Register is a place outside of Australia or Challenger otherwise believes the Holder may not be a resident of Australia. • Any such Nominee: <ul style="list-style-type: none"> – must not be Challenger or a member of the Challenger Group or a Related Entity of Challenger; and – will sell those Ordinary Shares and pay a cash amount equal to the net proceeds to the relevant Holder. • The issue of Ordinary Shares to the Nominee satisfies Challenger’s obligations in connection with the Conversion and Challenger and the Nominee do not owe any duty in relation to the price or terms on which the Ordinary Shares are sold and have no liability for any loss suffered as a result of such sale. 	Clauses 8.10, 8.11 and 18.2 of the Terms
2.7.5 What are the taxation implications of investing in Challenger Capital Notes 4?	<ul style="list-style-type: none"> • The taxation implications of investing in Challenger Capital Notes 4 will depend on an investor’s individual circumstances. Prospective investors should obtain their own taxation advice. • A general outline of the Australian taxation implications for certain investors of participating in the Offer (including through the Reinvestment Offer) is included in the Australian taxation summary in Section 8. 	Section 8

Topic	Summary	Further information
2.7.6 Trustee and Trust Deed	<ul style="list-style-type: none"> Challenger has appointed Equity Trustees Limited as Trustee for Holders, as required by Chapter 2L of the Corporations Act. The Trustee holds certain rights in relation to Challenger Capital Notes 4 on trust for Holders under the Trust Deed. In certain circumstances, the Trustee will act on behalf of Holders. The Trustee holds on trust for Holders the right to enforce any obligations of Challenger under the Terms and the Trust Deed. The Trustee will be entitled to take any action against Challenger to enforce any obligations of Challenger, subject to the Terms and the Trust Deed. A Holder is entitled to proceed directly against Challenger to enforce a right or remedy in respect of a Challenger Capital Note 4 or under the Trust Deed only in limited circumstances. A copy of the Trust Deed can be obtained from www.challengercapitalnotes.com.au. 	Section 9.12 and the Trust Deed
2.7.7 Notices	<ul style="list-style-type: none"> Where Challenger Capital Notes 4 are quoted on ASX, all notices by Challenger to Holders may be given by publication to ASX. The Terms also permit notices to be given by newspaper advertisement, post or by email or electronic message (if any). Notices to Challenger, the Trustee and the Registry must be in writing and may be sent by electronic message, post or may be left at the offices of Challenger, the Trustee or the Registry at the applicable address set out in the Corporate Directory at the end of this Prospectus. 	Clause 18 of the Trust Deed
2.7.8 Payments to bank accounts	<ul style="list-style-type: none"> Subject to the Terms and applicable law, payments will be made to the person shown as the Holder in the Register at the Relevant Time on the Record Date (in the case of Distributions) or on the applicable date for payment (in the case of the Redemption Price). See clause 14 of the Terms for further detail relating to payments in respect of Challenger Capital Notes 4. 	Clause 14 of the Terms
2.7.9 Time limit on claims	<ul style="list-style-type: none"> Holders should be aware that a claim against Challenger for a payment in respect of a Challenger Capital Note 4 is void unless made within 10 years (in the case of the Redemption Price) or five years (in the case of Distributions and other amounts) from the date on which the payment first became due. 	Clause 14.8 of the Terms
2.7.10 Determination and calculation final	<ul style="list-style-type: none"> Except where there is fraud or a manifest error, any determination or calculation which Challenger makes in accordance with the Terms (including with respect to the calculation of payments under a Challenger Capital Note 4) is final and binds Challenger, the Registry and each Holder. 	Clause 14.9 of the Terms
2.7.11 No set-off	<ul style="list-style-type: none"> A Holder does not have any right to set-off any amounts owing to it by Challenger in connection with the Challenger Capital Notes 4 against any amount owing by it to Challenger in connection with the Challenger Capital Notes 4 or otherwise. Subject to clause 15 of the Terms relating to withholding tax and FATCA, Challenger does not have any right to set-off any amounts owing to it by a Holder against any amount owing by it to the Holder in connection with the Challenger Capital Notes 4. 	Clauses 15 and 16.5 of the Terms
2.7.12 Power of attorney	<ul style="list-style-type: none"> Each Holder appoints each of the Issuer, its officers and any External Administrator of the Issuer (each an “Attorney”) severally to be the attorney of the Holder with power in the name and on behalf of the Holder to sign all documents and transfers and do any other thing as may in the Attorney’s opinion be necessary or desirable to be done in order for the Holder to observe or perform the Holder’s obligations under the Terms including, but not limited to, effecting any Conversion, Redemption or Resale or making any entry in the Register or the register of any Ordinary Shares. 	Clause 11.1 of the Terms



Section 3

About the Reinvestment Offer

3. About the Reinvestment Offer

This Section is intended to provide information about the Reinvestment Offer for Eligible CCN2 Holders. Detailed information about Challenger Capital Notes 4 and Challenger is provided in this Prospectus and it is important that you read this Prospectus, the Terms, Deed Poll and Constitution in full before deciding to participate in the Reinvestment Offer and invest in Challenger Capital Notes 4.

If you have any questions about the Reinvestment Offer, you should seek advice from your financial adviser or other professional adviser. You can also call the Offer Information Line on 1800 780 782 (within Australia) or +61 3 9415 4065 (outside Australia) Monday to Friday 8:00am to 5:00pm (Sydney time) during the Offer Period.

3.1 Overview of the Reinvestment Offer

Topic	Summary
3.1.1 What are Challenger Capital Notes 2?	<ul style="list-style-type: none">Challenger Capital Notes 2 are fully paid, perpetual, subordinated, unsecured convertible notes issued by Challenger in April 2017. Challenger Capital Notes 2 trade on ASX under the code "CGFPB".
3.1.2 What is happening to Challenger Capital Notes 2?	<ul style="list-style-type: none">Challenger Capital Notes 2 that are allocated under the Reinvestment Offer will be purchased by the CCN2 Nominated Purchaser on 5 April 2023. All other Challenger Capital Notes 2 will remain quoted on ASX and will continue trading until 10 May 2023.On the date of the Original Prospectus, Challenger issued the CCN2 Exchange Notice in accordance with the CCN2 Terms, confirming that on 5 April 2023, the CCN2 Nominated Purchaser will purchase all Reinvestment CCN2 for \$100 per Challenger Capital Note 2 ("CCN2 Resale Proceeds").The CCN2 Exchange Notice is irrevocable, except as provided by the CCN2 Terms. The CCN2 Resale may not occur for a number of reasons, including if a non-viability trigger event occurs, the CCN2 Nominated Purchaser does not for any reason pay the CCN2 Resale Proceeds in full on 5 April 2023, APRA revokes its approval of the CCN2 Resale or the Challenger Capital Notes 2 cannot be transferred for any reason. If the CCN2 Resale does not occur, except where a non-viability trigger event occurs in respect of Challenger Capital Notes 2, Eligible CCN2 Holders who are participating in the Reinvestment Offer will continue to hold their Challenger Capital Notes 2.Challenger intends to redeem all outstanding Challenger Capital Notes 2 for \$100 per Challenger Capital Note 2 on their optional exchange date of 22 May 2023, in accordance with the CCN2 Terms. While Challenger has obtained APRA's approval to redeem Challenger Capital Notes 2, it does not imply that Challenger's other outstanding capital instruments with call dates (including, when issued, Challenger Capital Notes 4) will be redeemed and any such redemption will be in accordance with the relevant capital instrument's terms and conditions and subject to APRA's approval, which may or may not be given.
3.1.3 What is the Reinvestment Offer?	<ul style="list-style-type: none">The Reinvestment Offer is an invitation to Eligible CCN2 Holders to:<ul style="list-style-type: none">apply to Challenger to have the CCN2 Resale Proceeds relating to all or some of their Challenger Capital Notes 2 reinvested in the Challenger Capital Notes 4; anddirect the CCN2 Nominated Purchaser to pay the relevant CCN2 Resale Proceeds to Challenger as Application Payment for that number of Challenger Capital Notes 4.The Reinvestment Offer is open to Eligible CCN2 Holders until the Closing Date.There are some differences between Challenger Capital Notes 2 and the Challenger Capital Notes 4 that Eligible CCN2 Holders should consider before deciding whether to apply to participate in the Reinvestment Offer. See Section 3.2 for further information.
3.1.4 What is the purpose of the Reinvestment Offer?	<ul style="list-style-type: none">The purpose of the Reinvestment Offer is to refinance Challenger Capital Notes 2 as well as to give Eligible CCN2 Holders the opportunity to reinvest their CCN2 Resale Proceeds in Challenger Capital Notes 4 and maintain an ongoing investment in securities issued by Challenger. The funds raised through the Reinvestment Offer will be used to fund a subscription for Additional Tier 1 Capital of CLC.
3.1.5 Am I eligible to participate in the Reinvestment Offer?	<ul style="list-style-type: none">Participation in the Reinvestment Offer is optional.For you to be eligible to participate in the Reinvestment Offer you must be registered as a holder of Challenger Capital Notes 2 at 7:00pm (Sydney time) on 3 March 2023 and you must still be the registered holder on 30 March 2023 at 5:00pm (Sydney time), which is the Closing Date for the Reinvestment Offer.In addition to this, to be eligible, unless determines Challenger otherwise, you must be:<ul style="list-style-type: none">shown on the Challenger Capital Notes 2 register as having an address in Australia;not an individual residing in a member state of the European Union;not in the United States or acting as a nominee for, or for the account or benefit of, a U.S. Person, and not otherwise prevented from receiving the Reinvestment Offer or Challenger Capital Notes 4 under the laws of any jurisdiction; and

	<ul style="list-style-type: none"> – an Institutional Investor or a client of a Syndicate Broker who is either a Wholesale Client or a Retail Investor who has received personal advice from a qualified financial adviser concerning an investment in the Challenger Capital Notes 4 (and must otherwise be within the Challenger Capital Notes 4 Target Market). • Satisfactory evidence must be held or provided to your Syndicate Broker that you are either a Wholesale Client or have received personal advice from a qualified financial adviser (in the form of a certificate from your adviser or a copy of your statement of advice from your adviser) to acquire Challenger Capital Notes 4.
<p>3.1.6 What distribution(s) will I receive?</p>	<ul style="list-style-type: none"> • To facilitate the Reinvestment Offer, the distribution payable in respect of the Challenger Capital Notes 2 for the final distribution period, being the period from (and including) 22 February 2023 to (but not including) 22 May 2023, has been split into two separate distributions. • Depending on the action you choose to take with respect to the Reinvestment Offer, you may receive a single distribution or two separate distributions, as detailed below. • If you choose to participate in the Reinvestment Offer – you will receive a single distribution representing the period from (and including) 22 February 2023 to (but not including) the Issue Date of Challenger Capital Notes 4 (being 5 April 2023). This distribution is referred to in this Prospectus as the “First CCN2 Pro Rata Distribution”. On the Issue Date of Challenger Capital Notes 4, CCN2 Holders that have chosen to participate in the Reinvestment Offer will receive a distribution of \$0.64 per Challenger Capital Note 2. The record date for the First CCN2 Pro Rata Distribution is 7:00pm (Sydney time) on 28 March 2023. The First CCN2 Pro Rata Distribution does not form part of the resale price. • If you choose not to participate in the Reinvestment Offer – you will receive two separate distributions representing the final distribution period from (and including) 22 February 2023 to (but not including) 22 May 2023 – as described below: <ul style="list-style-type: none"> – On the Issue Date of Challenger Capital Notes 4 (being 5 April 2023), you will receive the First CCN2 Pro Rata Distribution; and – On the optional exchange date in respect of the Challenger Capital Notes 2 (being 22 May 2023), you will receive a second distribution of \$0.71 per Challenger Capital Note 2 representing the period from (and including) the Issue Date of Challenger Capital Notes 4 (being 5 April 2023) to (but not including) 22 May 2023. This distribution is referred to in this Prospectus as the “Second CCN2 Pro Rata Distribution”. The record date for the Second CCN2 Pro Rata Distribution is 7:00pm (Sydney time) on 12 May 2023. • You should note that both payments of the First CCN2 Pro Rata Distribution and the Second CCN2 Pro Rata Distribution are subject to no payment condition existing in respect of the relevant distribution payment date (as defined in the CCN2 Terms).
<p>3.1.7 Can I elect to reinvest the First CCN2 Pro Rata Distribution in Challenger Capital Notes 4?</p>	<ul style="list-style-type: none"> • No. The First CCN2 Pro Rata Distribution will be paid to Eligible CCN2 Holders in respect of their Reinvestment CCN2 via direct credit on the Issue Date of Challenger Capital Notes 4, in accordance with your existing Challenger Capital Notes 2 payment instructions. If you wish to change your Challenger Capital Notes 2 payment instructions for the payment of the First CCN2 Pro Rata Distribution or the Second CCN2 Pro Rata Distribution, you must provide updated instructions to the Registry by 5:00pm (Sydney time) on the relevant record date for that distribution.
<p>3.1.8 Who is the CCN2 Nominated Purchaser?</p>	<ul style="list-style-type: none"> • UBS.
<p>3.1.9 How do I apply to participate?</p>	<ul style="list-style-type: none"> • All Applications under the Reinvestment Offer must be submitted through a Syndicate Broker. A list of the appointed Joint Lead Managers and Co-Managers who are Syndicate Brokers to the Offer can be found on the front cover and in the Corporate Directory of this Prospectus. • Applications under the Reinvestment Offer will only be accepted from investors who satisfy the eligibility requirements in accordance with the TMD. You should contact a Syndicate Broker or other professional adviser to obtain more information on whether you meet the eligibility requirements. • See Section 3.3 and Section 7.4 for information on how to apply to participate in the Reinvestment Offer. • The Reinvestment Offer will remain open until 30 March 2023 unless the Offer is withdrawn.
<p>3.1.10 Do I need to apply for a minimum number of Challenger Capital Notes 4?</p>	<ul style="list-style-type: none"> • There is no minimum number of Challenger Capital Notes 2 that you must hold to be able to participate in the Reinvestment Offer. • However, if you are an Eligible CCN2 Holder and own less than 50 Challenger Capital Notes 2, you can still apply to participate in the Reinvestment Offer but you must apply to reinvest the CCN2 Resale Proceeds relating to all of your Challenger Capital Notes 2. • If you are an Eligible CCN2 Holder and you own 50 or more Challenger Capital Notes 2, you must apply to reinvest the CCN2 Resale Proceeds relating to at least 50 of your Challenger Capital Notes 2.

Topic	Summary
3.1.11 Can I sell my Challenger Capital Notes 2 after I have completed and returned my Application?	<ul style="list-style-type: none"> No – once your Application has been received, a holding lock will be placed on your Challenger Capital Notes 2 and you will not be able to successfully deal with your Challenger Capital Notes 2. If you receive less CCN2 Resale Proceeds than the amount you have elected to reinvest because you sold some of your Challenger Capital Notes 2, you will be taken to have applied for the number of Challenger Capital Notes 4 that you can pay for using the CCN2 Resale Proceeds you received. An Application to participate in the Reinvestment Offer is irrevocable once submitted but will only be effective so long as it is accepted and the Offer proceeds.
3.1.12 Can I continue to sell my Challenger Capital Notes 2 on market if I do not participate in the Reinvestment Offer?	<ul style="list-style-type: none"> If you do not participate in the Reinvestment Offer, yes. You may choose to sell your Challenger Capital Notes 2 on market through your broker at the prevailing market price, that may be higher or lower than the price you would receive if you were to participate in the Reinvestment Offer. The market price of Challenger Capital Notes 2 is subject to change from time to time. The current market price of Challenger Capital Notes 2 is available on the ASX website (www.asx.com.au), under the code “CGFPB”. If you elect to sell your Challenger Capital Notes 2 on market, you: <ul style="list-style-type: none"> – may have to pay brokerage and may receive a price greater or less than the issue price of \$100 per Challenger Capital Note 2; and – have the option to use the sale proceeds of the Challenger Capital Notes 2 you sell to subsequently acquire Challenger Capital Notes 4 on market. Following completion of the Reinvestment Offer, it is expected that the number of Challenger Capital Notes 2 quoted on ASX will significantly reduce. This may affect the liquidity of the market for Challenger Capital Notes 2 and their market price.
3.1.13 Can I apply for additional Challenger Capital Notes 4?	<ul style="list-style-type: none"> Yes – Eligible CCN2 Holders may apply for more Challenger Capital Notes 4 than the number of Challenger Capital Notes 2 registered in their name at 7:00pm (Sydney time) on 3 March 2023 under the New Money Offer. The minimum number of additional Challenger Capital Notes 4 you can apply for is 50 Challenger Capital Notes 4 (\$5,000).
3.1.14 Will I receive a priority allocation of Challenger Capital Notes 4?	<ul style="list-style-type: none"> Reinvestment Offer Applications will be given priority over other Applicants in determining the allocation of Challenger Capital Notes 4. See Section 7.5 for information on the allocation policy.
3.1.15 What will happen to my Challenger Capital Notes 2 if I do not apply for them to be reinvested under the Reinvestment Offer?	<ul style="list-style-type: none"> Challenger Capital Notes 2 that are not subject to the Reinvestment Offer will remain on issue in accordance with their terms. Challenger intends to redeem all outstanding Challenger Capital Notes 2 for \$100 per Challenger Capital Note 2 on their optional exchange date of 22 May 2023, in accordance with the CCN2 Terms.
3.1.16 What will happen to the Challenger Capital Notes 2 once acquired by the CCN2 Nominated Purchaser?	<ul style="list-style-type: none"> Once acquired by the CCN2 Nominated Purchaser, Challenger intends to redeem all Reinvestment CCN2 in the hands of the CCN2 Nominated Purchaser by payment to the CCN2 Nominated Purchaser of an amount equal to the face value in respect of each Reinvestment CCN2.
3.1.17 What are the tax implications of participating in the Reinvestment Offer and will any brokerage or stamp duty be payable?	<ul style="list-style-type: none"> A general outline of the taxation implications for certain investors participating in the Offer (including through the Reinvestment Offer) can be found in the Australian taxation summary in Section 8. No brokerage or stamp duty is payable on the sale of your Challenger Capital Notes 2 to the CCN2 Nominated Purchaser, or your Application for Challenger Capital Notes 4, provided that no person obtains, either alone or with associates, an interest of 90% or more in Challenger. In some circumstances, interests of persons who are not associates can be aggregated together in determining whether that threshold is met or exceeded. CCN2 Holders who choose to sell their Challenger Capital Notes 2 on market through their broker may be required to pay applicable brokerage. The taxation implications of participating in the Reinvestment Offer will depend on an investor’s individual circumstances. You should obtain your own taxation advice before you hold or dispose of Challenger Capital Notes 2 or invest in Challenger Capital Notes 4 (including through the Reinvestment Offer).

3.2 Key differences between Challenger Capital Notes 4 and Challenger Capital Notes 2

While there are a number of similarities between Challenger Capital Notes 4 and Challenger Capital Notes 2, there are also some differences between them, particularly in relation to their margin and Challenger's early optional conversion and redemption rights. You should be aware of these differences before deciding to apply to participate in the Reinvestment Offer. The following table describes the key features of the Challenger Capital Notes 4 and Challenger Capital Notes 2 and highlights the main similarities and differences between them. You should consider the differences, highlighted below, in light of your investment objectives, financial situation and particular needs (including financial and taxation issues) before deciding to apply for Challenger Capital Notes 4.

Topic	Challenger Capital Notes 2	Challenger Capital Notes 4
Protected under the Financial Claims Scheme	No	No
Term	Perpetual ²³	Perpetual ²⁴
Margin	4.40% per annum	3.60% per annum, as determined under the Bookbuild
Distribution rate	Floating	Floating
Distribution payment dates	Quarterly	Quarterly
Franking	Expected to be fully franked	Expected to be fully franked
Conditions to payment of distribution	Subject to the discretion of Challenger, and only payable if a payment condition (as defined in the CCN2 Terms) does not exist on the distribution payment date. Distributions are non-cumulative	Subject to the discretion of Challenger, and only payable if a Payment Condition does not exist on the Distribution Payment Date. Distributions are non-cumulative
Restriction on ordinary share dividends if distribution not paid	Yes, applies to ordinary shares only, until the next distribution payment date (as defined in the CCN2 Terms)	Yes, applies to Ordinary Shares only, until the next Distribution Payment Date (see Section 2.1.8 for further information)
Transferable	Yes, quoted on ASX under the code "CGFPB"	Yes, expected to be quoted on ASX under the code "CGFPD"
Mandatory conversion into ordinary shares	Yes, on 22 May 2025 and each distribution payment date after this date, or at any time upon the occurrence of an acquisition event or a non-viability trigger event (as defined in the CCN2 Terms)	Yes, on 25 February 2032 and each Distribution Payment Date after this date, or at any time upon the occurrence of an Acquisition Event or a Non-Viability Trigger Event
Challenger's early conversion option	Yes, on 22 May 2023 and following a regulatory event, tax event or potential acquisition event (as defined in the CCN2 Terms)	Yes, on a Distribution Payment Date falling on or about 25 May 2029, 25 August 2029, 25 November 2029 and 25 February 2030 and following a Regulatory Event, Tax Event or Potential Acquisition Event
Challenger's early redemption option	Yes, on 22 May 2023 and following a regulatory event or tax event (as defined in the CCN2 Terms)	Yes, on a Distribution Payment Date falling on or about 25 May 2029, 25 August 2029, 25 November 2029 and 25 February 2030 and following a Regulatory Event or Tax Event
Loss absorption event	Yes	Yes – see Section 2.4 for further information
Treated as APRA regulatory capital?	No, but used to fund a subscription for Additional Tier 1 Capital of CLC	No, but used to fund a subscription for Additional Tier 1 Capital of CLC ²⁵
Voting rights	No right to vote at general meetings of holders of Ordinary Shares	No right to vote at general meetings of holders of Ordinary Shares

²³ On the date of the Original Prospectus, Challenger issued the CCN2 Exchange Notice in accordance with the CCN2 Terms. That notice confirms that on 5 April 2023, the CCN2 Nominated Purchaser will purchase all Reinvestment CCN2 for \$100 per Challenger Capital Note 2.

²⁴ The Challenger Capital Notes 4 are scheduled to Convert into Ordinary Shares on 25 February 2032, or on the occurrence of certain Acquisition Events. Challenger may also be required to Convert the Challenger Capital Notes 4 as a result of a Non-Viability Trigger Event. In addition, the Challenger Capital Notes 4 may be Converted, Redeemed or Resold with the prior written approval of APRA on a Distribution Payment Date falling on or about 25 May 2029, 25 August 2029, 25 November 2029 and 25 February 2030. Challenger Capital Notes 4 may also be Written-Off in certain circumstances.

²⁵ APRA has advised that it does not object to Challenger using the proceeds of Challenger Capital Notes 4 to fund a subscription for Additional Tier 1 Capital of CLC.

3.3 Options available to Eligible CCN2 Holders


Option	Summary
Option 1 – Apply through a Syndicate Broker to participate in the Reinvestment Offer	<ul style="list-style-type: none">• If you are an Eligible CCN2 Holder and you are an Australian resident client of a Syndicate Broker, you must apply to participate in the Reinvestment Offer through a Syndicate Broker. A list of the appointed Joint Lead Managers and Co-Managers who are Syndicate Brokers to the Offer can be found on the front cover and in the Corporate Directory of this Prospectus.• Applications under the Reinvestment Offer will only be accepted from investors who satisfy the eligibility requirements in accordance with the TMD. You should contact a Syndicate Broker or other professional adviser to obtain more information on whether you meet the eligibility requirements.• You may apply to reinvest the CCN2 Resale Proceeds relating to all or some of the Challenger Capital Notes 2 registered in your name at 7:00pm (Sydney time) on 3 March 2023 in Challenger Capital Notes 4. If you do this, your CCN2 Resale Proceeds will be used as the Application Payment and you will not be required to pay any additional amount in respect of your Application. You may also choose to apply for more Challenger Capital Notes 4 under the New Money Offer (see Section 3.1.13 above).• You should contact your Syndicate Broker for instructions on how to submit an Application and, if applicable, the Application Payment.
Option 2 – Sell your Challenger Capital Notes 2 on market through your broker	<ul style="list-style-type: none">• You may choose to sell your Challenger Capital Notes 2 on market through your broker or otherwise at the prevailing market price in the usual course.• The market price of Challenger Capital Notes 2 is subject to change from time to time. The current market price of Challenger Capital Notes 2 is available on the ASX website (www.asx.com.au), under the code "CGFPB".• If you sell your Challenger Capital Notes 2 on market, you may have to pay brokerage and may receive a price greater or less than the face value of \$100 per Challenger Capital Note 2.
Option 3 – Take no action	<ul style="list-style-type: none">• Participation in the Reinvestment Offer is optional. Eligible CCN2 Holders are not required to participate in the Reinvestment Offer and as such are not required to take any action.• CCN2 Holders who continue to hold Challenger Capital Notes 2 not subject to the Reinvestment Offer will continue to receive distributions on their Challenger Capital Notes 2, subject to no payment condition existing in respect of the relevant distribution payment date (as defined in the CCN2 Terms).• Challenger Capital Notes 2 that are not subject to the Reinvestment Offer will remain on issue in accordance with their terms. Challenger intends to redeem all outstanding Challenger Capital Notes 2 for \$100 per Challenger Capital Note 2 on their optional exchange date of 22 May 2023, in accordance with the CCN2 Terms.

3.4 Risks associated with participating in the Reinvestment Offer

If you are an Eligible CCN2 Holder and you apply under the Reinvestment Offer, you may receive an allocation of Challenger Capital Notes 4. As such, you will be subject to the risks associated with an investment in the Challenger Capital Notes 4 and in Challenger, many of which are outside the control of Challenger and its Directors. These risks are outlined in Section 6 and should be considered before you apply under the Reinvestment Offer.

The Reinvestment Offer is not a simple rollover into an identical investment. The Challenger Capital Notes 4 and Challenger Capital Notes 2 have some differences, and must be evaluated separately (see Section 3.2 above).

Additionally, instead of participating in the Reinvestment Offer, Eligible CCN2 Holders may obtain a better financial outcome by selling their Challenger Capital Notes 2 on market and subsequently acquiring Challenger Capital Notes 4 on market or not reinvesting at all.



Section 4

About the Challenger Group

4. About the Challenger Group

This Section sets out information about Challenger Limited (“**Challenger**”) and the Challenger Group.

4.1 Introduction

Challenger Limited is a non-operating holding company of an investment management group with a purpose to provide its customers with financial security for a better retirement. Founded in 1985, Challenger is listed on the Australian Securities Exchange (“**ASX**”), under the code “CGF” with a market capitalisation of approximately \$5 billion as at 10 March 2023.

Challenger operates two core businesses, a Life business (“**Life**”) which is Australia’s largest annuity provider²⁶ and a Funds Management business (“**Funds Management**”) which is one of Australia’s largest active fund managers²⁷.

Challenger’s Life and Funds Management businesses are expected to benefit from long-term growth in Australia’s superannuation system and savings culture.

Australia’s compulsory superannuation system commenced in 1992 and is now the fifth largest pension system globally and one of the fastest growing, with assets increasing by 11% per annum over the past 20 years²⁸.

Critical features driving the growth of Australia’s superannuation system include Government-mandated and increasing contributions, tax incentives to encourage retirement savings and an efficient and competitive institutional model.

Australia’s superannuation system is forecast to grow from over \$3 trillion today²⁹ to almost \$9 trillion³⁰ over the next 20 years.

Growth in the retirement phase of the system is supported by ageing demographics and the Government’s focus on enhancing the retirement phase of superannuation.

The Life business is regulated by APRA, the Australian banking, superannuation, general insurance and life insurance regulator. Challenger Group’s activities are also subject to supervision by other regulatory agencies both in Australia and in other offshore markets in which it operates (refer to Section 4.6 for further information).

As at 31 December 2022, the Challenger Group employed over 761 people on a full-time equivalent basis and had total assets under management of \$99 billion and total shareholder equity of \$4 billion.

For the half year ended 31 December 2022, Challenger’s normalised net profit after tax was \$167 million, and statutory net profit after tax was \$123 million. A reconciliation between normalised and statutory net profit after tax is included in Section 5 (“Financial information”).

Challenger is a disclosing entity for the purposes of the Corporations Act and, as a result, is subject to regular reporting and disclosure obligations under the Corporations Act and the ASX Listing Rules, including an obligation to lodge half-yearly

and annual financial reports with ASIC and ASX. Copies of documents lodged with ASIC in relation to Challenger may be obtained from, or inspected at, an ASIC office. A copy of documents lodged with ASIC in relation to Challenger may also be obtained from ASIC’s website www.asic.gov.au (a fee may apply). Copies of these documents can also be obtained from www.asx.com.au and Challenger’s online Shareholder Centre, www.challenger.com.au/shareholder, together with Challenger’s other market announcements.

4.2 Overview of the Challenger Group

The Challenger Group operates two core operating segments, as set out below.

1. Life – focuses on the retirement spending phase of superannuation, with products helping customers convert retirement savings into safe, secure and reliable income in retirement; and

2. Funds Management – focuses on wealth accumulation, predominantly in the pre-retirement phase of superannuation, through supporting customers to build savings by providing investment strategies and products seeking to deliver superior investment returns.

These core operating segments are supported by shared support functions which are responsible for providing centralised regulatory, compliance, finance, treasury, tax, legal, risk management, human resource services and strategy.

4.3 Business lines

4.3.1 Life

Challenger Life Company Limited (“**CLC**” or “**Life**”) is Australia’s leading provider of annuities³¹ and guaranteed retirement income products.

Life’s annuity products appeal to retirees as they provide security and certainty of guaranteed³² income while protecting against the risks of investment market downturns and rising inflation. Lifetime annuities also protect retirees from the risk of outliving their savings by paying an income for life. Depending on the payment option selected, payments will either be fixed, indexed to inflation, linked to changes in the RBA cash rate or indexed to investment markets.

The retirement incomes that Life pays to its customers are backed by a high-quality investment portfolio, predominantly invested in high-grade fixed income. These investments generate reliable investment income, which is used to fund the retirement incomes paid to customers.

26 Plan for Life – September 2022 – based on annuities under administration.

27 Calculated from Rainmaker Roundup, September 2022 data.

28 Willis Towers Watson Global Pension Asset Study 2022.

29 APRA, as at September 2022.

30 Deloitte Dynamics of the Australian Superannuation System: The Next 20 Years to 2041.

31 Refer to footnote 26.

32 The word “guaranteed” means payments are guaranteed by CLC from assets of its relevant statutory fund.

Life has won the Association of Financial Advisers “Annuity Provider of the Year” for the last 14 years. Life’s leading retirement income position was also recognised by Plan For Life, with Life winning the Overall Longevity Cover Excellence Award for 2022.

Life is expected to continue to benefit from the long-term growth in Australia’s superannuation system and regulatory reforms designed to enhance the retirement phase of superannuation.

As Australia’s superannuation system grows, the retirement phase of superannuation is expected to increase significantly. The number of Australians over the age of 65, which is Life’s target market, is expected to increase by nearly 50% over the next 20 years³³. Reflecting these demographic changes, and growth in the superannuation system, the annual transfer from the savings phase of superannuation to the retirement phase was estimated to be approximately \$76 billion³⁴ in 2021.

The purpose of superannuation is to provide income in retirement to substitute or supplement the Government-funded age pension. As the superannuation system grows and individual superannuation savings increase, retirees are transitioning from Government-funded age pensions to private superannuation-funded pensions. Retirees need retirement income products that convert their superannuation savings into safe, secure and reliable income, which helps provide financial security and confidence to spend in retirement.

The Australian Government is progressing a range of retirement income regulatory reforms designed to enhance the retirement phase and better align it with the objective of the superannuation system. The Retirement Income Covenant took effect from 1 July 2022 as part of the *Superannuation Industry Supervision Act 1993* (“**SIS Act**”) and requires all APRA-regulated superannuation funds to have a documented retirement income strategy that outlines how they plan to assist their members in retirement.

In March 2022, the Australian Government commenced the Quality of Advice Review (“**QAR**”), focused on the effectiveness and availability of financial advice in Australia.

Both of these reforms provide an opportunity to increase the proportion of savings invested in products that deliver retirees stable, regular and reliable retirement income. Annuities deliver these benefits yet currently only represent a very small part of the retirement phase of superannuation.

Life’s products are distributed in Australia via both independent financial advisers and financial adviser administrative platforms. Life’s products are included on all major advice hubs’ Approved Product Lists (“**APLs**”) and are available on leading independent investment and administration platforms.

Life is also focused on building institutional partnerships with large superannuation funds. As their members transition to retirement, superannuation funds are increasingly focused on providing more comprehensive retirement solutions to their members. As the retirement system develops, the institutional (including profit-for-member) superannuation sector provides a significant growth opportunity for Life and Challenger.

In Japan, Life has an annuity relationship with Mitsui Sumitomo Primary Life Insurance Company Limited (“**MS Primary**”) to provide Australian dollar and US dollar annuities. MS Primary is a leading provider of annuity products in Japan and is part of MS&AD Insurance Group Holdings Inc. (“**MS&AD**”).


Under the reinsurance arrangement, MS Primary reinsures at least ¥50 billion (equivalent to approximately A\$530 million³⁵) of its Australian and US dollar annuities with Life each year³⁶. This is subject to review in the event of a material adverse change for either MS Primary or Life.

MS&AD also holds an approximate 15%³⁷ equity interest in Challenger and an MS&AD representative has been appointed to the Board.

Life also participates in wholesale reinsurance longevity and mortality transactions.

The diagram below shows total Life sales for the last five and a half years:

Total Life sales (\$bn)



33 2022–2042 comparison based on Australian Bureau of Statistics, Population Projections Series B, cat no. 3222.0.

34 Based on Taxation Statistics 2019-20 from the ATO.

35 Based on the exchange rate as at 30 June 2022.

36 Reinsurance across both Australian and US dollar annuities, of at least ¥50 billion per year for a minimum of five years, commencing 1 July 2019.


37 As at 31 December 2022.

The Life business provides a range of income product solutions aimed at helping customers during retirement by converting retirement savings into safe and secure retirement income. Life's retirement income solutions are summarised below.

Product categories	Product features
Fixed term annuities	<p>Term annuity products provide a guaranteed regular income for a fixed term, regardless of how investment markets perform. Term annuities have flexible features, including length of term and ability to draw principal and interest over the term of the product.</p> <p>Term annuities complement other retirement income products and investments, including an account-based pension, a lifetime annuity, or the Government-funded age pension. Products are sold principally via financial advisers to retail customers and directly to institutional customers.</p> <p>Term annuities include long term fixed rate annuities reinsured under an agreement with MS Primary.</p>
Lifetime annuities	<p>Lifetime annuities pay a guaranteed regular income for the life of the holder (and may also include a second person). Depending on the payment option selected, payments will either be fixed, indexed to inflation, linked to changes in the RBA cash rate or indexed to investment markets. Lifetime annuities may also include death and surrender benefits.</p> <p>Lifetime annuities complement other retirement investments and sources of income, such as superannuation, an account-based pension or the Government-funded age pension.</p> <p>Lifetime annuities comprises Liquid Lifetime and CarePlus, a lifetime annuity specifically designed to help people receiving, or planning to receive, Government-subsidised residential aged care services. CarePlus provides guaranteed regular income for life, with a lump sum payable to the holders' beneficiaries or estate upon death.</p> <p>Products are sold principally via financial advisers to retail customers, and are also sold in bulk to institutional customers.</p>
Challenger Index Plus	<p>Challenger Index Plus is an institutional product offering guaranteed returns equal to the return of a relevant index plus a specified margin.</p> <p>Products are sold to institutional clients, such as superannuation funds.</p>

The diagram below shows the contribution of each product category to Life's total sales for the last five and a half years:

Total Life sales by product (\$bn)




Life does not charge its customers fees or charges on any of its annuity products. Life generates income by investing the capital received from annuity holders in assets that, in aggregate, are expected to generate a greater return than the payments required to be made to annuity holders.

As at 31 December 2022, the Life business had \$23 billion in assets under management which was up from \$17 billion five years ago (as at 31 December 2017), and has been growing at a compound annual growth rate of approximately 6.3% over this period. Life's assets under management have grown due to annuity net flows, growth in other products, new capital and retained Life earnings.


Life's investment assets comprising both policyholder and shareholder funds as at 31 December 2022 were invested in the following asset classes:

Life investment portfolio as at 31 December 2022 (%)



Fixed income is further broken down as at 31 December 2022 as follows:

Life fixed income portfolio (%)



Life is exposed to a number of risks in relation to both its liabilities and its assets (for a description of the risks associated with Challenger, CLC and the Challenger Group, see Section 6.2). These risks are managed in accordance with Life's risk management framework and policies and procedures approved by its Board and with supervision by APRA.


4.3.2 Funds Management

Funds Management focuses on wealth accumulation, predominantly in the pre-retirement phase of superannuation, through supporting customers to build savings by providing investment strategies and products seeking to deliver superior investment returns. Funds Management has operations in Australia, the United Kingdom, Europe and Asia.

Funds Management is one of Australia's largest active fund managers³⁸ and comprises Fidante and Challenger Investment Management ("CIM").

As at 31 December 2022, Funds Management had \$93 billion in funds under management ("FUM"), up from \$73 billion five years ago (as at 31 December 2017) with FUM growing at a compound annual growth rate of approximately 4.8% over this period. Growth in FUM is supported by Challenger's award-winning retail and institutional distribution teams and business model, which is focused on high-quality managers with strong long-term investment performance and alignment with clients.

Funds Management FUM (\$bn)



Funds Management, through its Fidante affiliates and CIM, invests across a broad range of asset classes, including fixed income, commercial property, Australian and global equities and alternative investments.

38 Calculated from Rainmaker Roundup, September 2022 data.

Funds Management affiliate brands, strategies and asset classes

\$93 billion of FUM as at 31 December 2022

Equities \$38bn	Australian equities	   
		  
	Global, regional & EM equities	  
	Sustainable investments	 
Fixed Income \$49bn		    
Alternatives \$6bn		   

Fidante

The Fidante business model involves taking minority equity interests in separately branded affiliate funds management firms, with Challenger providing distribution services and business support, and Artega Investment Administration Pty Limited (“**Artega**”) providing investment administration services, leaving investment managers to focus entirely on managing investment portfolios. Fidante earns distribution fees, transaction fees, administration fees and shares in the equity accounted profits of affiliate managers in which it has an equity interest.

Fidante has been successful in attracting and building active equity, fixed income and alternative investment managers, while also maintaining strong investment performance. Over the last five years, long-term performance for Fidante’s Australian affiliates was strong with 97% of funds and mandates outperforming their respective benchmarks³⁹.

Fidante is focused on broadening its product and investment offering, and accessing new distribution channels.

Fidante had \$72 billion of FUM as at 31 December 2022, increasing from \$56 billion five years ago (as at 31 December 2017) and growing at a compound annual growth rate of approximately 5.1% over this period.

For the half year ended 31 December 2022, Fidante generated net income of \$57.1 million, representing 65% of the Funds Management business total net fee income.

Challenger Investment Management

CIM principally originates and manages fixed income and commercial real estate for leading global and Australian institutions, including Life. Life accounts for approximately 80% of CIM’s FUM.

CIM had \$21 billion of FUM as at 31 December 2022, increasing from \$17 billion five years ago (as at 31 December 2017) by a compound annual growth rate of approximately 3.8% over this period.

CIM earns fee income in relation to the assets it manages. This fee income includes management fees, other income such as leasing fees, acquisition and disposal fees, development and placement fees, and performance fees.

For the half year ended 31 December 2022, CIM generated net income of \$30.8 million, representing 35% of the Funds Management business total net fee income.

4.3.3 Bank

In 2020, Challenger announced the acquisition of MyLifeMyFinance Limited, an Australian-based ADI and digital bank offering a range of savings and lending products. MyLifeMyFinance was subsequently rebranded to Challenger Bank Limited (“**Bank**”).

As a result of changing market conditions and inability to realise expected benefits from the Bank acquisition in the timeframe anticipated, Challenger announced a strategic review of the Bank in August 2022.

Following completion of the strategic review, it was determined the sale of the Bank was the best option for Challenger, allowing it to focus on its core Life and Funds Management businesses and leverage the scale that can be achieved through Challenger’s strategic partnerships.

In October 2022, Challenger announced it had entered into a share sale agreement to sell the Bank to Heartland Group Holdings Limited (NZX/ASX:HGH). The Bank sale is subject to regulatory approval in Australia and New Zealand and expected to settle in the first half of 2023. For the half year ended 31 December 2022, the Bank’s normalised earnings before interest and tax loss was \$4.3 million.

As at 31 December 2022, the Bank had lending and financing assets of \$407 million, with approximately 70% invested in cash and equivalents and only approximately 30% deployed to retail and corporate lending.

³⁹ As at 31 December 2022. Percentage of Fidante affiliates meeting or exceeding the performance benchmark, with gross performance weighted by FUM.

4.3.4 Other strategic initiatives

Apollo strategic relationship

Apollo Global Management, Inc (NYSE:APO) ("**Apollo**") and Athene acquired approximately 19% minority interest in Challenger over the course of 2021 and 2022.

Challenger and Apollo share a common purpose, strong complementary skills and capabilities.

Both parties are working together on a range of opportunities to help customers achieve financial security in retirement and deliver meaningful value for shareholders, including product development and distribution opportunities.

During the second half of 2022, Challenger and Apollo commenced collaboration to bring the Apollo Aligned Alternatives fund ("**AAA**") to the Australian market. AAA is an open-ended fund, which is positioned as an equity replacement product and provides clients access to invest alongside Apollo, across a full cross-section of alternative investments, including flagship funds. The AAA targets investment net returns in the low to mid-teens per annum. Challenger and Apollo intend to build an Australian unitised version of AAA, to appeal to Australia's retail market and be made available on Australia's leading investment administration platforms. Through an agreement with Apollo, Challenger will lead AAA distribution in Australia to retail, high-net-worth and smaller institutions.

In August 2022, Challenger and Apollo entered a definitive agreement to establish a joint venture to build an Australian and New Zealand non-bank lending platform. The joint venture is equally owned by Challenger and Apollo, and is expected to provide a variety of financing solutions across a range of sectors, such as accounts receivable finance, invoice and trade finance, equipment finance, auto finance and agricultural funding.

The joint venture will pursue both organic and inorganic opportunities and leverage the capabilities of both Challenger and Apollo. It will bring together Challenger's operating platform and relationships across Australian lending markets with Apollo's extensive global scale and credit investing capabilities, while also providing origination capability to support growth across Challenger's balance sheet.

Artega Investment Administration

In November 2022, Artega, a joint venture between Challenger and SimCorp A/S (CSE:SIM) ("**SimCorp**"), was launched. Artega will provide market-leading investment administration services to investment managers and owners across Australia and Asia.

Artega will leverage the capabilities of both Challenger and SimCorp to provide Australia's first fully technology-led, integrated front-to-back, cloud-based investment operations platform to service Challenger, Fidante and third-party investment managers and asset owners.

SimCorp is a global leader in investment administration services. The platform is powered by SimCorp's investment management solution, Dimension, and operated by Challenger's experienced investment operations team.

In the second half of 2022, Artega became operational and commenced providing investment administration services to its existing clients, Challenger and Fidante affiliates.

Artega has been engaging with potential clients and in early 2023 won its first third-party client, an independent multi-manager with \$2 billion of assets under management.

4.4 Financial summary for the half year ended 31 December 2022

The following summarises the financial results for Challenger Limited for the half year ended 31 December 2022 (with comparisons against the half year ended 31 December 2021):

- Normalised net profit before tax ("**NPBT**") increased by 5% to \$250 million.
- Normalised net profit after tax ("**NPAT**") increased by 1% to \$167 million.
- Statutory net profit after tax attributable to equity holders decreased by 56% to \$123 million.
- Normalised earnings per share ("**EPS**") was unchanged at 24.5 cents per share.
- Total Group assets under management ("**AUM**") decreased by 14% to \$99 billion.
- Normalised return on equity (pre-tax) increased by 20 basis points to 12.3%.
- Life annuity sales increased by 41% to \$3.5 billion.
- Total Life book growth was \$1.0 billion or 5.5% for the period.
- Life investment assets increased by 1% to \$23 billion.
- Life Prescribed Capital Amount ("**PCA**") ratio decreased by 0.01 times to 1.59 times⁴⁰.
- Funds Management funds under management ("**FUM**") decreased by 15% to \$93 billion.
- The financial year 2023 interim dividend increased by 0.5 cents per share to 12.0 cents per share (fully franked).

Life Normalised cash operating earnings ("**NCOE**") is Challenger's non-IFRS preferred profitability measure for the Life business, as it aims to reflect the underlying performance trends of the Life business by removing the volatility of fair value movements of assets and liabilities from the profit and loss (see Section 5.2.3 below). The Life NCOE framework removes the impact of market and economic variables, which are generally non-cash and are a result of external market factors.

Life NCOE includes cash earnings plus normalised growth and excludes investment experience. Cash earnings represents investment yield and other income, less interest expenses and distribution expenses.

Normalised capital growth is the expected capital growth for each asset class through the investment cycle and is based on Challenger's long-term expected investment returns for each asset class.

The asset and liability valuation movements are recorded as investment experience (for a description of investment experience, see Section 5.2.3). By separating these movements from the Life business result, the Life business's reported normalised earnings more closely represent the cash earnings of the business.

40 PCA ratio represents Life's Regulatory Capital Base divided by the PCA and is as at 31 December 2022.

Challenger Group Normalised Earnings Before Interest and Tax ("EBIT") by Division and Normalised Net Profit Before Tax ("NPBT")

	For the half year ended 31 December 2022 (\$m)	For the half year ended 31 December 2021 (\$m)
Life	263.3	233.0
Funds Management	30.7	45.1
Bank	(4.3)	(3.3)
Corporate and other ⁴¹	(37.3)	(35.4)
Normalised EBIT	252.4	239.4
Interest and borrowing costs	(2.0)	(1.9)
Normalised NPBT	250.4	237.5

4.5 Strategy

Challenger's purpose is to provide its customers with financial security for a better retirement. Challenger has four strategic priorities to ensure that it achieves its purpose. The four strategic priorities are:

- broaden customer access across multiple channels;
- expand the range of financial products and services for a better retirement;
- leverage the combined capabilities of the Challenger Group; and
- strengthen resilience and sustainability of Challenger.

4.6 Regulation

As a provider of annuities, funds management and banking products, the Challenger Group is subject to ongoing oversight by financial services regulators in the markets in which it operates. The principal regulators in Australia that supervise and regulate the activities of the Challenger Group and the activities of the businesses and funds that members of the Challenger Group manage are APRA, ASIC, ASX, the ACCC and AUSTRAC.

APRA regulates companies operating in the Australian financial services industry, including Life. APRA has established prudential standards for life companies, general insurers, superannuation entities and banks.

Challenger's Funds Management business has operations in the United Kingdom, Europe and Asia, which are subject to regulation in each jurisdiction.

4.7 Directors of Challenger

The Directors of Challenger at the date of this Prospectus are:

- Duncan West, Independent Non-Executive Director and Chair;
- Nicolas (Nick) Hamilton, Managing Director and Chief Executive Officer;
- John M Green, Independent Non-Executive Director;
- Steven Gregg, Independent Non-Executive Director;
- Masahiko Kobayashi⁴², Non-Executive Director;
- Heather Smith, Independent Non-Executive Director;
- JoAnne Stephenson, Independent Non-Executive Director; and
- Melanie Willis, Independent Non-Executive Director.

The Directors of Challenger may change from time to time due to the appointment or resignation of Directors.

The roles and responsibilities of the Directors are set out in the Challenger Board charter. The Board charter and further information on the Directors of Challenger, including their experience, qualifications and expertise can be found on Challenger's website at www.challenger.com.au. Information on the Board of Directors can be found by selecting "About" and then "Board"; while the Board charter can be found by selecting "About" and then "Corporate governance".

⁴¹ Corporate and other comprises central functions such as Challenger Group executives, finance, treasury, legal, human resources, risk management and strategy. Corporate and other also includes interest received on the Challenger Group's cash balances.

⁴² Hiroyuki Iioka was appointed as an Alternate Director to Masahiko Kobayashi on 13 December 2019.



Section 5

Financial information

5. Financial information

This Section sets out the following financial information:

- the historical consolidated statements of comprehensive income of Challenger Group for the half years ended 31 December 2021 and 31 December 2022, and the financial years ended 30 June 2021 and 30 June 2022;
- the historical statements of comprehensive income of Challenger (as parent entity) for the half years ended 31 December 2021 and 31 December 2022, and the financial years ended 30 June 2021 and 30 June 2022;
- the historical consolidated statement of financial position of Challenger Group and the historical statement of financial position of Challenger (as parent entity) as at 31 December 2022, (together, the “**Historical Financial Information**”);
- the pro forma consolidated statement of financial position of Challenger Group as at 31 December 2022;
- the pro forma statement of financial position of Challenger (as parent entity) as at 31 December 2022, (together, the “**Pro Forma Historical Financial Information**”);
- pro forma capital adequacy position as at 31 December 2022 demonstrating the effect of the Offer and the resale/redemption of Challenger Capital Notes 2 on CLC; and
- reconciliation of normalised profit to statutory profit for the Challenger Group for the half years ended 31 December 2021 and 31 December 2022, and the financial years ended 30 June 2021 and 30 June 2022.

The Historical Financial Information and Pro Forma Historical Financial Information of the Challenger Group and Challenger (as parent entity) are collectively referred to as the “**Financial Information**”.

5.1 Introduction

The presentation currency of the financial and capital adequacy position is Australian dollars.

The Pro Forma Historical Financial Information has been included to illustrate the Challenger Group’s and Challenger’s (as parent entity) financial position as at 31 December 2022, assuming Challenger Capital Notes 4 were issued on that date and the resale/redemption of all of Challenger Capital Notes 2 on that date. The adjustments do not impact Challenger’s or the Challenger Group’s historical consolidated statement of comprehensive income as they are assumed to occur at the balance sheet date.

The pro forma capital adequacy position has been included to illustrate CLC’s capital position as at 31 December 2022, assuming the issuance of Challenger Capital Notes 4 on that date and the resale/redemption of all of Challenger Capital Notes 2 on that date.

The Challenger Group and the Challenger Historical Financial Information presented in this Section has been derived from the Challenger Group’s unaudited Interim Financial Report for the half year ended 31 December 2022 (including the comparative for 31 December 2021), and the Annual Report for the financial year ended 30 June 2022 (including the comparative for 30 June 2021). These reports are available at www.challenger.com.au/shareholder/financial-information.

The Historical Financial Information has been prepared in accordance with the measurement and recognition requirements of the Australian Accounting Standards and other mandatory reporting requirements in Australia.

The Pro Forma Historical Financial Information has been prepared with the measurement and recognition requirements consistent with the accounting standards and requirements which are detailed in the Interim Financial Report of the Challenger Group for the half year ended 31 December 2022 and the Annual Report for the financial year ended 30 June 2022, except that it includes adjustments to reflect the impact of the pro forma adjustments as if they had occurred as at 31 December 2022.

Investors should note that past performance is not a reliable indicator of future performance.

5.2 Consolidated financial information of the Challenger Group

5.2.1 Consolidated statement of comprehensive income

The following table sets out the Challenger Group's consolidated statement of comprehensive income for the half year ended 31 December 2022 and the financial year ended 30 June 2022 (as well as the prior period comparatives).

\$ million	For the half year ended 31 December 2022	For the half year ended 31 December 2021	For the financial year ended 30 June 2022	For the financial year ended 30 June 2021
Revenue	1,505.4	1,480.1	1,860.7	2,769.8
Expenses	(1,187.0)	(931.1)	(1,872.9)	(1,646.5)
Finance costs	(143.7)	(172.7)	331.5	(327.9)
Share of profits of associates	13.6	21.0	38.0	35.2
Profit before income tax	188.4	397.3	357.3	830.6
Income tax expense	(60.2)	(111.2)	(103.6)	(238.3)
Profit for the period after income tax from continuing operations	128.2	286.1	253.7	592.3
Loss for the period after income tax from discontinued operations	(5.5)	(4.1)	-	-
Total profit for the period after income tax	122.7	282.0	253.7	592.3
Other comprehensive income				
Items that may be reclassified to profit and loss, net of tax				
Translation of foreign entities	13.6	6.5	(20.6)	(49.7)
Hedge of net investment in foreign entities	(14.9)	(4.0)	20.8	46.8
Net gain/(loss) on cash flow hedges	0.1	0.1	0.4	(0.5)
Other comprehensive (loss) / income for the period	(1.2)	2.6	0.6	(3.4)
Total comprehensive income for the period after tax	121.5	284.6	254.3	588.9

5.2.2 Pro forma consolidated statement of financial position

The following table sets out the Challenger Group's consolidated statement of financial position as at 31 December 2022, as well as the pro forma consolidated statement of financial position as at 31 December 2022 assuming the Offer and the resale/redemption of Challenger Capital Notes 2 occurred on 31 December 2022.

\$ million	Historical as at 31 December 2022	Adjustments ⁱⁱ	Pro forma Historical as at 31 December 2022
Assets			
Cash and cash equivalents	693.7	(116.3)	577.4
Receivables	799.8	-	799.8
Current tax assets	68.7	-	68.7
Derivative assets	676.5	-	676.5
Investment assets	23,364.1	-	23,364.1
Bank assets held for sale ⁱ	358.2	-	358.2
Investment property	3,440.1	-	3,440.1
Loan assets	452.7	-	452.7
Finance leases	15.5	-	15.5
Property, plant and equipment	24.0	-	24.0
Investments in associates	74.3	-	74.3
Other assets	44.7	-	44.7
Right-of-use lease assets	27.3	-	27.3
Deferred tax assets	98.9	-	98.9
Goodwill	579.9	-	579.9
Other intangible assets	6.9	-	6.9
Total assets of shareholders of Challenger Limited	30,725.3	(116.3)	30,609.0
Liabilities			
Payables	951.7	-	951.7
Derivative liabilities	730.8	-	730.8
Bank liabilities held for sale	297.0	-	297.0
Interest bearing financial liabilities	5,691.4	(116.3)	5,575.1
External unit holders' liabilities	4,620.2	-	4,620.2
Provisions	39.0	-	39.0
Lease liabilities	59.2	-	59.2
Deferred tax liabilities	10.1	-	10.1
Life contract liabilities	14,278.4	-	14,278.4
Total liabilities of shareholders of Challenger Limited	26,677.8	(116.3)	26,561.5
Net assets of shareholders of Challenger Limited	4,047.5	-	4,047.5
Equity			
Contributed equity	2,496.9	-	2,496.9
Reserves	(49.8)	-	(49.8)
Retained earnings	1,600.4	-	1,600.4
Total equity of shareholders of Challenger Limited	4,047.5	-	4,047.5

Notes:

- i Current year balances have been impacted by the Bank being held for sale. For detail refer to Note 16 on page 47 of Challenger's 2023 Interim Financial Report.
- ii These adjustments assume Offer proceeds of \$350 million less \$6.3 million in transaction fees (to be amortised over the life of the Challenger Capital Notes 4) and the resale/redemption of all Challenger Capital Notes 2 (\$460 million). The final amount raised under the Offer may be more than \$350 million as a result of amounts allocated under the Reinvestment Offer.

5.2.3 Reconciliation of normalised profit to statutory profit

Challenger Life Company Limited (“CLC”) represents the largest contributor to the Challenger Group’s profits. CLC and its consolidated entities are required by the life insurance accounting standard AASB 1038 *Life Insurance Contracts* to value all assets and liabilities at fair value unless otherwise stated in the standard. This gives rise to fluctuating valuation movements on assets and liabilities being recognised in the profit and loss of CLC and on consolidation for Challenger Limited. CLC is generally a long-term holder of assets, due to holding assets to match the term of life contract liabilities. As a result, Challenger takes a long-term view of the expected capital growth of the portfolio rather than a focus on short-term movements. The Challenger Group reports its earnings on a non-IFRS NCOE basis which removes from the profit and loss period-on-period volatility within CLC caused by the fair value movements of the assets and liabilities.

Investment experience represents the difference between the actual investment gains/losses (both realised and unrealised) and expected gains/losses based on CLC’s medium to long-term expected returns together with new business strain that results from writing new annuities. Investment experience also includes any impact from changes in economic and other actuarial assumptions.

A reconciliation of normalised earnings and investment experience to statutory profit for the Challenger Group is shown below. This reconciliation has been prepared in accordance with the methodology as detailed in Challenger’s unaudited Interim Financial Report for the half year ended 31 December 2022 and Annual Report for the financial year ended 30 June 2022 (as well as the prior period comparatives).

\$ million	For the half year ended 31 December 2022	For the half year ended 31 December 2021	For the financial year ended 30 June 2022	For the financial year ended 30 June 2021
Net income ⁱ	410.5	386.5	776.9	682.1
Comprising:				
- Life normalised cash operating earnings	317.3	287.4	582.8	512.8
- Funds Management net income	87.9	98.2	191.8	169.3
- Bank net income	4.7	0.9	2.3	-
- Corporate and other net income	0.6	-	-	-
Operating expenses ⁱ	(158.1)	(147.1)	(300.5)	(281.3)
Normalised earnings before interest and tax (EBIT)	252.4	239.4	476.4	400.8
Comprising:				
- Life normalised EBIT	263.3	233.0	472.3	398.9
- Funds Management normalised EBIT	30.7	45.1	82.8	71.0
- Bank normalised EBIT	(4.3)	(3.3)	(11.1)	-
- Corporate and other income normalised EBIT	(37.3)	(35.4)	(67.6)	(69.1)
Interest and borrowing costs	(2.0)	(1.9)	(4.1)	(5.0)
Normalised net profit before tax	250.4	237.5	472.3	395.8
Tax on normalised profit	(83.2)	(71.9)	(150.8)	(117.3)
Normalised net profit after tax	167.2	165.6	321.5	278.5
Investment experience after tax	(42.4)	109.1	(81.2)	318.6
Bank impairments after tax ⁱⁱ	(2.1)	-	(0.9)	-
Significant items after tax	-	7.3	14.3	(4.8)
Statutory net profit after tax attributable to equity holders	122.7	282.0	253.7	592.3

Notes:

i “Net income” and “Operating expenses” are internal classifications. These differ from the statutory revenue and expenses classifications, as certain costs (including distribution expenses, property expenses, management fees, special purpose vehicle expenses and finance costs) are netted against gross revenues. While the allocation of amounts to the above items and investment experience differs to the statutory view, both approaches result in the same statutory net profit after tax attributable to equity holders.

ii Represents the provision for expected credit losses and fair value movements due to AASB 5 *Non-Current Assets Held for Sale and Discontinued Operations*.

5.3 Financial information of Challenger Limited parent entity (standalone)

Challenger Limited is the issuing entity for Challenger Capital Notes 4. It is a non-operating holding company and the ultimate parent company of the Challenger Group. The following tables contain information derived from Challenger Limited's unaudited trial balance for the half year ended 31 December 2022 and the parent entity note disclosure in the Annual Report for the financial year ended 30 June 2022 (as well as the prior period comparatives). Challenger applies the amendments to the Corporations Act that removed the requirement to prepare full parent entity financial statements. The disclosures below represent the specific parent entity disclosures for the half year ended 31 December 2022 and financial year ended 30 June 2022 (as well as the prior period comparatives).

5.3.1 Financial results

The following table sets out unaudited historical standalone financial results of Challenger (as parent entity).

Statement of comprehensive income

\$ million	For the half year ended 31 December 2022	For the half year ended 31 December 2021	For the financial year ended 30 June 2022	For the financial year ended 30 June 2021
Dividends and interest from controlled entities	26.4	19.6	288.7	244.3
Finance costs	(21.1)	(15.3)	(31.6)	(28.5)
Profit before income tax	5.3	4.3	257.1	215.8
Income tax benefit	0.4	0.3	0.9	0.6
Total comprehensive income for the period	5.7	4.6	258.0	216.4

5.3.2 Pro forma historical statement of financial position

The following table sets out the unaudited standalone financial position for Challenger (as parent entity) as at 31 December 2022, as well as the pro forma financial position as at 31 December 2022, assuming the Offer and the resale/redemption of Challenger Capital Notes 2 occurred on 31 December 2022.

\$ million	Historical as at 31 December 2022	Adjustments ⁱⁱ	Pro forma Historical as at 31 December 2022
Assets			
Cash and cash equivalents	2.8	-	2.8
Receivables	1,707.4	-	1,707.4
Investment assets – fixed income securities ⁱ	845.0	(110.0)	735.0
Current tax assets	67.6	-	67.6
Deferred tax assets	14.1	-	14.1
Investment in controlled entities	2,464.7	-	2,464.7
Total assets	5,101.6	(110.0)	4,991.6
Liabilities			
Payables	738.0	6.3	744.3
Interest bearing financial liabilities	840.2	(116.3)	723.9
Total liabilities	1,578.2	(110.0)	1,468.2
Net assets	3,523.4	-	3,523.4
Equity			
Contributed equity	2,516.2	-	2,516.2
Share-based payments reserve	(110.9)	-	(110.9)
Retained earnings	1,118.1	-	1,118.1
Total equity	3,523.4	-	3,523.4

Notes:

- i "Investment assets – fixed income securities" relates to the subscription by Challenger of notes issued by CLC that qualify as Additional Tier 1 Capital of CLC.
- ii "Investment assets – fixed income securities" represents assumed Offer proceeds of \$350 million which is invested in Additional Tier 1 Capital notes issued by CLC and offset by the redemption of \$460 million of Additional Tier 1 Capital notes previously issued by CLC in April 2017. The final amount raised under the Offer may be more than \$350 million as a result of amounts allocated under the Reinvestment Offer. "Interest bearing financial liabilities" represents the assumed liability for Challenger Capital Notes 4 issued under the Offer of \$350 million, less total transaction fees of \$6.3 million (to be amortised over the life of the Challenger Capital Notes 4). This is offset by the resale/redemption of \$460 million of Challenger Capital Notes 2. "Payables" represents transaction fees of \$6.3 million paid by another entity in the Challenger Group on behalf of Challenger (as parent entity).

5.4 Capital management

Challenger holds capital to ensure that under a range of adverse scenarios it can continue to meet its regulatory requirements and contractual obligations to customers. The Challenger Group's Australian-based companies are regulated by APRA and/or ASIC. The Funds Management business also has operations in the United Kingdom, Europe and Asia, which are subject to regulation in each jurisdiction. The relevant regulator in each jurisdiction requires a minimum level of regulatory capital to be held.

APRA has developed a supervision framework for conglomerate groups which include APRA-regulated institutions, referred to as "Level 3 groups". APRA's non-capital conglomerate prudential standards relating to measurement, management, monitoring and reporting aggregate risk exposures and intragroup transactions and exposures came into effect on 1 July 2017.

In 2017, APRA announced that it would defer the implementation of conglomerate capital requirements until a number of other domestic and international policy initiatives were further progressed.

On 24 October 2022, APRA further announced a new roadmap for the review of the prudential framework that applies to Level 3 groups. The aim of the review is to ensure that the Level 3 group prudential framework is fit for purpose to cater to an increasing array of new groups, and consistently applied to existing structures to ensure a level playing field. The multi-year review of the Level 3 group prudential framework will be conducted in 2023 and 2024, with revised prudential standards expected to be effective from 2025.

Challenger's capital position is managed with the objective of maintaining the financial stability of Challenger Group, CLC and the Bank, while ensuring that shareholders earn an appropriate risk-adjusted return.

The Challenger Group reports a consolidated or Level 3 equivalent capital position⁴³ for the entire business. The Challenger Group's total regulatory capital base as at 31 December 2022 was \$4.5 billion, and is based on the Challenger Group's shareholder equity adjusted for items such as goodwill, intangibles and investments in associates and other items.

The Minimum Regulatory Requirements⁴⁴ of capital for the Challenger Group's businesses are as follows:

- (a) CLC: capital requirements as specified under APRA's life insurance prudential capital standards (further information is outlined in Section 5.4.1 below);
- (b) Bank: capital requirements as specified under APRA's ADI prudential capital standards; and
- (c) Funds Management: capital requirements as specified by ASIC and regulators in other foreign jurisdictions.

The Challenger Group's Minimum Regulatory Requirement as at 31 December 2022 was \$2.7 billion, and includes:

- (a) CLC of \$2.6 billion (further information is outlined in Section 5.4.1 below);
- (b) Bank of \$27 million; and
- (c) Other⁴⁵, which includes the Funds Management business, of \$40 million.

The Challenger Group's excess regulatory capital above the Minimum Regulatory Requirement as at 31 December 2022 was \$1.8 billion. The Challenger Group's Minimum Regulatory Requirement ratio was 1.67 times, which is equivalent to the Challenger Group holding 67% more regulatory capital than minimum requirements.

5.4.1 CLC's regulatory capital

CLC represents the largest contributor to the Challenger Group's regulatory capital position. The capital management strategy of CLC is to ensure that there is sufficient capital to support the asset, market, operational and life insurance risks it takes within its risk appetite, to invest its capital to support those risks and to deliver a return on equity above its cost of capital. CLC's Internal Capital Adequacy Assessment Process ("ICAAP") provides the framework to ensure that it is independently capitalised to meet internal and external requirements. CLC is subject to, and in compliance with, externally imposed capital requirements set and monitored by APRA. The ICAAP is reviewed annually and, where appropriate, adjustments are made to reflect changes in economic conditions and risk characteristics of Challenger's business activities.

Challenger Capital Notes 4 will not constitute regulatory capital of Challenger, although APRA has confirmed that the proceeds of Challenger Capital Notes 4 may be used to fund a subscription for Additional Tier 1 Capital of CLC.

For regulatory purposes, capital for CLC is classified as follows:

- Common Equity Tier 1 Capital comprising accounting equity with adjustments for intangible assets and regulatory reserves;
- Tier 1 Capital comprising Common Equity Tier 1 Capital plus Additional Tier 1 Capital such as certain hybrid capital instruments with "equity-like" qualities; and
- Tier 2 Capital comprising certain securities recognised as Tier 2 Capital such as subordinated debt.

The sum of Tier 1 Capital and Tier 2 Capital is called the "**Regulatory Capital Base**".

⁴³ The Challenger Group's reported consolidated or Level 3 equivalent capital position represents the minimum capital requirement as required by regulators, including APRA, ASIC and other foreign jurisdictions. The implementation of APRA's prudential framework that applies to Level 3 groups from 2025 may impact on the measurement and presentation of any consolidated or Level 3 equivalent capital position reported by the Challenger Group in future periods.

⁴⁴ Represents the minimum capital requirement as required by regulators, including APRA, ASIC and other foreign jurisdictions.

⁴⁵ Includes Funds Management, Corporate and other Life/Bank entities. Funds Management Minimum Regulatory Requirement for capital is based on requirements set by ASIC and regulators in other foreign jurisdictions. Challenger Retirement and Investment Services Limited Minimum Regulatory Requirement is based on APRA and ASIC requirements.

Common Equity Tier 1 Capital has the greatest capacity to absorb potential losses, followed by Additional Tier 1 Capital and then Tier 2 Capital.

The capital position across CLC as at 31 December 2022 was as follows:


- CLC's Regulatory Capital Base was 1.59 times the prescribed capital amount ("PCA"), and Common Equity Tier 1 Capital was 1.12 times the PCA; and
- CLC's excess Regulatory Capital Base over the PCA was \$1,563.6 million.

5.5 Pro forma capital adequacy position

The proceeds of Challenger Capital Notes 4 will be used to fund a subscription for Additional Tier 1 Capital of CLC. The following table and chart set out CLC's pro forma capital adequacy position based on CLC's financial position as at 31 December 2022. The capital adequacy position as at 31 December 2022 has been obtained from Challenger's 2023 Interim Financial Report.

CLC Regulatory Capital Base \$ million	Actuals as at 31 December 2022	Adjustmentsⁱⁱ	Pro forma as at 31 December 2022
Common Equity Tier 1 Capital	2,947.9	-	2,947.9
Additional Tier 1 Capital	845.0	(110.0)	735.0
Tier 2 Capital – subordinated debt	407.8	-	407.8
CLC total Regulatory Capital Baseⁱ	4,200.7	(110.0)	4,090.7
CLC prescribed capital amount	2,637.1	-	2,637.1
CLC excess over prescribed capital amount	1,563.6	(110.0)	1,453.6
CLC PCA ratio (times)	1.59		1.55

CLC PCA ratio (times)



Notes:

- CLC's regulatory capital base includes a \$400 million subordinated debt instrument which is fully admissible as Tier 2 Capital as at 31 December 2022.
- Assumes Challenger uses the proceeds from the issue of Challenger Capital Notes 4 of \$350 million to fund a subscription for Additional Tier 1 Capital of CLC for the same amount and offset by the redemption of \$460 million of Additional Tier 1 Capital of CLC. APRA has confirmed that the proceeds of Challenger Capital Notes 4 can be used for such a purpose. The final amount raised under the Offer may be more than \$350 million as a result of amounts allocated under the Reinvestment Offer. Additionally, there is no assumed change in prescribed capital amount upon receipt and repayment of the funds by CLC.
- While CLC does not target a specific PCA ratio, CLC's internal capital models result in a PCA ratio under current circumstances in the range of 1.3 to 1.7 times. This range will change over time and is dependent on a number of factors.



Section 6

Investment risks

6. Investment risks

This Section describes some of the risks associated with an investment in Challenger Capital Notes 4 and in Challenger, CLC and the Challenger Group.

Challenger is subject to continuous disclosure obligations, requiring new material information to be announced to ASX. The risks described in this Section are based on an assessment of a combination of the probability of the risk occurring and the impact of the risk if it did occur. They are not an exhaustive statement of all risks that might emerge, they are not listed in order of likelihood of occurrence or impact, and there is no guarantee or assurance that the importance of different risks will not change or that other risks will not emerge. Holders may suffer loss as a result of these risks. If you have any questions about these risks, you should seek personal advice from a qualified financial adviser before you make an investment decision.

Before applying for Challenger Capital Notes 4, you should consider whether Challenger Capital Notes 4 are a suitable investment for you. There are risks associated with an investment in Challenger Capital Notes 4 and in Challenger, CLC and the Challenger Group, many of which are outside the control of Challenger and its Directors. These risks include those referred to in this Section and other matters referred to in this Prospectus.

6.1 Risks associated with investing in Challenger Capital Notes 4

6.1.1 Challenger Capital Notes 4 are not policy or deposit liabilities

Investments in Challenger Capital Notes 4 are an investment in Challenger, CLC and the Challenger Group, and may be affected by the ongoing performance, financial position and solvency of Challenger. Challenger Capital Notes 4 are not:

- policy liabilities of CLC, Challenger or any other member of the Challenger Group;
- protected accounts or deposit liabilities of Challenger Bank, Challenger or any other member of the Challenger Group;
- guaranteed or insured by any government, government agency or compensation scheme of Australia or any other jurisdiction; or
- secured over the assets of Challenger or any member of the Challenger Group.

The investment performance of Challenger Capital Notes 4 is not guaranteed by Challenger, any other member of the Challenger Group or any other person.

6.1.2 Challenger Capital Notes 4 are perpetual, unsecured and subordinated obligations

Challenger Capital Notes 4 are unsecured and subordinated obligations issued by Challenger. They are perpetual instruments, meaning they have no maturity date, so Holders may never be repaid the principal they have invested, and Challenger Capital Notes 4 may never be Converted to Ordinary Shares.

Challenger Capital Notes 4 are claims on Challenger, a non-operating holding company of the companies in the Challenger Group. The majority of Challenger's assets consist of investments in companies which are other members of the Challenger Group. Challenger's claims in respect of those investments rank behind the relevant company's creditors, behind CLC's policyholders, and behind Challenger Bank's depositors, in a winding-up of those companies. Holders have no claim on any other member of the Challenger Group for payment of any amount in respect of Challenger Capital Notes 4.

In a winding-up of Challenger, if Challenger Capital Notes 4 have not already been Converted or Written-Off on account of a Non-Viability Trigger Event, Challenger Capital Notes 4 are subordinated and Holders rank behind Senior Creditors for payment of the Face Value. Challenger Capital Notes 4 will rank equally with, and shall be paid in proportion to, the claims

of holders of other instruments issued as Relevant Perpetual Subordinated Instruments. Challenger Capital Notes 4 will rank ahead only of Ordinary Shares of Challenger. Holders will lose their investment in Challenger Capital Notes 4 if there are insufficient assets to satisfy Senior Creditors in a winding-up of Challenger. Distributions, which are payable at Challenger's absolute discretion, would not be payable and no claim may be brought in respect of any unpaid Distributions in a winding-up of Challenger.

If APRA determines that a Non-Viability Trigger Event has occurred, it will adversely affect the claims of Holders in the event of a winding-up. If a Non-Viability Trigger Event occurs, Challenger is required to Convert some or all Challenger Capital Notes 4 to Ordinary Shares. After Challenger Capital Notes 4 are Converted, Holders will then hold Ordinary Shares and rank below all creditors in a winding-up of Challenger. If Conversion does not occur for any reason within five Business Days of the Non-Viability Conversion Date, those Challenger Capital Notes 4 which are required to be Converted will be Written-Off. If Challenger Capital Notes 4 are Written-Off, all rights in relation to those Challenger Capital Notes 4 will be terminated, and Holders will lose the entire amount of their investment without compensation.

Although Challenger Capital Notes 4 may pay a higher rate of distribution than comparable securities and instruments which are not subordinated, there is a significant risk that Holders will lose all or some of their investment in Challenger Capital Notes 4 should Challenger become insolvent.

6.1.3 Market price of Challenger Capital Notes 4

There is a risk that the market price of Challenger Capital Notes 4 may fluctuate due to various factors, including but not limited to investor perceptions, Australian and international economic conditions, major Australian or international events including a pandemic, acts of terrorism, an outbreak of international hostilities or tensions (including the ongoing conflict between Russia and Ukraine), geopolitical instability, better rates of return on other securities, interest rates, inflation rates, movements in foreign exchange rates, impacts of regulatory change (including intervention by ASIC in the market for Challenger Capital Notes 4 or similar securities), changes in the laws relating to the availability of franking, movements in the market price of Ordinary Shares or senior or subordinated debt, Challenger's financial performance and position, as a result of information disclosed to the market by Challenger in order to comply with its continuous disclosure requirements and other factors that may affect that performance and position. The market price of Challenger Capital Notes 4 may also be affected by changes in Challenger's credit rating (see Section 6.1.2.1 for further information).

In recent years, markets have sometimes been volatile. In particular, since March 2020 global financial markets have become more volatile due to the impact of the COVID-19 pandemic and the Ukraine war. Moreover, there has been increased volatility recently due to interest rate increases, rising inflation and other factors. Investing in volatile conditions implies a greater level of volatility risk for investors than an investment in a more stable market. Volatility risk is the potential for fluctuations in the price of securities, sometimes markedly and over a short period. You should carefully consider the impact of volatility risk on the potential market price of the Challenger Capital Notes 4 before deciding whether to make an investment in Challenger Capital Notes 4.

Challenger Capital Notes 4 may trade at a market price below the Face Value and the market price may be more sensitive than that of equity to changes in interest rates, credit margins and other market prices. Should credit margins on comparable securities or investments increase, there is a risk that the return on Challenger Capital Notes 4 may become less attractive, which could lead to a fall in the market price for Challenger Capital Notes 4.

There is no guarantee that Challenger Capital Notes 4 will remain continuously quoted on ASX or will not be suspended from trading. ASX has broad powers to suspend Challenger Capital Notes 4, including because Challenger has not complied with the ASX Listing Rules.

Holders who wish to sell or otherwise transfer their Challenger Capital Notes 4 prior to Exchange may incur loss if Challenger Capital Notes 4 trade at a market price below the amount for which Challenger Capital Notes 4 were acquired by those Holders.

6.1.4 Suitability of Challenger Capital Notes 4 as an investment

Challenger Capital Notes 4 are a complex investment and may be difficult to understand, even for experienced investors. You should ensure that you understand the Terms and risks of investing in Challenger Capital Notes 4 and consider whether it is an appropriate investment for your particular circumstances.

If you are a Retail Investor and you wish to participate in the Offer, you must seek professional advice as to whether you are within the Challenger Capital Notes 4 Target Market and if an investment in Challenger Capital Notes 4 is suitable given your particular investment objectives, financial situation and needs. You can only apply for Challenger Capital Notes 4 if you are within the Challenger Capital Notes 4 Target Market and you have received personal advice from a qualified financial adviser.

For more information on the Challenger Capital Notes 4 Target Market, see Section 7.4.2.

6.1.5 Liquidity of Challenger Capital Notes 4

There is a risk that there may be no liquid market for Challenger Capital Notes 4. Although Challenger intends to have Challenger Capital Notes 4 quoted on ASX, there is no guarantee that there may be a liquid market or that any market will develop for Challenger Capital Notes 4. Any market for Challenger Capital Notes 4 may be less liquid than the market for Ordinary Shares or comparable securities issued by Challenger or other entities, and may be volatile. The market price of Challenger Capital Notes 4 is likely to fluctuate and, if Holders wish to sell or otherwise transfer their Challenger Capital Notes 4 prior to Exchange, they may be unable to do so at a price acceptable to them, or at all, if insufficient liquidity exists in the market for Challenger Capital Notes 4.

6.1.6 Market price and liquidity of Ordinary Shares

Challenger Capital Notes 4 may Convert into Ordinary Shares as described in Sections 2.2 to 2.5 of this Prospectus, but there is no guarantee that this will necessarily occur. Conversion may be disadvantageous in light of market conditions or not suit the individual circumstances and preferences of Holders. The only conditions to Conversion are, in the case of Mandatory Conversion, the Mandatory Conversion Conditions and, in the case of an Exchange at Challenger's option or following an Acquisition Event, the conditions expressly applicable to such Conversion under clauses 6 and 7 of the Terms. No other conditions apply upon Conversion except as expressly provided in the Terms.

Where Challenger Capital Notes 4 are Converted, there may be no liquid market for Ordinary Shares at the time of Conversion (particularly if Conversion is in connection with a Non-Viability Trigger Event), or the market for Ordinary Shares may be less liquid than that for comparable securities issued by other entities at the time of Conversion.

Upon Conversion, other than Conversion resulting from a Non-Viability Trigger Event, Holders will receive Ordinary Shares with a value of approximately \$101 per Challenger Capital Note 4 (based on the VWAP during a period, typically 20 Business Days, immediately preceding (but not including) the relevant Conversion date).

The market price of Ordinary Shares may fluctuate due to various factors, including Australian equity markets, recommendations by brokers, analysts and proxy advisers, investor perceptions, any potential takeover offers, acquisition, mergers or divestments, third-party reports, interest rates and inflation, Australian and international economic conditions (including, but limited to, the ongoing impact of the COVID-19 pandemic and any future pandemics), changes in government, fiscal and monetary policy, global and geo-political events, hostilities and acts of terrorism, Challenger's financial performance and position, impacts of regulatory change (including product intervention by ASIC in the market for Challenger Capital Notes 4 or similar securities), as a result of information disclosed to the market by Challenger in order to comply with its continuous disclosure requirements and other factors that may affect that performance and position, and may also be affected by the actual or prospective Conversion of Challenger Capital Notes 4. These risks can be more extreme during periods of high volatility and financial market disruption, such as that which occurred in the wake of the COVID-19 pandemic.

The VWAP during the relevant period before the date of Conversion that is used to calculate the number of Ordinary Shares that Holders receive will most likely differ from the Ordinary Share price on or after the date of Conversion. As a result, the value of Ordinary Shares received upon Conversion may be greater than or less than \$101 per Challenger Capital Note 4 when they are issued or at any time after that, and could be less than the Face Value. Holders receiving Ordinary Shares on Conversion may not be able to sell those Ordinary Shares at the price on which the Conversion calculation was based, or at all.

Certain events and conditions may affect the ability of Holders to trade or dispose of Ordinary Shares issued on Conversion; for example, the willingness or ability of ASX to accept Ordinary Shares issued on Conversion for quotation or any practical issues which affect that quotation, any suspension of trading of Ordinary Shares, any disruption to the market for Ordinary Shares or to capital markets generally, the availability of purchasers for

Ordinary Shares and any costs or practicalities associated with trading or disposing of Ordinary Shares at that time.

The Ordinary Shares held as a result of any Conversion will, following Conversion, rank equally with existing Ordinary Shares. Accordingly, the ongoing value of any Ordinary Shares received upon Conversion will depend upon the market price of Ordinary Shares after the date on which Challenger Capital Notes 4 are Converted.

The market price of Ordinary Shares may also be affected by changes in Challenger's credit rating. For further information about the impacts of credit ratings on Challenger, see Section 6.1.21.

6.1.7 Distributions may not be paid

There is a risk that Distributions will not be paid. The Terms do not oblige Challenger to pay Distributions, and Challenger has absolute discretion not to pay any Distribution.

In addition, a Distribution will not be paid if on a Distribution Payment Date:

- the consolidated retained earnings of the Challenger Group are negative (or would become negative on payment of the Distribution);
- the payment of the Distribution would result in Challenger becoming, or being likely to become, insolvent for the purposes of the Corporations Act; or
- APRA objects to the payment.

No Distribution will be paid on Conversion where Conversion occurs due to a Non-Viability Trigger Event.

Challenger may also be prevented from paying Distributions by the terms of securities issued, or which may be issued in future, by other members of the Challenger Group if a dividend, distribution or other payment has not been paid on those securities. The terms of securities issued by a member of the Challenger Group may also restrict that member from paying dividends, distributions or making other payments to Challenger if a payment on the relevant security is not paid. If Challenger or a member of the Challenger Group is subject to such a constraint, Challenger may not be able to pay Distributions on Challenger Capital Notes 4 without the approval of the holders of those other securities.

Changes in regulations applicable to Challenger, including changes in accounting standards (such as AASB 17, see Section 6.1.24), may affect Challenger's ability to pay a Distribution, or a dividend, distribution or other payment on other securities.

The Terms contain no events of default and, accordingly, failure to pay a Distribution when scheduled will not constitute an event of default or entitle a Holder to require Challenger to Redeem Challenger Capital Notes 4 early. Further, in the event that Challenger does not, or may become unable to, pay a Distribution when scheduled, a Holder:

- has no right to apply for Challenger to be wound up or placed in administration, or to cause a receiver or a receiver and manager to be appointed in respect of Challenger; and
- has no right of set-off and no offsetting rights or claims on Challenger under the Terms.

Distributions are non-cumulative, meaning that if not paid they may never be paid. If a Distribution is not paid for any reason, Holders will have no recourse whatsoever to Challenger for the unpaid amount. Holders will not receive any interest on unpaid Distributions.

However, if Challenger does not pay a Distribution in full on a Distribution Payment Date, a limited restriction applies to the payment of dividends on Ordinary Shares (see Section 6.1.16 for further information).

6.1.8 Changes in Distribution Rate and Distributions

There is a risk that the rate of return in respect of Challenger Capital Notes 4 may become less attractive when compared to rates of return available on comparable securities issued by Challenger or other entities. The Distribution Rate is calculated for each Distribution Period by reference to the BBSW Rate (which is a benchmark floating interest rate for the Australian money market) plus the Margin (which is fixed). The BBSW Rate is influenced by a number of factors and varies over time, resulting in the Distribution Rate also varying over time.

In some offshore money markets in recent times certain benchmark floating interest rates have been negative for periods of time. If the BBSW Rate were to become negative, then the Distribution Rate would be less than the Margin, and in some cases could become equal to zero. In addition, the methodology used to calculate the BBSW Rate may change over time. The Distribution Rate will go up or down over time as a result of movements in the BBSW Rate.

Changes in the Australian corporate tax rate applicable to Challenger will also affect the Distribution Rate (see Section 6.1.22 for further information). The Distribution Rate may be less than the Margin even where the BBSW Rate is positive depending on the level of the Australian corporate tax rate, since the Distribution Rate is equal to the sum of the BBSW Rate and the Margin, multiplied by one minus the Australian corporate tax rate applying at the time.

If Challenger determines that a Rate Disruption Event has occurred, then, subject to APRA's prior written approval, Challenger will use as the BBSW Rate such Replacement Rate as it may determine and will make such adjustments to the Terms as it determines are reasonably necessary to calculate Distributions in accordance with such Replacement Rate. Holders should note that APRA's approval may not be given for any proposed Replacement Rate that it considers to have the effect of increasing the rate of Distributions contrary to applicable prudential standards.

As the Distribution Rate fluctuates, there is a risk that it may become less attractive when compared to the rates of return available on comparable securities issued by Challenger or other entities.

Distributions will fluctuate over time (both increasing and decreasing) as a result of changes in the Distribution Rate due to the factors outlined above, changes in the Franking Rate (see Section 6.1.9 below), and also as a function of the number of days in each Distribution Period.

6.1.9 Distributions may or may not be franked

The Distributions paid on Challenger Capital Notes 4 are expected to be fully franked; however there is a risk that Challenger will not have sufficient franking credits in the future to frank Distributions to any extent. The Franking Rate for a Distribution Period will vary depending upon Challenger's level of available franking credits. The effect of Distributions being franked is to reduce the cash amount received by Holders on each Distribution Payment Date by an amount equal to the franking credit attached to the Distribution.

The Franking Rate for a Distribution Period will be affected by Challenger's level of available franking credits and Challenger's

distributable profits. Challenger's level of available franking credits may be affected by a wide range of factors, including its business performance, the applicable Australian corporate tax rate, the assessment of relevant tax authorities and the amount of other frankable distributions. Challenger's distributable profits may also be affected by a wide range of factors including its level of earnings and other distributions it makes.

Distributions will be franked at the same rate as Ordinary Shares. The Distribution Rate will be adjusted depending on the franking percentage and the Australian corporate tax rate both applicable to Challenger's franking account.

The value and availability of franking credits to a Holder will differ depending on that Holder's particular tax circumstances. Holders should be aware that the potential value of any franking credits does not accrue at the same time as the receipt of any cash Distribution, and that the ability to use any franking credits, either by offsetting a tax liability or by claiming a refund after the end of the income year, will depend on the individual tax position of each Holder. Each Holder should refer to the Australian taxation summary in Section 8 and obtain professional advice in relation to its tax position and monitor any such potential changes on an ongoing basis.

6.1.10 Exchange is at Challenger's option and may never occur

Challenger has the option, subject to APRA's prior written approval, to Exchange (Convert, Redeem or Resell) some or all Challenger Capital Notes 4 on any Optional Exchange Date or on the occurrence of a Tax Event or a Regulatory Event. Challenger is not obliged to Exchange any Challenger Capital Notes 4 on an Optional Exchange Date.

Challenger may also Exchange by way of Conversion all (but not some only) Challenger Capital Notes 4 after a Potential Acquisition Event. Challenger is not obliged to Exchange the Challenger Capital Notes 4 after a Potential Acquisition Event, and Holders should not expect that Challenger will do so. Challenger may not select Redemption or Resale as the Exchange Method for an Exchange after a Potential Acquisition Event.

Holders have no right to request or require an Exchange in any circumstances.

Any Exchange at Challenger's option may occur on dates not previously contemplated by Holders. This may be disadvantageous to Holders in light of market conditions or their individual circumstances and may not coincide with their individual preference in terms of timing. This also means that the period for which Holders will be entitled to the benefit of the rights attaching to Challenger Capital Notes 4 (such as Distributions) is unknown.

Subject to certain restrictions, Challenger has discretion to elect which Exchange Method will apply to an Exchange, being Conversion, Redemption or Resale (and a combination of Exchange Methods may be chosen, as explained below). The method chosen by Challenger may be disadvantageous to Holders and may not coincide with their individual preference in terms of whether they receive Ordinary Shares or cash on the Exchange Date.

For example, if APRA approves an election by Challenger to Redeem or Resell Challenger Capital Notes 4, Holders will receive cash equal to \$100 per Challenger Capital Note 4 rather than Ordinary Shares and, accordingly, they will not benefit from any subsequent increases in the Ordinary Share price after the Exchange occurs. In addition, where Holders receive cash on Redemption or Resale, the rate of return at which they could

reinvest their funds may be lower than the Distribution Rate at the time. Where Holders receive Ordinary Shares on Conversion, they will have the same rights as other holders of Ordinary Shares, which are different to the rights attaching to Challenger Capital Notes 4.

Subject to certain restrictions on which Exchange Method may be selected by Challenger, Challenger may select a combination of Conversion, Redemption or Resale to apply to Challenger Capital Notes 4 held by a Holder and may select a different combination of Conversion, Redemption or Resale in respect of Challenger Capital Notes 4 held by different Holders. Challenger's choice may differ from the Holder's preference. Challenger must nevertheless endeavour to treat Holders, in the case of an Exchange of only some Challenger Capital Notes 4, on an approximately proportionate basis (although it may differentiate between individual Holders to take account of the effect on marketable parcels and other logistical considerations).

6.1.11 Exchange at Challenger's option is subject to certain conditions

If Challenger elects to Exchange Challenger Capital Notes 4 by way of Conversion, Redemption or Resale, APRA's prior written approval is required. Holders should not expect that APRA will give its approval to any Exchange. Challenger may not elect Conversion as the Exchange Method if an Optional Conversion Restriction applies. See Sections 2.3.4 and 2.3.5 for further information.

Challenger may not proceed to Conversion on an Exchange Date if further restrictions apply. These restrictions are that either the Second Mandatory Conversion Condition or the Third Mandatory Conversion Condition would not be satisfied in respect of the Exchange Date (as if the Exchange Date were a "Relevant Date" for the purposes of the Mandatory Conversion Conditions). See Section 2.3.6 for further information.

If the requirements for Conversion on the Exchange Date are not satisfied, Challenger will notify Holders, and the Conversion will be deferred until the next Distribution Payment Date on which the requirements for Conversion would be satisfied.

Even if Challenger has elected to Exchange Challenger Capital Notes 4 and selected Conversion as the Exchange Method, and APRA has approved such election, the conditions to Conversion may never be satisfied, and Holders should not expect that it will occur.

Challenger may not select Redemption as the Exchange Method unless APRA is satisfied that either:

- Challenger Capital Notes 4 the subject of the Redemption will be replaced concurrently or beforehand with Relevant Perpetual Subordinated Instruments of the same or better quality, or Ordinary Shares, and the replacement of Challenger Capital Notes 4 is done under conditions that are sustainable for Challenger's income capacity; or
- having regard to the projected capital position of Challenger and the Challenger Group, Challenger does not have to replace Challenger Capital Notes 4 which are the subject of the Redemption.

A weakening of Challenger and the Challenger Group's capital position may make it less likely that APRA would approve a Redemption of Challenger Capital Notes 4.

In addition, APRA has recently stated that, consistent with its prudential requirements, where it considers any replacement capital to be more expensive (including because of higher credit margins), APRA may not approve a Redemption unless

Challenger satisfies it as to the economic and prudential rationale for the Redemption and that the Redemption will not create an expectation that Challenger's other regulatory capital instruments will be redeemed in similar circumstances.

The matters to which APRA may have regard in considering whether to give its approval are not limited and may change.

Challenger may not select Redemption or Resale as the Exchange Method for an Exchange after a Potential Acquisition Event.

The timing of Exchange and the Exchange Method chosen by Challenger may be disadvantageous to Holders and may not coincide with their individual preference in terms of whether they receive Ordinary Shares or cash on the relevant date.

6.1.12 Mandatory Conversion is subject to certain conditions and may not occur when expected or at all

Challenger Capital Notes 4 must be Converted into Ordinary Shares on the Scheduled Mandatory Conversion Date (25 February 2032) (unless they have been Redeemed for cash, Converted to Ordinary Shares or Written-Off on an earlier date). However, Mandatory Conversion is subject to satisfaction of the Mandatory Conversion Conditions and may not occur on the Scheduled Mandatory Conversion Date, or at all. The Mandatory Conversion Conditions are described in Section 2.2.4. There is a risk that Conversion will not occur because the Mandatory Conversion Conditions are not satisfied due to a significant reduction in the Ordinary Share price relative to the Issue Date VWAP, or a Delisting Event applies. The Ordinary Share price may be affected by transactions impacting the share capital of Challenger, such as rights issues, placements, returns of capital, certain buy-backs and other corporate actions. The Issue Date VWAP is adjusted only for transactions by way of pro rata bonus issues of Ordinary Shares and a reorganisation of share capital as described in clause 8 of the Terms and not for other transactions, including rights issues, placements, returns of capital, buy-backs or special distributions. The Terms do not limit the transactions which Challenger may undertake with respect to its share capital (except in limited circumstances where a Distribution has not been paid in full on a scheduled Distribution Payment Date) and any such action may affect whether Conversion will occur and the Conversion Number of Ordinary Shares, and may adversely affect the position of Holders.

If Mandatory Conversion does not occur on the Scheduled Mandatory Conversion Date, Mandatory Conversion will be deferred until the next Distribution Payment Date on which all of the Mandatory Conversion Conditions are satisfied (unless Challenger Capital Notes 4 are otherwise Exchanged on or before that date).

If Mandatory Conversion does not occur on a possible Mandatory Conversion Date and Challenger Capital Notes 4 are not otherwise Exchanged or Written-Off, Distributions may continue to be paid on Challenger Capital Notes 4, subject to Challenger's discretion and to no Payment Condition existing in connection with the relevant Distribution Payment Date.

Challenger Capital Notes 4 are a perpetual instrument. If the price of Ordinary Shares deteriorates significantly and never recovers or a Delisting Event continues to subsist, it is possible that the Mandatory Conversion Conditions will never be satisfied and, if this occurs, Challenger Capital Notes 4 will never Convert under the Mandatory Conversion provisions.

6.1.13 Conversion as a result of an Acquisition Event

Challenger Capital Notes 4 are issued by Challenger, which, as an ASX-listed company, may be affected by merger and acquisition activity, including the possibility of being acquired by, or merged with, another company or group of companies, potentially resulting in a change of control.

Where this corporate activity constitutes an Acquisition Event, as defined in the Terms, Challenger is required, subject to satisfaction of certain conditions, to Convert all Challenger Capital Notes 4 to Ordinary Shares in accordance with clause 7 of the Terms. An Acquisition Event may occur at any time. Where this corporate activity constitutes a Potential Acquisition Event, as defined in the Terms, Challenger may (but is not required to) elect, subject to satisfaction of certain conditions, to Convert all Challenger Capital Notes 4 in accordance with clause 6 of the Terms. Conversion may occur on dates not previously contemplated by Holders, which may be disadvantageous in light of market conditions or their individual circumstances and may not coincide with their individual preference in terms of timing. This also means that the period for which Holders will be entitled to the benefit of the rights attaching to Challenger Capital Notes 4 (such as Distributions) is unknown. Where Holders receive Ordinary Shares on Conversion, they will have the same rights as other holders of Ordinary Shares, which are different to the rights attaching to Challenger Capital Notes 4.

There is a risk that Conversion may not occur on the Acquisition Conversion Date or at all because one of the restrictions on when Conversion is required or restrictions on completing a Conversion in connection with an Acquisition Event apply, for example, due to a significant reduction in the Ordinary Share price relative to the Issue Date VWAP, or where a Delisting Event applies. The Ordinary Share price may be affected by many factors, including transactions affecting the share capital of Challenger as described in Section 6.1.6.

If Conversion does not occur on the Acquisition Conversion Date, then Conversion will occur on the following Distribution Payment Date for which the restrictions do not apply, unless Challenger Capital Notes 4 are otherwise Exchanged or Written-Off on or before that date. If Conversion does not occur on a possible Acquisition Conversion Date and Challenger Capital Notes 4 are not otherwise Exchanged or Written-Off, Distributions may continue to be paid on Challenger Capital Notes 4, subject to Challenger's discretion and to no Payment Condition existing in connection with the relevant Distribution Payment Date.

Challenger Capital Notes 4 are a perpetual instrument. If the price of Ordinary Shares deteriorates significantly and never recovers or a Delisting Event continues to subsist, it is possible that the restrictions on Conversion will continue to apply and, if this occurs, unless Challenger Capital Notes 4 are otherwise Exchanged, Challenger Capital Notes 4 will never Convert.

Not all corporate activities that have the effect of a change of control of Challenger or its business operations will be an Acquisition Event. In particular, it would not be an Acquisition Event if APRA were to require the compulsory transfer of the Challenger Group's life insurance business (see Section 6.2.2 for further information). Where the corporate activity is not an Acquisition Event, Challenger is not obliged to Convert the Challenger Capital Notes 4. Therefore, the outcomes for Holders arising from that corporate activity will be uncertain and Holders may face increased or different risks in holding the Challenger Capital Notes 4.

6.1.14 Conversion or Write-Off on account of a Non-Viability Trigger Event

Challenger must immediately Convert some or all Challenger Capital Notes 4 into Ordinary Shares on the occurrence of a Non-Viability Trigger Event. As APRA will determine if and when a Non-Viability Trigger Event has occurred, it may occur at any time and on dates not previously contemplated by Holders. This may be disadvantageous in light of market conditions or Holders' individual circumstances.

What is a Non-Viability Trigger Event?

A Non-Viability Trigger Event occurs when APRA has provided a written determination to Challenger that:

- the conversion or write-off of Relevant Perpetual Subordinated Instruments is necessary because without the conversion or write-off, APRA considers that Challenger would become non-viable; or
- without a public sector injection of capital into, or equivalent support with respect to, Challenger, APRA considers that Challenger would become non-viable.

APRA has not provided specific guidance as to how it would determine non-viability (however, in the context of regulatory capital instruments issued by ADIs, APRA has indicated that non-viability is likely to arise prior to the insolvency of an ADI). Non-viability could be expected to include serious impairment of Challenger's financial position and insolvency; however, it is possible that APRA's definition of non-viability may not necessarily be confined to solvency or capital measures, and APRA's position on these matters may change over time.

CLC represents a substantial part of the business of the Challenger Group. If APRA determines CLC to be non-viable, then there is a significant risk it will also determine Challenger to be non-viable. As the occurrence of a Non-Viability Trigger Event is at the discretion of APRA, there can be no assurance given as to the factors and circumstances that might give rise to this event.

Effect of a Non-Viability Trigger Event

If a Non-Viability Trigger Event occurs:

- Challenger must immediately Convert to Ordinary Shares all (or, if less than all Challenger Capital Notes 4 are required to be Converted, some) Challenger Capital Notes 4 on issue;
- if Converted, Conversion is immediate and, from the Non-Viability Conversion Date, Challenger will treat each Holder of a Challenger Capital Note 4 as having been issued the Conversion Number of Ordinary Shares. Challenger expects that any ASX trades in Challenger Capital Notes 4 that have not settled on the date a Non-Viability Trigger Event occurs will continue to settle in accordance with the normal ASX T+2 settlement, although Challenger expects that the seller of a Challenger Capital Note 4 will be treated as having delivered, and the buyer of a Challenger Capital Note 4 will be treated as having acquired, the Conversion Number of Ordinary Shares into which that Challenger Capital Note 4 has been Converted as a result of the occurrence of the Non-Viability Trigger Event;
- alternatively, Challenger may immediately seek a trading halt to prevent further trading in Challenger Capital Notes 4 on ASX, and if ASX permits, may refuse to register transfers of Challenger Capital Notes 4 that have not settled – this may result in disruption or failures in trading or dealings in Challenger Capital Notes 4 (which may cause a Holder to suffer loss);
- Challenger may make such decisions with respect to the identity of Holders as at the Non-Viability Conversion Date as may be necessary or desirable to ensure that Conversion

occurs in an orderly manner, including disregarding any transfers of Challenger Capital Notes 4 that have not been settled or registered at that time;

- Conversion is not subject to the Mandatory Conversion Conditions or any other conditions being satisfied;
- Holders will not receive prior notice of Non-Viability Conversion or have any rights to vote in respect of any Non-Viability Conversion; and
- the Ordinary Shares issued on Non-Viability Conversion may not be quoted at the time of issue, or at all.

Conversion following a Non-Viability Trigger Event

The number of Ordinary Shares the Holder of a Challenger Capital Note 4 will receive on Conversion following a Non-Viability Trigger Event is calculated in accordance with the Conversion Number formula and is subject to a Maximum Conversion Number. There are no tests or conditions to Non-Viability Conversion occurring, and there is a substantial risk that this may result in a Holder receiving a number of Ordinary Shares which have an aggregate value significantly below the total Face Value of their Challenger Capital Notes 4, or receiving Ordinary Shares which are not listed or otherwise able to be traded on ASX. Holders may suffer loss as a result due to a number of factors:

- the number of Ordinary Shares which the Holder of a Challenger Capital Note 4 may be allocated on Conversion is limited to the Maximum Conversion Number. The Maximum Conversion Number is calculated as the number of Ordinary Shares a Challenger Capital Note 4 would Convert to based on an Ordinary Share price equal to 20% of the Issue Date VWAP. If the relevant VWAP at the time of Conversion is less than 20% of the Issue Date VWAP, Holders of Challenger Capital Notes 4 will receive fewer Ordinary Shares than their Challenger Capital Notes 4 are worth and may suffer loss as a consequence;
- the Conversion Number of Ordinary Shares per Challenger Capital Note 4 is calculated by reference to the VWAP during the five Business Days immediately preceding (but not including) the Non-Viability Conversion Date. This VWAP is likely to differ from the Ordinary Share price on or after that date. The Ordinary Shares may not be listed or may not be able to be sold at prices representing their value based on the VWAP, or at any price; and
- as noted in Section 2.2.8, the Maximum Conversion Number may be adjusted to reflect a reorganisation of share capital or pro rata bonus issue of Ordinary Shares. However, no adjustment will be made to it on account of other transactions which may affect the price of Ordinary Shares, including, for example, rights issues, placements, returns of capital, buy-backs or special distributions. The Terms do not limit the transactions that Challenger may undertake with respect to its share capital, and any such action may increase the risk that the Maximum Conversion Number is triggered if Challenger Capital Notes 4 are Converted. Such transactions may adversely affect the position of Holders.

If less than all Challenger Capital Notes 4 and other Relevant Perpetual Subordinated Instruments are required to be converted, Challenger:

- must determine which Challenger Capital Notes 4 will Convert and in doing so must endeavour to treat Holders and holders of other Relevant Perpetual Subordinated Instruments on an approximately proportionate basis, but may discriminate to take account of the effect on marketable parcels, other logistical considerations and the need to effect conversions immediately. Accordingly, should

a Non-Viability Trigger Event occur and some (but not all) Challenger Capital Notes 4 are required to be Converted, not all Holders may have their Challenger Capital Notes 4 Converted; and

- where Relevant Perpetual Subordinated Instruments are not all in the same currency, Challenger may treat them as if converted into a single currency of Challenger's choice at such rate of exchange as Challenger considers reasonable (but may make adjustments among Holders and holders of other Relevant Perpetual Subordinated Instruments having regard to effect Conversion immediately).

Accordingly, should a Non-Viability Trigger Event occur, and Challenger is permitted to Convert only some and not all Challenger Capital Notes 4, not all Holders may have their Challenger Capital Notes 4 Converted into Ordinary Shares.

Write-Off if Conversion does not occur

Notwithstanding any other provisions of the Terms, if for any reason (including, without limitation, an Inability Event) Conversion of any Challenger Capital Notes 4 on account of a Non-Viability Trigger Event does not occur within five Business Days of the Non-Viability Conversion Date, Conversion of those Challenger Capital Notes 4 will not occur and the relevant Holders' rights (including to Distributions and payment of Face Value in relation to such Challenger Capital Notes 4, and to be issued with Ordinary Shares) will be immediately and irrevocably Written-Off and terminated (with effect on and from the Non-Viability Conversion Date). This means Holders will lose all of their investment in the Challenger Capital Notes 4 without compensation.

An "Inability Event" means that Challenger is prevented by applicable law, or order of any court, or action of any government authority (including regarding the insolvency, winding-up or other external administration of Challenger) or any other reason from Converting the Challenger Capital Notes 4.

The laws under which an Inability Event may arise include laws relating to the ability of a person to acquire interests in an Australian corporation or financial sector entity. The laws and other grounds on which an Inability Event may arise may change and may be adverse to the interests of Holders. An Inability Event is taken to subsist if Challenger receives legal advice to that effect.

The law gives statutory recognition to conversion and write-off provisions in regulatory capital instruments such as Challenger Capital Notes 4, subject to limited exceptions.

6.1.15 Conversion into Ordinary Shares

There is a risk that Challenger Capital Notes 4 will Convert into Ordinary Shares, which may be disadvantageous in light of market conditions or not suit individual Holders' circumstances and preferences. The only conditions to Conversion are, in the case of Mandatory Conversion, the Mandatory Conversion Conditions and, in the case of an Exchange at Challenger's option or following an Acquisition Event, the conditions expressly applicable to such Conversion under clauses 6.6 and 7.5 of the Terms. No other conditions will affect the Conversion, except as expressly provided by the Terms.

Although one condition to Conversion is that a Delisting Event does not apply (other than in connection with a Conversion on account of a Non-Viability Trigger Event, which is not subject to conditions), other events and conditions may affect the ability of Holders to trade or dispose of the Ordinary Shares issued on Conversion including, for example, the willingness or ability of ASX to accept the Ordinary Shares

issued on Conversion for quotation or any practical issues which affect that quotation, whether ASX has suspended trading in Ordinary Shares, any disruption to the market for the Ordinary Shares or to capital markets generally, the availability of purchasers for Ordinary Shares and any costs or practicalities associated with trading or disposing of Ordinary Shares at that time. Further, as outlined in Section 6.1.14, Conversion following a Non-Viability Trigger Event is not subject to any conditions.

Ordinary Shares are a different type of investment from Challenger Capital Notes 4. For example, dividends on Ordinary Shares are not determined by a formula and are generally declared and paid on a semi-annual basis. APRA's prudential standards for life insurers may also impose restrictions in respect of CLC's ordinary shares in certain circumstances, specifically, on CLC's ability to pay dividends or other distributions to Challenger as its parent entity, which may in turn impact Challenger's ability to fund dividend payments on Ordinary Shares in a timely manner. Holders of Ordinary Shares will rank behind the claims of all other securities and debts of the Challenger Group in a winding-up of Challenger.

6.1.16 A Distribution Restriction applies but only in limited circumstances

If a Distribution is not paid in full within three Business Days of the scheduled Distribution Payment Date then, subject to certain exceptions set out in clause 3.9 of the Terms, Challenger must not declare, determine to pay, or pay a dividend on any Ordinary Shares, or buy back or reduce capital on any Ordinary Shares without the approval of a Special Resolution. This restriction applies only to payments on, or buy-backs or capital reductions in respect of, Ordinary Shares, and not to payments on, or buy-backs or capital reductions in respect of, securities ranking equally with Challenger Capital Notes 4 or any other class of security (if on issue). These restrictions will apply only until and including the next Distribution Payment Date.

The dates for the declaration, determination or payment of dividends on Ordinary Shares of Challenger, or on which Challenger may undertake a capital reduction or buy-back on any Ordinary Shares, are determined by Challenger in its discretion and are not related to the Distribution Payment Dates for Challenger Capital Notes 4. Accordingly, as soon as the next scheduled Distribution on Challenger Capital Notes 4 is paid, the restriction ceases to apply and Challenger will not be restricted from declaring, determining to pay, or paying a dividend or undertaking any buy-back or capital reduction.

6.1.17 Future issues or redemptions of securities by Challenger and other dealings

The Terms do not in any way restrict Challenger or other members of the Challenger Group from issuing further securities or from incurring further indebtedness (and which may rank senior to the Challenger Capital Notes 4). Challenger's obligations under Challenger Capital Notes 4 rank subordinate and junior in a winding-up to Challenger's obligations to holders of senior ranking securities and instruments, and other creditors, including subordinated creditors (other than creditors whose claims are subordinated to or rank equally with or behind Challenger Capital Notes 4). Accordingly, Challenger's obligations under Challenger Capital Notes 4 will not be satisfied unless it can satisfy in full all of its other obligations ranking senior to Challenger Capital Notes 4.

Challenger and other members of the Challenger Group may in the future issue securities that:

- rank for distributions or payments of capital (including on the winding-up of Challenger) equally with, behind or ahead of Challenger Capital Notes 4;
- have the same or different dividend, interest or distribution rates as the Distribution Rate for Challenger Capital Notes 4;
- have payment tests and distribution restrictions or other covenants which affect Challenger Capital Notes 4 (including by restricting circumstances in which Distributions can be paid or Challenger Capital Notes 4 can be Redeemed); or
- have the same or different terms and conditions as Challenger Capital Notes 4.

Challenger may incur further indebtedness and may issue further securities including further Relevant Perpetual Subordinated Instruments before, during or after the issue of Challenger Capital Notes 4.

An investment in Challenger Capital Notes 4 carries no right to participate in any future issue of securities (whether common equity, preference shares, subordinated or senior debt or otherwise) by Challenger.

The Terms of the Challenger Capital Notes 4 do not restrict any member of the Challenger Group from redeeming, buying back or undertaking a reduction of capital in certain circumstances or otherwise repaying its other securities (whether existing securities or those that may be issued in the future), other than to the extent the Distribution Restriction applies.

No prediction can be made as to the effect, if any, which a future issue of securities by Challenger, or a redemption, buy-back or capital reduction by Challenger, may have on the market price or liquidity of Challenger Capital Notes 4 or of the likelihood of Challenger making payments on Challenger Capital Notes 4.

Subject to APRA's prior written approval, Challenger or any member of the Challenger Group may purchase Challenger Capital Notes 4 at any time and at any price.

An investment in Challenger Capital Notes 4 carries no right to be redeemed or otherwise repaid at the same time as Challenger redeems or otherwise repays other securities (whether common equity, preference shares, subordinated or senior debt or otherwise).

6.1.18 Challenger Capital Notes 4 expose investors to Challenger's financial performance and position

If Challenger's financial performance or position declines, or if market participants anticipate that it may decline, an investment in Challenger Capital Notes 4 could decline in value even if Challenger Capital Notes 4 have not been Converted. Accordingly, when you evaluate whether to invest in Challenger Capital Notes 4, you should carefully evaluate the investment risks associated with an investment in Challenger and the Challenger Group. For the risks that may affect Challenger's financial performance or position, see Section 6.2.

6.1.19 Regulatory treatment

Challenger Capital Notes 4 will not constitute Additional Tier 1 Capital or any other form of regulatory capital of Challenger. APRA has advised that it does not object to Challenger using the proceeds of Challenger Capital Notes 4 to fund a subscription for Additional Tier 1 Capital of CLC.

However, in certain circumstances, if APRA subsequently determines that it objects to Challenger using the proceeds of Challenger Capital Notes 4 to fund a subscription for Additional Tier 1 Capital of CLC, Challenger may decide that a Regulatory Event has occurred. Challenger may then elect, at its option, to Exchange all or some Challenger Capital Notes 4 on issue (subject to APRA's prior written approval, which may or may not be given). A Regulatory Event will not have occurred if the change in regulatory treatment was expected by Challenger at the Issue Date.

Any such Exchange at Challenger's option may occur on dates not previously contemplated by Holders, which may be disadvantageous in light of market conditions or their individual circumstances. This also means that the period for which Holders will be entitled to the benefit of the rights attaching to Challenger Capital Notes 4 (such as Distributions) is unknown.

The Exchange Method chosen by Challenger may also be disadvantageous to Holders and may not coincide with their individual preference in terms of whether they receive Ordinary Shares or cash on the relevant date.

6.1.20 DDO Legislation

On 5 April 2019, the DDO Legislation came into force and introduced new product intervention powers for ASIC, which took effect immediately, as well as product design and distribution obligations on certain issuers and distributors of financial products (including hybrids such as Challenger Capital Notes 4) to retail investors, which took effect in October 2021.

The product design and distribution obligations require (among other things) issuers to prepare and make publicly available a target market determination, issuers to take reasonable steps to ensure compliance with the target market determination by distributors and distributors to take reasonable steps to ensure their distribution is consistent with the target market determination. The impact of these new obligations remains largely untested. However, there is a risk that they may adversely impact the issue, distribution and reinvestment of financial products, including instruments like Challenger Capital Notes 4. It is possible that investors who may have previously invested in Challenger Capital Notes 2 and/or Challenger Capital Notes 3 are no longer eligible to apply for Challenger Capital Notes 4 in the Offer. These changes may also affect the liquidity of existing and new instruments (including hybrids such as Challenger Capital Notes 4), if they lead to a material reduction in future issuance volumes or secondary trading activity by investors.

6.1.21 Changes to credit ratings

Challenger's cost of funds, margins, access to capital markets and competitive position and other aspects of its performance may be affected by its credit ratings (including any long-term credit ratings or the ratings assigned to any class of its securities). Credit rating agencies may withdraw, revise or suspend credit ratings or change the methodology by which securities are rated. Even though Challenger Capital Notes 4 will not be rated, such changes could adversely affect the market price, liquidity and performance of Challenger Capital Notes 4 or Ordinary Shares received on Conversion. A rating of Challenger is not a rating of Challenger Capital Notes 4.

6.1.22 Australian tax consequences

There is a risk that the position of Holders may be adversely affected if a change is made in Australian tax law, or an administrative pronouncement or ruling. A general outline of

the tax consequences of investing in Challenger Capital Notes 4 for certain potential investors is set out in the Australian taxation summary in Section 8. This discussion is in general terms and is not intended to provide specific advice addressing the circumstances of any particular potential investor.

Accordingly, potential investors should seek independent advice concerning their own individual tax position.

If a change is made in Australian tax law, or an administrative pronouncement or ruling, and that change leads to a more than insubstantial risk that there would be a more than insignificant increase in Challenger's costs in relation to Challenger Capital Notes 4 or that any Distribution would not be frankable, Challenger may decide that a Tax Event has occurred. Challenger may then elect, at its option, to Exchange all or some Challenger Capital Notes 4 (subject to APRA's prior written approval, which may or may not be given). A Tax Event will not have occurred if the change in tax treatment was expected by Challenger at the Issue Date.

If the corporate tax rate were to change, the Distribution Rate, the cash amount of Distributions and the amount of any franking credits may change.

Challenger has applied for a Class Ruling from the ATO to confirm certain Australian tax consequences for certain Australian tax resident Holders, as discussed in Section 8.

6.1.23 FATCA and Common Reporting Standard

It is possible that, in order to comply with FATCA, Challenger (or if Challenger Capital Notes 4 are held through another non-U.S. financial institution, such other financial institution) may be required (pursuant to an agreement with the U.S. Internal Revenue Service ("IRS") or under an applicable law, including a non-U.S. law implementing an intergovernmental approach to FATCA) to request certain information from Holders or beneficial owners of Challenger Capital Notes 4, which information may be provided to the IRS, and to withhold at the rate of 30% on all or a portion of certain payments made with respect to Challenger Capital Notes 4 if (i) such information is not provided; or (ii) if payments are made to certain foreign financial institutions ("FFIs") that have not entered into a similar agreement with the IRS or are otherwise exempt from FATCA withholding. However, such FATCA withholding is not expected to apply if Challenger Capital Notes 4 are treated as debt for U.S. federal income tax purposes unless Challenger Capital Notes 4 are issued or "materially modified" after the date that is six months after the date on which final regulations defining the term "foreign passthru payment" are filed with the U.S. Federal Register.

In any event, FATCA withholding is not expected to apply on payments made before the date that is two years after the date on which final regulations defining the term 'foreign passthru payment' are filed with the U.S. Federal Register.

Reporting Australian Financial Institutions ("RAFI") under the Australia-US FATCA Intergovernmental Agreement dated 28 April 2014 ("Australian IGA") must comply with specific due diligence procedures. In general, these procedures seek to identify account holders and provide the ATO with information on financial accounts (which may include the Challenger Capital Notes 4) held by U.S. persons and recalcitrant account holders. The ATO is required to provide such information to the IRS. Consequently, Holders may be requested to provide certain information and certifications to Challenger and to any other financial institutions through which payments on the Challenger Capital Notes 4 are made. A RAFI that complies with its obligations under the Australian IGA will not be subject

to FATCA withholding on amounts it receives, and will not be required to deduct FATCA withholding from payments it makes, other than in certain prescribed circumstances.

If Challenger is required to withhold amounts under or in connection with FATCA from any payments made in respect of Challenger Capital Notes 4, or from the issue of Ordinary Shares on Conversion of Challenger Capital Notes 4, Holders and beneficial owners of Challenger Capital Notes 4 will not be entitled to receive any gross up or additional amounts to compensate them for such withholding, and any issue of Ordinary Shares on Challenger Capital Notes 4 will be made net of FATCA withholding.

FATCA is particularly complex legislation. Holders should obtain their own professional advice about the requirements of FATCA, and how the Australian IGA may apply to them under the Challenger Capital Notes 4.

In addition, the OECD Common Reporting Standard for Automatic Exchange of Financial Account Information in Tax Matters ("CRS") requires certain financial institutions to report information regarding certain accounts (which may include the Challenger Capital Notes 4) to their local tax authority and follow related due diligence procedures. Holders may be requested to provide certain information and certifications to ensure compliance with the CRS. A jurisdiction that has signed a CRS Competent Authority Agreement may provide this information to other jurisdictions that have signed the CRS Competent Authority Agreement.

The Australian Government has enacted legislation amending, among other things, the *Taxation Administration Act 1953* (Cth) to give effect to the CRS.

6.1.24 Accounting standards

New accounting standards or amendments to existing accounting standards issued by either the International Accounting Standards Board or the Australian Accounting Standards Board may affect the reported earnings and financial position of Challenger in future financial periods, which may in turn (among other things) affect the Challenger Group's capital position for the purposes of APRA's prudential standards. This may adversely affect the ability of Challenger to pay Distributions and/or the likelihood that a Non-Viability Trigger Event will occur.

AASB 17 *Insurance Contracts* ("AASB 17") replaces AASB 4 *Insurance Contracts* and AASB 1038 *Life Insurance Contracts* ("AASB 1038") and is effective for the Challenger Group from 1 July 2023.

AASB 17 requirements affect recognition, measurement, presentation and disclosure relating to insurance contracts. AASB 17 is likely to introduce significant changes to the profit emergence profiles of life insurance contracts but does not affect the underlying economics or cash flows of the contracts. The impacts on capital requirements are not expected to be material. The impact on income tax is subject to responses from the Treasury and the ATO.

The main changes anticipated for the Challenger Group under AASB 17 are set out below.

- (a) Insurance contract portfolios will be disaggregated to more granular levels and will be required to be evaluated by risk type, issue year and profitability.
- (b) Although conceptually similar, the Contractual Service Margin ("CSM") recognises profit on a different basis to the current Margin on Services ("MoS") approach and therefore the profit signature is likely to change for portfolios with positive profit margins. Given the

Challenger Group's long-duration longevity reinsurance business having significant levels of profit margins under the AASB 1038 measurement basis, the use of different discount rates for the fulfilment cash flows and CSM can have a material impact on annual reported profits.

- (c) A new risk adjustment for non-financial risk will be introduced which reflects the compensation that the Challenger Group requires for bearing the uncertainty in relation to the amount and timing of cash flows. The confidence level associated with the risk adjustment will need to be disclosed.
- (d) Financial disclosures will be more extensive, requiring increased detail and more analysis of movements.

Under the new accounting standard, CLC's statutory earnings may be more volatile due to the nature of the profit emergence profiles of life insurance contracts with profit margins (noting that AASB 17 does not affect the underlying economics or cash flows of the underlying life insurance contracts).

The impact of AASB 17 (together with other factors which may impact upon Challenger's consolidated retained earnings from time to time) is relevant to an assessment of the existence of any Payment Condition, which may affect Challenger's ability to pay a Distribution (refer to Section 6.1.7). In addition, the volatility impact on earnings may also affect the earnings available in any given financial period for distribution as dividends on Ordinary Shares (refer to Section 6.1.15).

The interpretation and implementation of the various components of AASB 17 are complex. Further information about the expected impacts of the introduction of AASB 17 can be found in the section titled "Basis of preparation and overarching significant accounting policies" and under sub-heading "(iii) New and revised accounting standards and policies" on page 22 of Challenger's 2023 Interim Financial Report, which can be found at www.challenger.com.au/shareholder/financial-information.

6.1.25 Shareholding limits and Nominee sales

There is a risk that a Holder may, by acquiring any Challenger Capital Notes 4 (taking into account any Ordinary Shares into which they may Convert), breach applicable restrictions on ownership.

Laws, including the *Financial Sector (Shareholdings) Act 1998* (Cth) restrict ownership by people (together with their associates) of life insurers and their holding companies, such as Challenger, to a 20% stake. A shareholder may apply to the Australian Treasurer to extend its ownership beyond 20%, but approval will not be granted unless the Treasurer is satisfied that a holding by that person greater than 20% is in the national interest.

Further, the SIS Act restricts ownership of a registrable superannuation entity as defined under section 10 of the SIS Act ("RSE") and their holding companies, such as Challenger, to a 15% stake. Shareholders may apply to APRA to extend their ownership to beyond 15%, but approval will not be granted unless APRA is satisfied that the controlling stake in the RSE will not mean that the RSE licensee will not be able to satisfy one or more of the trustee's obligations prescribed in sections 52 to 53 of the SIS Act.

Mergers, acquisitions and divestments of Australian public companies listed on ASX (such as Challenger) are regulated by detailed and comprehensive legislation and the rules and regulations of ASX. These provisions include restrictions on the acquisition and sale of relevant interests in certain shares in an Australian listed company under the Corporations Act and a requirement that acquisitions of certain interests in Australian listed companies by foreign interests are subject to review and

approval by the Treasurer. Australian competition law also regulates acquisitions which would have the effect, or be likely to have the effect, of substantially lessening competition in a market.

Holders should take care to ensure that by acquiring any Challenger Capital Notes 4 (taking into account any Ordinary Shares into which they may Convert), Holders do not breach any applicable restrictions on ownership, and Holders should seek personal advice from a qualified financial adviser in relation to their obligations.

Holders who do not wish to receive Ordinary Shares on Conversion may notify Challenger of this no less than 15 Business Days prior to the Conversion Date. In addition, if you are a Foreign Holder, you will not receive Ordinary Shares on Conversion (unless Challenger is satisfied that it may issue them to you). Instead, if you elect not to receive Ordinary Shares or are a Foreign Holder, the relevant number of Ordinary Shares will be issued to the Nominee (which must not be Challenger, a member of the Challenger Group or a Related Entity of Challenger), on terms that the Nominee will sell the Ordinary Shares and pay a cash amount equal to the net proceeds to the relevant Holder. No guarantee is given in relation to the timing or price at which any sale will occur. The issue of Ordinary Shares to the Nominee satisfies Challenger's obligations in connection with the Conversion, and Challenger and the Nominee do not owe any duty in relation to the price or terms on which the Ordinary Shares are sold and have no liability for any loss suffered as a result of such of Ordinary Shares where required in the circumstances described above. Challenger will treat you as a Foreign Holder if your address in the Register is a place outside of Australia or Challenger otherwise believes you may not be a resident of Australia.

Further, if a FATCA Withholding is required to be made in respect of Ordinary Shares to be issued on Conversion, Challenger will only issue those Ordinary Shares to the Holder to the extent (if at all) that the issue of Ordinary Shares is net of FATCA Withholding. To the extent that a FATCA Withholding is required, Challenger will issue the Ordinary Shares to a Nominee who will sell those Ordinary Shares on the basis outlined above and will deal with the proceeds of sale in accordance with FATCA. See Section 6.1.23 for an explanation of circumstances in which a FATCA Withholding may be required.

6.1.26 No rights to vote

There is a risk that Holders may be affected by corporate decisions made by Challenger. Holders have no voting or other rights in relation to Ordinary Shares until Ordinary Shares are issued to them. In addition, the Challenger Capital Notes 4 do not confer on Holders any right to subscribe for new securities in Challenger or to participate in any bonus issue of securities. The rights attaching to Ordinary Shares, if Ordinary Shares are issued, will be the rights attaching to Ordinary Shares at that time. Holders have no right to vote on or otherwise to approve any changes to the Constitution in relation to the Ordinary Shares that may in the future be issued to them. Therefore, Holders will not be able to influence decisions that may have adverse consequences for them.

6.1.27 Amendment of Terms or Trust Deed

There is a risk that either or both the Terms and the Trust Deed may be amended in a way that Holders do not agree with. Challenger may, with the approval of the Trustee and, where required, with APRA's prior written approval, make certain amendments to the Terms or the Trust Deed without the approval of Holders. These include amendments of a formal, technical or minor nature, necessary or expedient for the listing or sale of Challenger Capital Notes 4 or to comply with applicable laws or any change which Challenger considers is not materially prejudicial to the interests of Holders as a whole.

In the case of alterations made to enable the Challenger Capital Notes 4 to be quoted on ASX, or sold, or to comply with applicable laws or listing rules, or which are not materially prejudicial to Holders as a whole, Challenger must provide to the Trustee an opinion of independent legal advisers of recognised standing in New South Wales that such alteration is otherwise not materially prejudicial to the interests of Holders as a whole.

Challenger may also amend the Terms if a Rate Disruption Event occurs, including in circumstances where the BBSW Rate ceases to be available or is no longer generally accepted as an appropriate reference rate, and, subject to APRA's prior written approval, may replace the BBSW Rate with an alternative rate that Challenger considers appropriate, acting in good faith and in a commercially reasonable manner, and make certain other consequential adjustments to the Terms. Such amendments could adversely affect the interests of Holders.

Challenger may also, with the approval of the Trustee and, where required, with APRA's prior written approval, amend the Terms or the Trust Deed if the amendment has been approved by a Holder Resolution or, in relation to certain amendments, a Special Resolution. Amendments under these powers are binding on all Holders despite the fact that a Holder may not agree with or did not attend or vote at any meeting in relation to the amendment.

APRA's prior written approval to amend the Terms is required where the amendment may cause APRA to object to the proceeds of Challenger Capital Notes 4 being used to fund Additional Tier 1 Capital of CLC.

See Section 2.7.3 and clauses 17.4 to 17.6 of the Terms for a more detailed list of the types of amendments Challenger may make to the Terms without the approval of Holders.

6.1.28 Powers of APRA

Under the Life Insurance Act, APRA has power to issue directions to Challenger. These powers of APRA are broad and may be exercised to intervene in the performance of obligations and the exercise of rights under the Challenger Capital Notes 4 (see Sections 6.2.2 and 6.2.3 for further information).

The Life Insurance Act gives APRA extensive powers to facilitate the resolution of the entities that it regulates (and their subsidiaries) in times of distress. Powers given to APRA include oversight, management and directions powers in relation to Challenger, CLC and other members of the Challenger Group, and powers with respect to statutory management. The Life Insurance Act also gives statutory recognition to provisions for the conversion or write-off of an instrument such as the Challenger Capital Notes 4.

In addition, APRA has powers to require the compulsory transfer of all or part of the business of Challenger pursuant to the *Financial Sector (Transfer and Restructure) Act 1999* (Cth) ("**FSTR Act**"). This power arises in circumstances where APRA has decided to make a compulsory transfer of the business of, or shares in, CLC. A transfer under the FSTR Act overrides anything in any contract or agreement to which Challenger is a party, including the Terms.

These powers of APRA may be exercised in a way which adversely affects the ability of Challenger to comply with its obligations in respect of the Challenger Capital Notes 4 (including in connection with the Exchange of the Challenger Capital Notes 4), and this may adversely affect the position of Holders.

In addition, Holders should be aware that secrecy obligations may apply to action taken by APRA. This means that information about action taken by APRA (including in exercise of its powers under the Life Insurance Act) may not be publicly disclosed.

6.2 Risks associated with Challenger, CLC and the Challenger Group

Set out below are some specific investment risks associated with Challenger, CLC and the Challenger Group. The Challenger Group is subject to risks that can adversely impact its businesses, results of operations, financial condition and future performance. These are relevant to an investment in Challenger Capital Notes 4, as Challenger's ability to fulfil its obligations under, or in respect of, Challenger Capital Notes 4 (including Challenger's ability to pay principal and Distributions) and the value of your investment will depend on the results of operations, financial condition and future performance and position of Challenger, CLC and the Challenger Group, regardless of whether Challenger Capital Notes 4 remain outstanding or are Exchanged or Written-Off. The risks and uncertainties described below are not the only ones that Challenger, CLC or the Challenger Group may face. Additional risks and uncertainties that Challenger is not aware of, or that Challenger currently deems to be immaterial, may also become important factors that affect Challenger, CLC or the Challenger Group.

6.2.1 Changes in Government policy, legislation or regulation

There is a risk that the Challenger Group fails to meet its corporate, industry, licensing, market conduct or prudential obligations. This risk is amplified by the significant volume of regulatory change that has impacted the Australian life insurance, superannuation and banking industries in recent years. If this risk materialised it could result in fines, remediation activity which necessarily diverts management attention away from strategic priorities, and/or regulatory intervention, potentially including a requirement to hold additional capital. This could, in turn, materially and adversely impact the Challenger Group's financial performance, position and creditworthiness.

The Challenger Group provides annuity and banking products, and other guaranteed and non-guaranteed investment products. Providers and distributors of these products and services in Australia are subject to various legislative and regulatory requirements (including prudential regulation), including the Corporations Act, the Life Insurance Act, the Banking Act, the SIS Act (including the regulations made under the SIS Act), the Competition and Consumer Act, the Anti-Money Laundering and Counter-Terrorism Financing Act and the Privacy Act. This regulatory regime is complex and continues to undergo significant change in Australia.

In addition, the Challenger Group's businesses may be affected by changes to the regulatory framework in other jurisdictions, including the cost of complying with regulation that has extra-territorial application such as the *Bribery Act 2010* (UK), FATCA, the *Dodd-Frank Wall Street Reform and Consumer Protection Act 2010* (US) and other regulations and reforms.

The Challenger Group is also subject to supervision and oversight by regulators which have broad administrative power over its businesses. These regulators include APRA, ASIC, ASX, the ATO, the ACCC and AUSTRAC along with offshore regulators (for example, those in the United Kingdom and Japan). An example of a broad administrative power available to regulatory authorities is the power available to APRA, in certain circumstances, to investigate the Challenger Group's affairs or issue a direction to it (such as a direction to comply with a prudential requirement to conduct an audit, to remove a Director or senior manager from office, or not to undertake transactions).

Challenger and its subsidiaries are responsible for ensuring they comply with all applicable legal and regulatory requirements (including accounting standards), industry codes of practice in the jurisdictions in which they operate and rules of external disputes resolution organisations of which they are members, including the Australian Financial Complaints Authority.

There are a number of ongoing or proposed regulatory changes relevant to the Challenger Group. For example, the Australian government has effected, or announced its intentions to effect, regulatory change in relation to the following matters which may have an impact on the Challenger Group:

- introduction of the consumer data right which is intended to give Australians greater control over their data, empowering customers to choose to share their data with trusted recipients only for the purposes that they have authorised;
- the “Financial Accountability Regime” (“**FAR**”) was first introduced to Parliament in October 2021 through the *Financial Accountability Regime Bill 2021* (Cth) (“**FAR 2021**”), with the Australian Government at that time aiming to implement FAR from 1 July 2022 for ADIs, and from 1 July 2023 for superannuation entities and insurers. With the dissolution of Parliament on 11 April 2022, FAR 2021 lapsed but the *Financial Accountability Regime Bill 2022* (Cth) (“**FAR 2022**”) was released by the Australian Government on 8 September 2022. FAR 2022 essentially reflects FAR 2021 with no substantive changes. FAR is expected to apply to the banking industry sometime in 2023 and to the insurance and superannuation industries from mid-2024. FAR was developed to extend and replace the Banking Executive Accountability Regime (“**BEAR**”), which currently applies to ADIs. When, and if, FAR is implemented, it is expected to impose a number of obligations on regulated entities (including insurers), their directors and senior executives in relation to the conduct of business (i.e., to act honestly and with care, skill and diligence), remuneration, notifications and other matters. Regulated entities, their directors and senior executives that breach the FAR requirements may be liable for civil penalties and/or other regulatory enforcement. FAR 2022 does not impose direct financial penalties for individual accountable persons as a sanction for breaching their accountability obligations. However, FAR 2022 does still leave open the potential for financial penalties to be imposed on an individual under ancillary liability provisions;
- APRA, ASIC and the Reserve Bank of Australia are increasing the scrutiny of entities’ approaches to climate change as a material risk and using the Taskforce on Climate-related Disclosures as the mechanism to facilitate entities conducting a deeper assessment and issuing greater disclosure. The Australian Accounting Standards Board (“**AASB**”) and Auditing and Assurance Standards Board has released guidance stating that if climate-related risks are important to investors’ decision-making, it should be considered material and reflected in the financial statements of the relevant entity. Further, in November 2021 the AASB released a proposed interim climate change reporting standards framework for industry feedback and in December 2022 the Treasury released a consultation paper seeking initial views on the requirements for disclosure of climate-related financial risks and opportunities; and
- the Challenger Group, alongside the broader APRA-regulated entity population, is contending with a large regulatory reform agenda over the medium-term. As outlined in Section 6.2.2, APRA has a number of policy priorities that are expected to impact on the members of the

Challenger Group which may lead to incremental costs or higher capital requirements in responding to or complying with the requirements of the policy priorities once finalised and implemented.

There is also a risk that the manner in which superannuation funds respond to the retirement income covenant (“**Covenant**”) and other regulatory changes may impact the sales of annuities. In response to the 2014 Financial System Inquiry (“**FSI**”) and the Retirement Income Review in 2020, the Australian Government met its previous Budget commitments to legislate the Covenant. The Covenant, which took effect from 1 July 2022, has been introduced to the SIS Act. The Covenant requires the trustees of APRA regulated funds to formulate, review regularly, and give effect to a retirement income strategy for their members in, and approaching, retirement. The trustee’s strategy is intended to assist members to achieve and balance key objectives of the Covenant, to:

- maximise their expected retirement income;
- manage the expected risks to the sustainability and stability of their expected retirement income; and
- have flexible access to expected funds during retirement.

Any future legislation and regulatory change in any jurisdiction where the Challenger Group carries on business may affect the insurance and finance sectors and adversely affect the Challenger Group. This could include changes to capital requirements, accounting standards, taxation laws, and prudential regulatory requirements, and may affect the likelihood of Challenger being able to make payments on Challenger Capital Notes 4 or a Non-Viability Trigger Event occurring.

6.2.2 Prudential regulation and capital adequacy

Certain regulated entities within the Challenger Group are required to meet capital and liquidity standards prescribed by APRA. If those regulated entities fail to meet these prudential standard requirements or these standards change, APRA has a number of broad powers at its disposal which may have an adverse effect on the regulated entities within the Challenger Group and on the Challenger Group as a whole.

In addition, in certain circumstances (for example, contravention of the Life Insurance Act), APRA has the power to order the compulsory transfer of the business of a life insurer to another entity, including to an entity which is not a life insurer in particular circumstances. This could include a compulsory transfer of the business of CLC.

Challenger, as a non-operating holding company (“**NOHC**”), is subject to the requirements of the Life Insurance Act and APRA’s prudential standards applicable to NOHCs of life insurers. APRA has powers which, if exercised, may be adverse to the interests of Holders, including powers to direct Challenger not to pay or transfer any amount to any person (including in respect of any Challenger Capital Notes 4) or not to issue Ordinary Shares or not to pay a dividend in respect of any Ordinary Shares.

The Challenger Group is subject to APRA’s non-capital related prudential standards for the supervision of conglomerate groups (known as a “Level 3 group”). APRA has published draft capital-related prudential standards applicable to Level 3 groups (such as the Challenger Group) but had deferred their implementation until a number of domestic and international policy initiatives are further progressed.

On 24 October 2022, APRA further announced a new roadmap for the review of the prudential framework that applies to Level 3 groups. The aim of the review is to ensure that the Level 3 group

prudential framework is fit for purpose to cater to an increasing array of new groups, and consistently applied to existing structures to ensure a level playing field. The multi-year review of the Level 3 group prudential framework will be conducted in 2023 and 2024, with revised prudential standards expected to be effective from 2025. It is possible that any new capital-related prudential standards for Level 3 groups will impact the level and nature of regulatory capital resources attributed to the Challenger Group and the level of capital requirements.

Several regulated entities within the Challenger Group operate an Internal Capital Adequacy Assessment Process (“ICAAP”) to manage their capital levels and to maintain them above the minimum levels approved by their respective boards (which are currently set to exceed regulatory requirements). The ICAAPs include forecasting and stress testing of capital levels, which guide the respective Challenger Group regulated entities in selecting any capital management initiatives they may undertake. Should the ICAAP forecasts or stress tests prove to be ineffective, the respective regulated entities within Challenger Group, and Challenger, may not be holding sufficient capital and may need to raise additional capital.

As at the date of this Prospectus APRA has a number of policy priorities that are expected to impact on the Challenger Group, including:

- On 2 December 2021, APRA released draft Prudential Standard CPS 900 Resolution Planning (“CPS 900”), which aims to ensure that APRA-regulated entities can be resolved by APRA in an orderly manner, where an entity has become non-viable. In such circumstances, the aim of the resolution is to protect beneficiaries, minimise disruption to the financial system, and provide continuity of functions that are critical for the economy. CPS 900 is expected to be finalised in the first half of calendar year 2023 and to become effective from 1 January 2024.
- On 6 July 2022, APRA released for consultation new remuneration disclosure and reporting requirements for all banks, insurers and superannuation funds regulated by APRA. The proposed remuneration requirements will support the cross-industry Prudential Standard CPS 511 Remuneration (“CPS 511”), which was introduced in 2021 to strengthen transparency on remuneration. The proposed remuneration disclosure and reporting requirements will take effect after the implementation of CPS 511 in 2023 for large entities and 2024 for smaller entities.
- On 28 July 2022, APRA released for consultation a draft prudential standard designed to strengthen the management of operational risk in the banking, insurance and superannuation industries. Prudential Standard CPS 230 Operational Risk Management aims to establish minimum standards for managing operational risk, including updated requirements for business continuity and service provider management.
- On 27 September 2022, APRA announced that it had finalised changes to the capital and reporting frameworks for insurance in response to the introduction of the new accounting standard AASB 17. The changes aim to minimise any additional regulatory requirements caused by a misalignment between APRA’s framework and AASB 17, while ensuring sound prudential outcomes. Given the changes AASB 17 may have on the balance sheet of insurers, including CLC, APRA is conducting a targeted consultation on additional requirements to ensure the regulatory capital levels are sufficient to protect the prudential soundness of insurers and to encourage appropriate accounting decisions. The revised prudential and reporting standards will come into effect from 1 July 2023.

- On 1 December 2022, APRA released its final Prudential Standard CPS 190 Recovery and Exit Planning (“CPS 190”), aimed at reinforcing the resilience of the financial system. In particular, the new standard aims to ensure that APRA-regulated entities are better prepared to manage periods of severe financial stress and it complements recent prudential reforms aimed at strengthening financial resilience. CPS 190 will come into effect from 1 January 2024 for banks and insurers, and 1 January 2025 for registrable superannuation entities.

In certain circumstances, APRA may require Challenger and regulated entities of the Challenger Group to hold a greater level of capital to support their businesses or require those entities not to pay dividends or restrict the amount of dividends that can be paid by them, including dividends paid by Challenger and any dividends paid by CLC or Challenger Bank to Challenger.

The results of the above regulatory changes may require the Challenger Group to revise or withdraw its range of products or services, change its product pricing, fees or charges, redesign its technology or other systems incurring significant expense and having to retrain its staff, pay additional tax, hold more capital or incur other costs. It is also possible that global events could result in further changes to requirements prescribed by regulators. While the Challenger Group may try to mitigate the impacts of these changes should they occur, they may still have a material adverse impact on the financial performance and position of the Challenger Group, and may affect the likelihood of Challenger being able to make payments on Challenger Capital Notes 4.

There are other regulatory capital reviews currently underway or which may occur in the future which may also impact the business, financial performance or prospects of the Challenger Group.

6.2.3 Structural subordination

Challenger is a NOHC whose assets consist of ownership interests in a life business (CLC), a funds management business (CIM and Fidante) and banking business (Challenger Bank). There is a risk that Challenger’s subsidiaries may not be in a position to make funds available to Challenger to enable it to make payments on the Challenger Capital Notes 4. If Challenger or one or more of its subsidiaries are wound up, Holders may lose some or all of their investment in Challenger Capital Notes 4.

In the event that a Challenger subsidiary is wound up, the claims of Challenger in respect of the subsidiary would be limited to the net assets (if any) of that subsidiary after all liabilities, including to policyholders and depositors, and regulatory capital securityholders in relation to the relevant subsidiary, have been discharged or provided for. There may be insufficient net assets after satisfaction of senior claims to pay any amount to Holders in respect of Challenger Capital Notes 4.

In addition, Challenger is reliant on the continued receipt of dividends, distributions or other funding from its subsidiaries, in particular, CLC, to make payments on its securities, including Challenger Capital Notes 4. The terms of securities issued by CLC or other subsidiaries of Challenger may restrict CLC or another relevant subsidiary from paying dividends, distributions, or other payments to Challenger in certain circumstances, or such payments to Challenger may be subject to other regulatory, contractual or legal restrictions.

The Terms do not in any way restrict Challenger or subsidiaries of Challenger, including CLC, from issuing further securities or from incurring further indebtedness in future which may rank senior to the Challenger Capital Notes 4, or which may contain terms restricting the payment of dividends, distributions or other payments to Challenger in certain circumstances.

6.2.4 Distribution channels

CLC distributes its products in Australia through third-party financial planning networks. Some of these financial planning networks are owned by product manufacturers that sell products that compete with CLC's products. This exposes CLC and therefore Challenger to the risk that it may lose access to certain distribution networks because of actions by its competitors to limit distribution of competing products.

Advisers and licensees in third-party financial planning networks may be subject to ASIC bans and disqualifications as a result of misconduct. Challenger has a process to monitor ASIC notifications regarding banned and disqualified advisers and licensees, and to remove them from Challenger's registry. Additionally, conduct by third-party advisers may lead to reputational damage and have other material adverse effects on the Challenger Group and its businesses.

CLC also has agreements with MS&AD Insurance Group Holdings Inc. ("**MS&AD**") under which MS&AD's subsidiary, MS Primary, must provide a minimum annual amount of reinsurance to CLC in respect of MS Primary's foreign currency annuities issued in Japan in aggregate across reinsurance agreements entered into between CLC and MS Primary. The agreement provides that the parties are to agree in good faith any necessary adjustments to enable arrangements to continue in the event of a significant change in investment markets which has a material adverse effect on the economic returns of either MS Primary or CLC. The reinsurance agreements between CLC and MS Primary include mechanisms to regulate volumes between MS Primary and CLC, and also usual termination rights for both parties (including material breach, failure to pay and events that may be triggered by changes in MS Primary's regulatory environment). Nevertheless, CLC and therefore Challenger could be exposed to declines in reinsurance amounts under these arrangements if MS Primary's sales of foreign currency annuities in Japan fall.

6.2.5 Market risks

There is a risk that the financial performance of the Challenger Group is significantly affected by changes in investment markets and economic conditions both in Australia and globally in New Zealand, Japan, the United States, Canada, the United Kingdom and Europe, where the Challenger Group primarily conducts business. Domestic and international economic conditions and forecasts are influenced by a number of factors such as economic growth rates, cost and availability of capital, central bank intervention, inflation and deflation rates and market volatility and uncertainty. Economic conditions may also be impacted by major shock events such as natural disasters, pandemics or disease outbreaks such as the COVID-19 pandemic, war such as the ongoing Russia/Ukraine conflict, terrorism, geopolitical events such as the United Kingdom's departure from the European Union, political and social unrest, and sovereign debt restructuring and defaults.

Additionally, changes in market factors such as potential developments or future changes in the administration of financial benchmark interest rates could result in adverse consequences to the return on, value of, and market for, securities and other instruments whose returns are linked to any such benchmark, including those securities issued by the Challenger Group.

Any deterioration in investment markets, investor sentiment or economic conditions in the Challenger Group's core markets may lead to reductions in the value of the Challenger

Group's investments, which may have an adverse impact on the overall financial performance and position of the Challenger Group.

In addition, any changes in economic conditions, investment markets, investor sentiment or customer preferences could adversely impact demand for the Challenger Group's financial products and services, leading to lower new business sales and/or higher withdrawals, and therefore reduce earnings.

In particular, product margins across the Challenger Group may be adversely impacted by a number of factors, including interest rates, investment returns, foreign exchange and inflation, each of which are described in further detail below.

6.2.5.1 Interest rate risk

Interest rate risk is the risk of financial loss arising from adverse fluctuations in interest rates and/or unforeseen interest rate settings.

The Challenger Group currently manages interest rate risk through hedging arrangements. Disruptions in financial markets may affect the availability of hedging and, even if available, hedging may become more expensive or be provided on unfavourable terms. In addition, movements in interest rates may require the Challenger Group to post collateral to support derivative instruments, which may impact the Challenger Group's liquidity. These factors may have a material adverse impact on the financial performance and position of the Challenger Group.

Notwithstanding that the Challenger Group hedges its interest rate risk, fluctuations in interest rates can impact:

- the rate at which certain liabilities are discounted, causing the liabilities in respect of CLC's annuity products to vary. CLC values annuity liabilities at a risk-free discount rate, whereas some assets, and in particular, fixed income assets, are valued at a margin to the relevant interest rate benchmark (usually the swap rate) which is a higher discount rate. Accordingly, the balance sheet value of these liabilities is more sensitive to interest rate movements than the assets. This may lead to losses where there is a reduction in interest rates, as the value of liabilities will increase more than the assets;
- the investment returns on funds under the management of CIM and Fidante and the CLC investment portfolio, which may lead to changes in income or demand for the Challenger Group products; and
- the Challenger Group's funding costs.

6.2.5.2 Foreign exchange risk

Foreign exchange risk is the risk of the Challenger Group sustaining loss through adverse movements in exchange rates.

From an operational perspective, the Challenger Group faces exposure to foreign exchange risks through its investment in foreign currency denominated assets and certain foreign currency denominated liabilities, and some direct foreign income and expenses.

The Challenger Group hedges its foreign exchange exposure through derivative instruments that are rolled periodically. Foreign exchange losses can occur when rolling these derivative instruments, and this can impact the liquidity of funds. In addition, movements in foreign exchange rates may require the Challenger Group to post collateral to support derivative instruments, which may impact the Challenger Group's liquidity. These factors may have a material adverse impact on the Challenger Group's reputation, other asset values, financial performance and position.

Adverse movements in exchange rates may also impact sales of US dollar and Australian dollar annuities in Japan by MS Primary in respect of which CLC has a reinsurance agreement (see Section 4.3.1 for further information), which may adversely impact the Challenger Group's financial performance.

Foreign exchange fluctuations can also change the Challenger Group's effective exposure to assets and therefore change the asset allocation mix. This movement may have a negative capital impact by requiring the Challenger Group to hold more capital against the assets that it owns.

6.2.5.3 Inflation risk

The combined impacts of the COVID-19 pandemic, rising geopolitical tensions and the conflict in Ukraine have resulted in elevated energy prices, consumer demand spikes, wage inflation from labour shortages due to lower immigration levels and supply shortages from global production disruptions. This has led to higher levels of inflation in many countries (including Australia), and resulted in many central banks taking action to control inflation by increasing short-term interest rates and/or making adjustments to other monetary policy settings. Persistent high inflation levels could result in a protracted period of rising interest rates, lower consumption and other adverse economic impacts.

Further, CLC offers certain products where the benefits of those products are indexed at rates related to the CPI. CLC currently manages the inflation risk associated with these products through hedging arrangements, such as entering into inflation-linked derivatives, or purchasing assets such as property and infrastructure, the income derived from which may be CPI indexed or have inflation-related characteristics. There is a risk that the hedging arrangements entered into may not perfectly offset the underlying exposures in the liability portfolio, and this may give rise to losses or it may result in additional capital being required.

6.2.6 Investment performance

The Challenger Group has a significant investment portfolio supporting liabilities arising from its life and banking businesses and is also exposed to investment performance in its funds management business. The Challenger Group's investment portfolio consists of:

- assets backing product liabilities (annuity and other investment products issued by CLC);
- shareholder assets, e.g. CLC shareholder funds and Challenger Bank shareholder funds;
- assets backing deposit liabilities (deposit products issued by Challenger Bank);
- assets as part of investment mandates managed by the CIM business; and
- assets forming part of funds managed as part of the Fidante business.

CLC's investment portfolio is managed in accordance with CLC's risk appetite, investment policy, investment approach and asset allocation plan. CLC's investment approach for the assets backing product liabilities and shareholder assets is to invest in a range of assets comprising fixed income, property, equities, infrastructure and alternative investments. Challenger Bank's investment approach for the assets backing deposit liabilities and shareholder assets is to invest in a range of fixed income assets. Investment mandates operated by CIM and the funds managed by Fidante are also exposed to some or all of the aforementioned asset classes.

The Challenger Group, through its investment in these assets, is exposed to risk and volatility in the markets (including, but not limited to, the impact of the COVID-19 pandemic), securities and other assets in which it invests. Those risks include, but are not limited to:

- **investment risk** – the risk that the Challenger Group will not be able to invest in assets at a rate of return which is sufficient to service its annuity or deposit liabilities;
- **asset/liability risk** – the risk that the value of an investment portfolio will decrease relative to the value of the liabilities as a result of fluctuation in investment factors including interest rates, credit spreads, counterparty default, exchange rates, property prices or share prices; and
- **liquidity risk** – the risk that assets cannot be sold without a significant impairment in value.

Such risks can be heightened during periods of high volatility, market disruption and periods of sustained low interest rates, such as those that occurred during the COVID-19 pandemic, and could adversely affect the Challenger Group's businesses, financial performance, capital resources, fee income and financial condition. In particular, the Challenger Group's management may take actions from time to time to rebalance its investment portfolio in response to adverse market conditions and volatility. Such actions may potentially adversely impact on the short term profitability of the Challenger Group's investment portfolio.

Relative investment performance to peers or market returns more generally also affect the demand for products offered by the Challenger Group; particularly, the investment mandates operated by CIM and the funds managed as part of the Fidante business. If CIM or the funds managed as part of the Fidante business underperform peer investment managers or the market more generally for a prolonged period, the demand for these products may reduce materially. To the extent that this risk materialises, it may have a material adverse impact on the financial performance and position of the Challenger Group.

Fee income in the funds management business is primarily based on the level of assets under management and investment performance. A deterioration in investment performance may lead to a decline in assets under management and a decline in fee income including distribution, administration, performance and transaction fees, which may have an adverse impact on the financial performance and position of the Challenger Group.

6.2.7 Declines in asset markets

The Challenger Group's performance is influenced by asset markets in Australia and other jurisdictions, including fixed income, property, infrastructure, equity and other investment asset markets.

Declining asset prices caused by less favourable business or economic conditions (including, but not limited to, rising interest rates or the ongoing impact of the COVID-19 pandemic and any future pandemics), whether generally or in a specific industry sector or geographic region, could impact counterparties and cause them to fail to meet their obligations in accordance with agreed terms. Further, this may result in a material reduction in the value of those assets or write-offs.

In particular, the fixed income and property markets are important to the overall performance of the Challenger Group. Credit spreads on fixed income securities that the Challenger Group owns can deteriorate in less favourable business or economic conditions, or counterparties may default. Additionally, valuations of unlisted investments are subject to a number of assumptions which may not be accurate or which

may change. These factors individually or combined may result in unrealised or realised losses which will affect the profitability, financial performance, capital resources and prospects of the Challenger Group.

As part of its asset portfolio backing the product liabilities it has originated, CLC provides loans in respect of, and owns, residential and commercial property primarily in Australia and Japan. Property markets in these jurisdictions can be variable, and some locations may experience reduced asset values. Declining property valuations may result in either unrealised or realised losses which will affect the profitability, financial performance, capital resources and prospects of the Challenger Group.

6.2.8 Fair value impact on earnings

CLC and its consolidated entities are required by the life insurance accounting standard AASB 1038⁴⁶ to fair value all assets and policy liabilities unless otherwise stated in the standard. This gives rise to unrealised gains and losses being included in CLC's statutory statement of comprehensive income. This effect may reverse over time depending upon market conditions and may not be realised if CLC is not required to sell assets or repay liabilities ahead of their stated maturity date.

Generally, in order to establish fair value for financial instruments, CLC relies on quoted market prices or, where the market for a financial instrument is not sufficiently active, fair values are based on present value estimates or other accepted valuation techniques. In certain circumstances, the data for individual financial instruments or classes of financial instruments used by such estimates or techniques may not be available or may become unavailable due to changes in market conditions. In these circumstances, the fair value is determined using data derived and extrapolated from market data, and tested against historical transactions and observed market trends.

The methods used to determine fair values, or any changes made to the methods used, may have a material adverse effect on the Challenger Group's earnings.

6.2.9 Asset and liability matching risks

Asset and liability matching risk refers to the risk that the duration of the assets does not match those of the liabilities. CLC sells products whose durations range from less than one year to the life of the person purchasing the annuity. CLC may or may not be able to purchase assets with a duration that exactly matches the duration of the underlying annuity liabilities. If the duration of the assets is less than the duration of the product liabilities, then CLC will be exposed to the risk that it is unable to reinvest the asset proceeds at the same or a better rate of return to service the product liabilities. This is known as reinvestment risk.

If the duration of the product liabilities is less than the duration of the assets, then CLC will be required to sell assets before their stated maturity to meet the obligations it may have in relation to maturing product liabilities. CLC may not be able to sell sufficient assets to meet these liabilities or it may be required to sell assets at lower prices in order to meet its product liabilities. This is known as liquidity risk.

Reinvestment risk and liquidity risk may affect the financial performance, capital resources and prospects of both CLC and the Challenger Group.

6.2.10 Insurance risks

In addition to other risks associated with its business, CLC is, or may become, exposed to a number of types of risk:

- **mortality risk** – the risk of death rates being higher than expected (including, but not limited to, the impact of pandemics or disease outbreaks such as COVID-19);
- **longevity risk** – the risk of insured lives living longer than expected; and
- **morbidity risk** – the risk of insured lives suffering greater disability than expected, which can be in respect of either the frequency or the severity of disability.

CLC sells annuity products that extend for the life of the policyholder. In addition, CLC issues longevity reinsurance treaties. These expose CLC and Challenger to longevity risk. CLC retains the longevity risk associated with these open for sale products and does not currently reinsure this risk. While CLC holds capital for this risk, the amount of capital held is based on certain assumptions about the longevity risk retained. The actual longevity risk experienced may be different to the risk that was assumed at the time the policy was written.

CLC has exposure to mortality risk through reinsurance treaties. There is a risk of higher than expected mortality in relation to these reinsurance treaties. Higher than expected mortality may occur for a variety of reasons including as a result of pandemics or disease outbreaks such as COVID-19, natural disasters or other factors outside of CLC's and Challenger's control. If this were to occur, losses may be incurred. These losses may exceed the capital set aside for this risk.

CLC's longevity risk exposures and mortality risk exposures generally relate to different underlying cohorts of lives. Therefore, it is possible that CLC could experience lower mortality where it is exposed to longevity risk at the same time as it experiences higher mortality where it is exposed to mortality risk.

The uncertainty surrounding the outcome of these risks may expose the Challenger Group and its businesses to losses, and adversely impact on the Challenger Group's financial performance, position and creditworthiness.

6.2.11 Funding and liquidity risks

Funding risk relates to the risk of one or more of the Challenger Group's sources of funding being reduced or eliminated or there being a significant increase in the cost of funding through either a systemic or a company-specific event.

If the Challenger Group's current sources of funding prove insufficient, it may be forced to seek alternative funding, which may not be available on acceptable terms or at all. The availability of such funding, and the terms on which it may be made available, will depend on a number of factors, including market conditions, the availability of credit, the Challenger Group's credit ratings and credit and capital market capacity.

These funding risks may arise due to an increased cost of funding, reduced availability of credit and capital, a decline in asset values, or reduced financial performance of these assets or funds and/or a downgrade in the credit rating of any member of the Challenger Group. An inability to manage the funding risks for the Challenger Group may result in forced asset sales or default, which could adversely impact the Challenger Group's debt and equity market relationships, reputation and brand, and the financial performance and position of the Challenger Group.

46 AASB 17 replaces AASB 1038 effective for Challenger Group from 1 July 2023 (see Section 6.1.24 for further information).

Further, business entities owned as investments by CLC, or funds managed by CIM and Fidante, may breach or risk breaching their loan and other debt covenants. In the event of a breach, the financiers have the ability to demand immediate repayment of the debt and enforce their other rights, which may give rise to the funding risks described above. To the extent those circumstances arise, this may have a material adverse impact on the financial performance and position of the Challenger Group.

Liquidity risk is the risk that the Challenger Group fails to meet its payment obligations, which may arise as a result of a mismatch between those payment obligations and the Challenger Group's access to liquid assets, adequate funding or access to capital on acceptable terms, or cash flows generated by its businesses. Both the Challenger Group's payment obligations and accessibility to liquid assets may be impacted by a systemic or a company-specific event. An inability to manage the liquidity risk may have a material adverse impact on the Challenger Group's reputation, credit rating, financial position and performance.

6.2.12 Credit ratings

Credit ratings are opinions on Challenger's creditworthiness. Challenger's credit ratings affect the cost and availability of its funding from capital markets and other funding sources, and they may be important to customers or counterparties when evaluating Challenger's products and services. Therefore, maintaining high quality credit ratings is important.

The credit ratings assigned to Challenger and its subsidiaries by rating agencies are based on an evaluation of a number of factors, including financial strength. A credit rating downgrade could be driven by the occurrence of one or more of the risks identified in this Section or by other events including changes to the methodologies used by the rating agencies to determine ratings.

If Challenger, or a member of the Challenger Group, fails to maintain its current credit rating, this could adversely affect Challenger's cost of funds and related margins, competitive position and its access to capital and funding markets, which, in turn, could adversely affect Challenger Group's businesses, financial performance, and prospects. The extent and nature of these impacts would depend on various factors, including the extent of any ratings change, and whether the factors affecting the ratings of Challenger, or any member of the Challenger Group, also impact Challenger's peers or the life insurance sector.

6.2.13 Credit risks

Credit risk is the risk that default by a counterparty or customer will result in a financial loss to the Challenger Group. The Challenger Group is exposed to credit risk with the counterparties and customers it deals with, including for lending products, derivative contracts and reinsurance arrangements. The risk also exists in the investment portfolios of CLC, Challenger Bank, and the funds managed by CIM and Fidante.

A default by a counterparty or customer can impact the Challenger Group's financial position and performance and the level of capital supporting the Challenger Group's businesses. Such a default can also impact investments of CLC, Challenger Bank, and funds managed by CIM and Fidante, which may have a material adverse impact on Challenger Group's reputation, management fee income, other asset values, financial performance, position and liquidity.

Credit risk arises primarily in relation to exposures to debt securities, property leases, futures and options broker clearers and over-the-counter derivative counterparties. While the Challenger Group utilises mechanisms to mitigate a number

of those exposures, including security, collateral and netting agreements, there can be no assurance that these arrangements fully limit those exposures and losses may occur.

CLC's annuity portfolio is managed with assets matched to expected annuity cash outflows. A significant proportion of the annuity portfolio is invested in fixed income assets where CLC has lent money to counterparties. CLC is exposed to the risk of counterparty default as well as the risk of widening credit spreads on the portfolio of fixed income assets.

The Challenger Group is also exposed to credit losses from borrowers who are customers of Challenger Bank. Challenger Bank holds collective and individually assessed provisions for its credit exposures. If economic conditions were to materially deteriorate, some customers could experience higher levels of financial stress and the Challenger Group may experience an increase in defaults and write-offs and be required to increase its provisioning.

To the extent that any of the above risks arise, this may have a material adverse impact on the financial performance and position of the Challenger Group.

6.2.14 Operational risks

Operational risk is the risk of loss resulting from inadequate or failed internal processes, people and systems, or from external events. As a financial services organisation, the Challenger Group is exposed to a variety of operational risks such as fraud and other dishonest activities, cyber-attacks, management practices, workplace safety, project and change management, compliance, business continuity and crisis management, key person risk, information and systems integrity as well as reliance on suppliers and outsourcing.

Operational risks can be heightened because of environmental factors outside the control of the Challenger Group. A recent example is the COVID-19 pandemic and the government responses which triggered the Challenger Group to enact a pandemic plan that supplemented its business contingency plan. This displaced the majority of the Challenger Group's workforce and partners from their normal working conditions which required the adoption of remote working practices. This exposed the Challenger Group to additional operating risks, including increased risk relating to technology (including cyber-security risks) as well as employee health and safety risks.

6.2.14.1 Technology risks

The Challenger Group relies to a significant degree on information technology systems. Most of the Challenger Group's daily operations are computer based, and its information technology systems are essential to maintaining effective communication with customers and keeping pace with the competitive environment. The Challenger Group is exposed to a number of system risks, including:

- complete or partial failure of the information technology systems;
- inadequacy of internal, partner or third-party information technology systems;
- data inadequacy and corruption;
- incapacity of the existing systems to effectively accommodate Challenger's planned growth and integrate existing and future acquisitions and alliances;
- information technology systems changes not being implemented appropriately or not working in accordance with intended operation;
- systems integration programs not being completed within the timetable or budget; and

- compromise or loss of information or technology arising from external or internal security threats, including cyber-attacks or other information security breaches.

The growing sophistication and activities of organised crime have resulted in increased information security risks for financial institutions, including Challenger. The Challenger Group has information technology security systems in place to detect cyber-attacks and has implemented measures to protect the security, integrity and confidentiality of its information; however, these systems and measures may not be successful in all circumstances.

The Challenger Group has disaster recovery and systems development roadmaps in place to mitigate some of these risks. However, any failure in the Challenger Group's information technology systems could result in business interruption, the loss of customers, damaged reputation and weakening of its competitive position.

Operational risks, including information technology, could impact on the Challenger Group's operations or adversely affect demand for its products and services and its reputation, which could adversely affect Challenger's businesses, financial performance and prospects.

6.2.14.2 Information security including cyber-security risks

The primary focus of information security is to protect information and technology systems from disruptions to confidentiality, integrity or availability. As a life insurer, the Challenger Group handles a considerable amount of personal and confidential information about its customers and its own internal operations. This information is processed and stored on both internal and third party hosted environments. Any failure of security controls operated by the Challenger Group or its third parties could adversely affect Challenger's businesses, financial performance and prospects.

Further, the Challenger Group is exposed to industry-wide cyber security threats, including (but not limited to) denial of service attacks, network intrusions, malware, Trojans, viruses and insider attacks. Cyber and information security risk may arise from an array of factors including complexity within the technology environment and failure to keep technology up-to-date, a failure of Challenger's systems to operate effectively, an inability to restore or recover such systems in acceptable timeframes, a breach of data security, or other forms of cyber-attack or physical attack. The continuing evolution of cyber security threats and their increasing sophistication means constant vigilance and continuing control improvements are required.

Additionally, failure in the Challenger Group's cyber-security policies, procedures or controls could result in loss of customer data or other sensitive information (including as a result of an outage) and may cause reputational damage. An information security breach may also result in operational disruption, regulatory enforcement actions, financial losses or breach of privacy laws, all of which may adversely impact the Challenger Group's ability to retain and attract customers, and thus may adversely affect the Challenger Group's financial performance and position.

6.2.14.3 Outsourcing and supplier risks

Outsourcing involves an organisation entering into an agreement with another party (including a related company) to perform, on a continuing basis, a business activity that currently is, or could be, undertaken within that organisation. While Challenger, CLC and the Challenger Group require that all material outsourcing arrangements are structured, managed and controlled in such a manner that its market reputation, service to customers, financial performance and obligations to

regulators are enhanced or preserved, there remains a risk that these arrangements might fail.

This risk extends to the suppliers of Challenger's outsourced partners, referred to as "fourth parties". There is a risk that inadequate supervision of fourth parties by Challenger's third parties could result in loss to Challenger that may not be fully recoverable from the relevant third parties.

6.2.14.4 Organisational conduct and customer risks

There is a risk the Challenger Group's financial performance, position and creditworthiness is materially and adversely impacted by behaviour or action taken by entities and employees associated with the Challenger Group that may have negative outcomes for its customers, staff, communities, and markets in which it operates. This includes the risk that the Challenger Group's products are designed, priced, distributed or managed in a way that does not meet the reasonable needs, expectations and objectives of its customers. While the Challenger Group has policies and processes to manage employee, contractor and external service provider misconduct, these may not always be effective.

Further, the Challenger Group could also be adversely affected if an employee, contractor or external service provider does not act in accordance with regulations or the Challenger Group's policies and procedures, engages in inappropriate or fraudulent conduct, or unintentionally fails to meet a professional obligation to specific clients. Examples are privacy or data security breaches, AML/CTF Act breaches, market manipulation, insider trading and misleading or deceptive conduct in advertising. As a result, the Challenger Group could incur losses, financial penalties and reputational damage and could be subject to legal or regulatory action.

6.2.14.5 Human error risks

The Challenger Group's business, including the internal processes and systems that support in business decisions, relies on inputs from its employees, agents and third-party vendors. The Challenger Group is exposed to operational risk due to process or human errors including incorrect or incomplete data capture and records maintenance, trading errors, incorrect or incomplete documentation to support activities, or inadequate design of processes or controls. The materialisation of any of these risks could lead to direct financial loss, loss of customer, employee or commercially sensitive data, regulatory penalties and reputational damage.

6.2.14.6 Model risk

There is a risk the Challenger Group's financial performance, position and creditworthiness is materially and adversely impacted by decisions based on incorrect, misapplied or misused model outputs and reports. The Challenger Group uses models in a broad range of activities, including valuing exposures, pricing, measuring risk, and determining capital and reserve adequacy. These expose the Challenger Group to model risk. While the Challenger Group has policies and processes to manage model risk, these may not always be effective.

6.2.15 Staff retention and key person risks

The Challenger Group has a large base of qualified and experienced personnel. The Challenger Group's future success will depend on its continued ability to attract and retain highly skilled, qualified and experienced personnel. There can be no assurance that key personnel will continue to be employed by, or contracted to, the Challenger Group or that the Challenger Group will be able to attract and retain qualified personnel in the future. Failure to retain or attract key personnel could have

a material adverse impact on the Challenger Group's businesses, reputation, financial performance and position.

6.2.16 Strategic risk

Strategic risk is the risk of material value destruction or less than planned value creation, due to changes in the Challenger Group's external and internal operating environment or decisions made by Challenger in response to these changes. The Challenger Group faces risks in connection with the competitive positioning of the business, and its ability to respond in a timely manner to changes in its competitive landscape and protect the value of the Challenger brand. Examples of these risks include competitor disruption, changing customer preferences, and changing political and regulatory environments. The Challenger Board sets the overall strategic direction of Challenger and the Challenger Group as part of the strategic planning process in connection with these risks.

6.2.16.1 Competitive environment

The wealth management industry in which the Challenger Group operates in Australia is becoming increasingly competitive. Factors contributing to this include entry of new participants, development of alternative distribution methods, increased diversification of product mix by major competitors and opportunities arising from regulatory reforms such as the introduction of the Retirement Income Covenant. Responses to increased competition may include lower fees and prices, increased costs (such as marketing), higher redemptions, more aggressive risk taking or a combination of these, which may have a material adverse impact on the financial performance and position of the Challenger Group.

Customer preferences continue to change rapidly in the current financial services environment, driven in particular by advances in technology and competitive dynamics. The failure of the Challenger Group to adapt its capabilities and operating model in order to remain relevant to customers within a rapidly changing environment may impact new business and retention of existing business, resulting in lower than anticipated revenues and profits. This could have a material adverse impact on the financial performance and position of the Challenger Group.

6.2.16.2 Dependence on the Australian economy

As the Challenger Group primarily conducts its life insurance, funds management and banking businesses in Australia, its performance is influenced by the level and cyclical nature of business activity in Australia. This in turn is impacted by both domestic and international economies and political events. A weakness in the Australian economy, and/or in the economic and business conditions of other countries, may have an adverse effect on the Challenger Group's financial conditions and on the results of its operations. This may include credit losses, reduced demand for products and services, and lower investment performance and increased costs, which could have a material adverse impact on the Challenger Group's financial performance, financial condition and prospects.

The electoral cycle in Australia may lead to new regulatory, taxation or other legislative proposals. If enacted, these may impact the underlying performance of the Challenger Group or an investment in Challenger Capital Notes 4.

6.2.16.3 Investor activism

The Challenger Group may be challenged on its strategy by shareholders, including institutional shareholders, and special interest groups. Areas which have attracted investor activism in Australia include making socially responsible investments and avoiding financing or interacting with businesses that do

not demonstrate responsible management of environmental and social issues. The prevalence of investor activism could impact management's decision-making and the implementation of the Challenger Group's initiatives, which could have a material adverse impact on the Challenger Group's financial performance, financial condition and prospects.

6.2.16.4 Transformation and change programs

There is a risk that implementation of transformation and change programs across the Challenger Group to achieve its strategic objectives, meet ongoing customer expectations and respond to competitive pressures may not realise some or all of the anticipated benefits, which may adversely impact the Challenger Group's financial performance, position and creditworthiness.

6.2.17 Reputational damage

The Challenger Group's reputation is a valuable asset and a key contributor to the support that it receives from the community for its business initiatives and its ability to obtain funding and capital. Damage to the Challenger Group's reputation may arise where there are differences between stakeholders' expectations and the Challenger Group's actual or perceived practices. The risk of reputational damage may also be a secondary outcome of other sources of risk described in this Section or other risks that are not covered and which may emerge. The Challenger Group's ability to attract and retain customers and investors and its prospects could also be adversely affected if the Challenger Group's reputation is damaged.

There are various potential sources of reputational damage including potential conflicts of interest, pricing policies, failing to comply with legal and regulatory requirements (including money laundering laws, trade sanctions legislation or privacy laws), ethical issues, litigation, failing to comply with information security policies, improper sales and trading practices, personnel policies, supplier policies, unfair or inappropriate behaviour of staff of the Challenger Group (or staff of its strategic business partners), improper conduct of companies in which it holds strategic investments, technology failures, security breaches and risk management failures. The Challenger Group's reputation could also be adversely affected by the actions of the financial services, wealth management and allied industries in general or from the actions of its customers and counterparties.

Failure to appropriately address issues that could or do give rise to reputational damage could also give rise to additional legal risks, subject the Challenger Group to regulatory enforcement actions, fines and penalties and could lead to loss of business, which could adversely affect the Challenger Group's financial performance, financial condition and prospects.

6.2.18 Mergers, acquisitions and divestments

The Challenger Group at times evaluates and may undertake a range of initiatives, including mergers, acquisitions, joint ventures, strategic alliances and relationships, and divestment activity which facilitates the Challenger Group's strategic direction. These strategic initiatives can be complex and costly and may require the Challenger Group to comply with additional local or foreign regulatory requirements which may carry additional risks. There can also be no guarantee that Challenger Group will identify any future strategic initiatives or that these strategic initiatives will deliver the anticipated positive business results. Strategic initiatives could also have a material adverse impact on the business, prospects, engagement with regulators, financial performance or position of the Challenger Group. Strategic alliances and relationships and joint ventures may involve significant counterparty risk.

It is likely that the Challenger Group would raise additional debt or raise equity to finance any major merger or acquisition, and this would cause the Challenger Group to face the financial risks and costs associated with additional debt or equity.

Mergers or acquisitions may require assimilation of new operations and new personnel and may cause dissipation of the Challenger Group's management resources. Changes in ownership and management may result in impairment of relationships with employees and customers of the acquired businesses. Depending on the type of transaction, it could take a substantial period of time for the Challenger Group to realise the financial benefits of the transaction, if any. During the period immediately following this type of transaction, the Challenger Group's operating results may be adversely affected.

Where the Challenger Group decides to divest a business or asset, this may involve a loss against book value, particularly of any goodwill or other intangibles.

On 20 October 2022, Challenger announced that it had signed a share sale agreement with Heartland Group Holdings Limited to sell Challenger Bank for consideration of approximately \$36 million⁴⁷. The sale of Challenger Bank is subject to regulatory approvals in Australia and New Zealand, and follows the completion of a strategic review announced by Challenger in August 2022.

The Challenger Group's failure to adequately manage the risks associated with any mergers, acquisitions or divestments could adversely affect the Challenger Group's businesses, financial performance, financial condition and prospects.

6.2.19 New investment assets

The Challenger Group may invest in types of assets not currently represented in its asset portfolio. These new types of assets may have risks associated with them that are not currently contemplated by the Challenger Group's policies and procedures, which may require change to those policies and procedures and potentially a change to the capital being held in respect of those risks.

6.2.20 Accounting policies

Australian accounting standards require accounting policies to be selected and applied by the Challenger Group in a manner which ensures that the resultant financial information satisfies the concepts of relevance and reliability, and is comparable and understandable. A change to an accounting policy is only permitted if it is necessary in order to comply with another Australian accounting standard, or if the change will result in an overall improvement in the relevance and reliability of financial information about the performance and financial position of the Challenger Group. The choice of accounting policies and the Life NCOE framework can materially affect the analysis and interpretation of the Challenger Group's financial position and performance, particularly in comparison to other companies.

6.2.21 Tax risks

Australian tax law is frequently being changed, both prospectively and retrospectively. Of particular relevance to the Challenger Group are expected future changes to tax laws affecting the superannuation and financial services industries, following a number of recent Australian Government reviews.

There are risks that any changes to the tax law, including the current rate of company income tax, may both impact on demand for financial products and services and also impact on shareholder

returns and the level of franking available for dividends on Ordinary Shares and Distributions on Challenger Capital Notes 4.

The ATO, as part of its ordinary processes in reviewing large business taxpayers, takes into account their size and complexity. The Challenger Group, as a large and complex group, can be expected to be subject to a high level of review by the ATO and overseas tax regulators in respect of ongoing taxation compliance.

From time to time, the Challenger Group has interactions and matters under review or audit with the ATO in relation to the taxation treatment of various matters. The outcome of these reviews or audits may not always favour the Challenger Group and as a result, there is a risk that an adverse finding by the ATO may impact the Challenger Group's financial position and performance.

6.2.22 Litigation and contingent liabilities

From time to time, the Challenger Group may be subject to material litigation, regulatory actions, legal or arbitration proceedings and other contingent liabilities which, if they crystallise, may adversely affect the Challenger Group's results.

The Challenger Group has made certain capital commitments to external counterparties for future investment opportunities such as development or investment purchases. Details of these contingent liabilities are contained in Note 17 of Challenger's Interim Financial Report for the half year ended 31 December 2022.

There is a risk that these contingent liabilities may be larger than anticipated or that additional litigation or other contingent liabilities may arise.

6.2.23 Climate change and environmental, social and governance risks

The Challenger Group and its customers operate and invest in businesses and assets in a diverse range of geographical locations and industries. Any significant environmental change, climate change related impacts or external events (including fire, storm, drought, flood, earthquake or pandemic) or regulatory responses to any of the foregoing in any of these locations or industries has the potential to disrupt the Challenger Group and its customers' business activities, damage property or otherwise affect the value of assets held in the affected locations or industries. Challenger Group considers environmental factors in investment decision-making and ownership practices, including, where relevant, assessment of climate-related risks. However, environmental changes (including adverse climatic events), climate change-related impacts or external events or regulatory responses to any of the foregoing may directly impact Challenger Group, its customers and its assets (including the Challenger Group's investment portfolio) through reputational damage, environmental factors, insurance risk and business disruption and may have an adverse impact on financial performance.

Initiatives to mitigate or respond to adverse impacts of climate change may in turn impact market and asset prices, economic activity, and customer behaviour, particularly in geographic locations and industry sectors adversely affected by these changes. Failure to effectively manage these transition risks could adversely affect Challenger's business, prospects, reputation, financial performance or financial condition.

Further, the Challenger Group could be exposed to financial losses or reputational and brand damage if it fails to act responsibly in a number of areas, such as the management of

⁴⁷ The agreed sale price is subject to a number of completion adjustments and based on a net asset value of approximately \$25 million.

environmental risks, diversity and inclusion, support for local communities, corporate governance and transparency, and considering other social factors (including human rights breaches such as modern slavery) in its investment and procurement processes. Failure to effectively manage these risks could adversely affect the Challenger Group's businesses, prospects, reputation, financial performance or financial condition.

6.2.24 Failure of risk management strategies

The Challenger Group has implemented risk management strategies and internal controls involving processes and procedures intended to identify, mitigate and monitor the risks to which it is subject, including market risk (including interest rate and foreign exchange risk), strategic risk, insurance risk, credit and counterparty risk, regulatory and compliance risk, and operational risk. The Board's Risk Appetite Statement outlines the level of risk that is acceptable in striving to achieve the Challenger Group's strategic goals and financial objectives. This is combined with a robust risk management framework which identifies, assesses, mitigates and monitors the risks to which the Challenger Group is exposed.

However, there are inherent limitations with any risk management framework as there may exist, or develop in the future, risks that the Challenger Group has not anticipated or identified or controls that may not operate effectively.

If any of the Challenger Group's risk management processes and procedures prove ineffective or inadequate or are otherwise not appropriately implemented, the Challenger Group could suffer unexpected losses and reputational damage which could adversely affect the Challenger Group's businesses, financial performance, capital resources, financial condition and prospects.



Section 7

About the Offer

7. About the Offer

This Section provides information about the Offer, including how to apply. The key dates in relation to the Offer are outlined on page 8.

7.1 The Offer

The Offer is for the issue of Challenger Capital Notes 4 with a Face Value of \$100 per Challenger Capital Note 4 to raise approximately \$350 million, with the ability to raise more or less.

The Offer comprises:

- a New Money Offer made to eligible clients of the Syndicate Brokers and Institutional Investors wishing to make a new investment in Challenger Capital Notes 4; and
- a Reinvestment Offer made to clients of the Syndicate Brokers and Institutional Investors, who are Eligible CCN2 Holders wishing to reinvest some or all of their Challenger Capital Notes 2 in Challenger Capital Notes 4.

The final amount raised under the Offer may be more than \$350 million as a result of amounts allocated under the Reinvestment Offer.

All Challenger Capital Notes 4 will be issued under and subject to the disclosure in this Prospectus.

7.2 Applications

All Applications must be submitted through a Syndicate Broker. A list of the appointed Joint Lead Managers and Co-Managers who are Syndicate Brokers to the Offer can be found on the front cover and in the Corporate Directory of this Prospectus.

7.4 Applying for Challenger Capital Notes 4

7.4.1 Apply through a Syndicate Broker

Who may apply	<ul style="list-style-type: none">• Applications will only be accepted from clients of Syndicate Brokers who are either a Wholesale Client, or a Retail Investor who has received personal advice from a qualified financial adviser concerning an investment in Challenger Capital Notes 4 and who are otherwise within the Challenger Capital Notes 4 Target Market.• If you are an Eligible CCN2 Holder and are an Australian resident client of a Syndicate Broker, you must apply to reinvest your Challenger Capital Notes 2 in Challenger Capital Notes 4 through a Syndicate Broker (see to Section 3 for further information).
When to apply	<ul style="list-style-type: none">• Applications will only be accepted during the Offer Period, which commences on 15 March 2023.• The Closing Date for the Offer is expected to be 5:00pm (Sydney time) on 30 March 2023. Your completed Application and Application Payment (if applicable) must be received by your Syndicate Broker in accordance with arrangements made between you and your Syndicate Broker.
How to apply	<ul style="list-style-type: none">• Contact a Syndicate Broker for instructions on how to apply.
Minimum application amount	<ul style="list-style-type: none">• For the New Money Offer, Applications must be for a minimum of 50 Challenger Capital Notes 4 (\$5,000).• For the Reinvestment Offer, there is no minimum number of Challenger Capital Notes 2 that you must hold to be able to participate. However, if you are an Eligible CCN2 Holder and own less than 50 Challenger Capital Notes 2, you must apply to reinvest the CCN2 Resale Proceeds relating to all of your Challenger Capital Notes 2. If you are an Eligible CCN2 Holder and you own 50 or more Challenger Capital Notes 2, you must apply to reinvest the CCN2 Resale Proceeds relating to at least 50 of your Challenger Capital Notes 2.• Your Syndicate Broker will inform you of your allocation.

Applications (under both the New Money Offer and Reinvestment Offer) will only be accepted from Retail Investors who satisfy the eligibility requirements in accordance with the TMD. You should contact a Syndicate Broker or other professional adviser to obtain more information on whether you satisfy the eligibility requirements.

As there is no general public offer or securityholder offer, no Application can be made directly to Challenger.

7.3 Obtaining a Prospectus

During the Offer Period, an electronic version of a replacement prospectus will be available at www.challengercapitalnotes.com.au and may be available through a Syndicate Broker.

The following additional conditions apply if this Prospectus is accessed electronically:

- you must download the entire Prospectus; and
- you must access and download or print the electronic copy of the Prospectus in Australia.

Eligible CCN2 Holders will also have access to download an electronic version of this Prospectus.

7.4.2 Challenger Capital Notes 4 Target Market

Challenger has made the TMD for Challenger Capital Notes 4 in accordance with its obligations under the DDO Regime. The TMD is available at www.challengercapitalnotes.com.au.

The TMD describes, among other things, the class of Retail Investors that comprises the target market for Challenger Capital Notes 4 (“**Challenger Capital Notes 4 Target Market**”), being Retail Investors who:

- are seeking to acquire an investment product to generate income;
- are able to bear the risks associated with an investment in Challenger Capital Notes 4 (which are summarised in Section 1.5 and detailed in Section 6, in particular, the lack of certainty as to payment of Distributions and potential loss of some or all of the investment capital in Challenger Capital Notes 4);
- do not require certainty as to repayment of invested capital within a specific timeframe; and
- seek the ability to dispose of Challenger Capital Notes 4 by sale on a licensed securities exchange, at the variable price available on the exchange.

If you are a Retail Investor and wish to participate in the Offer, you must seek professional advice as to whether you are within the Challenger Capital Notes 4 Target Market and if an investment in Challenger Capital Notes 4 is suitable for you in light of your particular investment objectives, financial situation and needs. You can only apply for Challenger Capital Notes 4 if you are within the Challenger Capital Notes 4 Target Market and you have received personal advice from a qualified financial adviser.

If you have any questions about the Offer, Challenger Capital Notes 4, or the Challenger Capital Notes 4 Target Market, you should contact a Syndicate Broker or other professional adviser or seek personal advice from a qualified financial adviser who is licensed by ASIC to give that advice.

7.4.3 Brokerage, commission and stamp duty

No brokerage, commission or stamp duty is payable on your Application, provided that no person obtains, either alone or with associates, an interest of 90% or more in Challenger. In some circumstances, interests of persons who are not associates can be aggregated together in determining whether that threshold is met or exceeded.

You may have to pay brokerage, but will not have to pay any stamp duty, on any later sale of your Challenger Capital Notes 4 on ASX after Challenger Capital Notes 4 have been quoted on ASX.

7.4.4 Refunds

In the event that the Offer does not proceed for any reason, all Applicants will have their Application Payments refunded (without interest) as soon as practicable.

Challenger takes no responsibility for handling of Application Payments by any Syndicate Broker.

7.5 Bookbuild and allocation policy

7.5.1 Bookbuild

The Bookbuild is a process that was conducted by the Joint Lead Managers before the Opening Date to determine the Margin and firm allocations of Challenger Capital Notes 4 to Bookbuild participants (being Syndicate Brokers and certain Institutional Investors), by agreement with Challenger. In this process,

the Bookbuild participants were invited to lodge bids for a number of Challenger Capital Notes 4. On the basis of those bids, the Joint Lead Managers and Challenger have, by mutual agreement, determined the Margin and the firm allocations to Syndicate Brokers and to certain Institutional Investors.

The final amount raised under the Offer may be more than \$350 million as a result of amounts allocated under the Reinvestment Offer.

7.5.2 What is the allocation policy?

Allocations to Syndicate Brokers and Institutional Investors were agreed by the Joint Lead Managers and Challenger following completion of the Bookbuild.

Allocations to Applicants by a Syndicate Broker (including in respect of Applications under the Reinvestment Offer) are at the discretion of that Syndicate Broker. However, priority is intended to be given to Applicants applying to reinvest their Challenger Capital Notes 2 over other Applicants.

It is possible for Applications to be scaled back by a Syndicate Broker. Challenger takes no responsibility for any allocation, scale back or rejection decision of a Syndicate Broker.

No assurance is given that any Applicant (including an Applicant under the Reinvestment Offer) will receive an allocation of Challenger Capital Notes 4.

7.5.3 How will the final allocations be announced?

Applicants will be able to confirm their allocation through the Syndicate Broker from whom they received their allocation.

However, if you sell Challenger Capital Notes 4 before receiving a Holding Statement, you do so at your own risk, even if you confirmed your firm allocation through a Syndicate Broker.

7.6 Other information

7.6.1 Restrictions on distribution

No action has been taken to register or qualify this Prospectus, Challenger Capital Notes 4, the Offer or otherwise to permit a public offering of Challenger Capital Notes 4 in any jurisdiction outside Australia.

The distribution of this Prospectus (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Prospectus outside Australia, then you should seek advice on, and observe, any such restrictions. Any failure to comply with such restrictions may violate securities laws. This Prospectus and the Offer do not constitute an offer or invitation in any jurisdiction in which, or to any person to whom, it would not be lawful to make such an offer or invitation.

This Prospectus (including an electronic copy) may not be distributed or released, in whole or in part, in the United States. Neither Challenger Capital Notes 4 nor Ordinary Shares have been or will be registered under the U.S. Securities Act or the securities laws of any state of the United States, and they may not be offered or sold in the United States. Challenger Capital Notes 4 are being offered and sold in the Offer solely outside the United States pursuant to Regulation S under the U.S. Securities Act.

Any offer, sale or resale of Challenger Capital Notes 4 in the United States by a dealer (whether or not participating in the Offer) may violate the registration requirements of the U.S. Securities Act.

Each person submitting an Application will be deemed to have acknowledged that they are aware of the restrictions referred to in this Section 7 and to have represented and warranted that they are able to apply for and acquire Challenger Capital Notes 4 in compliance with those restrictions.

7.6.2 Application to ASX for quotation of Challenger Capital Notes 4

Challenger has applied to ASX for Challenger Capital Notes 4 to be quoted on ASX. If ASX does not grant permission for Challenger Capital Notes 4 to be quoted within three months after the date of the Original Prospectus, Challenger Capital Notes 4 will not be issued and all Application Payments will be refunded (without interest) to Applicants as soon as practicable.

7.6.3 CHESS and issuer sponsored holdings

Challenger has applied for Challenger Capital Notes 4 to participate in CHESS. No certificates will be issued for Challenger Capital Notes 4. Challenger expects that Holding Statements for issuer sponsored Holders and confirmations for CHESS Holders will be dispatched to successful Applicants by 11 April 2023.

7.6.4 Trading and selling on market

It is expected that Challenger Capital Notes 4 will begin trading on ASX on a normal settlement basis on 6 April 2023 under the ASX code "CGFPD".

You are responsible for confirming your holding before trading in Challenger Capital Notes 4. If you are a successful Applicant and sell your Challenger Capital Notes 4 before receiving your Holding Statement, you do so at your own risk.

You can call your Syndicate Broker after the Issue Date to enquire about your allocation.

7.6.5 Provision of bank account details for Distributions

Challenger's current policy is that all Holders will be paid Distributions by direct credit into a nominated Australian financial institution account (excluding credit card accounts). Where no account is specified by a Holder, Distributions will be held by Challenger for the Holder until the relevant account details are provided.

7.6.6 Provision of TFN or ABN and other information

If you are an Applicant who has not already quoted your TFN or ABN to Challenger and are issued any Challenger Capital Notes 4, then you may be contacted in relation to quoting your TFN, ABN or both.

The collection and quotation of TFNs and ABNs are authorised, and their use and disclosure is strictly regulated, by tax laws and the Privacy Act. It is not an offence not to quote your TFN or ABN; however, not doing so may result in tax being withheld from Distributions. See Section 8.4.4 ("Provision of TFN and/or ABN") for further information.

Successful Applicants who do not have an address in Australia registered with the Registry, or who direct the payment of any Distribution to an address outside of Australia, may have an amount deducted for Australian withholding tax from any Distribution paid, to the extent that the Distribution is not fully franked or declared to be conduit foreign income.

Challenger may also be required to request information from successful Applicants to comply with its obligations under FATCA and CRS. See Section 6.1.23 for further information.

7.6.7 Discretions regarding the Offer

Challenger reserves the right not to proceed with, and may withdraw, the Offer (including the Reinvestment Offer) at any time before the issue of Challenger Capital Notes 4 to successful Applicants.

If the Offer, or any part of it, does not proceed, all relevant Application Payments will be refunded (without interest) as soon as practicable.

Challenger and the Joint Lead Managers also reserve the right to close the Offer (including the Reinvestment Offer) or any part of it early, extend the Offer (including the Reinvestment Offer) or any part of it, accept late Applications or bids either generally or in particular cases, reject any Application or bid, or allocate to any Applicant or bidder fewer Challenger Capital Notes 4 than applied or bid for. This is at Challenger's discretion, and Challenger is under no obligation to exercise that discretion in any particular way.

Investors should also note that no cooling-off rights (whether by law or otherwise) apply to an Application for Challenger Capital Notes 4. This means that, in most circumstances, Applicants may not withdraw their Applications once submitted, except as permitted by the Corporations Act.

7.7 Enquiries

You can view the Offer website at www.challengercapitalnotes.com.au or call the Offer Information Line on 1800 780 782 (within Australia) or +61 3 9415 4065 (outside Australia) Monday to Friday 8:30am to 5:00pm (Sydney time) if you:

- have further questions on how to apply for Challenger Capital Notes 4; or
- have any other questions about the Offer (including the Reinvestment Offer).

You should contact your Syndicate Broker if you have further questions about your Application.



Section 8

Australian taxation summary

8. Australian taxation summary

8.1 Introduction

The following is a summary of the Australian income tax, capital gains tax (“**CGT**”), goods and services tax (“**GST**”) and stamp duty consequences for Australian tax resident Holders (“**Resident Note Holders**”) and Holders who are not tax residents of Australia (“**Non-Resident Note Holders**”) who subscribe for Challenger Capital Notes 4 and hold them on capital account for tax purposes.

This tax summary does not include tax consequences which may arise for the following types of Holders:

- Resident Note Holders who are in the business of share trading;
- Resident Note Holders who are dealing in securities or otherwise hold Challenger Capital Notes 4 on revenue account;
- Resident Note Holders who hold their Challenger Capital Notes 4 through a permanent establishment outside Australia; and
- Non-Resident Note Holders who hold their Challenger Capital Notes 4 through a permanent establishment in Australia.

This summary is based on the Australian tax law and administrative practice currently in force as at the date of the Prospectus. It is necessarily general in nature and is not intended to be definitive tax advice to Resident Note Holders or Non-Resident Note Holders. Accordingly, each Resident Note Holder and each Non-Resident Note Holder should seek their own tax advice that is specific to their particular circumstances.

8.2 Anticipated Class Ruling – applicable to certain Resident Note Holders

Challenger has applied to the ATO for a public class ruling (“**Class Ruling**”) confirming certain tax consequences for Resident Note Holders. The Class Ruling does not become operative until it is published by the ATO.

When issued, the Class Ruling will be available free of charge from the ATO’s website (www.ato.gov.au).

It is expected that, when issued, the Class Ruling will:

- only be binding on the Commissioner of Taxation (“**Commissioner**”) if the Offer is carried out in the specific manner described in the Class Ruling;
- only apply to Resident Note Holders that are within the class of entities specified in the Class Ruling (“**Applicable Resident Note Holders**”), being Resident Note Holders who acquire their Challenger Capital Notes 4 by initial subscription and hold them on capital account for tax purposes;
- only rule on the taxation laws as at the date the Class Ruling is issued;
- not consider the tax implications of the Conversion of Challenger Capital Notes 4 on a Non-Viability Trigger Event;
- not consider the tax implications of a Redemption of Challenger Capital Notes 4;
- not consider the taxation treatment of Distributions received by partnerships or trustee investors;
- not consider the tax implications for Resident Note Holders for whom gains and losses from Challenger Capital Notes

4 are subject to the taxation of financial arrangement rules in Division 230 of the *Income Tax Assessment Act 1997* (Cth) (see Section 8.5 below). It is noted that Division 230 will generally not apply to the financial arrangements of individuals, unless an election has been made for those rules to apply; and

- not consider the tax implications of the Reinvestment Offer.

The issue of the Class Ruling will not mean that the ATO guarantees or endorses the commercial viability of investing in Challenger Capital Notes 4.

Subject to the above qualifications or where otherwise indicated, it is expected that the Class Ruling will confirm the taxation consequences as outlined in Sections 8.3.1 to 8.3.6 below. As at the date of this taxation summary, the Class Ruling has not yet been published. Publication will not occur until after the date that the Challenger Capital Notes 4 are issued. Holders should refer to the class ruling once it is published.

8.3 Tax consequences for Applicable Resident Note Holders expected to be addressed in the Class Ruling

8.3.1 Status of the Challenger Capital Notes 4 for tax purposes

The Challenger Capital Notes 4 should be characterised as non-share equity interests for Australian income tax purposes. This means that Distributions on the Challenger Capital Notes 4 should be treated as non-share dividends that are frankable, as outlined in Section 8.3.2 below.

It is anticipated that the Class Ruling will take the view that the Challenger Capital Notes 4 are not “traditional securities” for tax purposes. Accordingly, gains and losses on the Challenger Capital Notes 4 should be subject to the CGT rules, as summarised further below.

8.3.2 Distributions on Challenger Capital Notes 4

Distributions may be franked, unfranked or only partially franked. The amount of the cash Distribution payable will take into account the level of franking credits attached and the prevailing corporate tax rate.

Distributions paid on Challenger Capital Notes 4 (together with any attached franking credits) must be included in the assessable income of an Applicable Resident Note Holder.

Provided an Applicable Resident Note Holder is a “qualified person” (see discussion in Section 8.4.1 below) in relation to a Distribution on their Challenger Capital Note 4 holding, the Applicable Resident Note Holder will be entitled to a tax offset equal to the amount of the franking credits attached to the Distribution. To the extent that the tax offset attributable to the franking credits on a Distribution exceeds the income tax liability for an income year of an Applicable Resident Note Holder who is an individual or complying superannuation entity, the excess tax offset may be refunded to the Applicable Resident Note Holder.

If a Distribution is either exempt income or non-assessable non-exempt income in the hands of an Applicable Resident Note Holder, then the amount of any franking credit on the Distribution should not be included in the assessable income of the Applicable Resident Note Holder, and the Applicable Resident Note Holder should not be entitled to a tax offset.

However, certain tax-exempt entities may qualify for a refund of any tax offset to which they are entitled as a result of a franked Distribution.

There are anti-avoidance rules contained in the Australian tax law that may apply in certain circumstances to deny the benefit of franking credits. However, it is anticipated that the Commissioner will not apply any such anti-avoidance provisions to deny the whole or any part of the imputation benefits received by Applicable Resident Note Holders in relation to the Distributions payable in respect of the Challenger Capital Notes 4.

8.3.3 CGT cost base and acquisition date for Challenger Capital Notes 4

The cost base (or reduced cost base) of each Challenger Capital Note 4 acquired by an Applicable Resident Note Holder should include \$100 (being the Face Value of each Challenger Capital Note 4). Although it is not expected to be addressed in the Class Ruling, the cost base (or reduced cost base) of each Challenger Capital Note 4 should also include any non-deductible incidental costs (e.g. broker fees, adviser fees) associated with the acquisition and disposal of the Challenger Capital Note 4. This will be relevant in determining the capital gain or capital loss resulting on a disposal of Challenger Capital Notes 4.

Each Challenger Capital Note 4 will be taken to have been acquired by an Applicable Resident Note Holder on the date Challenger accepts an Applicable Resident Note Holder's application for Challenger Capital Notes 4 (which is expected to be on the Issue Date).

8.3.4 Conversion of Challenger Capital Notes 4

Under specific provisions of the *Income Tax Assessment Act 1997* (Cth) dealing with convertible interests, any gain or loss that would arise on Conversion should be disregarded. The consequence of this is that the gain or loss on Conversion is effectively deferred, with an Applicable Resident Note Holder's cost base (or reduced cost base) in the Ordinary Shares acquired on Conversion reflecting the Applicable Resident Note Holder's cost base in their Challenger Capital Notes 4.

Upon Conversion, the cost base (or reduced cost base) of the Ordinary Shares issued to an Applicable Resident Note Holder will be determined by spreading the cost base (or reduced cost base) of all of the original Challenger Capital Notes 4 of an Applicable Resident Note Holder across all of the Ordinary Shares issued to that Applicable Resident Note Holder.

The Ordinary Shares issued on Conversion will be taken to have been acquired by an Applicable Resident Note Holder at the time of Conversion. This means that the 12-month holding period for the purposes of the CGT discount mentioned in Section 8.4.2 below will start from the acquisition date of the Ordinary Shares (i.e. on Conversion), and not from the time of acquisition of the Challenger Capital Notes 4.

Applicable Resident Note Holders may elect not to take and hold their allocation of Ordinary Shares upon Conversion and instead may instruct a nominee appointed by Challenger to sell those Ordinary Shares on their behalf. Under this arrangement, once an Applicable Resident Note Holder's allocation of Ordinary Shares has been sold, the nominee will pay to the Applicable Resident Note Holder a cash amount equal to the Proceeds (broadly, the net sale proceeds).

A capital gain for an Applicable Resident Note Holder will arise if the cash amount received exceeds the cost base of their Challenger Capital Notes 4. Conversely, a capital loss will arise if the reduced cost base of their Challenger Capital

Notes 4 exceeds the cash amount received (capital losses of an Applicable Resident Note Holder may only be offset against capital gains of the same or later years of income).

Applicable Resident Note Holders who dispose of their Ordinary Share allocation via the sale facility should not be entitled to CGT discount treatment (in respect of any gain arising on disposal of their Ordinary Shares) where Ordinary Shares are sold by the nominee within 12 months of Conversion. In this regard, as noted above, the date of acquisition of Ordinary Shares for CGT discount purposes is the date of Conversion, rather than when the relevant Challenger Capital Notes 4 were acquired.

8.3.5 Write-Off of Challenger Capital Notes 4

In certain circumstances, an Inability Event may prevent Challenger Capital Notes 4 from being Converted into Ordinary Shares. In this situation, an Applicable Resident Note Holder's rights in relation to their Challenger Capital Notes 4 (including to Distributions and to the repayment of the Face Value) will be immediately and irrevocably Written-Off and terminated (with effect on and from the Non-Viability Conversion Date).

A CGT event arises for Applicable Resident Note Holders when Challenger Capital Notes 4 are Written-Off. No capital proceeds will be provided to Applicable Resident Note Holders for their Written-Off Challenger Capital Notes 4. Accordingly, Applicable Resident Note Holders should make a capital loss equal to the reduced cost base of their Written-Off Challenger Capital Notes 4. As noted in Section 8.4.2 below, capital losses of an Applicable Resident Note Holder may only be offset against capital gains of the same or later years of income.

8.3.6 Resale of Challenger Capital Notes 4

Challenger may elect to Resell Challenger Capital Notes 4 in certain circumstances. For each Challenger Capital Note 4 subject to a Resale, a Holder will be entitled to receive the Resale Price (which is equal to the Face Value) from the Nominated Purchaser. A Resale will constitute a disposal of Challenger Capital Notes 4 by an Applicable Resident Note Holder for CGT purposes. Accordingly, an Applicable Resident Note Holder may realise a capital gain or capital loss on such disposal to the extent that the Resale proceeds are greater or less than the Applicable Resident Note Holder's cost base or reduced cost base for the Challenger Capital Notes 4. The Applicable Resident Note Holder's capital proceeds should be equal to the Face Value of the Challenger Capital Notes 4 (i.e. being the amount the Applicable Resident Note Holder is entitled to be paid if a Resale occurs).

If the Challenger Capital Notes 4 have been held for at least 12 months prior to the Resale (excluding the days of acquisition and disposal), a qualifying Applicable Resident Note Holder (an individual, qualifying trust or complying superannuation fund) may be entitled to the CGT discount concession in respect of any capital gain arising on disposal, in the manner discussed in Section 8.4.2 below.

8.4 Other tax consequences for Resident Note Holders not expected to be addressed in the Class Ruling

The following tax consequences for Resident Note Holders are not expected to be addressed in the Class Ruling.

8.4.1 Qualification for franking credits on Distributions – “qualified person”

A Resident Note Holder is not required to include the amount of the franking credits in its assessable income and is not entitled

to the tax offset unless the Resident Note Holder is a “qualified person” in relation to a Distribution.

A Resident Note Holder is a “qualified person” if the “holding period” and “related payments” rules in the tax laws are satisfied in respect of the Distribution.

In relation to the “holding period” rule, a Resident Note Holder must have held Challenger Capital Notes 4 “at risk” for a continuous period of at least 90 days (excluding the days of acquisition and disposal) within a period beginning on the day after the date on which the Resident Note Holder acquired the Challenger Capital Notes 4 and ending on the 90th day after the date on which Challenger Capital Notes 4 became ex-Distribution.

If the “related payments” rule applies, a Resident Note Holder is required to hold Challenger Capital Notes 4 “at risk” for at least 90 days (excluding the days of acquisition and disposal) within a period beginning 90 days before and ending 90 days after the date on which Challenger Capital Notes 4 became ex-Distribution (i.e. the day on which Challenger Capital Notes 4 cease carrying the entitlement for their Holders to receive a particular Distribution). Broadly speaking, the related payments rule would apply where a Resident Note Holder makes a payment which passes the benefit of a Distribution to another person.

Alternatively, a Resident Note Holder is taken to be a qualified person in relation to Distributions if the total amount of the tax offsets in respect of all franked distributions to which the Resident Note Holder would be entitled in an income year is \$5,000 or less. This is referred to as the “small shareholder rule”. However, a Resident Note Holder will not be a “qualified person” by virtue of the small shareholder rule if related payments have been made, or will be made, in respect of a Distribution.

8.4.2 Sale of Challenger Capital Notes 4

A sale of Challenger Capital Notes 4 by a Resident Note Holder on ASX will give rise to a capital gain if the sale proceeds exceed the cost base of the Challenger Capital Notes 4. Conversely, a capital loss will arise if the reduced cost base of the Challenger Capital Notes 4 exceeds the sale proceeds.

If Challenger Capital Notes 4 have been owned for at least 12 months prior to the sale (excluding the days of acquisition and disposal), certain Resident Note Holders (individuals, trusts and complying superannuation entities) may be entitled to receive CGT discount treatment in respect of any gain arising on disposal of Challenger Capital Notes 4, such that a percentage of the gain is not included in assessable income. The discount percentage is applied to the amount of the capital gain after offsetting any current year or carried forward capital losses. The discount percentages are 50%, 50% and 33⅓% for Resident Note Holders who are individuals, trusts and complying superannuation entities respectively.

8.4.3 Redemption of Challenger Capital Notes 4

Challenger may elect to Redeem Challenger Capital Notes 4 in certain circumstances, in which case Challenger will pay an amount equal to the Face Value for each Challenger Capital Note 4 that is being Redeemed.

Redemption of Challenger Capital Notes 4 will constitute a disposal of Challenger Capital Notes 4 for CGT purposes. Accordingly, a Resident Note Holder may derive a capital gain or a capital loss on such disposal to the extent to which the Redemption proceeds paid to the Resident Note Holders are greater than the cost base or are less than the reduced cost base

of the Challenger Capital Notes 4 respectively. As noted in Section 8.4.2 above, capital losses of a Resident Note Holder may only be offset against capital gains of the same or later years of income.

The Redemption proceeds will be an amount equal to the Face Value of each Challenger Capital Note 4, unless the market value of a Challenger Capital Note 4 on the Redemption Date (determined as if Redemption of the Challenger Capital Note 4 had not occurred or been proposed to occur) is greater or less than the Face Value. In that case, the greater or lesser market value amount will be deemed to be the capital proceeds of the Redemption, instead of the Face Value actually received. The Redemption proceeds should not be treated as a dividend to the extent to which they are debited against an amount standing to the credit of Challenger's non-share capital account.

A qualifying Resident Note Holder (an individual, trust or complying superannuation entity) may be entitled to CGT discount treatment in respect of any capital gain, in the same manner as discussed in Section 8.4.2 above.

8.4.4 Provision of TFN and/or ABN

Resident Note Holders may, if they choose, notify Challenger of their Tax File Number (“TFN”), Australian Business Number (“ABN”), or a relevant exemption from withholding tax with respect to Distributions.

In the event that Challenger is not so notified, tax will be deducted at the highest marginal tax rate (including applicable levies) from the cash amount of the unfranked part (if any) of the Distributions. The rate of withholding is currently 47%.

Challenger is required to withhold and remit to the ATO such tax until such time as the relevant TFN, ABN or exemption notification is given to it. Resident Note Holders will be able to claim a tax credit or refund (as applicable) in respect of any tax withheld on the Distributions in their income tax returns.

8.4.5 Goods and services tax (“GST”)

Holders should not be liable for GST in respect of their investment in Challenger Capital Notes 4 or the disposal or Conversion of Challenger Capital Notes 4.

Holders registered for GST are unlikely to be entitled to an input tax credit for any GST paid in respect of costs associated with the acquisition of Challenger Capital Notes 4 (e.g. adviser fees).

8.4.6 Stamp duty

No stamp duty should be payable on the issue, transfer or disposal of Challenger Capital Notes 4 as long as no Holder (alone or with associates) will acquire or hold a 90% or more interest in Challenger.

Further, the conversion of Challenger Capital Notes 4 to Ordinary Shares will not be subject to duty as long as Challenger is listed, all of its shares are quoted on ASX and no person alone or with associates obtains an interest of 90% or more in Challenger.

In some circumstances, interests of persons who are not associates can be aggregated together in determining whether those thresholds are met or exceeded.

8.5 Taxation of financial arrangements

Rules on the taxation of financial arrangements (“TOFA”) are contained in Division 230 of the *Income Tax Assessment Act 1997* (Cth). The TOFA regime generally applies to “financial arrangements” (as defined) such as the Challenger Capital Notes 4. However, the TOFA regime should generally not apply to individual Resident Note Holders in respect of their investment in Challenger Capital Notes 4.

In addition, the TOFA regime should generally not apply to other Resident Note Holders (such as companies and trusts) in respect of their investment in Challenger Capital Notes 4. This should be the case even if they exceed the relevant asset/turnover thresholds, unless certain specific elections under the TOFA regime are made by the relevant Resident Note Holder.

It is recommended that Resident Note Holders who have made one of the specific elections under the TOFA regime obtain tax advice relating to their particular circumstances regarding the application of the TOFA regime to their investment in Challenger Capital Notes 4.

8.6 Non-Resident Note Holders

Below is a summary of certain Australian income tax consequences for Non-Resident Note Holders who do not carry on a business at or through a permanent establishment in Australia.

With respect to Distributions received by Non-Resident Note Holders, the following should apply:

- Dividend withholding tax (“DWT”) should not apply to the extent the Distributions are franked.
- To the extent Distributions are unfranked, DWT should apply unless Challenger has declared the unfranked portion to be “conduit foreign income” (“CFI”). The rate of withholding tax is 30%, unless reduced under the terms of a double tax treaty that Australia has with the jurisdiction of the applicable Non-Resident Note Holder.
- A credit or refund for franking credits attached to Distributions will not be available to Non-Resident Note Holders.

For Non-Resident Note Holders, any capital gain or capital loss resulting from a disposal of Challenger Capital Notes 4 should be disregarded for CGT purposes.

8.7 Eligible CCN2 Holders who participate in the Reinvestment Offer

Under the Reinvestment Offer, Eligible CCN2 Holders who elect to participate in the Reinvestment Offer may apply to sell some or all of their Challenger Capital Notes 2 to the CCN2 Nominated Purchaser for \$100 per Challenger Capital Note 2, and apply to reinvest the proceeds of their Reinvestment CCN2 in a corresponding number of Challenger Capital Notes 4. This will be effected via a direction to the CCN2 Nominated Purchaser to pay the relevant CCN2 Resale Proceeds (\$100 per Challenger Capital Note 2) to Challenger as the Application Payment for the Challenger Capital Notes 4.

We have set out below some high level comments in relation to Eligible CCN2 Holders who are subject to Class Ruling CR 2017/25 (*Income tax: Challenger Limited: Challenger Capital Notes 2*) (“CR 2017/25”), to the extent that they elect to participate in the Reinvestment Offer. This summary is not exhaustive, and you should seek advice from your own financial or tax adviser or other professional adviser before deciding to participate in the Reinvestment Offer.

In particular, this tax summary does not include tax consequences which may arise for Eligible CCN2 Holders who:

- are not Australian residents for tax purposes;
- are Australian residents but hold the Challenger Capital Notes 2 through a permanent establishment outside Australia;
- acquired Challenger Capital Notes 2 otherwise than under the initial offer of Challenger Capital Notes 2;
- hold Challenger Capital Notes 2 in their business of share trading or dealing in securities, or who otherwise hold their Challenger Capital Notes 2 on revenue account or as trading stock; or

- are subject to the TOFA provisions in Division 230 of the *Income Tax Assessment Act 1997* (Cth) in relation to their holding of Challenger Capital Notes 2.

8.7.1 Final distribution on Reinvestment CCN2

Eligible CCN2 Holders who successfully participate in the Reinvestment Offer will receive a single distribution representing the period from (and including) 22 February 2023 to (but not including) the Issue Date of the Challenger Capital Notes 4 (being 5 April 2023) (i.e. the First CCN2 Pro Rata Distribution). On the Issue Date of Challenger Capital Notes 4, CCN2 Holders that have chosen to participate in the Reinvestment Offer will receive a distribution of \$0.64 per Challenger Capital Note 2. The First CCN2 Pro Rata Distribution does not form part of the Resale Price.

This will be the final distribution that such holders will receive on their Reinvestment CCN2.

This final distribution should be subject to the same taxation treatment as other distributions paid on the Challenger Capital Notes 2, as outlined in CR 2017/25.

8.7.2 CGT consequences for Eligible CCN2 Holders

A CGT event will occur for Eligible CCN2 Holders upon sale of their Reinvestment CCN2 to the CCN2 Nominated Purchaser.

Eligible CCN2 Holders may make a capital gain if their capital proceeds from the disposal are more than their cost base for their Reinvestment CCN2, or may make a capital loss if their capital proceeds are less than their reduced cost base for their Reinvestment CCN2:

- *Cost base or reduced cost base:* the first element of an Eligible CCN2 Holder’s cost base, or reduced cost base, for their Reinvestment CCN2 should be the amount paid by the Eligible CCN2 Holder for their Reinvestment CCN2. Certain other non-deductible incidental costs associated with the acquisition or disposal of the Reinvestment CCN2 (e.g. broker fees, adviser fees) may be included in the cost base or reduced cost base.
- *Capital proceeds:* assuming the Eligible CCN2 Holder is dealing at arm’s length with the CCN2 Nominated Purchaser, the capital proceeds that will be received by the Eligible CCN2 Holder from the sale of their Reinvestment CCN2 to the CCN2 Nominated Purchaser should be \$100 per Reinvestment CCN2.

A qualifying Eligible CCN2 Holder (an individual, qualifying trust or complying superannuation entity) may be entitled to the CGT discount concession in relation to any capital gain realised on the sale of their Reinvestment CCN2. In this regard, the CGT discount concession outlined in Section 8.4.3 above in relation to disposals by Resident Note Holders of Challenger Capital Notes 4 should be equally applicable to disposals by Eligible CCN2 Holders of Reinvestment CCN2.

8.7.3 CGT cost base and acquisition date for Challenger Capital Notes 4 acquired under the Reinvestment Offer

The amount of an Eligible CCN2 Holder’s disposal proceeds that is applied in subscribing for Challenger Capital Notes 4 under the Reinvestment Offer should be included in the Eligible CCN2 Holder’s cost base (and reduced cost base) for the purposes of determining any future capital gain or capital loss on the disposal, Conversion, Redemption or Resale of Challenger Capital Notes 4.

Each Challenger Capital Note 4 acquired by an Eligible CCN2 Holder under the Reinvestment Offer will be taken to have been acquired by that Holder on the Issue Date of Challenger Capital Notes 4.



Section 9

Additional information

9. Additional information

This Section provides information about a number of other matters not covered elsewhere in this Prospectus.

9.1 Interests and benefits

9.1.1 Directors' relevant interests

The Directors as at the date of this Prospectus had the following relevant interests in issued securities of Challenger:

Directors	Direct interests in Ordinary Shares	Indirect interests in Ordinary Shares
Duncan West	-	25,901
Nicolas Hamilton ¹	75,413	-
John M Green	-	22,784
Steven Gregg	14,000	-
Masahiko Kobayashi ²	-	-
Dr Heather Smith	-	18,705
JoAnne Stephenson	-	26,629
Melanie Willis	-	156,836

Notes:

- Nicolas Hamilton also holds 160,706 Restricted Shares, 51,094 Deferred Performance Share Rights and 1,202,394 Hurdled Performance Share Rights.
- Hiroyuki Iioka was appointed as an Alternate Director to Masahiko Kobayashi on 13 December 2019 and he has no direct interests or indirect interests in Ordinary Shares.

Other than as set out in this Prospectus, no Director or proposed Director holds, at the time of lodgement of this Prospectus with ASIC, or has held in the two years before lodgement of this Prospectus with ASIC, an interest in:

- the formation or promotion of Challenger;
- the Offer; or
- any property acquired or proposed to be acquired by Challenger in connection with the formation or promotion of Challenger or the Offer.

Other than as set out in this Prospectus, no amount (whether in cash, Ordinary Shares or otherwise) has been paid or agreed to be paid, nor has any benefit been given or agreed to be given, to any Director or proposed Director:

- to induce a person to become, or qualify as, a Director; or
- for services provided by a Director or proposed Director in connection with the formation or promotion of Challenger or the Offer.

9.1.2 Directors' fees

The Constitution contains provisions about the remuneration of the Directors. As remuneration for their services as Directors, the non-executive Directors are entitled to be paid an amount of remuneration for his or her services as a Director as determined by the Board, subject to a maximum annual aggregate amount of \$2.5 million or such other amount fixed by the shareholders of Challenger in a general meeting. All Directors are entitled to be paid all travelling and other expenses properly incurred by them in connection with the affairs of Challenger.

Additional fees are paid to the Chair of the Board and its committees to reflect the additional responsibilities. The remuneration of the Chief Executive Officer is fixed by the Board. The remuneration may consist of salary or any other elements and may be provided as a contribution to a superannuation fund, but must not be a commission on or percentage of profits or operating revenue.

9.1.3 Participation in the Offer

The Directors (and certain related persons) may collectively acquire up to 0.2% of Challenger Capital Notes 4 offered under the Offer without shareholder approval (subject to certain conditions) – see Section 9.4 for further information.

9.1.4 Professionals

UBS, NAB and WIB have acted as the Arrangers to the Offer, and each of UBS, ANZ, Morgans, NAB and WIB have acted as Joint Lead Managers to the Offer, in respect of which they will receive fees from Challenger. The estimated aggregate fees payable by Challenger to the Joint Lead Managers are approximately \$5.3 million (exclusive of GST), making certain assumptions as to the allocation of Challenger Capital Notes 4 between the New Money Offer and the Reinvestment Offer, as well as to the total value of Challenger Capital Notes 4 issued. The aggregate fees include an Arranger fee paid to UBS, and a Joint Lead Manager fee paid proportionately to each Joint Lead Manager on the basis of their Challenger Capital Notes 4 allocation.

The Joint Lead Managers on behalf of Challenger are responsible for paying all selling fees and other commissions payable to the Syndicate Brokers. Challenger reserves the right to pay select institutional investors a cornerstone fee.

The Joint Lead Managers and their respective affiliates and any of their respective directors, officers, employees, partners, advisers, contractors or agents (the "**JLM Parties**") are involved in a wide range of financial services and businesses, or may provide products and services to, or in connection with, a wide range of companies and individuals, in respect of or from which they may receive fees, profits and other benefits and out of which conflicting interests or duties may arise. In the ordinary course of these activities, each of the JLM Parties may at any time hold long or short positions, and may trade or otherwise effect transactions, or take or enforce security, for their own account or the account of persons directly or indirectly involved with the Challenger Group or the Offer or interests associated with any other person, including (without limitation) investors in Challenger and their respective officers, directors, employees, partners, agents and advisers ("**Relevant Persons**"). These transactions, services and businesses may involve, without limitation, debt or equity securities issuing and trading, brokerage activities, provision of retail, business, private, commercial and investment banking, investment management, corporate finance, credit and derivatives, trading and research products and services or the provision of loans, financing arrangements or other financial accommodation, financial products or services, in connection with, or which rely on the performance of obligations by, any Relevant Person. The Joint Lead Managers have represented to Challenger that they will manage any conflicts in connection with their role as Joint Lead Managers in compliance with applicable legal obligations.

King & Wood Mallesons has acted as Challenger's Australian legal and tax adviser in relation to the Offer. In respect of this work, King & Wood Mallesons will be paid approximately \$430,000 (excluding disbursements and GST) for work performed by it until the date of this Prospectus. Further amounts may be paid to King & Wood Mallesons in accordance with its time-based charges.

Ernst & Young has provided due diligence services in connection with the Challenger Group's financial information included in this Prospectus in relation to the Offer. In respect of this work, Ernst & Young will be paid approximately \$92,000 (excluding disbursements and GST) for work performed by it up until the date of this Prospectus. Further amounts may be paid to Ernst & Young in accordance with its time-based charges.

Except as set out in this Prospectus, no:

- person named in this Prospectus as performing a function in a professional, advisory or other capacity in connection with the preparation or distribution of this Prospectus; or
- Joint Lead Manager,

holds at the time of lodgement of this Prospectus with ASIC, or has held in the two years before lodgement of this Prospectus with ASIC, an interest in:

- the formation or promotion of Challenger;
- the Offer; or
- any property acquired or proposed to be acquired by Challenger in connection with the formation or promotion of Challenger or the Offer,

nor has anyone paid or agreed to pay or given or agreed to give any benefit to such persons in connection with the formation or promotion of Challenger or the Offer.

9.2 Expenses of the Offer

Assuming the Offer raises \$350 million, then the total expenses of the Offer (including fees payable to the Joint Lead Managers, legal, accounting, tax, marketing, administrative fees, advertising and other expenses related to this Prospectus and the Offer) are expected to be \$6.3 million. All of these expenses have been, or will be, borne by a Challenger Group entity.

9.3 Consents

Except as set out below, each of the parties referred to in the following table:

- has given, and has not, before the lodgement of this Prospectus with ASIC, withdrawn, its written consent to be named in this Prospectus in the form and context in which it is named;
- has not made any statement in this Prospectus, or any statement on which a statement made in this Prospectus is based; and
- does not cause or authorise the issue of this Prospectus, and, to the maximum extent permitted by law, expressly disclaims and takes no responsibility for any statements in or omissions from this Prospectus.

Role	Consenting parties
Arrangers	UBS AG, Australia Branch National Australia Bank Limited Westpac Institutional Bank
Joint Lead Managers	UBS AG, Australia Branch ANZ Securities Limited National Australia Bank Limited Morgans Financial Limited Westpac Institutional Bank
Co-Managers	LGT Crestone Wealth Management Limited JBWere Limited
Auditor	Ernst & Young
Australian legal and tax adviser	King & Wood Mallesons
Registry	Computershare Investor Services Pty Limited
Trustee	Equity Trustees Limited

9.4 ASX confirmations and waivers

9.4.1 Offer

In accordance with the ASX Listing Rules, the Challenger Capital Notes 4 will be classified as "equity securities" for the purposes of the ASX Listing Rules and ASX has confirmed, in relation to the Offer, that:

- ASX Listing Rule 3.20.2 and 3.20.5 will not apply to the Conversion of Challenger Capital Notes 4 following a Non-Viability Trigger Event;
- the Terms are appropriate and equitable for the purposes of ASX Listing Rule 6.1;
- the Terms concerning APRA constraints on the payment of Distributions and potential exercise of the limited amendment powers do not amount to a removal of a right to a dividend for the purposes of ASX Listing Rule 6.10;
- ASX Listing Rule 6.12 does not apply to the Terms which provide for Conversion, Exchange, Write-Off or Redemption;
- it does not consider Challenger Capital Notes 4 to be options for the purposes of ASX Listing Rule 6.14 to 6.23;
- it does not consider Challenger Capital Notes 4 to be preference securities for the purposes of ASX Listing Rules 6.4 to 6.7;
- Challenger should count the maximum number of fully paid Ordinary Shares into which the Challenger Capital Notes 4 can convert in line with Listing Rule 7.1B.1(e) for the purposes of Listing Rule 7.1;
- the issue of Ordinary Shares on Exchange or Conversion of Challenger Capital Notes 4 would fall under ASX Listing Rule 7.2 (exception 9) and ASX Listing Rule 10.12 (exception 7);
- ASX Listing Rule 10.11 has been waived to the extent necessary to permit Directors and certain related persons (being the spouses, parents, children and associates of Directors) to participate in the Offer without shareholder approval, up to a maximum of 0.2% of the total number of Challenger Capital Notes 4 issued under the Offer collectively, provided that:

- the participation of the Directors and their related persons in the Offer is on the same terms and conditions as applicable to other subscribers for Challenger Capital Notes 4;
 - Challenger releases the terms of the waiver to the market when it announces the Offer; and
 - when Challenger Capital Notes 4 are issued, Challenger announces to the market the total number of Challenger Capital Notes 4 issued to Directors and their related persons in aggregate; and
- the timetable for the Offer is acceptable.

ASX has also provided in-principle approval of the quotation of Challenger Capital Notes 4.

9.4.2 Reinvestment Offer

ASX has confirmed in relation to the Reinvestment Offer that:

- the amendments to the CCN2 Terms are appropriate and equitable under ASX Listing Rule 6.1;
- CHES will apply a holding lock to any Challenger Capital Notes 2 the subject of an Application from a CCN2 Holder;
- the amendments to the CCN2 Terms for the payment of distributions on the Challenger Capital Notes 2 do not amount to a removal of a right to a dividend for the purposes of ASX Listing Rule 6.10; and
- the timetable for the Reinvestment Offer is acceptable.

9.5 Reporting and disclosure obligations

Challenger is admitted to the official list of ASX and is a disclosing entity for the purposes of the Corporations Act. As a disclosing entity, it is subject to regular reporting and disclosure obligations under the Corporations Act and ASX Listing Rules. Broadly, these obligations require Challenger to prepare both yearly and half yearly financial statements and to report on its operations during the relevant accounting period, and to obtain an audit or review report from its auditor.

Copies of documents lodged with ASIC in relation to Challenger may be obtained from, or inspected at, an ASIC office.

A copy of documents lodged with ASIC in relation to Challenger may also be obtained from ASIC's website www.asic.gov.au (a fee may apply).

Challenger must ensure that ASX is continuously notified of information about specific events and matters as they arise for the purposes of ASX making the information available to the Australian securities market.

Subject to certain exceptions, Challenger has an obligation under the ASX Listing Rules to notify ASX immediately of any information concerning it of which it becomes aware, which a reasonable person would expect to have a material effect on the price or value of its quoted securities.

9.6 ASIC relief

ASIC has granted relief from the provisions of Division 5A of Part 7.9 of the Corporations Act relating to unsolicited offers for Challenger to conduct the Reinvestment Offer (subject to certain conditions).

Challenger has obtained relief from section 734(2) of the Corporations Act to enable it to provide securityholders with details on the structure of the Offer before the release of this Prospectus.

9.7 Design and distribution obligations and ASIC product intervention powers

The DDO Legislation imposes additional obligations on Challenger regarding the design and distribution of certain financial products offered to Retail Investors (including hybrid securities), and grants product intervention powers to ASIC if it believes significant consumer detriment has occurred, or is likely to occur as a result of the financial product.

The design and distribution obligations in the DDO Legislation are limited to an initial offering of securities, which means that they will not apply to secondary market trading of Challenger Capital Notes 4.

The DDO Legislation gives ASIC a significant, proactive power to issue a product intervention order if it believes that a financial product has resulted in or will, or is likely to, result in significant detriment to retail clients. The DDO Legislation requires ASIC to undertake a consultation process before it makes a product intervention order.

9.8 Amendments to the CCN2 Terms

To facilitate the Reinvestment Offer, certain amendments have been made to the CCN2 Terms under clause 17.4 of those terms and clause 15.1 of the Challenger Capital Notes 2 Trust Deed. Those amendments have been released to ASX.

The amendments include terms permitting the resale of the Reinvestment CCN2 on the terms set out in this Prospectus.

9.9 Availability of documents

Challenger will provide a copy of any of the following documents free of charge to any person upon their request during the Offer Period:

- the Annual Report for the financial year ended 30 June 2022 lodged with ASIC by Challenger;
- the Interim Financial Report for the half year ended 31 December 2022 lodged with ASIC by Challenger;
- any continuous disclosure notices given by Challenger in the period after the lodgement of the Interim Financial Report of Challenger for the half year ended 31 December 2022 and before lodgement of this Prospectus with ASIC; and
- the Constitution.

The Annual Report for the financial year ended 30 June 2022, and the Interim Financial Report for the half year ended 31 December 2022 released to ASX are available at www.asx.com.au or at www.challenger.com.au/shareholder/financial-information.

Challenger's continuous disclosure notices lodged with ASX are available at www.asx.com.au or at www.challenger.com.au/shareholder/market-announcements.

Challenger's Constitution is available at www.challengercapitalnotes.com.au.

All written requests for copies of the above documents should be addressed to Challenger Investor Relations at the address set out in the Corporate Directory at the end of this Prospectus or by email to investorrelations@challenger.com.au.

9.10 Rights and liabilities attaching to Challenger Capital Notes 4

The rights and liabilities attaching to Challenger Capital Notes 4 are contained in the Trust Deed (which includes the Terms). The Terms are set out in Appendix A and a summary of the Trust Deed is set out in Section 9.12. Challenger must provide a copy of the Trust Deed to a Holder on request.

Rights and liabilities attaching to Challenger Capital Notes 4 may also arise under the Corporations Act, the ASX Listing Rules, the Constitution and other laws.

9.11 Rights and liabilities attaching to Ordinary Shares

Holders will receive Ordinary Shares on Conversion. The rights and liabilities attaching to the Ordinary Shares are set out in the Constitution and are also regulated by the Corporations Act, the ASX Listing Rules and the general law.

This Section 9.11 briefly summarises the key rights attaching to Ordinary Shares. It is not intended to be an exhaustive summary of the rights and obligations of holders of Ordinary Shares. Investors who wish to inspect the Constitution may obtain a copy as provided under Section 9.9.

The key rights attaching to Ordinary Shares are as follows:

- the right to receive notice of, attend and vote at general meetings of Challenger (either in person or by proxy, attorney or representative) on the basis of one vote on a show of hands or one vote for each fully paid Ordinary Share (or a fraction of a vote in proportion to the capital paid up on that Ordinary Share) on a poll;
- the right to be paid dividends from time to time, as determined by the Board, in their judgement, as the financial position of Challenger justifies. Challenger may also be constrained from paying dividends on Ordinary Shares by the operation of prudential standards of APRA, or potentially in particular circumstances by the terms of certain instruments issued by it;
- the right to receive information required to be distributed under the Corporations Act and the ASX Listing Rules; and
- the right to participate in a surplus of assets on a winding-up of Challenger in proportion to the Ordinary Shares held (subject to the rights of holders of securities carrying preferred rights on winding-up, including Challenger Capital Notes 4).

9.12 Summary of the Trust Deed

Challenger has entered into a Trust Deed dated on or about the date of the Original Prospectus with the Trustee. The following is a summary only of the principal provisions of the Trust Deed.

9.12.1 Appointment of Trustee

The Trustee has been appointed under the Trust Deed and holds the following on trust for the Holders and itself in accordance with the terms of the Trust Deed:

- the right to enforce Challenger's duty to repay under Challenger Capital Notes 4 in accordance with the Terms;
- the right to enforce Challenger's obligation to pay all other amounts payable under Challenger Capital Notes 4 in accordance with the Terms;
- the right to enforce any other duties or obligations that Challenger has under the Terms, under the Trust Deed, to the Holders under the Trust Deed or under Chapter 2L of the Corporations Act;
- the amount of \$10; and
- any other property held by the Trustee on the trust established under the Trust Deed (including, without limitation, the benefit of any covenants, undertakings, representations, warranties, rights, powers, benefits or remedies in favour of the Trustee under the Trust Deed).

9.12.2 Undertakings

In respect of each Challenger Capital Note 4, Challenger has undertaken to the Trustee, subject to any obligation of Challenger to Convert or Write-Off Challenger Capital Notes 4, to pay the amounts due and payable in respect of that Challenger Capital Note 4 under and in accordance with the Terms. The Trustee directs Challenger to pay such amounts under the Trust Deed directly to the Holders, unless:

- a Winding-up Event has occurred and is subsisting;
- a Controller (as defined in the Corporations Act), statutory manager or similar official has been appointed to the Issuer; or
- the Issuer advises the Trustee that it is not likely to meet its obligations under the Trust Deed,

in which event the payment must be made to the Trustee.

Challenger also makes covenants with the Trustee for the benefit of the Holders to, among other things:

- comply with the Terms; and
- comply with all statutory and regulatory requirements applicable to it to the extent they relate to its obligations under the Terms and the Trust Deed, where a failure to do so would have or be likely to have a material adverse effect on the ability of Challenger to meet its payment obligations in respect of Challenger Capital Notes 4 or the validity and enforceability of the rights and remedies of Holders under the Transaction Documents.

9.12.3 Sale of Ordinary Shares

Under the Terms, if Challenger Capital Notes 4 held by a Foreign Holder are Converted, a Holder has elected not to receive Ordinary Shares as a result of Conversion or to the extent that a FATCA Withholding is required to be made in respect of Ordinary Shares, the number of Ordinary Shares which that Holder is obliged to accept on Conversion will be issued to the Nominee who will sell that number of Ordinary Shares and pay a cash amount equal to the net proceeds to the relevant Holder.

The Trustee is not liable to any Holder for the acts of any Nominee appointed in accordance with the Terms to sell the Ordinary Shares and has no duties in connection with any such sale and no responsibility for any costs, losses, liabilities, expenses, demands or claims which arise as a result of such sale.

9.12.4 Enforcement

Subject to the Transaction Documents and to section 283DA(h) of the Corporations Act, the Trustee may at any time in its discretion take action to enforce the Transaction Documents in accordance with their terms (which includes the Terms), but is not required to take any such action unless:

- it is requested to take such action by Holders who hold in aggregate at least 25% or more of the Face Value of all Challenger Capital Notes 4 then outstanding or by a Special Resolution;
- it is indemnified and/or placed in funds, to its reasonable satisfaction, against all actions, proceedings, claims and demands to which the Trustee may render itself liable by taking such action, all costs which the Trustee may incur in taking the action and all reasonable management time spent by employees or officers of the Trustee in relation to such action; and
- the action is permitted under the Transaction Documents and is not prohibited by law.

No Holder is entitled to proceed directly against Challenger to enforce the performance of any of the provisions of the Challenger Capital Notes 4 or the Trust Deed (including any rights, powers or remedies in connection with the Challenger Capital Notes 4, whether under the Trust Deed or any other Transaction Document) unless the Trustee, being entitled, and having become bound, to proceed, fails to do so within 14 days and the failure is continuing.

The Trustee may not take any enforcement action which is contrary to the Transaction Documents.

Neither the Trustee nor any Holder may exercise any powers in a manner inconsistent with, or take any enforcement action which is contrary to, the Transaction Documents.

9.12.5 Liability

Except to the extent arising as a result of the Trustee's fraud, gross negligence, wilful default or breach of section 283DA(a), (b) or (c) of the Corporations Act ("**Trustee Default**"), the Trustee is not liable to Challenger or any other person in any capacity other than as trustee of the Trust and the Trustee's liability is further limited to the assets of the Trust available to indemnify the Trustee for the liability and to the extent permitted by law. The full limitation on the Trustee's liability is set out in clause 7.1 of the Trust Deed.

9.12.6 Fees and expenses

Challenger will pay the Trustee fees as agreed between Challenger and the Trustee from time to time. Challenger will also pay, on demand, the Trustee's:

- reasonable expenses incurred in connection with negotiating, preparing and executing the Transaction Documents and certain related expenses;
- losses and expenses incurred in connection with exercising, enforcing or preserving rights under the Transaction Documents (or attempting to do so);
- losses and expenses incurred by the Trustee which arise out of or in the course of acting as Trustee (except where these expenses are incurred by the Trustee as a direct result of a Trustee Default); and
- expenses reasonably and properly incurred by the Trustee as a result of a Winding-up Event.

9.12.7 Retirement and removal

Subject to applicable laws, the Trustee may retire at any time by giving notice to Challenger at least 60 days before the date it wants to retire or any other period which is agreed between Challenger and the Trustee.

Challenger may remove the Trustee at any time by giving notice to the Trustee of at least 60 days (or such other period as Challenger and the Trustee may agree) in certain circumstances, including where:

- the Trustee is in breach of its obligations under any Transaction Document in any material respect and has not rectified the breach within seven Business Days of receiving notice from Challenger requesting the breach be remedied;
- a Trustee Default has occurred and is continuing;
- the Trustee ceases or has ceased or has expressed an intention to cease to carry on business;
- the Trustee ceases to be a person which can be appointed as a trustee under the Corporations Act;
- the Trustee is placed in liquidation or is wound-up or dissolved or a receiver, liquidator, administrator or similar person is appointed to the Trustee;

- Challenger is authorised or requested to do so by a meeting of Holders; or
- the Trustee has breached section 283DA(a), (b) or (c) of the Corporations Act.

The removal or retirement of the Trustee does not take effect until the appointment of a new trustee is effective. Challenger has the power to appoint a new trustee and in certain circumstances, the retiring Trustee may do so.

9.12.8 Meetings

The Trustee or Challenger may at any time call a meeting of Holders. Challenger must call a meeting of Holders (or the relevant Holders) on request in writing of Holders who together hold 10% or more of the aggregate Face Value of all Challenger Capital Notes 4 to consider the financial statements that were laid before the last annual general meeting of Challenger or to give the Trustee directions in relation to the exercise of its powers under the Trust Deed. The Trustee must call a meeting of Holders as soon as reasonably practicable after becoming aware of a Winding-up Event occurring.

At a meeting of Holders, by a Holder Resolution, Holders have the power to give directions to the Trustee in respect of the performance or exercise of its duties under the Transaction Documents or in respect of a Challenger Capital Note 4 or approve an amendment to the Trust Deed which is required to be approved by a Holder Resolution. By Special Resolution, Holders have the power to release the Trustee from liability, approve any act taken by the Trustee or approve any amendment to the Trust Deed which is required to be approved by a Special Resolution.

Resolutions proposed in any meeting of Holders must be passed with the requisite majority of the persons voting on a show of hands unless a poll is demanded, then by a majority consisting of at least the requisite majority of the votes cast. A poll can be demanded by the chairperson, the Trustee or Challenger or by one or more Holders present or by attorney or proxy holding (in aggregate) Challenger Capital Notes 4 representing at least 5% of the aggregate Face Value of Challenger Capital Notes 4 outstanding when the meeting begins. On a show of hands, every Holder who is present has one vote and on a poll every Holder of Challenger Capital Notes 4 who is present has one vote for every Challenger Capital Note 4 with respect to which it is the Holder.

9.12.9 No monitoring obligations

The Trustee has no obligation to monitor compliance by Challenger with its covenants and obligations under the Trust Deed or any other activities or status of Challenger, including taking steps to ascertain whether there has occurred or is likely to occur any Non-Viability Trigger Event or Inability Event, subject to the Trustee's obligations under the Corporations Act. In this regard, the Trustee is subject to certain statutory duties imposed on it under Chapter 2L of the Corporations Act including to:

- exercise reasonable diligence to ascertain whether:
 - the property of Challenger that is or should be available will be sufficient to repay the amounts lent by Holders in respect of Challenger Capital Notes 4 if and when it becomes due in accordance with the Terms; and
 - Challenger has breached the Terms, the Trust Deed or the provisions of Chapter 2L of the Corporations Act; and
- unless the Trustee is satisfied the breach will not materially prejudice Holders' interests, do everything in its power to ensure Challenger remedies any breach known to the Trustee of the Terms, the Trust Deed or the provisions of Chapter 2L of the Corporations Act.

9.12.10 Receipt of monies

All monies that are received by the Trustee under the Trust Deed must be held by the Trustee on trust and will be applied first in payment of any amounts owing to the Trustee in connection with any Transaction Document (including all remuneration payable to the Trustee and any payments under the Trustee's indemnity), secondly in or towards payment of all amounts due but unpaid under Challenger Capital Notes 4 to the relevant Holders, and thirdly in payment of the balance (if any) of the money remaining after those payments to Challenger.

9.13 Summary of the Offer Management Agreement

9.13.1 Overview

Challenger and the Joint Lead Managers signed the Offer Management Agreement on 7 March 2023. Under the Offer Management Agreement, Challenger appointed UBS, NAB and WIB as Arrangers and UBS, NAB, WIB, ANZ and Morgans as Joint Lead Managers of the Offer. The following is a summary of the principal provisions of the Offer Management Agreement.

Under the Offer Management Agreement, the Joint Lead Managers have agreed to manage the Bookbuild and related allocation process for the Offer and to provide settlement support for the settlement obligations of successful Applicants under the Offer.

9.13.2 Fees

The estimated aggregate fees payable by Challenger to the Joint Lead Managers under the Offer Management Agreement are set out in Section 9.1.4. The actual amount payable will not be known until the allocation of Challenger Capital Notes 4 under the Offer. In addition, Challenger must reimburse each Joint Lead Manager for reasonable expenses, including legal costs (up to \$60,000, excluding GST and disbursements) and travel costs, incurred by the Joint Lead Managers in relation to the Offer.

9.13.3 Representations and warranties

Customary and usual representations and warranties are given by the parties in relation to matters such as the power to enter into the Offer Management Agreement and corporate authority. Challenger gives a number of further representations and warranties, including that this Prospectus and the related public documents are not misleading or deceptive or likely to mislead or deceive and do not contain any statements that are misleading or deceptive and do not omit information required by applicable law.

9.13.4 Indemnity

Subject to certain exclusions relating to, among other things, fraud, recklessness, wilful misconduct, gross negligence or wilful default of an indemnified party, Challenger indemnifies the Joint Lead Managers and certain affiliated parties against losses suffered directly or indirectly by, or claims made against, such parties in connection with the Offer or the appointment of the Joint Lead Managers pursuant to the Offer Management Agreement.

9.13.5 Termination events

Each Joint Lead Manager may terminate its obligations under the Offer Management Agreement on the occurrence of a number of customary termination events, including (among others):

- credit rating downgrade of Challenger or CLC, withdrawal of either of those credit ratings, or placement of either of those credit ratings on credit watch negative or negative outlook;
- a specified fall in the S&P/ASX 200 index;

- a specified rise in mid-rate for the iTraxx Australia Index for a term of five years;
- ASIC issues a stop order in relation to this Prospectus;
- ASX refuses to quote Challenger Capital Notes 4 on ASX;
- Challenger withdraws this Prospectus, the Offer or the Target Market Determination; and
- trading of Ordinary Shares is suspended from quotation, or Ordinary Shares cease to be quoted on ASX.

Certain other termination events will only give rise to a right to terminate if, in the reasonable opinion of the relevant Joint Lead Manager, the event has or is likely to have a material adverse effect on the success or settlement of the Offer, or leads, or is likely to lead, give rise to a contravention by that Joint Lead Manager, or liability for that Joint Lead Manager under, applicable laws. If termination occurs, the Joint Lead Manager who terminates will no longer be a Joint Lead Manager and will not be obliged to provide settlement support under the Bookbuild.

Under the Offer Management Agreement, if one Joint Lead Manager terminates, each other Joint Lead Manager may give notice in writing to Challenger and the terminating Joint Lead Manager(s) stating whether it will also terminate or whether it will assume the rights and obligations of the terminating Joint Lead Manager(s).

9.14 Acknowledgements

By submitting an Application you, as Applicant, will be deemed to have:

- agreed to be bound by the Terms and other terms and conditions of the Offer and on Conversion of Challenger Capital Notes 4, agreed to become a member of Challenger and to be bound by the terms of the Constitution;
- acknowledge having personally received an electronic copy of this Prospectus accompanying the Application Form (and any supplemental or replacement Prospectus);
- represented and warranted that you have read and understood this Prospectus (and any supplementary or replacement document) and accompanying Application Form in full;
- declared that the Application has been completed and submitted according to this Prospectus and subject to the declarations, statements and acknowledgements in the Application;
- declared that you make the warranties, representations and acknowledgements contained in this Prospectus and the Application;
- represented and warranted that all details and statements in your Application are complete and accurate;
- declared that you, if a natural person, are over 18 years of age;
- acknowledged that you understand the Terms and have had the opportunity to consider the suitability of an investment in Challenger Capital Notes 4 with your professional advisers;
- acknowledged that investments can be subject to investment risk, including possible delays in repayment and loss of income and principal invested, and that Challenger does not in any way guarantee or stand behind the capital value or performance of Challenger Capital Notes 4;
- declared that you (if you are a Retail Investor) have received personal advice from a qualified financial adviser in connection with the Offer;
- acknowledged that, in some circumstances, Challenger may not pay Distributions or any other amount payable on Challenger Capital Notes 4;

- applied for the number of Challenger Capital Notes 4 set out in or determined in accordance with the Application and agreed to being allocated that number of Challenger Capital Notes 4 (or a lower number, or no Challenger Capital Notes 4 at all) in a way described in this Prospectus;
- acknowledged that if you are not issued any Challenger Capital Notes 4 or issued fewer Challenger Capital Notes 4 than the number that you applied and paid for as a result of the scale back, all or some of your Application Payment (as applicable) will be refunded to you (without interest) as soon as practicable after the Issue Date;
- authorised Challenger and the Joint Lead Managers, and their respective officers or agents, to do anything on your behalf which may be necessary for Challenger Capital Notes 4 to be allocated to you, including to act on instructions received by the Registry;
- acknowledged that the information contained in this Prospectus (or any supplementary or replacement document) is not investment advice or a recommendation that Challenger Capital Notes 4 are suitable for you, given your investment objectives, financial situation or particular needs (including financial and taxation issues);
- declared that you are an Australian resident or otherwise a person to whom the Offer can be made, and Challenger Capital Notes 4 issued, in accordance with Section 7.6.1;
- consented to the use and disclosure of your personal information as described in Section 9.15, and understood and agreed that the use and disclosure of such personal information applies to any personal information collected by Challenger and any member of the Challenger Group in the course of the relationship between you and Challenger and any member of the Challenger Group;
- acknowledged that Challenger Capital Notes 4 have not been, and will not be, registered under the U.S. Securities Act or pursuant to the securities laws of any other jurisdiction outside Australia;
- declared that you are not an individual residing in a member state of the European Union;
- represented and warranted that you are not in the United States or any other place outside Australia and are not a U.S. Person (as defined in Regulation S of the U.S. Securities Act) (and not acting for the account or benefit of a U.S. Person), and you will not offer, sell or resell Challenger Capital Notes 4 in the United States to, or for the account or benefit of, any U.S. Person;
- represented and warranted that you have not distributed this Prospectus or any other materials concerning the Offer in the United States or to any U.S. Person and have not accessed this Prospectus or any other materials concerning the Offer in the United States;
- represented and warranted that the laws of any other place, including any restrictions set out in Section 7.6.1 of this Prospectus, do not prohibit you from being given the Prospectus (or any supplementary or replacement Prospectus) or making an Application or being issued with Challenger Capital Notes 4;
- acknowledged that your Application to acquire Challenger Capital Notes 4 is irrevocable and may not be varied or withdrawn except as allowed by law; and
- acknowledged that an Application may be rejected without giving any reason, including where the Application is not properly completed.

In addition, by submitting an Application in respect of the Reinvestment Offer, you, as Applicant will be deemed to have:

- represented and warranted to Challenger and the CCN2 Nominated Purchaser that you are an Eligible CCN2 Holder;
- represented and warranted to Challenger and the CCN2 Nominated Purchaser that you have good title to the Reinvestment CCN2 the subject of your Application, and that the CCN2 Nominated Purchaser will receive good title to those Challenger Capital Notes 2 free from any encumbrance of security interests on paying the CCN2 Resale Proceeds to you;
- offered to sell the number of Challenger Capital Notes 2 in your Application to the CCN2 Nominated Purchaser for \$100 per Challenger Capital Note 2;
- directed the CCN2 Nominated Purchaser to pay the CCN2 Resale Proceeds for each Reinvestment CCN2 the subject of your Application to Challenger as the Application Payment for the Challenger Capital Notes 4;
- authorised the Joint Lead Managers (or any person acting on their behalf) to complete and execute any documents and take any other actions necessary to effect the sale of Reinvestment CCN2 through the Reinvestment Offer, the reinvestment of CCN2 Resale Proceeds in Challenger Capital Notes 4 and the allocation of Challenger Capital Notes 4;
- applied to Challenger for a corresponding number of Challenger Capital Notes 4, at \$100 per Challenger Capital Note 4;
- agreed not to transfer or dispose of the Challenger Capital Notes 2 that you wish to be sold under the Reinvestment Offer and authorise Challenger and its related bodies corporate and their respective officers to request the application of a holding lock on your Challenger Capital Notes 2;
- agreed to indemnify Challenger for all costs or losses it incurs as a result of you selling or disposing of your Challenger Capital Notes 2 if you do sell or dispose of any of those Challenger Capital Notes 2;
- appointed Challenger (or its officers) as your attorney and agent to execute a master transfer form to transfer to the CCN2 Nominated Purchaser the Reinvestment CCN2 the subject of your Application, in such form as Challenger (or its officers) determines, and to transfer those Reinvestment CCN2 to the CCN2 Nominated Purchaser; and
- authorised Challenger to take all necessary steps to give effect to the sale of your Challenger Capital Notes 2 under the Reinvestment Offer and any reinvestment of the CCN2 Resale Proceeds that are the subject of your Application.

9.15 Privacy

The Registry has been engaged to maintain the Register on behalf of Challenger. Protecting your privacy and your personal information is important to the Registry and Challenger.

If you apply for Challenger Capital Notes 4, the Registry on behalf of Challenger and a Syndicate Broker will collect, use and disclose your personal information to process your Application and register you as a Holder, to communicate with you and service your needs as a Holder, and to carry out appropriate administration of your investment.

The Corporations Act requires the collection of certain information and for that information to be included in Challenger's register of investors. This Register is public and able to be inspected by any person.

If you do not provide your personal information, then it may not be possible to set up or administer your security holding.

The Registry may disclose your personal information to Syndicate Brokers, agents, contractors and service providers, including printers, mailing houses, call centres and general advisers who enable the Registry to provide its services to Challenger and Challenger activities applicable to you as a Holder. Some of these recipients may be located outside Australia, including in the following countries: Canada, India, New Zealand, the Philippines, the United Kingdom and the United States of America.

Under the Privacy Act, an Applicant may request access to their personal information held on behalf of Challenger. To request access to, or to correct, your personal information, please contact the Registry via the Offer Information Line on 1800 780 782 (within Australia) or +61 3 9415 4065 (outside Australia) Monday to Friday 8:30am to 5:00pm (Sydney time), or the Computershare Investor Services Privacy Officer can be contacted by email at privacy@computershare.com.au, or write to the Computershare Investor Services Privacy Officer at Computershare's address set out in the Corporate Directory at the back of this Prospectus.

You may also elect not to receive marketing material by contacting the Registry via the Offer Information Line (details in the paragraph above) or emailing privacy@computershare.com.au.


The Registry's privacy policy contains further information on how you can access or correct your personal information as well as how to complain about the handling of your personal information. The Registry's privacy policy can be found at www.computershare.com/au/privacy-policies.

The Registry may also disclose your personal information to Challenger and Challenger will have access to the Register. You can find Challenger's privacy policy at www.challenger.com.au/privacy.

In addition, your Syndicate Broker may ask for your personal information for the purposes of your Application.

9.16 Statement of Directors

This Prospectus is authorised by each Director who consents, and who has not withdrawn their consent, to its lodgement with ASIC and its issue.



Appendix A

Challenger Capital Notes 4 Terms

A. Challenger Capital Notes 4 Terms

1 Form of Capital Notes 4

1.1 Constitution under Trust Deed

Challenger Capital Notes 4 (the **Capital Notes**) are non-cumulative, convertible, transferable, redeemable, subordinated, perpetual, unsecured notes of the Issuer constituted by, and owing under, the Trust Deed. The Capital Notes (including any amounts payable in respect of each Capital Note) do not have the benefit of security granted by, and are not guaranteed by, the Issuer or a Related Entity of the Issuer or any other person.

1.2 Form

The Capital Notes are issued in registered form by entry in the Register.

1.3 Face Value

The Capital Notes have a Face Value of A\$100 and are issued fully paid.

1.4 Currency

The Capital Notes are denominated in Australian dollars.

1.5 Clearing system

The Capital Notes will be entered into and dealt with in CHES. For so long as the Capital Notes remain in CHES, the rights of a person holding an interest in the Capital Notes are subject to the rules and regulations of CHES but without affecting any Term which may cause APRA to object to the Challenger Group using, or having used, the proceeds of the issue of some or all of the Capital Notes to fund Additional Tier 1 Capital of CLC.

1.6 No certificates

No certificates will be issued to Holders unless the Issuer determines that certificates should be available or are required by any applicable law.

1.7 ASX quotation

The Issuer must use all reasonable endeavours and furnish all such documents, information and undertakings as may be reasonably necessary in order to procure that the Capital Notes are, and until Redeemed, Converted or Written-Off remain, quoted on ASX.

1.8 No other rights

No Holder has:

- (a) any claim against the Issuer (except as expressly set out in these Terms or the Trust Deed) or any other member of the Challenger Group; or
- (b) any right to:
 - (i) vote at any meeting of shareholders of the Issuer;
 - (ii) subscribe for new securities (except in respect of Conversion) or to participate in any bonus issues of securities of the Issuer; or
 - (iii) otherwise participate in the profits or property of the Issuer.

2 Status and ranking

2.1 Status and ranking

The Capital Notes constitute direct and unsecured subordinated debt obligations of the Issuer, ranking for payment of Distributions and for payment of the Redemption Price in a winding-up of the Issuer:

- (a) ahead of Ordinary Shares;
- (b) equally among themselves and with all other instruments issued as Relevant Perpetual Subordinated Instruments; and
- (c) behind the claims of Senior Creditors.

2.2 Unsecured Notes

The Capital Notes are unsecured notes for the purposes of section 283BH of the Corporations Act.

2.3 Not policies under Life Insurance Act

The Capital Notes are not policies with any member of the Challenger Group for the purposes of the Life Insurance Act.

3 Distributions

3.1 Distributions

Subject to these Terms, each Capital Note entitles the Holder on a Record Date to receive, in respect of a Distribution Period, on the Distribution Payment Date following the end of that Distribution Period, interest (**Distribution**) on its Face Value calculated according to the following formula:

$$\text{Distribution} = \frac{\text{Distribution Rate} \times \text{A\$100} \times \text{N}}{365}$$

where:

Distribution Rate (expressed as a percentage per annum) in respect of a Capital Note for a Distribution Period is the rate calculated according to the following formula:

$$\text{Distribution Rate} = (\text{BBSW Rate} + \text{Margin}) \times (1 - \text{Tax Rate})$$

where:

BBSW Rate means:

- (a) subject to paragraph (b) immediately below:
 - (i) for a Distribution Period, the rate (expressed as a percentage per annum) in respect of prime bank eligible securities having a tenor of three months which is designated as the "AVG MID" on the 'Refinitiv Screen ASX29 Page' or the 'Bloomberg Screen BBSW Page' (or any designation which replaces that designation on the applicable page, or any replacement page) at the Publication Time on the first Business Day of that Distribution Period; or
 - (ii) if the Issuer determines that such rate as is described in paragraph (i) above;
 - (A) is not published by midday (or such other time that the Issuer considers appropriate on that day); or
 - (B) is published, but is affected by an obvious error, such other rate (expressed as a percentage per annum) that the Issuer determines having regard to comparable indices then available; and

- (b) if the Issuer determines that a Rate Disruption Event has occurred, then, subject to APRA's prior written approval, the Issuer:
- (i) shall use as the BBSW Rate such Replacement Rate as it may determine;
 - (ii) shall make such adjustments to these Terms as it determines are reasonably necessary to calculate Distributions in accordance with such Replacement Rate; and
 - (iii) in making the determinations under paragraphs (i) and (ii) immediately above:
 - (A) shall act in good faith and in a commercially reasonable manner;
 - (B) may consult with such sources of market practice as it considers appropriate; and
 - (C) may otherwise make such determination in its discretion;

Holders should note that APRA's approval may not be given for any Replacement Rate it considers to have the effect of increasing the rate of Distributions contrary to applicable prudential standards.

Margin (expressed as a percentage per annum) means the margin determined under the Bookbuild;

Publication Time means 12:00pm (Sydney time) or any amended publication time for the final intraday refix of the rate specified by ASX Benchmarks Limited (ABN 38 616 075 417) (or any successor administrator or provider) in its applicable benchmark methodology;

Rate Disruption Event means that, in the Issuer's opinion, the rate described in paragraph (a) of the definition of "BBSW Rate" above:

- (a) has been discontinued or otherwise ceased to be calculated or administered; or
- (b) is no longer generally accepted in the Australian market as a reference rate appropriate to floating rate debt securities of a tenor and interest period comparable to that of the Capital Notes;

Replacement Rate means a rate other than the rate described in paragraph (a) of the definition of "BBSW Rate" that is generally accepted in the Australian market as the successor to the BBSW Rate, or if the Issuer is not able, after making reasonable efforts, to ascertain such rate, or there is no such rate;

- (a) a reference rate that is, in the Issuer's opinion, appropriate to floating rate debt securities of a tenor and interest period most comparable to that of the Capital Notes; or
- (b) such other rate as the Issuer determines having regard to available comparable indices;

Tax Rate (expressed as a decimal) means the Australian corporate tax rate applicable to the franking account of the Issuer at the relevant Distribution Payment Date; and

N means in respect of:

- (a) the first Distribution Payment Date, the number of days from (and including) the Issue Date until (but not including) the first Distribution Payment Date; and
- (b) each subsequent Distribution Payment Date, the number of days from (and including) the preceding Distribution Payment Date until (but not including) the relevant Distribution Payment Date.

3.2 Franking Rate determination and adjustments to Distributions

- (a) The Issuer must determine the Franking Rate for each Distribution in accordance with the Tax Act so that (unless the Tax Act otherwise requires):
- (i) the Franking Rate for a Distribution equals the Franking Rate of:
 - (A) a Dividend paid or expected to be paid by the Issuer during the Franking Period in which that Distribution is paid (**Applicable Franking Period**); or
 - (B) if a Dividend is not paid or expected to be paid by the Issuer in the Applicable Franking Period, a prior Distribution paid during the Applicable Franking Period; and
 - (ii) if the circumstances in paragraphs (i)(A) or (i)(B) do not apply in respect of a Distribution, then the Franking Rate for that Distribution will be determined at the absolute discretion of the Issuer.

- (b) If the Franking Rate for a Distribution is not 100%, the Distribution will be calculated according to the following formula:

$$\text{Distribution} = \frac{D}{1 - [\text{Tax Rate} \times (1 - F)]}$$

where:

D means the Distribution calculated under clause 3.1;

Tax Rate has the meaning given in clause 3.1; and

F means the applicable Franking Rate.

3.3 Payment of a Distribution

The payment of any Distribution on a Distribution Payment Date is subject to:

- (a) the absolute discretion of the Issuer; and
- (b) no Payment Condition existing in respect of the relevant Distribution Payment Date.

3.4 Distributions are discretionary, non-cumulative and only payable in cash

- (a) Payments of Distributions are within the absolute discretion of the Issuer and are non-cumulative. If all or any part of a Distribution is not paid because of this clause 3.4 or because of any other reason:
- (i) the Issuer has no liability to pay the unpaid amount of the Distribution;
 - (ii) Holders have no claim or entitlement in respect of such non-payment (including, without limitation, on a winding-up of the Issuer); and
 - (iii) such non-payment does not constitute an event of default.
- (b) No interest accrues on any unpaid Distributions and Holders have no claim or entitlement in respect of interest on any unpaid Distributions.
- (c) Any payments of Distributions to Holders must be made in the form of cash.

3.5 Distribution Payment Dates

Subject to this clause 3, Distributions will be payable in arrear in respect of a Capital Note on the following dates (each a **Distribution Payment Date**):

- (a) each 25 February, 25 May, 25 August and 25 November, commencing on 25 August 2023, until (but not including) the date on which the Capital Note is Converted or Redeemed in accordance with these Terms; and
- (b) each date on which a Conversion, Redemption or Resale of the Capital Note occurs, in each case, in accordance with these Terms.

If a Distribution Payment Date is a day which is not a Business Day, then the Distribution Payment Date becomes the next day which is a Business Day.

3.6 Record Dates

A Distribution is only payable on a Distribution Payment Date to those persons registered as Holders on the Record Date for that Distribution.

3.7 Notification of Distribution, Distribution Rate and other items

For each Distribution Period, the Issuer must notify the Trustee, the Registrar and ASX of the Distribution Rate and the expected Distribution payable as soon as practicable, but in any event no later than the fourth Business Day of the Distribution Period.

3.8 Restrictions in the case of non-payment of a Distribution

Subject to clause 3.9, if for any reason a Distribution has not been paid in full on a Distribution Payment Date (the **Relevant Distribution Payment Date**), the Issuer must not, without the approval of a Special Resolution, until and including the next Distribution Payment Date:

- (a) declare, determine to pay or pay a Dividend; or
- (b) undertake any Buy-Back or Capital Reduction, unless the Distribution is paid in full within three Business Days of the Relevant Distribution Payment Date.

3.9 Exclusions from restrictions in case of non-payment

The restrictions in clause 3.8 do not apply:

- (a) to a Buy-Back or Capital Reduction in connection with any employment contract, benefit plan or other similar arrangement; and
- (b) to the extent that at the time a Distribution has not been paid on the relevant Distribution Payment Date, the Issuer is legally obliged to pay on or after that date a Dividend or complete on or after that date a Buy-Back or Capital Reduction.

Nothing in these Terms prohibits the Issuer or a Controlled Entity from purchasing Challenger Shares (or an interest therein) in connection with a transaction for the account of a customer of the Issuer or a customer of a Controlled Entity or, with the prior written approval of APRA, in connection with the distribution or trading of Challenger Shares in the ordinary course of business. This includes where the Issuer or a Controlled Entity acquires Challenger Shares acting as trustee for another person and neither the Issuer nor any Controlled Entity has a beneficial interest in the trust (other than a beneficial interest that arises from a security given for the purposes of a transaction entered into in the ordinary course of business).

4 Mandatory Conversion

4.1 Mandatory Conversion

Subject to clauses 5, 6 and 7, on the Mandatory Conversion Date the Issuer must Convert all (but not some) of the Capital Notes on issue at that date into Ordinary Shares in accordance with clause 8 and this clause 4.

4.2 Mandatory Conversion Date

The **Mandatory Conversion Date** will be the first to occur of the following dates (each a **Relevant Date**) on which the Mandatory Conversion Conditions are satisfied:

- (a) 25 February 2032 (the **Scheduled Mandatory Conversion Date**); and
- (b) a Distribution Payment Date after the Scheduled Mandatory Conversion Date (a **Subsequent Mandatory Conversion Date**).

4.3 Mandatory Conversion Conditions

The Mandatory Conversion Conditions for each Relevant Date are:

- (a) the VWAP on the 25th Business Day immediately preceding (but not including) the Relevant Date (the **First Test Date**, provided that if no trading in Ordinary Shares took place on that date, the First Test Date is the first Business Day before the 25th Business Day immediately preceding (but not including) the Relevant Date on which trading in Ordinary Shares took place) is greater than the First Test Date Percentage of the Issue Date VWAP (the **First Mandatory Conversion Condition**);
- (b) the VWAP during the period of 20 Business Days on which trading in Ordinary Shares took place immediately preceding (but not including) the Relevant Date (the **Second Test Period**) is greater than the Conversion Test Date Percentage of the Issue Date VWAP (the **Second Mandatory Conversion Condition**); and
- (c) no Delisting Event applies in respect of the Relevant Date (the **Third Mandatory Conversion Condition** and together with the First Mandatory Conversion Condition and the Second Mandatory Conversion Condition, the **Mandatory Conversion Conditions**).

In this clause 4.3:

$$\begin{aligned} \text{First Test Date Percentage} &= 110\% \times \text{Relevant Fraction} \\ &\text{(expressed as a percentage)} \\ \text{Conversion Test Date Percentage} &= 101.01\% \times \text{Relevant Fraction} \\ &\text{(expressed as a percentage)} \end{aligned}$$

4.4 Non-Conversion Notices

If:

- (a) the First Mandatory Conversion Condition is not satisfied in relation to a Relevant Date, the Issuer will give notice to Holders and the Trustee between the 25th and the 21st Business Day before the Relevant Date; or
- (b) the Second Mandatory Conversion Condition or the Third Mandatory Conversion Condition is not satisfied in relation to a Relevant Date, the Issuer will give notice to Holders and the Trustee on or as soon as practicable after the Relevant Date,

that Mandatory Conversion will not (or, as the case may be, did not) occur on the Relevant Date (each such notice a **Non-Conversion Notice**).

5 Conversion on Non-Viability Trigger Event

5.1 Non-Viability Trigger Event

(a) A **Non-Viability Trigger Event** occurs upon:

- (i) the issuance of a notice, in writing, by APRA to the Issuer that the conversion to Ordinary Shares or write-off of Relevant Perpetual Subordinated Instruments in accordance with their terms or by operation of law is necessary because, without it, APRA considers that the Issuer would become non-viable; or
- (ii) a determination by APRA, notified in writing to the Issuer, that without a public sector injection of capital, or equivalent support, the Issuer would become non-viable.

A determination by APRA under this clause 5.1(a) is a **Non-Viability Determination**.

(b) If a Non-Viability Trigger Event occurs, the Issuer must convert to Ordinary Shares or write-off:

- (i) unless paragraph (ii) applies, all Relevant Perpetual Subordinated Instruments; or
- (ii) where clause 5.1(a)(i) applies, such amount of the Relevant Perpetual Subordinated Instruments which is required to enable APRA to conclude that the Issuer is viable without further conversion to Ordinary Shares or write-off.

(c) Where a Non-Viability Trigger Event occurs under clause 5.1(a)(ii), the Issuer must immediately convert or write-off all Relevant Perpetual Subordinated Instruments then outstanding (including the Capital Notes).

APRA has stated that it will not approve partial conversion or partial write-off in those exceptional circumstances where a public sector injection of funds is deemed necessary.

5.2 Consequences of a Non-Viability Trigger Event

(a) If a Non-Viability Trigger Event occurs:

- (i) on that date, whether or not that day is a Business Day (the **Non-Viability Conversion Date**), the Issuer must immediately determine in accordance with the Non-Viability Determination:

(A) the amount of Capital Notes that will be Converted into Ordinary Shares and the amount of other Relevant Perpetual Subordinated Instruments which will be converted into Ordinary Shares or written-off; and

(B) the identity of the Holders whose Capital Notes will Convert at the time that the Conversion is to take effect and in making that determination the Issuer may make any decisions with respect to the identity of the Holders at that time as may be necessary or desirable to ensure Conversion occurs in an orderly manner, including disregarding any transfers of Capital Notes that have not been settled or registered at that time;

- (ii) subject only to clauses 5.1(b)(ii) and 8.13 and despite any other provision in these Terms, on the Non-Viability Conversion Date the relevant amount of Capital Notes will be Converted, and the relevant amount of other Relevant Perpetual Subordinated Instruments will be converted to Ordinary Shares or written-off, in each case immediately and irrevocably; and

(iii) the Issuer must give notice of the Non-Viability Trigger Event (a **Non-Viability Trigger Event Notice**) to Holders and the Trustee as soon as practicable that Conversion has occurred which notice must state the Non-Viability Conversion Date, the amount of Capital Notes Converted and the relevant amount of Relevant Perpetual Subordinated Instruments converted to Ordinary Shares or written-off.

(b) Where the Issuer is required to convert or write-off some (but not all) Relevant Perpetual Subordinated Instruments on account of a Non-Viability Trigger Event:

(i) the Issuer must endeavour to treat Holders and holders of other Relevant Perpetual Subordinated Instruments on an approximately proportionate basis, but may discriminate to take account of the effect on marketable parcels and other logistical considerations and the need to effect the conversions or write-offs immediately; and

(ii) where the specified currency of Relevant Perpetual Subordinated Instruments is not the same for all Relevant Perpetual Subordinated Instruments, the Issuer may treat them as if converted into a single currency of the Issuer's choice at such rate of exchange as the Issuer considers reasonable but may make adjustments among Holders and holders of other Relevant Perpetual Subordinated Instruments having regard to the need to effect conversion immediately.

(c) None of the following shall prevent, impede or delay the Conversion of Capital Notes as required by this clause 5.2:

- (i) any failure or delay in the conversion to Ordinary Shares or write-off of any other Relevant Perpetual Subordinated Instruments;
- (ii) any failure or delay in giving a Non-Viability Trigger Event Notice;
- (iii) any failure or delay in quotation of the Ordinary Shares to be issued on Conversion;
- (iv) any decision as to the identity of Holders whose Capital Notes are to be Converted in accordance with clause 5.2(a)(i)(B); or
- (v) any requirement to treat Holders and holders of other Relevant Perpetual Subordinated Instruments as required by, or to make the determinations or adjustments in accordance with, clause 5.2(b).

(d) From the Non-Viability Conversion Date, the Issuer shall treat the Holder in respect of the Capital Notes as the holder of the Conversion Number of Ordinary Shares and will take all such steps, including updating any of its registers, required to record the Conversion.

5.3 Priority of Conversion obligations

(a) Conversion on account of the occurrence of a Non-Viability Trigger Event is not subject to the Mandatory Conversion Conditions.

(b) A Conversion required on account of a Non-Viability Trigger Event takes place on the date, and in the manner, required by clause 5.2 notwithstanding anything in clauses 4.1, 6, 7 or 16.

(c) If for any reason (including an Inability Event), a Conversion on account of a Non-Viability Trigger Event does not occur within five Business Days of the Non-Viability Conversion Date, the Capital Notes will not Convert and instead will be Written-Off in accordance with clause 8.13.

6 Optional Exchange by the Issuer

6.1 Optional Exchange by the Issuer

The Issuer may with APRA's prior written approval by notice to Holders and the Trustee (an **Exchange Notice**) elect to Exchange:

- (a) all or some Capital Notes on an Exchange Date following the occurrence of a Tax Event or a Regulatory Event;
- (b) all (but not some only) Capital Notes on an Exchange Date following the occurrence of a Potential Acquisition Event; or
- (c) all or some Capital Notes on any Optional Exchange Date.

An Exchange Notice under this clause 6:

- (i) cannot be given in the period of 20 Business Days preceding (and not including) a Relevant Date where the First Mandatory Conversion Condition has been met in respect of that Relevant Date; and
- (ii) once given is irrevocable, unless a Non-Viability Trigger Event occurs after the giving of such notice, in which case, such notice will be taken to be revoked immediately and automatically and clause 5 will apply.

6.2 Contents of Exchange Notice

An Exchange Notice must specify:

- (a) where clause 6.1(a) or clause 6.1(b) applies, the details of the Tax Event, Regulatory Event or Potential Acquisition Event to which the Exchange Notice relates;
- (b) the date on which Exchange is to occur (the **Exchange Date**), which:
 - (i) in the case of a Potential Acquisition Event, is the Business Day prior to the date reasonably determined by the Issuer to be the last date on which holders of Ordinary Shares can participate in the bid or scheme concerned or such other earlier date as the Issuer may reasonably determine having regard to the timing for implementation of the bid or scheme concerned or such later date as APRA may require;
 - (ii) in the case of a Tax Event or a Regulatory Event, is the last Business Day of the month following the month in which the Exchange Notice was given by the Issuer unless the Issuer determines an earlier Exchange Date having regard to the best interests of Holders as a whole and the relevant event; or
 - (iii) in the case of clause 6.1(c), is the relevant Optional Exchange Date, which must fall:
 - (A) no earlier than:
 - (aa) 25 Business Days, where the Exchange Method elected is Conversion; or
 - (ab) 15 Business Days, where the Exchange Method elected is Redemption or Resale; and
 - (B) in any case no later than 50 Business Days, after the date on which the Exchange Notice is given;
- (c) the Exchange Method in accordance with clause 6.3;
- (d) if less than all Capital Notes are subject to Exchange, the proportion of the Capital Notes that are to be Exchanged;
- (e) if the Exchange Notice provides that any Capital Notes are to be Resold, the identity of the Nominated Purchaser or Nominated Purchasers for that Resale; and
- (f) whether any Distribution will be paid in respect of the Capital Notes to be Exchanged on the Exchange Date.

6.3 Exchange Method

- (a) If the Issuer elects to Exchange Capital Notes in accordance with clause 6.1, it must, subject to clauses 6.3(b), 6.4 and 6.5 and subject to APRA's prior written approval, elect which of the following it intends to do in respect of Capital Notes (the **Exchange Method**):

- (i) Convert Capital Notes into Ordinary Shares in accordance with clause 8;
- (ii) Redeem Capital Notes in accordance with clause 9; or
- (iii) Resell Capital Notes in accordance with clause 10.

Holders should not expect that APRA's approval will be given for any Exchange of Capital Notes under these Terms.

- (b) Subject to clauses 6.4 and 6.5, in the election under clause 6.3(a), the Issuer may specify which of Conversion, Redemption or Resale applies to a particular Capital Note. Without limitation to the foregoing:

- (i) the Issuer may select any one or more of Conversion, Redemption or Resale to apply to the Capital Notes held by a Holder; and
- (ii) the Issuer may select a different combination of Conversion, Redemption and Resale in respect of Capital Notes held by different Holders,

but otherwise the Issuer must endeavour to treat Holders, in the case of an Exchange of only some Capital Notes, on an approximately proportionate basis (although it may discriminate to take account of the effect on marketable parcels and other logistical considerations).

6.4 Restrictions on election by the Issuer of Redemption or Resale as Exchange Method

The Issuer may elect Redemption or Resale as the Exchange Method in respect of an Exchange under this clause 6:

- (a) on any Optional Exchange Date; and
- (b) in the case of a Tax Event or Regulatory Event,

but not in any other case of Exchange and provided in all cases where the Issuer elects Redemption that APRA is satisfied that either:

- (i) Capital Notes the subject of the Exchange are replaced concurrently or beforehand with a Relevant Perpetual Subordinated Instrument of the same or better quality or Ordinary Shares and the replacement of the instrument is done under conditions that are sustainable for the Issuer's income capacity; or
- (ii) having regard to the projected capital position of the Issuer and the Challenger Group, the Issuer does not have to replace the Capital Notes the subject of the Redemption.

6.5 Restrictions on election by the Issuer of Conversion as Exchange Method

The Issuer may not elect Conversion as the Exchange Method in respect of an Exchange under this clause 6 if:

- (a) on the second Business Day before the date on which an Exchange Notice is to be sent by the Issuer (or, if trading in Ordinary Shares did not occur on that date, the last Business Day prior to that date on which trading in Ordinary Shares occurred) (the **Non-Conversion Test Date**) the VWAP on that date is less than or equal to the First Test Date Percentage of the Issue Date VWAP (the **First Optional Conversion Restriction**); or

- (b) a Delisting Event applies in respect of the Non-Conversion Test Date (the **Second Optional Conversion Restriction** and together with the First Optional Conversion Restriction, the **Optional Conversion Restrictions**).

6.6 Conditions to Conversion occurring once elected by the Issuer

If the Issuer has given an Exchange Notice in which it has elected Conversion as the Exchange Method but, if the Exchange Date were a Relevant Date for the purposes of clause 4, either the Second Mandatory Conversion Condition or the Third Mandatory Conversion Condition would not be satisfied in respect of that date, then, notwithstanding any other provision of these Terms:

- (a) the Exchange Date will be deferred until the first Distribution Payment Date on which the Mandatory Conversion Conditions would be satisfied if that Distribution Payment Date were a Relevant Date for the purposes of clause 4 (the **Deferred Conversion Date**);
- (b) the Issuer must Convert the Capital Notes on the Deferred Conversion Date (unless the Capital Notes are Exchanged earlier in accordance with these Terms); and
- (c) until the Deferred Conversion Date, all rights attaching to the Capital Notes will continue as if the Exchange Notice had not been given.

The Issuer will notify Holders and the Trustee on or as soon as practicable after an Exchange Date in respect of which this clause 6.6 applies that Conversion did not occur on that Exchange Date (a **Deferred Conversion Notice**).

7 Conversion on Acquisition Event

7.1 Notice of Acquisition Event

The Issuer must notify Holders and the Trustee of the occurrence of an Acquisition Event as soon as practicable after becoming aware of that event (an **Acquisition Event Notice**).

7.2 Conversion on occurrence of Acquisition Event

If an Acquisition Event occurs, subject to clause 7.4 and clause 7.5 the Issuer must give notice to Holders and the Trustee (an **Acquisition Conversion Notice**) and Convert all (but not some only) Capital Notes on the Acquisition Conversion Date in accordance with this clause 7 and clause 8.

7.3 Contents of Acquisition Conversion Notice

An Acquisition Conversion Notice must specify:

- (a) the details of the Acquisition Event to which the Acquisition Conversion Notice relates;
- (b) the date on which Conversion is to occur (the **Acquisition Conversion Date**), which must be:
 - (i) the Business Day prior to the date reasonably determined by the Issuer to be the last date on which holders of Ordinary Shares can participate in the bid or scheme concerned or such other earlier date as the Issuer may reasonably determine having regard to the timing for implementation of the bid or scheme concerned; or
 - (ii) such later date as APRA may require; and
- (c) whether any Distribution will be paid in respect of the Capital Notes on the Acquisition Conversion Date.

7.4 Where Acquisition Conversion Notice not required

Notwithstanding any provision of clause 7.2 or clause 7.3, the Issuer is not required to give an Acquisition Conversion Notice if either or both of the Optional Conversion Restrictions would apply if the Acquisition Conversion Notice were an Exchange Notice under clause 6 and in this case the provisions of clause 7.5 will apply.

7.5 Deferred Conversion on Acquisition Event

If clause 7.4 applies or the Issuer has given an Acquisition Conversion Notice but, if the Acquisition Conversion Date were a Relevant Date for the purposes of clause 4.2, either the Second Mandatory Conversion Condition or the Third Mandatory Conversion Condition would not be satisfied in respect of that date, then, notwithstanding any other provision of these Terms (but without limitation to the operation of clause 5.3):

- (a) the Acquisition Conversion Notice, if given, is taken to be revoked and Conversion will not occur on the Acquisition Conversion Date specified in the Acquisition Conversion Notice;
- (b) the Issuer will notify Holders and the Trustee as soon as practicable that Conversion will not (or, as the case may be, did not) occur (a **Deferred Acquisition Conversion Notice**); and
- (c) the Issuer must, unless clause 7.4 then applies, give an Acquisition Conversion Notice (or, as the case may be, a new Acquisition Conversion Notice) on or before the 25th Business Day prior to the immediately succeeding Distribution Payment Date which is at least 25 Business Days after the date on which the Deferred Acquisition Conversion Notice was given.

The Acquisition Conversion Notice given in accordance with paragraph (c) above must comply with the requirements in clause 7.3.

If this clause 7.5 applies but:

- (i) clause 7.4 applies in respect of the Distribution Payment Date referred to in paragraph (c) such that no Acquisition Conversion Notice (or, as the case may be, no new Acquisition Conversion Notice) is given under this clause 7.5; or
- (ii) an Acquisition Conversion Notice (or, as the case may be, a new Acquisition Conversion Notice) is given under this clause 7.5 but, if the Acquisition Conversion Date specified in the Acquisition Conversion Notice were a Relevant Date for the purposes of clause 4.2, either the Second Mandatory Conversion Condition or the Third Mandatory Conversion Condition would not be satisfied in respect of that date,

then this clause 7.5 will be reapplied in respect of each subsequent Distribution Payment Date until a Conversion occurs.

8 Conversion mechanics

8.1 Conversion

If the Issuer elects to Convert Capital Notes (with APRA's prior written approval) or must Convert Capital Notes in accordance with these Terms, then, subject to this clause 8, the following provisions shall apply:

- (a) each Capital Note that is being Converted will Convert into the Conversion Number of Ordinary Shares. The Conversion Number will be calculated by the Issuer in accordance with the following formula:

$$\text{Conversion Number} = \frac{\text{Face Value}}{99\% \times \text{VWAP}}$$

subject always to the Conversion Number being no greater than the Maximum Conversion Number.

where:

VWAP (expressed in dollars and cents) means the VWAP during the VWAP Period;

Maximum Conversion Number means a number calculated according to the following formula:

$$\text{Maximum Conversion Number} = \frac{\text{Face Value}}{\text{Issue Date VWAP} \times \text{Relevant Fraction}}$$

Relevant Fraction means:

- (i) in the case of a Mandatory Conversion, 0.5; and
 - (ii) in the case of any other Conversion, 0.2;
- (b) each Holder's rights in relation to each Capital Note that is being Converted will be immediately and irrevocably terminated in full for an amount equal to the Face Value and the Issuer will apply the Face Value of each Capital Note by way of payment for the subscription for the Ordinary Shares to be issued to the Holder under clause 8.1(a). Each Holder is taken to have irrevocably directed the Issuer to apply any amount payable under this clause 8.1 in this way and Holders do not have any right to payment in any other way. Termination of a Holder's rights in relation to a Capital Note will not limit the Issuer's discretion to pay a Distribution on that Capital Note on the Mandatory Conversion Date, the Exchange Date or the Acquisition Conversion Date (as the case may be) in accordance with and subject to clause 3 (except in the case of Non-Viability Conversion, when no Distribution will be paid);
- (c) if the total number of Ordinary Shares to be allotted and issued in respect of a Holder's aggregate holding of Capital Notes upon Conversion includes a fraction of an Ordinary Share, that fraction of an Ordinary Share will be disregarded; and
- (d) upon Conversion, a Holder will be given all of the rights attaching to the Conversion Number of Ordinary Shares allotted and issued in respect of such Holder's aggregate holding of Capital Notes but these rights do not take effect until 5:00pm Sydney time on the Mandatory Conversion Date, the Exchange Date or the Acquisition Conversion Date (as the case may be) or, in the case of a Conversion on the Non-Viability Conversion Date, the time at which such Conversion occurs on that date. At that time:
- (i) all other rights conferred or restrictions imposed on that Capital Note under these Terms will no longer have effect (except for rights relating to a Distribution which has been determined to be payable but has not been paid on or before the Mandatory Conversion

Date, the Non-Viability Conversion Date, the Exchange Date or the Acquisition Conversion Date (as the case may be), which rights will continue); and

- (ii) the Ordinary Share resulting from the Conversion will rank equally with all other Ordinary Shares.

8.2 Adjustments to VWAP

For the purposes of calculating the VWAP in these Terms:

- (a) where, on some or all of the Business Days in the relevant VWAP Period, Ordinary Shares have been quoted on ASX as cum dividend or cum any other distribution or entitlement and Capital Notes will Convert into Ordinary Shares after the date those Ordinary Shares no longer carry that dividend or any other distribution or entitlement, then the VWAP on the Business Days on which those Ordinary Shares have been quoted cum dividend or cum any other distribution or entitlement shall be reduced by an amount (the **Cum Value**) equal to:

- (i) (in the case of a dividend or other distribution), the amount of that dividend or other distribution including, if the dividend or other distribution is franked, the amount that would be included in the assessable income of a recipient of the dividend or other distribution who is both a resident of Australia and a natural person under the Tax Act;
- (ii) (in the case of any other entitlement that is not a dividend or other distribution under clause 8.2(a) (i) which is traded on ASX on any of those Business Days), the volume weighted average sale price of all such entitlements sold on ASX during the VWAP Period on the Business Days on which those entitlements were traded; or
- (iii) (in the case of any other entitlement which is not traded on ASX during the VWAP Period), the value of the entitlement as reasonably determined by the Directors; and

- (b) where, on some or all of the Business Days in the VWAP Period, Ordinary Shares have been quoted on ASX as ex dividend or ex any other distribution or entitlement, and Capital Notes will Convert into Ordinary Shares in respect of which the relevant dividend or other distribution or entitlement would be payable, the VWAP on the Business Days on which those Ordinary Shares have been quoted ex dividend or ex any other distribution or entitlement shall be increased by the Cum Value.

8.3 Adjustments to VWAP for divisions and similar transactions

- (a) Where during the relevant VWAP Period there is a change in the number of Ordinary Shares on issue as a result of a Reorganisation, in calculating the VWAP for that VWAP Period the VWAP on each Business Day in the relevant VWAP Period which falls before the date on which trading in Ordinary Shares is conducted on a post- Reorganisation basis shall be adjusted by multiplying it by the following formula:

$$\frac{A}{B}$$

where:

- A** means the aggregate number of Ordinary Shares immediately before the Reorganisation; and
- B** means the aggregate number of Ordinary Shares immediately after the Reorganisation.

- (b) Any adjustment made by the Issuer in accordance with clause 8.3(a) will be effective and binding on Holders under these Terms and these Terms will be construed accordingly. Any such adjustment must be promptly notified to all Holders.

8.4 Adjustments to Issue Date VWAP

For the purposes of determining the Issue Date VWAP, adjustments to the VWAP will be made in accordance with clauses 8.2 and 8.3 during the VWAP Period for the Issue Date VWAP. On and from the Issue Date, adjustments to the Issue Date VWAP:

- (a) may be made by the Issuer in accordance with clauses 8.5 to 8.7 (inclusive); and
- (b) if so made, will correspondingly:
- (i) affect the application of the Mandatory Conversion Conditions and the Optional Conversion Restrictions; and
 - (ii) cause an adjustment to the Maximum Conversion Number.
- (c) Any adjustment made by the Issuer in accordance with clause 8.5(a) or 8.6 will be effective and binding on all Holders under these Terms and these Terms will be construed accordingly.

8.5 Adjustments to Issue Date VWAP for bonus issues

- (a) Subject to clause 8.5(b), if at any time after the Issue Date the Issuer makes a pro rata bonus issue of Ordinary Shares to holders of Ordinary Shares generally, the Issue Date VWAP will be adjusted in accordance with the following formula:

$$V = V_o \times \frac{RD}{RD + RN}$$

where:

- V** means the Issue Date VWAP applying immediately after the application of this formula;
- V_o** means the Issue Date VWAP applying immediately prior to the application of this formula;
- RD** means the number of Ordinary Shares on issue immediately prior to the allotment of new Ordinary Shares pursuant to the bonus issue; and
- RN** means the number of Ordinary Shares issued pursuant to the bonus issue.
- (b) Clause 8.5(a) does not apply to Ordinary Shares issued as part of a bonus share plan, employee or executive share plan, executive option plan, share top-up plan, share purchase plan or a dividend reinvestment plan.
- (c) For the purposes of clause 8.5(a), an issue will be regarded as a pro rata bonus issue notwithstanding that the Issuer does not make offers to some or all holders of Ordinary Shares with registered addresses outside Australia, provided that in so doing the Issuer is not in contravention of the ASX Listing Rules.
- (d) No adjustments to the Issue Date VWAP will be made under this clause 8.5 for any offer of Ordinary Shares not covered by clause 8.5(a), including a rights issue or other essentially pro rata issue.
- (e) The fact that no adjustment is made for an issue of Ordinary Shares except as covered by clause 8.5(a) shall not in any way restrict the Issuer from issuing Ordinary

Shares at any time on such terms as it sees fit nor be taken to constitute a modification or variation of rights or privileges of Holders or otherwise requiring any consent or concurrence of the Holders.

8.6 Adjustment to Issue Date VWAP for divisions and similar transactions

- (a) If at any time after the Issue Date there is a change in the number of Ordinary Shares on issue as a result of a Reorganisation, the Issuer shall adjust the Issue Date VWAP by multiplying the Issue Date VWAP applicable on the Business Day immediately before the date of any such Reorganisation by the following formula:

$$\frac{A}{B}$$

where:

- A** means the aggregate number of Ordinary Shares immediately before the Reorganisation; and
- B** means the aggregate number of Ordinary Shares immediately after the Reorganisation.
- (b) Each Holder acknowledges that the Issuer may consolidate, divide or reclassify securities so that there is a lesser or greater number of Ordinary Shares at any time in its absolute discretion without any such action constituting a modification or variation of rights or privileges of Holders or otherwise requiring any consent or concurrence.

8.7 No adjustment to Issue Date VWAP in certain circumstances

Despite the provisions of clauses 8.5 and 8.6, no adjustment shall be made to the Issue Date VWAP where such adjustment (rounded if applicable) would be less than one percent of the Issue Date VWAP then in effect.

8.8 Announcement of adjustments

The Issuer will notify Holders and the Trustee (an **Adjustment Notice**) of any adjustment to the Issue Date VWAP under this clause 8 within 10 Business Days of the Issuer determining the adjustment.

8.9 Ordinary Shares

Each Ordinary Share issued or arising upon Conversion ranks pari passu with all other fully paid Ordinary Shares.

8.10 Issue of Ordinary Shares to Nominee

If:

- (a) Capital Notes held by a Foreign Holder are to be Converted (unless the Issuer is satisfied that the laws of the Foreign Holder's country of residence permit the issue of Ordinary Shares to the Foreign Holder (but as to which the Issuer is not bound to enquire), either unconditionally or after compliance with conditions which the Issuer in its absolute discretion regards as acceptable and not unduly onerous);
- (b) the Issuer has elected or is required to Convert Capital Notes and the Holder has notified the Issuer that it does not wish to receive Ordinary Shares as a result of Conversion, which notice may be given by the Holder at any time on or after the Issue Date and no less than 15 Business Days prior to the date scheduled for Conversion; or
- (c) the Issuer has elected or is required to Convert Capital Notes and a FATCA Withholding is required to be made in respect of Ordinary Shares issued on Conversion of the Capital Notes, then, on the date for Conversion:

- (i) in the case of paragraphs (a) and (b), the number of Ordinary Shares which the relevant Holder is obliged to accept, will be issued to a nominee appointed by the Issuer (which must not be a member of the Challenger Group or a Related Entity of the Issuer) ("**Nominee**"), which Nominee will sell that number of Ordinary Shares and pay a cash amount equal to the Proceeds to the relevant Holder accordingly; and
- (ii) in the case of a FATCA Withholding, the Ordinary Shares which the Holder is obliged to accept will be issued to the Holder only to the extent (if at all) that the issue is net of FATCA Withholding, and the number of Ordinary Shares the subject of the FATCA Withholding will be issued to the Nominee and dealt with in accordance with FATCA.

8.11 No duty on sale

For the purposes of clause 8.10:

- (a) the issue of Ordinary Shares to the Nominee satisfies all obligations of the Issuer in connection with the Conversion, the Capital Notes will be deemed Converted and will be dealt with in accordance with clause 8.1 and, on and from the issue of those Ordinary Shares, the rights of a Holder the subject of clause 8.10 in respect of those Ordinary Shares are limited to its rights in respect of the Ordinary Shares or the Proceeds as provided in clause 8.10; and
- (b) neither the Issuer nor the Nominee owes any obligations or duties to the Holders in relation to the price for which, or other terms on which, Ordinary Shares are sold nor has any liability for any loss suffered by a Holder as a result of the sale of Ordinary Shares.

8.12 Listing Ordinary Shares issued on Conversion

The Issuer shall use all reasonable endeavours to list the Ordinary Shares issued upon Conversion of Capital Notes on ASX.

8.13 Write-Off

- (a) Notwithstanding any other provisions of these Terms, if for any reason (including, without limitation, an Inability Event) Conversion of any Capital Notes on account of a Non-Viability Trigger Event does not occur within five Business Days of the Non-Viability Conversion Date, then Conversion of those Capital Notes will not occur, the Capital Notes will not be Exchanged on any subsequent date, and instead the relevant Holder's rights (including to Distributions and payment of Face Value in relation to such Capital Notes, and to be issued with Ordinary Shares), are immediately and irrevocably written-off and terminated (**Written-Off**) with effect on and from the Non-Viability Conversion Date.
- (b) The Issuer may, but is not required to, seek advice from reputable legal counsel as to whether an Inability Event has occurred and is subsisting. An Inability Event is taken to have occurred and subsist if the Issuer receives advice to that effect from such counsel. The seeking of advice by the Issuer under this clause 8.13(b) shall not delay or impede the Write-Off of the Capital Notes when required under clause 8.13(a).
- (c) The Issuer must give notice to Holders and the Trustee if Conversion has not occurred by operation of this clause 8.13 but failure to give that notice shall not affect the operation of this clause 8.13.

9 Redemption mechanics

9.1 Redemption mechanics

If, subject to APRA's prior written approval and compliance with the conditions in clause 6.4, the Issuer elects to Redeem Capital Notes in accordance with these Terms, the provisions of this clause 9 apply to that Redemption.

Holders should not expect that APRA's approval will be given for any Redemption of Capital Notes under these Terms.

9.2 Redemption

- (a) A Capital Note will be Redeemed by payment on the Exchange Date of the Face Value to the relevant Holder (**Redemption Price**).
- (b) Redemption may occur even if the Issuer, in its absolute discretion, does not pay a Distribution for the final Distribution Period.

9.3 Effect of Redemption on Holders

On the Exchange Date the only right Holders will have in respect of Capital Notes will be to obtain the Redemption Price payable in accordance with these Terms and upon payment of the Redemption Price, all other rights conferred, or restrictions imposed, by Capital Notes will no longer have effect.

10 Resale mechanics

10.1 Resale mechanics

If, subject to APRA's prior written approval and compliance with clause 6.4, the Issuer elects to Resell Capital Notes in accordance with these Terms, the provisions of this clause 10 apply to that Resale.

Holders should not expect that APRA's approval will be given for any Resale of Capital Notes under these Terms.

10.2 Appointment of Nominated Purchaser

- (a) Subject to paragraph (d), the Issuer must appoint one or more Nominated Purchasers for the Resale on such terms as may be agreed between the Issuer and the Nominated Purchasers, including:
 - (i) as to the conditions of any Resale, the procedures for settlement of such Resale and the circumstances in which the Exchange Notice in respect of such Resale may be amended, modified, added to or restated;
 - (ii) as to the substitution of another entity (which must not be a member of the Challenger Group or a Related Entity of the Issuer) as Nominated Purchaser if, for any reason, the Issuer is not satisfied that the Nominated Purchaser will perform its obligations under this clause 10; and
 - (iii) as to the terms (if any) on which any Capital Notes acquired by a Nominated Purchaser may be Redeemed, Converted or otherwise dealt with.
- (b) If the Issuer appoints more than one Nominated Purchaser in respect of a Resale, all or any of the Capital Notes held by a Holder which are being Resold may be purchased by any one or any combination of the Nominated Purchasers, as determined by the Issuer for the Resale Price.
- (c) The obligation of a Nominated Purchaser to pay the Resale Price on the Exchange Date may be subject to such conditions as the Issuer may reasonably determine.

(d) Any terms of the appointment or of the Resale which may cause APRA to object to Challenger Group using, or having used, the proceeds of the issue of some or all of the Capital Notes to fund Additional Tier 1 Capital of CLC, are subject to the prior written consent of APRA.

10.3 Identity of Nominated Purchasers

The Issuer may not appoint a person as a Nominated Purchaser unless that person:

- (a) has undertaken on such terms and subject to such conditions as the Issuer reasonably determines for the benefit of each Holder to acquire each Capital Note from each Holder for the Resale Price on the Exchange Date;
- (b) has a long-term counterparty credit rating from one of S&P Global Ratings, Moody's Investors Service, Inc. or Fitch Ratings Ltd. of not less than investment grade; and
- (c) is not a Related Entity of the Issuer.

10.4 Irrevocable offer to sell Capital Notes

Each Holder on the Exchange Date is taken irrevocably to offer to sell Capital Notes the subject of a Resale to the Nominated Purchaser or Nominated Purchasers on the Exchange Date for the Resale Price.

10.5 Effect of Resale

On the Exchange Date subject to payment by the Nominated Purchaser of the Resale Price to the Holders, all right, title and interest in such Capital Notes (excluding the right to any Distribution payable on that date) will be transferred to the Nominated Purchaser free from Encumbrances.

10.6 Effect of failure by Nominated Purchaser or Nominated Purchasers to pay

If a Nominated Purchaser does not pay the Resale Price to the Holders on the Exchange Date (a **Defaulting Nominated Purchaser**) (whether as a result of a condition to purchase not being satisfied or otherwise):

- (a) the Exchange Notice as it relates to the Defaulting Nominated Purchaser will be void;
- (b) Capital Notes will not be transferred to the Defaulting Nominated Purchaser on the Exchange Date; and
- (c) Holders will continue to hold the Capital Notes referable to the Defaulting Nominated Purchaser until they are otherwise Redeemed, Converted or Resold in accordance with these Terms.

10.7 Payment of Resale Price

Clause 14 applies to payment of the Resale Price as if a reference in that clause to the Redemption Price includes a reference to the Resale Price.

11 General rights

11.1 Power of attorney

(a) Each Holder appoints each of the Issuer, its officers and any External Administrator of the Issuer (each an **Attorney**) severally to be the attorney of the Holder with power in the name and on behalf of the Holder to sign all documents and transfers and do any other thing as may in the Attorney's opinion be necessary or desirable to be done in order for the Holder to observe or perform the Holder's obligations under these Terms including, but not limited to, effecting any Conversion, Redemption or Resale or making any entry in the Register or the register of any Ordinary Shares.

(b) The power of attorney given in this clause 11.1 is given for valuable consideration and to secure the performance by the Holder of the Holder's obligations under these Terms and is irrevocable.

11.2 Consent to receive Ordinary Shares and other acknowledgements

Each Holder irrevocably:

- (a) upon receipt of the Conversion Number of Ordinary Shares following Conversion of Capital Notes, consents to becoming a member of the Issuer and agrees to be bound by the constitution of the Issuer, in each case in respect of Ordinary Shares issued on Conversion;
- (b) acknowledges and agrees that it is obliged to accept Ordinary Shares on Conversion notwithstanding anything that might otherwise affect a Conversion of Capital Notes including:
 - (i) any change in the financial position of the Issuer or any member of the Challenger Group since the Issue Date;
 - (ii) any disruption to the market or potential market for Ordinary Shares or capital markets generally; or
 - (iii) any breach by the Issuer of any obligation in connection with the Capital Notes;
- (c) acknowledges and agrees that:
 - (i) where clause 5.2 applies:
 - (A) there are no other conditions to a Non-Viability Conversion occurring as and when provided in clauses 5.1 to 5.3 (inclusive);
 - (B) Conversion must occur immediately on the Non-Viability Conversion Date and that Conversion or Write-Off may result in disruption or failures in trading or dealings in Capital Notes;
 - (C) it will not have any rights to vote or right of approval in respect of any Non-Viability Conversion; and
 - (D) the Ordinary Shares issued on Non-Viability Conversion may not be quoted at the time of issue, or at all;
 - (ii) the only conditions to a Mandatory Conversion are the Mandatory Conversion Conditions;
 - (iii) the only conditions to a Conversion on account of an Exchange under clause 6 or a Conversion under clause 7 are the conditions expressly applicable to such Conversion as provided in clauses 6 and 7 of these Terms and no other conditions or events will affect Conversion; and
 - (iv) clause 8.13 is a fundamental term and where clause 8.13 applies, no other conditions or events will affect the operation of that clause and it will not have any rights to vote in respect of any Write-Off;
- (d) agrees to provide to the Issuer any information necessary to give effect to a Conversion; and
- (e) acknowledges and agrees that:
 - (i) a Holder has no right to request a Conversion, Redemption or Resale of any Capital Note or to determine the Exchange Method;
 - (ii) a Holder has no right to apply for the Issuer to be wound up, or placed in administration, or to cause a receiver, or a receiver and manager, to be appointed

in respect of the Issuer merely on the grounds that the Issuer does not or is or may become unable to pay a Distribution when scheduled in respect of Capital Notes;

- (iii) these Terms contain no events of default. Accordingly (but without limitation) failure to pay in full, for any reason, a Distribution on a scheduled Distribution Payment Date, or a failure by the Issuer to comply with any of its obligations, will not constitute an event of default; and
- (iv) it has no remedy on account of a failure by the Issuer to issue Ordinary Shares to a Holder or a Nominee in accordance with these Terms other than (and subject always to clause 8.13) to seek specific performance of the obligation to issue Ordinary Shares.

12 Takeovers and schemes of arrangement

If:

- (a) a takeover bid is made for Ordinary Shares, acceptance of which is recommended by the Directors; or
- (b) the Directors recommend a scheme of arrangement in respect of the Ordinary Shares of the Issuer which will result in a person other than the Issuer having a relevant interest in more than 50% of the Ordinary Shares,

in each case which would result in an Acquisition Event then, if the Directors consider that:

- (c) the Issuer will not be permitted to elect to Exchange the Capital Notes in accordance with clause 6 or to Convert the Capital Notes in accordance with clause 7; or
- (d) the Second Mandatory Conversion Condition or the Third Mandatory Conversion Condition will not be satisfied in respect of the Acquisition Conversion Date in accordance with clause 7,

the Directors will use all reasonable endeavours to procure that equivalent takeover offers are made to Holders or that they are entitled to participate in the scheme of arrangement or a similar transaction.

13 Title and transfer of Capital Notes

13.1 Title

Title to Capital Notes passes when details of the transfer are entered in the Register.

13.2 Effect of entries in Register

Each entry in the Register in respect of a Capital Note constitutes a separate and independent acknowledgement to the relevant Holder of the obligations of the Issuer to the relevant Holder.

13.3 Register conclusive as to ownership

Entries in the Register in relation to a Capital Note constitute conclusive evidence that the person so entered is the absolute owner of the Capital Note subject to correction for fraud or error.

13.4 Non-recognition of interests

- (a) Except as required by law and as provided by these Terms, the Issuer, the Trustee and the Registrar must treat the person whose name is entered in the Register as the Holder of a Capital Note as the absolute owner of that Capital Note. This clause 13.4 applies whether or not a payment has been made as scheduled in respect of a Capital Note and despite any notice of ownership, trust or interest in the Capital Note.

- (b) No notice of any trust, Encumbrance or other interest in, or claim to any Note will be entered in the Register.

13.5 Joint Holders

Where two or more persons are entered in the Register as the joint Holders of a Capital Note then they are taken to hold the Capital Note as joint tenants with rights of survivorship, but the Registrar is not bound to register more than four persons as joint Holders of any Capital Note.

13.6 Transfers in whole

Capital Notes may be transferred in whole but not in part.

13.7 Transfer

A Holder may, subject to this clause 13.7, transfer any Capital Notes:

- (a) by a proper Transfer according to the ASX Settlement Operating Rules;
- (b) by a proper transfer under any other computerised or electronic system recognised by the Corporations Act;
- (c) under any other method of transfer which operates in relation to the trading of securities on any securities exchange outside Australia on which Capital Notes are quoted; or
- (d) by any proper or sufficient instrument of transfer of marketable securities under applicable law.

The Issuer must not charge any fee on the transfer of a Capital Note.

13.8 Market obligations

The Issuer must comply with all Applicable Regulations and any other relevant obligations imposed on it in relation to the transfer of a Capital Note.

13.9 Issuer may request holding lock or refuse to register transfer

If Capital Notes are quoted on ASX, and if permitted to do so by the ASX Listing Rules and the Corporations Act, the Issuer may:

- (a) request the CS Facility Operator or the Registrar, as the case may be, to apply a holding lock to prevent a transfer of Capital Notes approved by and registered on the CS Facility's electronic sub-register or Capital Notes registered on an issuer-sponsored sub-register, as the case may be; or
- (b) refuse to register a transfer of Capital Notes.

13.10 Issuer must request holding lock or refuse to register transfer

- (a) The Issuer must request the CS Facility Operator or the Registrar, as the case may be, to apply a holding lock to prevent a transfer of Capital Notes approved by and registered on the CS Facility's electronic sub-register or Capital Notes registered on an issuer-sponsored sub-register, as the case may be, if the Corporations Act, the ASX Listing Rules or the terms of a Restriction Agreement require the Issuer to do so.
- (b) The Issuer must refuse to register any transfer of Capital Notes if the Corporations Act, the ASX Listing Rules or the terms of a Restriction Agreement require the Issuer to do so.
- (c) During a breach of the ASX Listing Rules relating to Restricted Securities, or a breach of a Restriction Agreement, the Holder of the Restricted Securities is not entitled to any Distribution (or other distribution on), or voting rights in respect of, the Restricted Securities.

13.11 Notice of holding locks and refusal to register transfer

If, in the exercise of its rights under clauses 13.9 and 13.10, the Issuer requests the application of a holding lock to prevent a transfer of Capital Notes or refuses to register a transfer of Capital Notes, it must, within five Business Days after the date the holding lock is requested or the refusal to register a transfer, give written notice of the request or refusal to the Holder, to the transferee and the broker lodging the transfer, if any. Failure to give such notice does not, however, invalidate the decision of the Issuer.

13.12 Delivery of instrument

If an instrument is used to transfer Capital Notes according to clause 13.7, it must be delivered to the Registrar, together with such evidence (if any) as the Registrar reasonably requires to prove the title of the transferor to, or right of the transferor to transfer, the Capital Notes.

13.13 Refusal to register

The Issuer may only refuse to register a transfer of any Capital Notes if such registration would contravene or is forbidden by Applicable Regulations or the Terms.

If the Issuer refuses to register a transfer, the Issuer must give the lodging party notice of the refusal and the reasons for it within five Business Days after the date on which the transfer was delivered to the Registrar.

13.14 Transferor to remain Holder until registration

A transferor of a Capital Note remains the Holder in respect of that Capital Note until the transfer is registered and the name of the transferee is entered in the Register.

13.15 Effect of transfer

Upon registration and entry of the transferee in the Register the transferor ceases to be entitled to future benefits under the Trust Deed in respect of the transferred Capital Notes and the transferee becomes so entitled in accordance with clause 13.2.

13.16 Estates

A person becoming entitled to a Capital Note as a consequence of the death or bankruptcy of a Holder or of a vesting order or a person administering the estate of a Holder may, upon producing such evidence as to that entitlement or status as the Registrar considers sufficient, transfer the Capital Note or, if so entitled, become registered as the Holder of the Capital Note.

13.17 Transfer of unidentified Capital Notes

Where the transferor executes a transfer of less than all Capital Notes registered in its name, and the specific Capital Notes to be transferred are not identified, the Registrar may register the transfer in respect of such of the Capital Notes registered in the name of the transferor as the Registrar thinks fit, provided the aggregate of the Face Value of all the Capital Notes registered as having been transferred equals the aggregate of the Face Value of all the Capital Notes expressed to be transferred in the transfer.

14 Payments

14.1 Payments subject to law

All payments are subject to applicable law, but without prejudice to the provisions of clause 15.

14.2 Payments on Business Days

If a payment in respect of a Capital Note:

- (a) is due on a day which is not a Business Day, then the due date for payment will be postponed to the first following day that is a Business Day; or
- (b) is to be made to an account on a Business Day on which banks are not open for general banking business in the place in which the account is located, then the due date for payment to that Holder will be the first following day on which banks are open for general banking business in that place and the Holder is not entitled to any additional payment in respect of that delay.

Nothing in this clause applies to any payment referred to in clause 8.1(b), which occurs on the date of Conversion as provided in clause 8.1.

14.3 Payment of Redemption Price

Payments of the Redemption Price will be made to each person registered at the Relevant Time on the payment date as the Holder of a Capital Note.

14.4 Payment of Distribution

Payments of Distributions will be made to each person registered at the Relevant Time on the Record Date as the Holder of a Capital Note.

14.5 Payments to accounts

Monies payable by the Issuer to a Holder in respect of a Capital Note may be paid in any manner in which cash may be paid as the Issuer decides, including by any method of direct credit determined by the Issuer to the Holder or Holders shown on the Register or to such person or place directed by them.

14.6 Unsuccessful attempts to pay

Subject to applicable law and the ASX Listing Rules, where the Issuer:

- (a) decides that an amount is to be paid to a Holder by a method of direct credit and the Holder has not given a direction as to where amounts are to be paid by that method;
- (b) attempts to pay an amount to a Holder by direct credit, electronic transfer of funds or any other means and the transfer is unsuccessful;
- (c) has made reasonable efforts to locate a Holder but is unable to do so; or
- (d) has issued a cheque which has not been presented within six months of its date, then the Issuer may cancel such cheque,

then, in each case, the amount is to be held by the Issuer for the Holder in a non-interest bearing deposit account with a bank selected by the Issuer until the Holder or any legal personal representative of the Holder claims the amount or the amount is paid by the Issuer according to the legislation relating to unclaimed monies.

When this clause 14.6 applies, the amount payable in respect of the Capital Notes shall be taken to have been paid on the date scheduled for payment and no interest is payable in respect of any delay in payment.

14.7 Payment to joint Holders

A payment to any one of joint Holders will discharge the Issuer's liability in respect of the payment.

14.8 Time limit for claims

A claim against the Issuer for a payment under a Capital Note is void unless made within 10 years (in the case of the Redemption Price) or five years (in the case of Distributions and other amounts) from the date on which payment first became due.

14.9 Determination and calculation final

Except where there is fraud or a manifest error, any determination or calculation which the Issuer makes in accordance with these Terms is final and binds the Issuer, the Registrar and each Holder.

15 Taxation

15.1 No set-off, counterclaim or deductions

All payments in respect of the Capital Notes must be made in full without set-off or counterclaim, and without any withholding or deduction in respect of Taxes, unless such withholding or deduction is required by law or made for or on account of, or to ensure compliance with FATCA.

15.2 Withholding tax

- (a) If a law requires the Issuer to withhold or deduct an amount in respect of Taxes from a payment in respect of the Capital Notes such that the Holder would not actually receive on the due date the full amount provided for under the Capital Notes, then the Issuer agrees to deduct the amount for the Taxes.
- (b) If any deduction is required, the Issuer must pay the full amount required to be deducted to the relevant revenue authority within the time allowed for such payment without incurring a penalty under the applicable law.
- (c) If:
 - (i) a deduction is made;
 - (ii) the amount of the deduction is accounted for by the Issuer to the relevant revenue authority; and
 - (iii) the balance of the amount payable has been paid to the Holder,

then the Issuer's obligation to make the payment to the Holder is taken to have been satisfied in full by the Issuer.

15.3 FATCA

- (a) If requested by the Issuer, each Holder agrees to provide certain information required by it or the Trustee to comply with any applicable law, including FATCA and the OECD Common Reporting Standard.
- (b) The Issuer may withhold or make deductions from payments or from the issue of Ordinary Shares to a Holder where it is required to do so under or in connection with FATCA, or where it has reasonable grounds to suspect that the Holder or a beneficial owner of Capital Notes may be subject to FATCA, and may deal with such amount deducted or withheld, and any Ordinary Shares deducted or withheld, in accordance with FATCA and, in the case of Ordinary Shares, clause 8.10(c) of these Terms. If any withholding or deduction arises under or in connection with FATCA, the Issuer will not be required to pay any further amounts and the Issuer will not be required to issue any further Ordinary Shares on account of such withholding or deduction or

otherwise reimburse or compensate, or make any payment to, a Holder or a beneficial owner of Capital Notes for or in respect of any such withholding or deduction. A dealing with such payment and any Ordinary Shares in accordance with FATCA satisfies the Issuer's obligations to that Holder to the extent of the amount of that payment or issue of Ordinary Shares.

16 Winding-up and Subordination

16.1 Winding-up

If an order of a court of competent jurisdiction is made (other than an order successfully appealed or permanently stayed within 30 days), or an effective resolution is passed, for the winding-up of the Issuer in Australia (a **Winding-up Event**), the Issuer is liable to Redeem each Capital Note for its Redemption Price in accordance with, and subject to, this clause 16.

16.2 Subordination

In a winding-up of the Issuer:

- (a) a Holder (and the Trustee) shall be entitled to prove for the Redemption Price in respect of a Capital Note only subject to, and contingent upon, the prior payment in full of, the Senior Creditors; and
- (b) the Holder's (and the Trustee's) claim for payment of the Redemption Price ranks equally with, and shall be paid in proportion to, the claims of holders of other instruments issued as Relevant Perpetual Subordinated Instruments,

so that the Holder receives, for the Capital Note, an amount equal to the amount it would have received if, in the winding up of the Issuer, it had held an issued and fully paid Preference Share.

16.3 Agreements of Holders and Trustee as to subordination

Each Holder (and the Trustee) irrevocably agrees:

- (a) that clause 16.2 is a debt subordination for the purposes of section 563C of the Corporations Act;
- (b) that it does not have, and waives to the maximum extent permitted by law, any entitlement to interest under section 563B of the Corporations Act to the extent that a holder of a preference share which is a Relevant Perpetual Subordinated Instrument would not be entitled to such interest;
- (c) that it shall not have, and is taken to have waived, to the fullest extent permitted by law, any right to prove in a winding-up of the Issuer as a creditor in respect of the Capital Notes so as to diminish any distribution, dividend or payment that any Senior Creditor would otherwise receive;
- (d) not to exercise any voting rights as a creditor in the winding-up or administration of the Issuer:
 - (i) until after all Senior Creditors have been paid in full; or
 - (ii) otherwise in a manner inconsistent with the ranking and subordination contemplated by clause 2 and clause 16.2;
- (e) that it must pay or deliver to the liquidator or administrator any amount or asset received on account of its claim in the winding-up or administration of the Issuer in respect of the Capital Notes in excess of its entitlement under clause 2 and clause 16.2;
- (f) that it must pay in full all liabilities it owes the Issuer before it may receive any amount or asset on account of its claim in the winding-up or administration in respect of a Capital Note;

- (g) that the debt subordination effected by clause 2 and clause 16.2 is not affected by any act or omission of the Issuer or a Senior Creditor which might otherwise affect it at law or in equity; and
- (h) that it has no remedy for the recovery of the Redemption Price other than to prove in the winding up in accordance with this clause 16.

16.4 No further rights

A Capital Note does not confer on the Holders any further right to participate in the winding-up of the Issuer beyond payment of the Redemption Price.

16.5 No set-off

Subject to clause 15, neither the Issuer nor any Holder shall be entitled to set-off any amounts, merge accounts or exercise any other rights the effect of which is or may be to reduce any amount payable by the Issuer in respect of the Capital Notes held by the Holder or by the Holder to the Issuer (as applicable).

16.6 No consent of Senior Creditors

Nothing in clause 2 or this clause 16 shall be taken:

- (a) to require the consent of any Senior Creditor to any amendment of these Terms; or
- (b) to create a charge or security interest over any right of the Holder or the Trustee.

17 General

17.1 Enforcement by Trustee

Subject to clause 17.2, only the Trustee may enforce the provisions of the Trust Deed or these Terms and only in accordance with their terms and subject to the limitation and to the protections of the Trustee set out in the Trust Deed.

17.2 Holder's right to take action

No Holder shall be entitled to proceed directly against the Issuer to enforce any right or remedy under or in respect of any Capital Note or the Trust Deed unless the Trustee, being entitled, and having become bound, to proceed, fails to do so within 21 days and such failure is continuing, in which case any Holder may itself institute proceedings against the Issuer for the relevant remedy to the same extent (but not further or otherwise) that the Trustee would have been entitled to do so.

17.3 Voting

- (a) The Trust Deed contains provisions for convening meetings of the Holders to consider any matter affecting their interests including certain variations of these Terms which require the consent of the Holders.
- (b) A Holder has no right to attend or vote at any general meeting of the shareholders of the Issuer.

17.4 Alterations without consent

At any time and from time to time, but subject to compliance with the Corporations Act and all other applicable laws, the Issuer may, with the approval of the Trustee (such approval not to be unreasonably withheld or delayed), but without the consent of the Holders, alter these Terms if the Issuer is of the opinion that such alteration is:

- (a) of a formal, technical or minor nature;
- (b) made to cure any ambiguity or correct any manifest error;
- (c) necessary or expedient for the purpose of enabling the Capital Notes to be:

- (i) listed for quotation, or to retain quotation, on any securities exchange; or
 - (ii) offered for subscription or for sale under the laws for the time being in force in any place;
- (d) necessary to comply with:
- (i) the provisions of any statute or the requirements of any statutory authority; or
 - (ii) the ASX Listing Rules or the listing or quotation requirements of any securities exchange on which the Issuer may propose to seek a listing or quotation of the Capital Notes;
- (e) made in accordance with the Issuer's adjustment rights in clause 8;
- (f) in respect of any date or time period stated, required or permitted in connection with any Mandatory Conversion, Non-Viability Conversion or Exchange in a manner necessary or desirable to facilitate the Mandatory Conversion, Non-Viability Conversion or Exchange (including without limitation where in connection with a Redemption the proceeds of Redemption are to be reinvested in a new security to be issued by the Issuer or a Related Entity);
- (g) made to:
- (i) alter the terms of any Capital Notes to align them with any Relevant Perpetual Subordinated Instruments issued after the date of such Capital Notes; or
 - (ii) alter the definition of "Relevant Perpetual Subordinated Instruments" on account of the issue (after the date of any Capital Notes) of capital instruments of the Challenger Group; or

- (h) in any other case, not materially prejudicial to the interests of the Holders as a whole,

provided that, in the case of an alteration pursuant to paragraph (c), (d) or (h), the Issuer has provided to the Trustee an opinion which is addressed to it and in a form reasonably satisfactory to it of independent legal advisers of recognised standing in New South Wales that such alteration is otherwise not materially prejudicial to the interests of Holders as a whole.

For the purposes of determining whether an alteration is not materially prejudicial to the interests of Holders as a whole, the taxation and regulatory capital consequences to a Holder (or any class of Holders) and other special consequences or circumstances which are personal to a Holder (or any class of Holders) do not need to be taken into account by the Issuer or its legal advisers.

17.5 Alteration with consent

At any time and from time to time, but subject to compliance with the Corporations Act and all other applicable laws, the Issuer may, with the approval of the Trustee (such approval not to be unreasonably withheld or delayed), alter these Terms:

- (a) except as otherwise provided in paragraphs (b), (c) and (d) below, if such alteration is authorised by a Holder Resolution;
- (b) in the case of an alteration to this clause 17.5 or any clause of the Trust Deed providing for Holders to give a direction to the Trustee by a Special Resolution, if a Special Resolution is passed in favour of such alteration;
- (c) in the case of an alteration to the Meeting Provisions and to which clause 17.4 does not apply, if a Special Resolution is passed in favour of such alteration; and
- (d) otherwise in accordance with the Trust Deed.

17.6 Consents

Prior to any alteration under this clause 17, the Issuer must obtain any consent needed to the alteration and, in particular, any alteration which may cause APRA to object to Challenger Group using, or having used, the proceeds of the issue of some or all of the Capital Notes to fund Additional Tier 1 Capital of CLC, is subject to the prior written consent of APRA.

17.7 Interpretation

In this clause 17, **alter** includes modify, cancel, amend, waive or add to, and **alteration** has a corresponding meaning.

17.8 Notices

The Trust Deed contains provisions for the giving of notices.

17.9 Further issues and dealings

- (a) The Issuer may from time to time, without the consent of any Holder, issue any securities ranking equally with the Capital Notes (on the same terms or otherwise) or ranking in priority or junior to the Capital Notes, or incur or guarantee any indebtedness upon such terms as it may think fit in its sole discretion.
- (b) Nothing in these Terms limits the ability of the Issuer or any other member of the Challenger Group, in its discretion from time to time, from redeeming, converting, buying back, returning or distributing capital in respect of any share capital or any other securities of any kind, whether ranking behind, equally with or in priority to the Capital Notes.

17.10 Purchase by agreement

Subject to APRA's prior written approval, the Issuer or any member of the Challenger Group may purchase Capital Notes at any time and at any price. Any Capital Note purchased by or on behalf of the Issuer shall be cancelled.

Holders should not expect that APRA's approval will be given for any purchase of Capital Notes under these Terms.

17.11 Governing law

These Terms and the Capital Notes are governed by the laws in force in New South Wales.

17.12 Rounding

For the purposes of any calculations required under these Terms:

- (a) all percentages resulting from the calculations must be rounded, if necessary, to the nearest ten-thousandth of a percentage point (with 0.00005% being rounded up to 0.0001%);
- (b) all figures must be rounded to four decimal places (with 0.00005 being rounded up to 0.0001); and
- (c) all amounts that are due and payable must be rounded to the nearest one Australian cent (with 0.5 of a cent being rounded up to 1 cent).

18 Interpretation and definitions

18.1 Interpretation

In these Terms, except where the context otherwise requires:

- (a) the singular includes the plural and vice versa, and a gender includes other genders;
- (b) another grammatical form of a defined word or expression has a corresponding meaning;
- (c) a reference to a document includes all schedules or annexes to it;

- (d) a reference to a clause or paragraph is to a clause or paragraph of these Terms;
- (e) a reference to a document or instrument includes the document or instrument as novated, altered, supplemented or replaced from time to time;
- (f) a reference to Australia includes any political sub-division or territory in the Commonwealth of Australia;
- (g) a reference to Australian dollars, A\$ or Australian cent is a reference to the lawful currency of Australia;
- (h) a reference to time is to Sydney, Australia time;
- (i) other than:
 - (i) in relation to a Non-Viability Trigger Event and a Conversion or Write-Off, in each case on account of a Non-Viability Trigger Event; and
 - (ii) where a contrary intention is expressed, if an event under these Terms must occur on a stipulated day which is not a Business Day, then the stipulated day will be taken to be the next Business Day;
- (j) a reference to a person includes a reference to the person's executors, administrators, successors and permitted assigns and substitutes;
- (k) a reference to a person includes a natural person, partnership, body corporate, association, governmental or local authority or agency or other entity;
- (l) a reference to a statute, ordinance, code, rule, directive or law (however described) includes regulations and other instruments under it and consolidations, amendments, re-enactments or replacements of any of them;
- (m) the meaning of general words is not limited by specific examples introduced by "including", "for example" or similar expressions;
- (n) any agreement, representation or warranty by two or more parties (including where two or more persons are included in the same defined term) binds them jointly and severally;
- (o) headings (including those in brackets at the beginning of paragraphs) are for convenience only and do not affect the interpretation of these Terms;
- (p) if the principal securities exchange on which Ordinary Shares are listed becomes other than ASX, unless the context otherwise requires, a reference to ASX shall be read as a reference to that principal securities exchange and a reference to the ASX Listing Rules, ASX Settlement Operating Rules or any term defined in any such rules, shall be read as a reference to the corresponding rules of that exchange or corresponding defined terms in such rules (as the case may be);
- (q) any provisions which refer to the requirements of APRA or any other prudential regulatory requirements will apply to the Issuer only if the Issuer is an entity subject to regulation and supervision by APRA at the relevant time;
- (r) a reference to any term defined by APRA (including, without limitation, Additional Tier 1 Capital) shall, if that term is replaced or superseded in any of APRA's applicable prudential regulatory requirements or standards, be taken to be a reference to the replacement or equivalent term;
- (s) any provisions which require APRA's consent or approval (written or otherwise) will apply only if APRA requires that such consent or approval be given at the relevant time; and
- (t) any provisions in these Terms requiring the prior approval of APRA for a particular course of action to be taken by the Issuer

do not imply that APRA has given its consent or approval to the particular action as of the Issue Date or that it will at any time give its consent or approval to the particular action.

18.2 Definitions

In these Terms, these meanings apply unless the contrary intention appears:

Acquisition Conversion Date has the meaning given in clause 7.3.

Acquisition Conversion Notice has the meaning given in clause 7.2.

Acquisition Event means:

(a) either:

- (i) a takeover bid is made to acquire all or some Ordinary Shares and the offer is, or becomes, unconditional and:
 - (A) the bidder has a relevant interest in more than 50% of the Ordinary Shares on issue; or
 - (B) the Directors issue a statement that at least a majority of the Directors who are eligible to do so recommend acceptance of the offer (which may be stated to be in the absence of a higher offer); or
- (ii) a court approves a scheme of arrangement which, when implemented, will result in a person other than the Issuer having a relevant interest in more than 50% of Ordinary Shares; and

(b) all regulatory approvals necessary for the acquisition to occur have been obtained.

Acquisition Event Notice has the meaning given in clause 7.1.

Additional Tier 1 Capital means Additional Tier 1 Capital as defined by APRA from time to time.

Adjustment Notice has the meaning given in clause 8.8.

Applicable Franking Period has the meaning given in clause 3.2.

Applicable Regulations means such provisions of the ASX Listing Rules, the ASX Settlement Operating Rules, the ASX Operating Rules, the Corporations Act and any regulations or rules pursuant under or pursuant to any such provisions as may be applicable to the transfer.

APRA means the Australian Prudential Regulation Authority or any authority succeeding to its powers and responsibilities.

ASX means ASX Limited (ABN 98 008 624 691) or the securities market operated by it, as the context requires.

ASX Listing Rules means the listing rules of ASX.

ASX Operating Rules means the market operating rules of ASX as amended, varied or waived (whether in respect of the Issuer or generally) from time to time.

ASX Settlement Operating Rules means the settlement operating rules of ASX as amended, varied or waived (whether in respect of the Issuer or generally) from time to time.

Attorney has the meaning given in clause 11.1.

BBSW Rate has the meaning given in clause 3.1.

Bookbuild means the process conducted prior to the opening of the Offer whereby certain investors and brokers lodge bids for Capital Notes and, on the basis of those bids, the Issuer determines the Margin and announces its determination of the Margin prior to the opening of the Offer.

Business Day means:

- (a) a day which is a business day within the meaning of the ASX Listing Rules; and
- (b) for the purposes of calculation or payment of Distributions or any other amount, a day on which banks are open for business in Sydney, New South Wales.

Buy-Back means a transaction involving the acquisition by the Issuer of Ordinary Shares pursuant to an offer made at the Issuer's discretion in any way permitted by the provisions of Part 2J of the Corporations Act.

Capital Note has the meaning given in clause 1.1.

Capital Reduction means a reduction in capital initiated by the Issuer in its discretion in respect of Ordinary Shares in any way permitted by the provisions of Part 2J of the Corporations Act.

Challenger Capital Notes 2 means the perpetual, subordinated, unsecured notes issued by the Issuer on 7 April 2017 and constituted by the trust deed between the Issuer and Australian Executor Trustees Limited (ABN 84 007 869 794) as trustee (subsequently replaced with Certane CT Pty Ltd (ABN 12 106 424 088)) dated 28 February 2017.

Challenger Capital Notes 3 means the perpetual, subordinated, unsecured notes issued by the Issuer on 25 November 2020 and constituted by the trust deed between the Issuer and Equity Trustees Limited (ABN 46 004 031 298) dated 13 October 2020.

Challenger Group means the Issuer and its Controlled Entities.

Challenger Shares means Ordinary Shares or any other shares in the capital of the Issuer.

CHESS means the Clearing House Electronic Subregister System operated by ASX Settlement Pty Limited (ABN 49 008 504 532) or any system that replaces it and which is relevant to the Capital Notes (including in respect of the transfer or Conversion of the Capital Notes).

CLC means Challenger Life Company Limited (ABN 44 072 486 938).

Control has the meaning given in the Corporations Act.

Controlled Entity means, in respect of the Issuer, an entity the Issuer Controls.

Conversion means, in relation to a Capital Note, the conversion of the Capital Note into an Ordinary Share in accordance with and subject to clause 8 as it may be amended. **Convert**, **Converting** and **Converted** have corresponding meanings.

Conversion Number has the meaning given in clause 8.1.

Conversion Test Date Percentage has the meaning given in clause 4.3.

Corporations Act means the Corporations Act 2001 (Cth).

CS Facility has the same meaning as "prescribed CS Facility" in the Corporations Act.

CS Facility Operator means the operator of a CS Facility.

Cum Value has the meaning given in clause 8.2(a).

Defaulting Nominated Purchaser has the meaning given in clause 10.6.

Deferred Acquisition Conversion Notice has the meaning given in clause 7.5.

Deferred Conversion Date has the meaning given in clause 6.6.

Deferred Conversion Notice has the meaning given in clause 6.6.

Delisting Event means, in respect of a date, that:

- (a) the Issuer has ceased to be listed or Ordinary Shares have ceased to be quoted on ASX on or before that date (and where the cessation occurred before that date, the Issuer or the Ordinary Shares continue not to be listed or quoted (as applicable) on that date);
- (b) trading of Ordinary Shares on ASX is suspended for a period of consecutive days which includes:
 - (i) at least five consecutive Business Days prior to that date; and
 - (ii) that date; or
- (c) an Inability Event subsists.

Directors means some or all of the directors of the Issuer acting as a board.

Distribution has the meaning given in clause 3.1.

Distribution Payment Date has the meaning given in clause 3.5.

Distribution Period means in respect of:

- (a) the first Distribution Period, the period from (and including) the Issue Date until (but not including) the first Distribution Payment Date after the Issue Date; and
- (b) each subsequent Distribution Period, the period from (and including) the preceding Distribution Payment Date until (but not including) the next Distribution Payment Date.

Distribution Rate has the meaning given in clause 3.1.

Dividend means any interim, final or special dividend payable in accordance with the Corporations Act and the Issuer's constitution in relation to Ordinary Shares.

Encumbrance means any mortgage, pledge, charge, lien, assignment by way of security, hypothecation, security interest, title retention, preferential right or trust arrangement, any other security agreement or security arrangement (including any security interest under the *Personal Property Securities Act 2009* (Cth)) and any other arrangement of any kind having the same effect as any of the foregoing other than liens arising by operation of law.

Exchange means:

- (a) Conversion in accordance with and subject to clause 8;
- (b) Redemption in accordance with and subject to clause 9;
- (c) Resale in accordance with clause 10; or
- (d) a combination of two or more of Conversion, Redemption or Resale in accordance with clause 6.3(b),

and **Exchanged** has a corresponding meaning.

Exchange Date has the meaning given in clause 6.2(b).

Exchange Method has the meaning given in clause 6.3.

Exchange Notice has the meaning given in clause 6.1.

External Administrator means, in respect of a person:

- (a) a liquidator, a provisional liquidator, an administrator or a statutory manager of that person; or
- (b) a receiver, or a receiver and manager, in respect of all or substantially all of the assets and undertakings of that person, or in either case any similar official.

Face Value means the principal amount of a Capital Note, being A\$100.

FATCA means:

- (a) sections 1471 to 1474 of the U.S. Internal Revenue Code of 1986 or any associated regulations;
- (b) any treaty, law or regulation of any other jurisdiction, or relating to an intergovernmental agreement between the U.S. and any other jurisdiction, which (in either case) facilitates the implementation of any law or regulation referred to in paragraph (a) above; or
- (c) any agreement pursuant to the implementation of any treaty, law or regulation referred to in paragraphs (a) or (b) above with the U.S. Internal Revenue Service, the U.S. government or any governmental or taxation authority in any other jurisdiction.

FATCA Withholding means any withholding or deduction imposed or required pursuant to FATCA.

First Mandatory Conversion Condition has the meaning given in clause 4.3.

First Optional Conversion Restriction has the meaning given in clause 6.5.

First Test Date has the meaning given in clause 4.3.

First Test Date Percentage has the meaning given in clause 4.3.

Foreign Holder means a Holder whose address in the Register is a place outside Australia or who the Issuer otherwise believes may not be a resident of Australia.

Franking Period means the franking period within the meaning of Part 3-6 of the Tax Act, or any provisions that revise or replace that Part, applicable to the Issuer.

Franking Rate (expressed as a decimal) means the franking percentage (within the meaning of Part 3-6 of the Tax Act or any provisions that revise or replace that Part) applicable to the franking account of the Issuer at the relevant Distribution Payment Date, as determined by the Issuer in accordance with clause 3.2.

Holder means, in respect of a Capital Note, the person whose name is entered on the Register as the holder of that Capital Note.

Holder Resolution means a resolution passed:

- (a) at a meeting of Holders of the Capital Notes, duly called and held under the Meeting Provisions:
 - (i) by at least 50% of the persons voting on a show of hands (unless paragraph (b) below applies); or
 - (ii) if a poll is duly demanded, by a majority consisting of at least 50% of the votes cast; or
- (b) by postal ballot or written resolution under the Meeting Provisions by Holders representing (in aggregate) at least 50% of the aggregate Face Value of the outstanding Capital Notes.

Inability Event means the Issuer is prevented by applicable law, or order of any court, or action of any government authority (including regarding the insolvency, winding-up or other external administration of the Issuer) or any other reason from Converting the Capital Notes.

Issue Date means the date on which the issue and allotment of Capital Notes to successful applicants is completed, in accordance with these Terms.

Issue Date VWAP means the VWAP during the period of 20 Business Days on which trading in Ordinary Shares took place immediately preceding (but not including) the Issue Date, as adjusted in accordance with clauses 8.4 to 8.7 (inclusive).

Issuer means Challenger Limited (ABN 85 106 842 371).

Life Insurance Act means the *Life Insurance Act 1995* (Cth).

Mandatory Conversion means the mandatory conversion of Capital Notes to Ordinary Shares on the Mandatory Conversion Date in accordance with clause 4.

Mandatory Conversion Conditions has the meaning given in clause 4.3.

Mandatory Conversion Date has the meaning given in clause 4.2.

Margin has the meaning given in clause 3.1.

Maximum Conversion Number has the meaning given in clause 8.1.

Meeting Provisions means the provisions for meetings of the Holders set out in schedule 2 to the Trust Deed.

Nominated Purchasers means, subject to clause 10.3, one or more third parties selected by the Issuer in its absolute discretion.

Nominee has the meaning given in clause 8.10.

Non-Conversion Notice has the meaning given in clause 4.4.

Non-Conversion Test Date has the meaning given in clause 6.5.

Non-Viability Conversion means the Conversion of Capital Notes to Ordinary Shares on the Non-Viability Conversion Date in accordance with clause 5.

Non-Viability Conversion Date has the meaning given in clause 5.2.

Non-Viability Trigger Event has the meaning given in clause 5.1.

Non-Viability Trigger Event Notice has the meaning given in clause 5.2.

Offer means the invitation under the Prospectus made by the Issuer for persons to subscribe for Capital Notes.

Optional Conversion Restrictions has the meaning given in clause 6.5.

Optional Exchange Date means a Distribution Payment Date falling on or about 25 May 2029, 25 August 2029, 25 November 2029, or 25 February 2030.

Ordinary Share means a fully paid ordinary share in the capital of the Issuer.

Payment Condition means, with respect to the payment of a Distribution on the Capital Notes on a Distribution Payment Date:

- (a) the consolidated retained earnings of the Challenger Group as at the Distribution Payment Date are, or would on payment of the Distribution become, negative;
- (b) the payment would result in the Issuer becoming, or being likely to become, insolvent for the purposes of the Corporations Act; or
- (c) APRA objecting to the payment.

Potential Acquisition Event means:

- (a) an event within paragraph (a) of the definition of Acquisition Event occurs (without the need that all regulatory approvals necessary for the acquisition to occur have been obtained); or
- (b) a court orders the holding of meetings to approve a scheme of arrangement under Part 5.1 of the Corporations Act and the scheme would result in a person having a relevant interest in more than 50% of the Ordinary Shares that will be on issue after the scheme is implemented.

Preference Share means a notional preference share in the capital of the Issuer conferring a claim in the winding up of the Issuer equal to the Redemption Price and ranking in respect of return of capital in the winding up ahead only of Ordinary Shares and equally with Relevant Perpetual Subordinated Instruments.

Proceeds means the net proceeds of a sale of Ordinary Shares attributable to the Holder actually received by the Nominee calculated after deduction of any applicable brokerage, stamp duty and other taxes and charges, including the Nominee's reasonable out of pocket costs, expenses and charges properly incurred by it or on its behalf in connection with such sale from the sale price of the Ordinary Shares.

Prospectus means the prospectus relating to the Offer dated on or about 7 March 2023 published by the Issuer and any supplementary or replacement prospectus.

Publication Time has the meaning given in clause 3.1.

Rate Disruption Event has the meaning given in clause 3.1.

Record Date means, for payment of a Distribution:

- (a) the date which is eight calendar days before the Distribution Payment Date for that Distribution (or, in the case of the first Distribution Payment Date, if the Issue Date is less than eight calendar days before the first Distribution Payment Date, the Issue Date); or
- (b) such other date as is determined by the Issuer in its absolute discretion, subject to compliance with any relevant requirements under the ASX Listing Rules and provided that such new date is communicated to ASX not less than seven Business Days before the specified Record Date,

or in either case such other date as may be required by ASX.

Redemption means the redemption of a Capital Note in accordance with clause 9 and the words **Redeem**, **Redeemable** and **Redeemed** have corresponding meanings.

Redemption Price has the meaning given in clause 9.2.

Register means the register of Holders (established and maintained under clause 13 of the Trust Deed) and, where appropriate, the term Register includes:

- (a) a sub-register maintained by or for the Issuer under the Corporations Act, the ASX Listing Rules or the ASX Settlement Operating Rules; and
- (b) any branch register.

Registrar means Computershare Investor Services Pty Limited (ABN 48 078 279 277) or any other person appointed by the Issuer to maintain the Register and perform any payment and other duties as specified in that agreement.

Regulatory Event means:

- (a) the receipt by the Directors of an opinion from a reputable legal counsel that, as a result of any amendment to, clarification of or change (including any announcement of a change that will be introduced) in any law or regulation or any official administrative pronouncement or action or judicial decision interpreting or applying such laws or regulations which amendment, clarification or change is effective, or pronouncement, action or decision is announced, on or after the Issue Date (and which the Issuer does not expect, as at the Issue Date, may come into effect) (a **Change in Law**), additional requirements would be imposed on the Issuer in relation to or in connection with Capital Notes which the Directors determine, in their absolute discretion, would have a not insignificant adverse impact on it; or

(b) as a result of a Change in Law or a statement received from APRA, the Directors determine that the Issuer is not or will not be entitled to treat some or all Capital Notes as a Relevant Perpetual Subordinated Instrument, (including where APRA has notified the Issuer in writing that it objects to the Challenger Group using or having used the proceeds of the Capital Notes to fund Additional Tier 1 Capital of CLC) except where the reason the Issuer is not or will not be entitled to treat some or all Capital Notes as a Relevant Perpetual Subordinated Instrument is because of a prudential limit or other restriction which is in effect on the Issue Date or which on the Issue Date is expected by the Issuer may come into effect.

Related Entity has the meaning given by APRA from time to time.

Relevant Date has the meaning given in clause 4.2.

Relevant Distribution Payment Date has the meaning given in clause 3.8.

Relevant Fraction has the meaning given in clause 8.1.

Relevant Perpetual Subordinated Instrument means a perpetual subordinated instrument (whether in the form of a note, preference share or other security or obligation) issued by the Issuer or another member of the Challenger Group which:

- (a) in accordance with its terms or by operation of law, is capable of being converted into Ordinary Shares or written-off where APRA makes a determination as referred to in clause 5.1(a); and
- (b) has been confirmed in writing by APRA to the Issuer as constituting as at the date of its issue an instrument the proceeds of which APRA does not object to the Challenger Group using to fund Additional Tier 1 Capital of CLC,

and, for so long as they remain outstanding, includes the Capital Notes, the Challenger Capital Notes 2 and the Challenger Capital Notes 3.

Relevant Time means, in the case of:

- (a) payment of a Distribution, 7:00 pm (or such other time as may be prescribed by ASX or, if not prescribed by ASX, a time determined by the Issuer and notified to ASX); and
- (b) payments of the Redemption Price, a time determined by the Issuer and notified to ASX (or such other time as may be prescribed by ASX).

Reorganisation means, in relation to the Issuer, a division, consolidation or reclassification of the Issuer's share capital not involving any cash payment or other distribution to or by holders of Ordinary Shares.

Replacement Rate has the meaning given in clause 3.1.

Resale means the sale of a Capital Note to a Nominated Purchaser in accordance with clause 10, and **Resold** and **Resell** have corresponding meanings.

Resale Price means, for a Capital Note, a cash amount equal to its Face Value.

Restricted Securities has the same meaning as in the ASX Listing Rules and extends to Capital Notes which are subject to voluntary restrictions by agreement between the Issuer and one or more Holders.

Restriction Agreement means an agreement which is required to be concluded under Chapter 9 of the ASX Listing Rules or is voluntarily concluded between the Issuer and one or more Holders.

Scheduled Mandatory Conversion Date has the meaning given in clause 4.2.

Second Mandatory Conversion Condition has the meaning given in clause 4.3.

Second Optional Conversion Restriction has the meaning given in clause 6.5.

Second Test Period has the meaning given in clause 4.3.

Senior Creditors means all creditors of the Issuer (present and future), including all holders of the Issuer's senior or subordinated debt whose claims:

- (a) are admitted in a winding-up of the Issuer; and
- (b) are not in respect of a Relevant Perpetual Subordinated Instrument.

Special Resolution means:

- (a) a resolution passed at a meeting of the Holders duly called and held under the Meeting Provisions:
 - (i) by at least 75% of the persons voting on a show of hands (unless paragraph (b) below applies); or
 - (ii) if a poll is duly demanded, then by a majority consisting of at least 75% of the votes cast; or
- (b) a resolution passed by postal ballot or written resolution under the Meeting Provisions by Holders representing (in aggregate) at least 75% of the aggregate Face Value of the outstanding Capital Notes.

Subsequent Mandatory Conversion Date has the meaning given in clause 4.2.

Tax Act means:

- (a) the *Income Tax Assessment Act 1936* (Cth) or the *Income Tax Assessment Act 1997* (Cth) as the case may be and a reference to any section of the *Income Tax Assessment Act 1936* (Cth) includes a reference to that section as rewritten in the *Income Tax Assessment Act 1997* (Cth); and
- (b) any other law setting the rate of income tax payable; and
- (c) any regulation made under any of those laws.

Tax Event means the receipt by the Directors of an opinion from a reputable legal counsel or other tax adviser in Australia experienced in such matters to the effect that, as a result of any change in, or amendment to, the laws in force in Australia affecting taxation (or any change in their application or official or judicial interpretation) which change or amendment becomes effective on or after the Issue Date and which was not expected by the Issuer on the Issue Date, there is more than an insubstantial risk which the Issuer determines at its absolute discretion to be unacceptable that:

- (a) any Distribution would not be a frankable distribution within the meaning of Division 202 of the Tax Act; or
- (b) the Issuer would be exposed to a more than insignificant increase in its costs, charges and expenses (including without limitation through the imposition of any Taxes or assessments) in relation to Capital Notes.

Tax Rate has the meaning given in clause 3.1.

Taxes means taxes, levies, imposts, charges and duties (including stamp and transaction duties) imposed by any authority together with any related interest, penalties, fines and expenses in connection with them, except if imposed on, or calculated having regard to, the net income of the Holder.

Terms means these terms and conditions.

Transfer has the meaning given in the ASX Settlement Operating Rules.

Trust Deed means the deed entitled "Challenger Capital Notes 4 Trust Deed" between the Issuer and the Trustee and dated on or about 7 March 2023.

Trustee means Equity Trustees Limited (ABN 46 004 031 298).

VWAP means, subject to any adjustments under clause 8, the average of the daily volume weighted average sale prices (such average being rounded to the nearest full cent) of Ordinary Shares sold on ASX during the relevant period or on the relevant days but does not include any "Crossing" transacted outside the "Open Session State" or any "Special Crossing" transacted at any time, each as defined in the ASX Operating Rules, or any overseas trades or trades pursuant to the exercise of options over Ordinary Shares.

VWAP Period means:

- (a) in the case of a Conversion resulting from a Potential Acquisition Event or an Acquisition Event, the lesser of:
 - (i) 20 Business Days on which trading in Ordinary Shares takes place; and
 - (ii) the number of Business Days on which trading in Ordinary Shares takes place and on which Ordinary Shares are quoted for trading on ASX after the occurrence of the Potential Acquisition Event or Acquisition Event (as the case may be),

in each case immediately preceding (but not including) the Business Day before the Exchange Date or Acquisition Conversion Date in respect of that event (as the case may be);

- (b) in the case of a Conversion resulting from a Non-Viability Trigger Event, the period of five Business Days on which trading in Ordinary Shares took place immediately preceding (but not including) the Non-Viability Conversion Date;
- (c) in the case of any other Conversion, the period of 20 Business Days on which trading in Ordinary Shares took place immediately preceding (but not including) the date on which Conversion is to occur in accordance with these Terms; or
- (d) otherwise, the period for which VWAP is to be calculated in accordance with these Terms.

Winding-up Event has the meaning given in clause 16.1.

Written-Off has the meaning given in clause 8.13 and **Write-Off** has a corresponding meaning.



Appendix B

Glossary

B. Glossary

This Appendix provides a glossary of key terms and abbreviations used throughout this Prospectus. There is also a list of further defined terms in clause 18.2 of the Terms immediately prior to this Glossary.

Term	Meaning
AASB	Australian Accounting Standards Board.
AASB 17	AASB 17 <i>Insurance Contracts</i> .
AASB 1038	AASB 1038 <i>Life Insurance Contracts</i> .
ABN	Australian Business Number.
ACCC	Australian Competition and Consumer Commission.
Acquisition Conversion Date	Has the meaning given in clause 7.3 of the Terms.
Acquisition Conversion Notice	Has the meaning given in clause 7.2 of the Terms. See also Section 2.5.2 of this Prospectus.
Acquisition Event	Has the meaning given in clause 18.2 of the Terms. See also Section 2.5.1 of this Prospectus.
Additional Tier 1 Capital	Additional Tier 1 Capital as defined by APRA from time to time.
ADI	Authorised deposit-taking institution.
AFSL	Australian Financial Services Licence.
Anti-Money Laundering and Counter-Terrorism Financing Act	<i>Anti-Money Laundering and Counter-Terrorism Financing Act 2006</i> (Cth).
ANZ	ANZ Securities Limited (ABN 16 004 997 111).
APLs	Approved Product Lists.
Apollo	Apollo Global Management, Inc.
Applicable Resident Note Holders	Resident Note Holders who acquire their Challenger Capital Notes 4 by initial subscription and hold them on capital account for tax purposes.
Applicant	A person who submits an Application.
Application	A valid application for a specified number of Challenger Capital Notes 4 made to a Syndicate Broker.
Application Form	A paper, online or electronic application form (as the context requires) accompanying this Prospectus, which Syndicate Brokers may require Applicants to complete.
Application Payment	The monies payable on each Application, calculated as the number of Challenger Capital Notes 4 applied for multiplied by the Face Value.
APRA	Australian Prudential Regulation Authority or any authority succeeding to its powers and responsibility.
Arrangers	UBS, NAB and WIB.
Artega	Artega Investment Administration Pty Limited.
ASIC	Australian Securities and Investments Commission (ABN 86 768 265 615).
ASX	The Australian Securities Exchange operated by ASX Limited (ABN 98 008 624 691), or the securities market operated by it, as the context requires, or any successor.
ASX Listing Rules	The listing rules of ASX, as amended, varied or waived (whether in respect of Challenger or generally) from time to time.
ATO	Australian Taxation Office.
Attorney	Has the meaning given in clause 11.1 of the Terms.
AUM	Assets under management.
AUSTRAC	The Australian Transaction Reports and Analysis Centre.

Term	Meaning
Australian IGA	Australia–US FATCA Intergovernmental Agreement dated 28 April 2014.
Bank or Challenger Bank	Challenger Bank Limited (ABN 54 087 651 750).
Banking Act	<i>Banking Act 1959</i> (Cth).
BBSW Rate	Has the meaning given in clause 3.1 of the Terms. See also Section 2.1.3 of this Prospectus.
BEAR	Bank Executive Accountability Regime.
Board	The board of directors of Challenger.
Bookbuild	The process described in Section 7.5 to determine the Margin.
Business Day	A business day as defined in the ASX Listing Rules, and for the purposes of calculation or payment of Distributions or any other amount, a day on which banks are open for business in Sydney, New South Wales.
CCN2 Exchange Notice	The “Exchange Notice” (as that term is defined in the CCN2 Terms) issued by Challenger in accordance with the CCN2 Terms on the date of the Original Prospectus.
CCN2 Holder	In relation to a Challenger Capital Note 2, the person whose name is registered in the Register as the holder of a Challenger Capital Note 2.
CCN2 Nominated Purchaser	UBS.
CCN2 Resale	The purchase of Challenger Capital Notes 2 by the CCN2 Nominated Purchaser on 5 April 2023 pursuant to the CCN2 Exchange Notice and the terms of the Reinvestment Offer.
CCN2 Resale Proceeds	\$100 per Reinvestment CCN2 acquired by the CCN2 Nominated Purchaser pursuant to the CCN2 Exchange Notice.
CCN2 Terms	Terms and conditions of Challenger Capital Notes 2, as amended from time to time.
CFI	Conduit foreign income.
CGT	Capital gains tax.
Challenger	Challenger Limited (ABN 85 106 842 371), the parent company of the Challenger Group.
Challenger Capital Notes 2	The perpetual, subordinated, unsecured notes issued by Challenger on 7 April 2017 and constituted by the trust deed between Challenger and Australian Executor Trustees Limited (ABN 84 007 869 794) as trustee (subsequently replaced with Certane CT Pty Ltd (ABN 12 106 424 088)) dated 28 February 2017.
Challenger Capital Notes 3	The perpetual, subordinated, unsecured notes issued by Challenger on 25 November 2020 and constituted by the trust deed between Challenger and Equity Trustees Limited (ABN 46 004 031 298) dated 13 October 2020.
Challenger Capital Notes 4	The non-cumulative, convertible, transferable, redeemable, subordinated, perpetual and unsecured notes to be issued by Challenger under this Prospectus.
Challenger Capital Notes 4 Target Market	The class of Retail Investors that comprise the target market for Challenger Capital Notes 4 as set out in the TMD and described in Section 7.4.2.
Challenger Group	The statutory consolidated group comprising Challenger and its subsidiaries. The Challenger Group and its activities are described in Section 4.
CHESS	Clearing House Electronic Subregister System operated by ASX Settlement Pty Limited (ABN 49 008 504 532) or any system that replaces it and which is relevant to the Challenger Capital Notes 4 (including in respect of the transfer or Conversion of the Challenger Capital Notes 4).
CIM	Challenger Investment Management.
Class Ruling	Public class ruling.
CLC	Challenger Life Company Limited (ABN 44 072 486 938, AFSL 234670).
Closing Date	The last date by which Applications must be lodged for the Offer, expected to be 5:00pm (Sydney time) on 30 March 2023 for the New Money Offer and Reinvestment Offer (unless varied).

Term	Meaning
Co-Managers	LGT Crestone Wealth Management Limited and JBWere Limited.
Commissioner	Commissioner of Taxation.
Common Equity Tier 1 Capital	Common Equity Tier 1 Capital as defined by APRA from time to time.
Competition and Consumer Act	<i>Competition and Consumer Act 2010</i> (Cth).
Constitution	The constitution of Challenger, as amended from time to time.
Conversion	Has the meaning given in clause 18.2 of the Terms (Convert, Converting and Converted have corresponding meanings).
Conversion Number	Has the meaning given in clause 8.1 of the Terms.
Conversion Test Date Percentage	Has the meaning given in clause 4.3 of the Terms.
Corporations Act	<i>Corporations Act 2001</i> (Cth).
Covenant or Retirement Income Covenant	Retirement income covenant as described in Section 6.2.1.
CPI	The Consumer Price Index, Australia, published by the Australian Bureau of Statistics.
CPS 511	Prudential Standard CPS 511 Remuneration.
CRS	OECD Common Reporting Standard for Automatic Exchange of Financial Account Information in Tax Matters.
CR 2017/25	Class Ruling CR 2017/25 (<i>Income tax: Challenger Limited: Challenger Capital Notes 2</i>).
CSM	Contractual Service Margin.
DDO Legislation	Corporations Act provisions (in Part 7.8A of the Corporations Act) which were introduced by the <i>Treasury Laws Amendment (Design and Distribution Obligations and Product Intervention Powers) Act 2019</i> (Cth).
DDO Regime	The design and distribution obligations regime contained in Part 7.8A of the Corporations Act.
Deferred Acquisition Conversion Notice	Has the meaning given in clause 7.5(b) of the Terms.
Delisting Event	Has the meaning given in clause 18.2 of the Terms.
Directors	Some or all of the directors of Challenger acting as a board or the individuals who are the directors of Challenger (as the context requires).
Distribution	Has the meaning given in clause 3.1 of the Terms. See also Section 2.1.1 of this Prospectus.
Distribution Payment Date	Has the meaning given in clause 3.5 of the Terms. See also Section 2.1.6 of this Prospectus.
Distribution Period	Has the meaning given in clause 18.2 of the Terms.
Distribution Rate	Has the meaning given in clause 3.1 of the Terms. See also Sections 2.1.2, 2.1.3 and 2.1.4 of this Prospectus.
Distribution Restriction	The restriction described in Sections 2.1.8 and 6.1.16 of this Prospectus.
DWT	Dividend withholding tax.
EBIT	Earnings before interest and tax.
Eligible CCN2 Holder	<p>A CCN2 Holder who is registered as a holder of Challenger Capital Notes 2 at 7:00pm (Sydney time) on 3 March 2023 (Challenger Capital Notes 2 must also be held at 5:00pm (Sydney time) on the Closing Date) and, unless otherwise determined by Challenger, is:</p> <ul style="list-style-type: none"> • shown on the Challenger Capital Notes 2 register as having an address in Australia; • not an individual residing in a member state of the European Union; and • not in the United States or acting as a nominee for, or for the account or benefit of, a U.S. Person, and not otherwise prevented from receiving the Reinvestment Offer or Challenger Capital Notes 4 under the laws of any jurisdiction.
EPS	Earnings per share.

Term	Meaning
Ernst & Young	Ernst & Young (ABN 75 288 172 749).
ESG	Environmental, social and governance.
Exchange	Has the meaning given in clause 18.2 of the Terms (Exchanged has a corresponding meaning).
Exchange Date	Has the meaning given in clause 6.2(b) of the Terms. See also Section 2.3 of this Prospectus.
Exchange Method	Has the meaning given in clause 6.3 of the Terms.
Exchange Notice	Has the meaning given in clause 6.1 of the Terms.
Expiry Date	The date which is 13 months after 7 March 2023.
Exposure Period	The seven-day period after the date the Original Prospectus was lodged with ASIC during which the Corporations Act prohibits the acceptance of Applications.
External Administrator	Has the meaning given in clause 18.2 of the Terms.
Face Value	The face value and issue price of Challenger Capital Notes 4, being \$100 per Challenger Capital Note 4.
FAR	Financial Accountability Regime.
FAR 2021	<i>Financial Accountability Regime Bill 2021</i> (Cth).
FAR 2022	<i>Financial Accountability Regime Bill 2022</i> (Cth).
FATCA	(a) sections 1471 to 1474 of the U.S. Internal Revenue Code or any associated regulations; (b) any treaty, law or regulation of any other jurisdiction, or relating to an intergovernmental agreement between the U.S. and any other jurisdiction, which (in either case) facilitates the implementation of any law or regulation referred to in paragraph (a) above; or (c) any agreement pursuant to the implementation of any treaty, law or regulation referred to in paragraphs (a) or (b) above with the U.S. Internal Revenue Service, the U.S. government or any governmental or taxation authority in any other jurisdiction.
FATCA Withholding	Any withholding or deduction imposed or required pursuant to FATCA.
FFIs	Foreign financial institutions.
Financial Claims Scheme	The Financial Claims Scheme for authorised deposit-taking institutions administered by APRA.
Financial Information	The Historical Financial Information and Pro Forma Historical Financial Information of Challenger and Challenger Group.
First CCN2 Pro Rata Distribution	The Distribution accrued over the period from (and including) 22 February 2023 to (but excluding) 5 April 2023 (being the Issue Date), in respect of each Challenger Capital Note 2 on issue, expected to be paid on the Issue Date.
First Mandatory Conversion Condition	Has the meaning given in clause 4.3 of the Terms.
First Test Date Percentage	Has the meaning given in clause 4.3 of the Terms.
Foreign Holder	Has the meaning given in clause 18.2 of the Terms. See also Section 2.7.4 of this Prospectus.
FSI	2014 Financial System Inquiry.
FSTR Act	<i>Financial Sector (Transfer and Restructure) Act 1999</i> (Cth).
FUM	Funds under management.
Funds Management	Challenger's Funds Management business.
GST	Has the meaning given by section 195-1 of the <i>A New Tax System (Goods and Services Tax) Act 1999</i> (Cth).

Term	Meaning
Holder	In relation to a Challenger Capital Note 4, the person whose name is registered in the Register as the holder of the Challenger Capital Note 4.
Holder Resolution	Has the meaning given in clause 18.2 of the Terms.
Holding Statement	A statement issued to Holders by the Registry which sets out details of Challenger Capital Notes 4 issued to them under the Offer.
ICAAP	Internal Capital Adequacy Assessment Process.
IFRS	International Financial Reporting Standards.
Inability Event	Has the meaning given in clause 18.2 of the Terms. See also Section 2.4.6 of this Prospectus.
Institutional Investor	An investor to whom offers or invitations in respect of Challenger Capital Notes 4 can be made without the need for a lodged prospectus (or other formality, other than a formality which Challenger is willing to comply with), including in Australia persons to whom offers or invitations can be made without the need for a lodged prospectus under section 708 of the Corporations Act, and who has been invited by the Joint Lead Managers to bid for Challenger Capital Notes 4 in the Bookbuild, provided that such investor may not be in the United States.
IRS	U.S. Internal Revenue Service.
Issue Date	The date on which the issue of Challenger Capital Notes 4 to successful Applicants is completed in accordance with the Terms, expected to be 5 April 2023.
Joint Lead Managers	UBS, ANZ, Morgans, NAB and WIB.
Life	CLC.
Life Insurance Act	<i>Life Insurance Act 1995 (Cth)</i> .
Mandatory Conversion	Has the meaning given in clause 18.2 of the Terms. See also Section 2.2.1 of this Prospectus.
Mandatory Conversion Conditions	Has the meaning given in clause 4.3 of the Terms. See also Section 2.2.4 of this Prospectus.
Mandatory Conversion Date	Has the meaning given in clause 4.2 of the Terms. See also Section 2.2.3 of this Prospectus.
Margin	Has the meaning given in clause 3.1 of the Terms. See also Section 2.1.2 of this Prospectus.
Maximum Conversion Number	Has the meaning given in clause 8.1 of the Terms. See also Section 2.2.7 of this Prospectus.
Minimum Regulatory Requirement	Represents the minimum capital requirement as required by regulators, including APRA, ASIC and regulators of other foreign jurisdictions.
Morgans	Morgans Financial Limited (ABN 49 010 669 726).
MoS	Margin on Services.
MoU	Memorandum of Understanding.
MS Primary	Mitsui Sumitomo Primary Life Insurance Company Limited.
MS&AD	MS&AD Insurance Group Holdings Inc.
NAB	National Australia Bank Limited (ABN 12 004 044 937).
NCOE	Normalised cash operating earnings.
New Money Offer	The offer made to eligible clients of the Syndicate Brokers and Institutional Investors, to apply for a new investment in Challenger Capital Notes 4 (i.e. not under the Reinvestment Offer).
NOHC	Non-operating holding company.
Nominee	Has the meaning given in clause 8.10 of the Terms. See also Section 2.7.4 of this Prospectus.
Nominated Purchaser(s)	UBS.

Term	Meaning
Non-Conversion Test Date	Has the meaning given in clause 6.5 of the Terms. See also Section 2.3.5 of this Prospectus.
Non-Resident Note Holders	Holders of Challenger Capital Notes 4 who are not tax residents of Australia.
Non-Viability Conversion	Has the meaning given in clause 18.2 of the Terms. See also Section 2.4 of this Prospectus.
Non-Viability Conversion Date	Has the meaning given in clause 5.2 of the Terms. See also Section 2.4.4 of this Prospectus.
Non-Viability Trigger Event	Has the meaning given in clause 5.1 of the Terms. See also Section 2.4.2 of this Prospectus.
NPAT	Net profit after tax.
NPBT	Normalised profit before tax.
Offer	The offer by Challenger of Challenger Capital Notes 4 under this Prospectus to raise \$350 million, with the ability to raise more or less, and incorporates the New Money Offer and Reinvestment Offer.
Offer Information Line	1800 780 782 (within Australia) or +61 3 9415 4065 (outside Australia) Monday to Friday 8:30am to 5:00pm (Sydney time).
Offer Management Agreement	The offer management agreement entered into between Challenger and the Joint Lead Managers, as described in Section 9.13.
Offer Period	The period from the Opening Date to the Closing Date.
Opening Date	The day the Offer opens, being 15 March 2023, unless varied.
Optional Conversion Restrictions	Has the meaning given in clause 6.5 of the Terms. See also Section 2.3.5 of this Prospectus.
Optional Exchange Date	Has the meaning given in clause 18.2 of the Terms. See also Section 2.3 of this Prospectus.
Ordinary Share	A fully paid ordinary share in the capital of Challenger.
Original Prospectus	The Prospectus dated 7 March 2023 and lodged with ASIC on that date, which this Prospectus replaces.
Payment Condition	Has the meaning given in clause 18.2 of the Terms. See also Section 2.1.7 of this Prospectus.
PCA	Prescribed capital amount.
Potential Acquisition Event	Has the meaning given in clause 18.2 of the Terms. See also Section 2.3.3 of this Prospectus.
Privacy Act	<i>Privacy Act 1988</i> (Cth).
Prospectus	This document (including the electronic form of this document), and any supplementary or replacement prospectus in relation to this document, including the Terms.
RAFI	Reporting Australian Financial Institutions.
Rate Disruption Event	Has the meaning given in clause 3.1 of the Terms.
Record Date	Has the meaning given in clause 18.2 of the Terms.
Redemption	Has the meaning given in clause 18.2 of the Terms (Redeem and Redeemed have corresponding meanings).
Redemption Price	Has the meaning given in clause 9.2 of the Terms.
Register	The register of Holders maintained by the Registry on Challenger's behalf, including any subregisters or branch register established and maintained by, or on behalf of, Challenger.
Registry	Computershare Investor Services Pty Limited (ABN 48 078 279 277) or any other registry that Challenger appoints to maintain the Register.
Regulatory Capital Base	The sum of Tier 1 Capital and Tier 2 Capital.

Term	Meaning
Regulatory Event	Has the meaning given in clause 18.2 of the Terms. See also Section 2.3.3 of this Prospectus.
Reinvestment CCN2	Challenger Capital Notes 2 held by an Eligible CCN2 Holder that are, or are to be, reinvested in Challenger Capital Notes 4, under the terms of the Reinvestment Offer.
Reinvestment Offer	The invitation to Eligible CCN2 Holders to reinvest the CCN2 Resale Proceeds relating to all or some of their Challenger Capital Notes 2 into Challenger Capital Notes 4 under this Prospectus.
Related Entity	Has the meaning given by APRA from time to time.
Relevant Date	Has the meaning given in clause 4.2 of the Terms.
Relevant Fraction	Has the meaning given in clause 8.1 of the Terms.
Relevant Perpetual Subordinated Instrument	Has the meaning given in clause 18.2 of the Terms and includes Challenger Capital Notes 2, Challenger Capital Notes 3 and Challenger Capital Notes 4 (when issued). See also Section 2.6.4 of this Prospectus.
Relevant Time	Has the meaning given in clause 18.2 of the Terms.
Relevant Persons	Has the meaning given in Section 9.1.4 of this Prospectus.
Replacement Rate	Has the meaning given in clause 3.1 of the Terms.
Resale	Has the meaning given in clause 18.2 of the Terms (Resold and Resell have corresponding meanings).
Resale Price	Has the meaning given in clause 18.2 of the Terms.
Resident Note Holders	Holdings of Challenger Capital Notes 4 who are tax residents of Australia.
Retail Investor	A person who is a “retail client” under the Corporations Act.
RSE	Registrable superannuation entity as defined under section 10 of the SIS Act.
Second CCN2 Pro Rata Distribution	The Distribution accrued over the period from (and including) 5 April 2023 (being the Issue Date) to (but excluding) 22 May 2023, in respect of each Challenger Capital Note 2 outstanding on the Record Date for the Second CCN2 Pro Rata Distribution.
Second Mandatory Conversion Condition	Has the meaning given in clause 4.3 of the Terms. See also Section 2.2.4 of this Prospectus.
Senior Creditors	Has the meaning given in clause 18.2 of the Terms.
SimCorp	SimCorp A/S.
SIS Act	<i>Superannuation Industry (Supervision) Act 1993</i> (Cth).
Special Resolution	Has the meaning given in clause 18.2 of the Terms.
Syndicate Broker	Any of the Joint Lead Managers (or their affiliated retail brokers), any Co-Manager and any other brokers appointed by the Joint Lead Managers following consultation with Challenger.
Target Market Determination or TMD	The target market determination for Challenger Capital Notes 4 issued by Challenger in accordance with its obligations under the DDO Regime, which can be obtained electronically at www.challengercapitalnotes.com.au .
Tax Event	Has the meaning given in clause 18.2 of the Terms. See also Section 2.3.3 of this Prospectus.
Terms	Terms and conditions of Challenger Capital Notes 4 as set out in Appendix A to this Prospectus, as amended from time to time.
TFN	Tax File Number.
Third Mandatory Conversion Condition	Has the meaning given in clause 4.3 of the Terms. See also Section 2.2.4 of this Prospectus.
Tier 1 Capital	Tier 1 Capital as defined by APRA from time to time.

Term	Meaning
Tier 2 Capital	Tier 2 Capital as defined by APRA from time to time.
TOFA	Taxation of financial arrangements.
Transaction Document	The Trust Deed and any other document agreed by the parties to the Trust Deed to be a Transaction Document under the terms of the Trust Deed.
Trust	The trust constituted by the Trust Deed.
Trust Deed	The trust deed between Challenger and the Trustee, dated on or about the date of the Original Prospectus.
Trustee	Equity Trustees Limited (ABN 46 004 031 298).
Trustee Default	Has the meaning given in the Trust Deed.
UBS	UBS AG, Australia Branch (ABN 47 088 129 613).
U.S. Person	Has the meaning given to it in Regulation S under the U.S. Securities Act.
U.S. Securities Act	<i>US Securities Act of 1933</i> , as amended.
VWAP	Has the meaning given in clause 18.2 of the Terms.
Wholesale Client	Has the meaning given in section 761G of the Corporations Act (as it may be modified for the purposes of the DDO Regime).
WIB	Westpac Institutional Bank, a division of Westpac Banking Corporation (ABN 33 007 457 141).
Winding-up Event	Has the meaning given in clause 16.1 of the Terms.
Written-Off	Has the meaning given in clause 8.13 of the Terms (Write-Off has a corresponding meaning).

Corporate directory

Issuer

Challenger Limited

Level 2
5 Martin Place
Sydney NSW 2000

Australian legal and tax adviser

King & Wood Mallesons

Level 61, Governor Phillip Tower
1 Farrer Place
Sydney NSW 2000

Auditor

Ernst & Young

200 George Street
Sydney NSW 2000

Registry

Computershare Investor Services Pty Limited

Yarra Falls
452 Johnston Street
Abbotsford VIC 3067

Trustee

Equity Trustees Limited

Level 4
7 Macquarie Place
Sydney NSW 2000

Arrangers

UBS AG, Australia Branch

Level 16, Chifley Tower
2 Chifley Square
Sydney NSW 2000

National Australia Bank Limited

Level 6, 2 Carrington Street
Sydney NSW 2000

Westpac Institutional Bank

(a division of Westpac Banking Corporation)
Level 3, Westpac Place
275 Kent Street
Sydney NSW 2000

Joint Lead Managers

UBS AG, Australia Branch

Level 16, Chifley Tower
2 Chifley Square
Sydney NSW 2000

ANZ Securities Limited

Level 9, ANZ Centre Melbourne
833 Collins Street
Docklands VIC 3008

Morgans Financial Limited

Level 29, Riverside Centre
123 Eagle Street
Brisbane QLD 4000

National Australia Bank Limited

Level 6, 2 Carrington Street
Sydney NSW 2000

Westpac Institutional Bank

(a division of Westpac Banking Corporation)
Level 3, Westpac Place
275 Kent Street
Sydney NSW 2000

Co-Managers

LGT Crestone Wealth Management Limited

Level 32, Chifley Tower
2 Chifley Square
Sydney NSW 2000

JBWere Limited

Level 31, 405 Bourke Street
Melbourne VIC 3000

How to contact us

Please call the Offer Information Line on 1800 780 782 (within Australia) or +61 3 9415 4065 (outside Australia) Monday to Friday 8:30am to 5:00pm (Sydney time).

Website: www.challengercapitalnotes.com.au